{"63856a1dd7dca08b03945213f2951e2a9dff6236": [["Along this line, complementary recommendations , which aim at exploring item compatible associations to enhance the qualities of each item or * Corresponding Author. another, have become a hot topic in both academia and industry in recent years.IntroductionIn the literature, previous researches can be clustered into two groups, i.e., unsupervised methods [Tan et al., 2004; Zheng et al., 2009 ] and supervised models .", [["hot", "OBSERVATION_MODIFIER", 189, 192], ["both", "OBSERVATION_MODIFIER", 202, 206], ["academia", "OBSERVATION", 207, 215]]], ["Meanwhile, some studies proposed supervised approaches to learn complementary relationships, such as co-purchased and content compatibility .", [["some studies", "TEST", 11, 23]]], ["In spite of the importance of existing studies, the exploration of compositional associations in the complementary item recommendations is still limited.IntroductionAs a matter of fact, when a user chooses the complementary items for the purchased products, it is intuitive that she will consider the visual coherence (such as color collocations, texture compatibilities) in addition to global impressions.", [["existing studies", "TEST", 30, 46], ["the exploration", "TEST", 48, 63]]], ["If we only consider co-purchased relations, we may recommend a creamy-white shirt to the user as shown in Figure 1 (a).", [["a creamy-white shirt", "TREATMENT", 61, 81]]], ["Then, a pair of black booties may be a suitable recommendation.", [["a pair of black booties", "TREATMENT", 6, 29]]], ["However, for considering compositional relationships and vi-sual semantic, we can find the mini skirt and shoulder bag are in blue.", [["shoulder", "ORGANISM_SUBDIVISION", 106, 114], ["bag", "ORGANISM_SUBDIVISION", 115, 118], ["the mini skirt and shoulder bag", "TREATMENT", 87, 118], ["shoulder", "ANATOMY", 106, 114]]], ["Therefore, as Figure 1 (c) shows, a pair of blue leather pumps is the best-matching.", [["blue leather pumps", "TREATMENT", 44, 62], ["blue", "OBSERVATION", 44, 48], ["leather pumps", "OBSERVATION", 49, 62]]], ["From this example, we can conclude that a good complementary recommender system should model the comprehensive compositional relationships on both global contents and semantic contents.", [["semantic contents", "OBSERVATION", 167, 184]]], ["Unfortunately, the exploration of this compositional coherence in the complementary recommendations is still limited.IntroductionIn this paper, we provide a focused study of the compositional coherence in item visual contents from two perspectives, i.e., the global visual coherence and the semantic-focal coherence.", [["the exploration", "TEST", 15, 30], ["a focused study", "TEST", 155, 170], ["focal", "OBSERVATION_MODIFIER", 300, 305]]], ["Along this line, we propose a novel Content Attentive Neural network (CANN) to address the complementary recommendations.", [["Neural network", "MULTI-TISSUE_STRUCTURE", 54, 68]]], ["More specifically, we first propose a Global Coherence Learning (GCL) module based on multiheads attention to model the global compositional coherence.", [["a Global Coherence Learning (GCL) module", "TREATMENT", 36, 76], ["multiheads attention", "TREATMENT", 86, 106], ["global", "OBSERVATION_MODIFIER", 120, 126], ["compositional coherence", "OBSERVATION", 127, 150]]], ["Then, considering the importance of visual semantics (such as color, texture), we generate the content semantic-focal representations of color-focal, texture-focal and hybrid-focal contents, respectively.", [["color-focal, texture-focal and hybrid-focal contents", "PROBLEM", 137, 189], ["focal", "OBSERVATION_MODIFIER", 112, 117], ["focal", "OBSERVATION_MODIFIER", 143, 148], ["texture", "OBSERVATION_MODIFIER", 150, 157], ["focal", "OBSERVATION_MODIFIER", 158, 163], ["hybrid", "OBSERVATION_MODIFIER", 168, 174], ["focal", "OBSERVATION_MODIFIER", 175, 180], ["contents", "OBSERVATION", 181, 189]]], ["Next, we design a Focal Coherence Learning (FCL) module based on a hierarchical attention model to learn the focal coherence from different semantic-focal representations.", [["a Focal Coherence Learning (FCL) module", "TREATMENT", 16, 55], ["a hierarchical attention model", "TREATMENT", 65, 95], ["the focal coherence", "PROBLEM", 105, 124], ["different semantic-focal representations", "PROBLEM", 130, 170], ["Focal", "OBSERVATION_MODIFIER", 18, 23], ["focal", "OBSERVATION_MODIFIER", 109, 114], ["different", "OBSERVATION_MODIFIER", 130, 139], ["semantic", "OBSERVATION_MODIFIER", 140, 148], ["focal", "OBSERVATION_MODIFIER", 149, 154]]], ["Finally, we optimize the CANN in a novel compositional optimization strategy.", [["CANN", "SIMPLE_CHEMICAL", 25, 29], ["CANN", "DNA", 25, 29], ["a novel compositional optimization strategy", "TREATMENT", 33, 76]]], ["Along this line, many researchers directly extracted the visual feature by a pretrained CNN model and enhanced traditional recommender systems, such as Matrix Factorization Hou et al., 2019] .", [["pretrained CNN model", "CELL_LINE", 77, 97]]], ["To further explore item visual contents, some studies developed deep neural networks to extract the aesthetic information of images .", [["neural networks", "ANATOMY", 69, 84], ["neural networks", "MULTI-TISSUE_STRUCTURE", 69, 84], ["some studies", "TEST", 41, 53]]], ["In this paper, we propose the compositional visual coherence, which is learning by the attention-based deep neural networks, to deeply model the item complementary relation for recommender systems.Complementary RecommendationsFor enhancing the recommendations, explicitly modeling the complex relations among items under domain-specific applications is an indispensable part .", [["neural networks", "ANATOMY", 108, 123], ["neural networks", "MULTI-TISSUE_STRUCTURE", 108, 123], ["deep", "ANATOMY_MODIFIER", 103, 107], ["neural", "ANATOMY", 108, 114]]], ["Along this line, many researchers focused on exploring the item combination-effect relations, such as substitutable relations [McAuley et al., 2015a; McAuley et al., 2015b] and complementary relations [Rudolph et al., 2016; .", [["this line", "TREATMENT", 6, 15]]], ["Along this line, since natural complementary relationships in the fashion items Lo et al., 2019] , there was a particular interest in understanding the compatibility [Song et al., 2017; Wang et al., 2019] of fashion items to generate complementary recommendations [Han et al., 2017; Hsiao and Grauman, 2018; Vasileva et al., 2018] .", [["this line", "TREATMENT", 6, 15]]], ["For example, learned the complicated and heterogeneous relationships between items and enhance fashion recommendations.", [["heterogeneous", "OBSERVATION_MODIFIER", 41, 54]]], ["[Han et al., 2017] developed Bi-LSTMs to model the outfit completion process and generate the complementary clothing recommendations.", [["Bi-LSTMs", "PROBLEM", 29, 37]]], ["Although these works have considered coreactions between items, the item compositional coherence in the global and semantic contents cannot be depicted and captured well.", [["global", "OBSERVATION_MODIFIER", 104, 110], ["semantic contents", "OBSERVATION", 115, 132]]], ["In this paper, we propose a focal study on exploring the item compositional relationship of visual content to enhance the complementary item recommendations.CANN: Content Attentive Neural NetworkIn this section, we introduce our proposed framework for addressing the complementary recommendations.CANN: Content Attentive Neural NetworkIn the real complementary item choosing process, people always want to buy some items that can be compatible with their purchased products.", [["people", "ORGANISM", 384, 390], ["people", "SPECIES", 384, 390], ["a focal study", "TEST", 26, 39], ["focal", "OBSERVATION_MODIFIER", 28, 33]]], ["Suppose we have a set of compatible item collections S = {O 1 , O 2 , ..., O N }, and for each collection O i = {p 1 , p 2 , .., p k } contains k compatible items p.", [["O", "CHEMICAL", 58, 59], ["O", "CHEMICAL", 64, 65], ["O", "CHEMICAL", 75, 76], ["N", "CHEMICAL", 77, 78], ["O N }", "SIMPLE_CHEMICAL", 75, 80], ["collections S", "TEST", 41, 54], ["each collection O i", "TEST", 90, 109], ["p", "TEST", 119, 120], ["k", "TEST", 131, 132]]], ["Meanwhile, we have a scenario that a user has purchased a seed collection of items P = {p 1 , p 2 , ..., p i }, but she is confused to choose complementary items P * which can make the item collection compatible.", [["confused", "PROBLEM", 123, 131]]], ["To that end, in this paper, we aim to give a complementary suggestion for the target user to help her make the best-matched choice.CANN: Content Attentive Neural NetworkAlong this line, we propose a content-based attention model, i.e., Content Attentive Neural network (CANN), to address the complementation recommendations.", [["Neural network", "MULTI-TISSUE_STRUCTURE", 254, 268], ["this line", "TREATMENT", 175, 184], ["a content-based attention model", "TREATMENT", 197, 228]]], ["As shown in Figure 2 , CANN consists of a Global Coherence Learning (GCL) component and a Focal Coherence Learning (FCL) component to jointly learn the compositional relationships from global and semantic-focal contents.", [["CANN", "PROTEIN", 23, 27], ["Global Coherence Learning (GCL) component", "PROTEIN", 42, 83], ["a Global Coherence Learning (GCL) component", "TREATMENT", 40, 83], ["a Focal Coherence Learning (FCL) component", "TREATMENT", 88, 130], ["Focal", "OBSERVATION_MODIFIER", 90, 95], ["global", "OBSERVATION_MODIFIER", 185, 191], ["focal contents", "OBSERVATION", 205, 219]]], ["In order to simulate users' decision-making process on complementary items, we propose a novel compositional optimization strategy to train our proposed CANN. ...Content Attentive Neural Networks (CANN).Global Coherence LearningConsidering the differences from traditional recommendations, the visual contents of items are an important part of the complementary recommendations e.g., the colors should be compatible and styles should be matching.", [["CANN", "CANCER", 153, 157], ["CANN", "PROTEIN", 153, 157], ["a novel compositional optimization strategy", "TREATMENT", 87, 130]]], ["Along this line, we propose an attention-based module, i.e., Global Coherence Learning (GCL) to learn compositional coherence of item global visual contents.Global Coherence LearningWe develop the Inception-V3 CNN model as the feature extractor to transform item global visual contents (item images) to original feature vectors.", [["Inception-V3 CNN model", "DNA", 197, 219], ["an attention-based module", "TREATMENT", 28, 53], ["line", "OBSERVATION", 11, 15], ["visual contents", "OBSERVATION", 141, 156], ["visual contents", "OBSERVATION", 270, 285]]], ["Then for each item collection P = {p 1 , p 2 , ..., p k }, we can generate the items visual representations P = {x 1 , x 2 , ..., x k } from the item images, where x i is the feature representation derived from the CNN model for the i-th item.", [["each item collection P", "TEST", 9, 31], ["the item images", "TEST", 141, 156], ["the CNN model", "TREATMENT", 211, 224]]], ["More formally, we generate the final visual representation as following:Global Coherence Learningwhere the weight matrices WGlobal Coherence Learning(1)Global Coherence Learningf are the bias terms, \u03c3 is the activation function, here, we use ReLU function.Global Coherence LearningAfter obtaining the visual representations of the item col-Global Coherence Learning., x f k }, we can generate the item embedding matrix M \u2208 R k\u00d7d f , where k is the maximum length of the item collections and d f is the latent dimension of item visual feature.", [["\u03c3", "GENE_OR_GENE_PRODUCT", 199, 200], ["ReLU", "GENE_OR_GENE_PRODUCT", 242, 246], ["ReLU", "PROTEIN", 242, 246], ["Global Coherence", "PROBLEM", 72, 88], ["maximum", "OBSERVATION_MODIFIER", 448, 455], ["length", "OBSERVATION_MODIFIER", 456, 462], ["latent", "OBSERVATION_MODIFIER", 502, 508], ["dimension", "OBSERVATION_MODIFIER", 509, 518], ["visual feature", "OBSERVATION", 527, 541]]], ["If the item collection length is shorter than k, we repeatedly use a 'padding' item until the length is k.", [["a 'padding' item", "TREATMENT", 67, 83], ["length", "OBSERVATION_MODIFIER", 23, 29]]], ["Next, an attention mechanism is applied to model the item compositional coherence in multiple visual spaces.", [["an attention mechanism", "TREATMENT", 6, 28], ["multiple", "OBSERVATION_MODIFIER", 85, 93], ["visual spaces", "OBSERVATION", 94, 107]]], ["Inspired by the multi-heads attention method [Vaswani et al., 2017] , in this paper, we use a stacked attention model to capture the global visual coherence.", [["a stacked attention model", "TREATMENT", 92, 117]]], ["More specifically, we transform the item visual features into various visual spaces and perform a linear projection asGlobal Coherence Learningis the projection matrix of shape R d f \u00d7ds , and b s is the bias term.", [["a linear projection asGlobal Coherence", "TREATMENT", 96, 134]]], ["Then we can model the global coherence between two items in the target collection as:Global Coherence Learningwhere \u03b1 s i,j is the visual coherence score of item p i and p j , weight matrices W q s , W k s are of shape R ds\u00d7ds .", [["weight matrices", "TEST", 176, 191], ["W k s", "TEST", 200, 205], ["global", "OBSERVATION_MODIFIER", 22, 28]]], ["Next, the coherence scores are normalized by a softmax function.", [["the coherence scores", "TEST", 6, 26], ["normalized", "OBSERVATION", 31, 41]]], ["Therefore, we model global coherence from multiple visual spaces within an attention-based block and item visual representation M a = [v 1 , v 2 , ..., v k ] is generated.", [["multiple visual spaces", "PROBLEM", 42, 64], ["based block", "PROBLEM", 85, 96], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["visual spaces", "OBSERVATION", 51, 64]]], ["However, the global coherence learning process is a linear operation and the interactions between different latent dimensions are largely unexploited.", [["a linear operation", "TREATMENT", 50, 68], ["global", "OBSERVATION_MODIFIER", 13, 19], ["linear", "OBSERVATION_MODIFIER", 52, 58], ["operation", "OBSERVATION", 59, 68], ["latent", "OBSERVATION_MODIFIER", 108, 114], ["dimensions", "OBSERVATION_MODIFIER", 115, 125], ["largely", "OBSERVATION_MODIFIER", 130, 137], ["unexploited", "OBSERVATION", 138, 149]]], ["With this in mind, we develop a feedforward network to endow the model with the nonlinear operation:Global Coherence Learningwhere the weight matrices WGlobal Coherence Learning(1)Global Coherence Learning(2) n are the bias terms.", [["a feedforward network", "TREATMENT", 30, 51], ["the nonlinear operation", "TREATMENT", 76, 99], ["Global Coherence Learningwhere the weight matrices", "TREATMENT", 100, 150]]], ["After that, we generated the attention output from a multi-heads attention block.", [["a multi-heads attention block", "TREATMENT", 51, 80]]], ["For modeling the sophisticated compositional coherence of global features, we stack multiple multi-heads attention blocks to build a deeper network architecture.", [["network architecture", "MULTI-TISSUE_STRUCTURE", 140, 160], ["global features", "PROBLEM", 58, 73], ["multiple multi-heads attention blocks", "TREATMENT", 84, 121], ["global features", "OBSERVATION", 58, 73]]], ["In order to prevent overfitting and unstable training process, we perform the Batch Normalization (BN) layer [Ioffe and Szegedy, 2015] after the output of each attention block.", [["overfitting", "PROBLEM", 20, 31], ["unstable training process", "PROBLEM", 36, 61], ["each attention block", "TREATMENT", 155, 175]]], ["More formally, the output of b\u2212th block can be defined as:Global Coherence Learningwhere \u2295 is the element plus, f a , f n are the attention function and feedforward function, respectively.", [["b\u2212th", "GENE_OR_GENE_PRODUCT", 29, 33], ["b\u2212th block", "PROTEIN", 29, 39], ["b\u2212th block", "PROBLEM", 29, 39]]], ["After the final attention block, we can generate global representations of the seed collection GGlobal Coherence Learningis the output of the last multi-heads attention block.Focal Coherence LearningAs mentioned above, for learning the compositional coherence from the item content, the content semantic attributes are also important to understanding item characteristics.", [["the final attention block", "TREATMENT", 6, 31], ["the seed collection", "PROBLEM", 75, 94], ["the last multi-heads attention block", "TREATMENT", 138, 174], ["output", "OBSERVATION_MODIFIER", 128, 134]]], ["To that end, we propose a novel Focal Coherence Learning (FCL) to model the compositional coherence from semantic-focal contents, i.e., color-focal contents, texture-focal contents and hybrid-focal contents.", [["a novel Focal Coherence Learning (FCL)", "TREATMENT", 24, 62], ["semantic-focal contents", "PROBLEM", 105, 128], ["color-focal contents", "PROBLEM", 136, 156], ["focal contents", "PROBLEM", 166, 180], ["hybrid-focal contents", "PROBLEM", 185, 206], ["Focal", "OBSERVATION_MODIFIER", 32, 37], ["semantic", "OBSERVATION_MODIFIER", 105, 113], ["focal contents", "OBSERVATION", 114, 128], ["focal", "OBSERVATION_MODIFIER", 142, 147], ["contents", "OBSERVATION_MODIFIER", 148, 156], ["texture", "OBSERVATION_MODIFIER", 158, 165], ["focal", "OBSERVATION_MODIFIER", 166, 171], ["contents", "OBSERVATION_MODIFIER", 172, 180], ["hybrid", "OBSERVATION_MODIFIER", 185, 191], ["focal", "OBSERVATION_MODIFIER", 192, 197], ["contents", "OBSERVATION", 198, 206]]], ["Firstly, we develop a Semantic-Focal Content Extraction (SFCE) based on the region-based segmentation methods as regions can yield much richer visual information than pixels [Uijlings et al., 2013] .", [["Focal Content Extraction", "TREATMENT", 31, 55], ["Focal", "OBSERVATION_MODIFIER", 31, 36], ["Content", "OBSERVATION", 37, 44]]], ["Inspired by Selective Search [Uijlings et al., 2013] , we firstly use a grouping algorithm to merge the semantic regions, which are based on the color or textual similarity computing.", [["a grouping algorithm", "TREATMENT", 70, 90], ["the color", "TEST", 141, 150]]], ["Specifically, we first generate the initial semantic regions by a segmentation algorithm [Felzenszwalb and Huttenlocher, 2004] .", [["a segmentation algorithm", "TEST", 64, 88]]], ["Then we develop the Selective Search algorithm to group regions which are similar in color, texture and both of them, respectively.", [["similar", "OBSERVATION_MODIFIER", 74, 81], ["color", "OBSERVATION_MODIFIER", 85, 90], ["texture", "OBSERVATION_MODIFIER", 92, 99], ["both", "OBSERVATION_MODIFIER", 104, 108]]], ["The similarity can be measured as Sim(r i , r j ) = n k=1 min(C k i , C k j ), where the C i is the measurement of characteristic feature histogram, i.e., the color histogram and texture histogram, n is the feature dimensionality.", [["k", "TEST", 54, 55], ["C k i", "TEST", 62, 67], ["the color histogram", "TEST", 155, 174], ["texture histogram", "TEST", 179, 196]]], ["Each color channel is discretized into 25 bins, and n = 75 for the color feature in total.", [["25 bins", "OBSERVATION_MODIFIER", 39, 46]]], ["And we obtain n = 240 dimensional texture histogram by computed SIFT-like [Liu et al., 2010] measurements on 8 different orientations of each color channel, for each orientation for each color using 10 bins.", [["dimensional texture histogram", "TEST", 22, 51], ["computed SIFT", "TEST", 55, 68]]], ["Both color histogram and texture histogram are normalized by L 1 norm.Focal Coherence LearningAfter computing the semantic similarity of regions i and k, we can group the similar regions and the target histogram C t can be efficiently propagated by:Focal Coherence LearningThe size of target regions can be simply computed size(r t ) = size(r i ) + size(r j ).", [["Both color histogram", "TEST", 0, 20], ["texture histogram", "TEST", 25, 42], ["Focal", "OBSERVATION_MODIFIER", 249, 254], ["size", "OBSERVATION_MODIFIER", 277, 281], ["size", "OBSERVATION_MODIFIER", 323, 327], ["size", "OBSERVATION_MODIFIER", 336, 340], ["size", "OBSERVATION_MODIFIER", 349, 353]]], ["Because we want to deeply explore the compositional coherence of different semantic contents.", [["semantic contents", "OBSERVATION", 75, 92]]], ["CANN extracts the semantic-focal contents R c , R t , R h respectively based on color similarity, texture similarity and hybrid similarity, and for each semantic-focal content we choose three content regions.", [["CANN", "DNA", 0, 4], ["focal contents", "PROBLEM", 27, 41], ["color similarity", "TEST", 80, 96], ["hybrid similarity", "PROBLEM", 121, 138], ["each semantic-focal content", "PROBLEM", 148, 175], ["focal", "OBSERVATION_MODIFIER", 27, 32], ["contents", "OBSERVATION", 33, 41], ["focal", "OBSERVATION_MODIFIER", 162, 167], ["content", "OBSERVATION", 168, 175]]], ["With a pre-trained Inception V3 [Szegedy et al., 2016], we can generate the feature vectors F = [y c , y t , y h ] of all the semantic-focal contents.", [["focal contents", "PROBLEM", 135, 149], ["semantic", "OBSERVATION", 126, 134], ["focal contents", "OBSERVATION", 135, 149]]], ["Next, we can learn the focal coherence among the content regions.Focal Coherence LearningActually, considering the computational complexity of the attention mechanism for all the regions in all the items, similar with [Ma et al., 2019], we propose a hierarchical attention module to model both the semantic-specific and cross-semantic dependency in a distinguishable way.", [["a hierarchical attention module", "TREATMENT", 248, 279], ["focal", "OBSERVATION_MODIFIER", 23, 28]]], ["As shown in Figure 2 , the input semantic-focal features V \u2208 R k\u00d7|F |\u00d7|R|\u00d7dy can be reshaped as input matrices V C \u2208 R |F |\u00d7d C in the semantic-specific space and V S \u2208 R k\u00d7d S in the cross-semantic space.", [["V S \u2208 R k\u00d7d S", "CELL_LINE", 163, 176], ["the input semantic", "TEST", 23, 41], ["focal features", "TEST", 42, 56], ["R|\u00d7dy", "TEST", 71, 76], ["matrices V", "TEST", 102, 112], ["C", "TEST", 113, 114], ["C", "TEST", 126, 127], ["the semantic", "TEST", 131, 143], ["specific space", "TEST", 144, 158], ["V S", "TEST", 163, 166], ["cross-semantic space", "ANATOMY", 184, 204]]], ["For each seed item collection, k is the seed item numbers, |F | is the number of semanticfocal features, |R| is the number of content regions of each semantic-focal feature, and d y is the dimension of each region representation.", [["each", "OBSERVATION_MODIFIER", 145, 149], ["semantic", "OBSERVATION_MODIFIER", 150, 158], ["focal", "OBSERVATION_MODIFIER", 159, 164], ["d y", "OBSERVATION_MODIFIER", 178, 181]]], ["Afterwards, we can compute our focal coherence by hierarchical multi-heads attention as:Focal Coherence Learningwhere\u00c2 C and\u00c2 S are attention matrices of semantic-specific and cross-semantic.", [["focal", "OBSERVATION_MODIFIER", 31, 36], ["Focal", "OBSERVATION_MODIFIER", 88, 93]]], ["Similar to GBL, the attention matrices are computed by Eq.2.", [["GBL", "CHEMICAL", 11, 14], ["GBL", "CHEMICAL", 11, 14], ["GBL", "SIMPLE_CHEMICAL", 11, 14], ["Eq.2", "PROTEIN", 55, 59], ["GBL", "OBSERVATION_MODIFIER", 11, 14]]], ["More specifically, we firstly model the compositional coherence of different semantic-focal regions.", [["compositional", "OBSERVATION_MODIFIER", 40, 53], ["coherence", "OBSERVATION_MODIFIER", 54, 63], ["different", "OBSERVATION_MODIFIER", 67, 76], ["semantic", "OBSERVATION_MODIFIER", 77, 85], ["focal", "OBSERVATION_MODIFIER", 86, 91]]], ["For aligning the attention matrices to the semantic-focal features, we reshape the attention matrices as\u00c2 C = A C \u00b7 I C and A S = A S \u00b7 I S , where I C , I S are the identity matrices.", [["I C", "PROTEIN", 148, 151], ["A S", "TEST", 124, 127], ["A S \u00b7 I S", "TEST", 130, 139], ["focal", "OBSERVATION_MODIFIER", 52, 57]]], ["To that end, the semantic-focal representation of the item seed collection P can be formulated as F (V ) = V .Optimization StrategySo far, from GCL and FCL modules, we can generate the global and semantic-focal representations, respectively.", [["GCL", "CELLULAR_COMPONENT", 144, 147], ["P", "DNA", 75, 76], ["GCL and FCL modules", "DNA", 144, 163], ["the item seed collection", "PROBLEM", 50, 74], ["Optimization Strategy", "TREATMENT", 110, 131], ["GCL and FCL modules", "PROBLEM", 144, 163], ["focal", "OBSERVATION_MODIFIER", 26, 31], ["FCL modules", "OBSERVATION", 152, 163], ["global", "OBSERVATION_MODIFIER", 185, 191], ["semantic", "OBSERVATION_MODIFIER", 196, 204], ["focal", "OBSERVATION_MODIFIER", 205, 210], ["representations", "OBSERVATION_MODIFIER", 211, 226]]], ["Following [Han et al., 2017] , we append a softmax layer on the x to calculate the probability of complementary items conditioned on the target seed collections:Optimization Strategywhere N contains all the items from the seed collections.", [["the seed collections", "PROBLEM", 218, 238], ["collections", "OBSERVATION", 227, 238]]], ["This can make model learn compositional coherence by means of considering a diverse collection of candidates.", [["a diverse collection of candidates", "PROBLEM", 74, 108]]], ["For optimizing our CANN, we propose a compositional trainingAlgorithm 1 Compositional Optimization StrategyInput: Initialization model f (Pi, C; \u03b8); The length of the seed collection k; The complementary item database S; The number of epochs T ; The size of batch m Parameter: Model parameter \u03b8 1: for i = 1, 2, 3, ..., T do 2: Random sample m seed collections O \u2208 S 3:Algorithm 1 Compositional Optimization StrategyInitial input mini-batch Input as \u2205 4:Algorithm 1 Compositional Optimization Strategyfor Oi in Batch do 5:Algorithm 1 Compositional Optimization StrategyRandom choose an item p from the collection Oi 6:Algorithm 1 Compositional Optimization StrategyGenerate the seed collection Pi \u2190 M ask(Oi, p) 7:Algorithm 1 Compositional Optimization Strategyif |Pi| < k then 8:Algorithm 1 Compositional Optimization StrategyAdd an padding to the left of Pi until |Pi| = k 9: end if 10:Algorithm 1 Compositional Optimization StrategyGenerate the input mini-batch Input \u2190 Input \u222a Pi 11: end for 12:Algorithm 1 Compositional Optimization StrategyBuild the training candidates N \u2190 \u2200x \u2208 Input 13:Algorithm 1 Compositional Optimization StrategyUpdate the model \u03b8 \u2190 SGD(f (Input, C; \u03b8), \u03b8) 14: end for strategy to simulate users' decision-making process on complementary items as Algorithm 1.", [["a compositional trainingAlgorithm", "TREATMENT", 36, 69], ["the seed collection k", "TEST", 163, 184], ["Model parameter", "TEST", 277, 292], ["Random sample m seed collections", "TEST", 328, 360], ["Algorithm", "TEST", 369, 378], ["Algorithm", "TEST", 714, 723], ["Algorithm", "TEST", 780, 789], ["an padding", "TREATMENT", 831, 841], ["k", "TEST", 873, 874], ["Algorithm", "TEST", 888, 897], ["length", "OBSERVATION_MODIFIER", 153, 159], ["size", "OBSERVATION_MODIFIER", 250, 254], ["left", "ANATOMY_MODIFIER", 849, 853]]], ["In the training stage, we use the M ask(O i , p) operation to delete prediction items p from the seed collections O. Moreover, we take all items in the mini-batch as the candidate collection N .", [["operation", "TREATMENT", 49, 58]]], ["Actually, for some small datasets, we can use all the items as the candidates, but this is not practical for large datasets because of the high dimensional item representations.Algorithm 1 Compositional Optimization StrategyWith the compositional optimization strategy, CANN can be trained end-to-end.", [["CANN", "SIMPLE_CHEMICAL", 270, 274], ["some small datasets", "PROBLEM", 14, 33], ["large datasets", "PROBLEM", 109, 123], ["the high dimensional item representations", "PROBLEM", 135, 176]]], ["During training, we minimize the following objective function:Algorithm 1 Compositional Optimization Strategywhere \u03b8 denotes the model parameters.", [["Algorithm", "TEST", 62, 71]]], ["Similar with [Han et al., 2017] , we add a visual-semantic embedding as a regularization.", [["a visual-semantic embedding", "TREATMENT", 41, 68], ["a regularization", "TREATMENT", 72, 88]]], ["We use Stochastic Gradient Decent (SGD) [Robbins and Monro, 1951] with mini-batch to update them through Algorithm 1.ExperimentsIn this section, we first introduce the experimental settings and compared methods.", [["mini-batch", "TREATMENT", 71, 81], ["the experimental settings", "TREATMENT", 164, 189]]], ["Then, we compare the performance of CANN against the compared approaches on the complementary recommendation task.", [["CANN", "SIMPLE_CHEMICAL", 36, 40], ["CANN", "PROTEIN", 36, 40]]], ["Then, we make an ablation study on the focal coherence learning process.", [["an ablation study", "TEST", 14, 31]]], ["At last, we conduct a case study to visualize the compositional coherence of our proposed CANN.Experimental SetupsDataset.", [["CANN", "DNA", 90, 94], ["a case study", "TEST", 20, 32], ["Experimental SetupsDataset", "TREATMENT", 95, 121]]], ["First, we merge the datasets and remove the noise samples that exclude the seed sets of more than 8 items.", [["the noise samples", "TEST", 40, 57]]], ["Then, we split the dataset into 59,212 outfits with 221,711 fashion items for training, 3,000 outfits for validation and 10,218 outfits for testing.", [["validation", "TEST", 106, 116], ["testing", "TEST", 140, 147]]], ["Next, we conduct a testing set (i.e., FITB Random) as fill-in-the-blank tasks [Han et al., 2017] , which we randomly choose candidates as the negative samples from the whole testing set.", [["a testing set", "TEST", 17, 30], ["the whole testing set", "TEST", 164, 185]]], ["Meanwhile, in order to further make our testing more difficult and similar to users' decision-making process, we conduct a more specific testing set, i.e., FITB Category.", [["our testing", "TEST", 36, 47]]], ["In this set, we remove the easily identifiable negative samples and replace these samples with other items which have the same category of the ground-truth.", [["samples", "ANATOMY", 56, 63], ["these samples", "TEST", 76, 89]]], ["Evaluation Metrics.", [["Evaluation", "TEST", 0, 10]]], ["We evaluate our model and all compared methods by two evaluation metrics, i.e., the Accuracy (ACC) [Han et al., 2017; Vasileva et al., 2018] and Mean Reciprocal Rank (MRR) [Song et al., 2017; .", [["two evaluation metrics", "TEST", 50, 72]]], ["We adopt the GoogleNet Incep-tionV3 model which was pretrained on ImageNet [Deng et al., 2009 ] to transform global visual contents (images) and semantic-focal visual contents (regions) to feature vectors.", [["the GoogleNet Incep-tionV3 model", "TREATMENT", 9, 41], ["semantic-focal visual contents", "PROBLEM", 145, 175], ["focal", "OBSERVATION_MODIFIER", 154, 159], ["visual contents", "OBSERVATION", 160, 175]]], ["For fair comparisons, we set all the image embedding size of d f = 512 unless otherwise noted.", [["size", "OBSERVATION_MODIFIER", 53, 57]]], ["The number of visual space is set to S = 4 and for each visual space, we set d s = d f /S = 128 and b * = 4 unless otherwise noted.", [["set d s = d f /S", "TEST", 73, 89], ["visual space", "OBSERVATION", 14, 26]]], ["Our model is trained with an initial learning rate of 0.2 and is decayed by a factor of 2 every 2 epochs.", [["an initial learning rate", "TEST", 26, 50]]], ["The batch size is set to 9, seed collection length k is set to 8.", [["The batch size", "TEST", 0, 14], ["seed collection length k", "TEST", 28, 52], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["We stop the training process when the loss on the validation set stabilizes.", [["the training process", "TREATMENT", 8, 28], ["the loss", "PROBLEM", 34, 42]]], ["Our model and all the compared methods are developed and trained on a Linux server with two 2.20 GHz Intel Xeon E5-2650 v4 CPUs and four TITAN Xp GPUs.", [["E5-2650 v4 CPUs", "DNA", 112, 127], ["TITAN Xp GPUs", "DNA", 137, 150], ["E5", "TEST", 112, 114], ["four TITAN Xp GPUs", "PROBLEM", 132, 150], ["TITAN Xp GPUs", "OBSERVATION", 137, 150]]], ["This model utilizes a Siamese CNN to project two items into a latent space to estimate their similarity.", [["a Siamese CNN", "TREATMENT", 20, 33]]], ["We use an L2 norm to normalize the item visual embedding before calculating the Siamese loss and set the margin parameter to 0.8. \u2022 VSE [Han et al., 2017] .", [["an L2 norm", "TREATMENT", 7, 17]]], ["Visual-Semantic Embedding (VSE) method learns a multimodal item embedding based on images and texts.", [["images", "TEST", 83, 89], ["Semantic Embedding", "OBSERVATION", 7, 25]]], ["This method builds a bidirectional LSTM to predict the complementary item condi-tioned on previously seen items in both directions.", [["LSTM", "DNA", 35, 39]]], ["We use the full model by jointly learning the multimodal inputs. \u2022 CSN-Best [Vasileva et al., 2018] .", [["CSN", "GENE_OR_GENE_PRODUCT", 67, 70], ["CSN", "PROTEIN", 67, 70]]], ["This method learns item complementary relations by the node-wise graph neural networks.", [["node", "ANATOMY", 55, 59], ["neural networks", "ANATOMY", 71, 86], ["neural networks", "MULTI-TISSUE_STRUCTURE", 71, 86], ["node", "OBSERVATION", 55, 59]]], ["This is the state-of-the-art method in fashion compatibility learning and clothing complementary recommendations.Compared ApproachesBesides, for verifying the effectiveness of components, we construct three variant implements based on CANN.Compared Approaches\u2022 CANN-G.", [["CANN", "PROTEIN", 235, 239]]], ["This is a variant of our model that only uses the Global Coherence Learning (GCL) module to generate complementary recommendations. \u2022 CANN-F.", [["CANN", "PROTEIN", 134, 138], ["the Global Coherence Learning (GCL) module", "TREATMENT", 46, 88]]], ["This is a specific implementation that only uses Focal Coherence Learning (FCL) module. \u2022 CANN.", [["CANN", "PROTEIN", 90, 94], ["Focal", "OBSERVATION_MODIFIER", 49, 54]]], ["This is the model with all proposed components.Recommendation PerformancesWe compare CANN with the other methods on the contentbased complementary recommendations.", [["components", "OBSERVATION_MODIFIER", 36, 46]]], ["The number of candidates is set to 4 for both FITB Random and FITB Category, which is the same as previous work [Han et al., 2017; Vasileva et al., 2018; Cui et al., 2019] .Recommendation PerformancesThe results of all methods on both testing sets are shown in Table 1 . we can make the following observations: 1) CANN outperforms all the compared methods in both datasets, which indicates the superiority of the proposed model for contentbased complementary recommendations.", [["all methods", "TEST", 215, 226], ["both testing sets", "TEST", 230, 247]]], ["2) SetRNN and VSE perform the worst on both datasets.", [["SetRNN", "DNA", 3, 9], ["VSE", "DNA", 14, 17]]], ["That indicates the complementary method is not a trivial problem which can be handled straightly by simple methods.", [["a trivial problem", "PROBLEM", 47, 64], ["trivial", "OBSERVATION", 49, 56]]], ["3) SiameseNet and CSN-Best are similar methods which model the item pairwise compatibility.", [["CSN", "GENE_OR_GENE_PRODUCT", 18, 21], ["SiameseNet", "PROTEIN", 3, 13], ["CSN", "PROTEIN", 18, 21]]], ["These models work better than SetRNN and VSE model, but worse than Bi-LSTM and CANN.", [["SetRNN", "TEST", 30, 36], ["VSE model", "TEST", 41, 50], ["CANN", "TEST", 79, 83]]], ["This may be due to the fact that SiameseNet and CSN-Best aim to learn the similarity between two fashion items but ignore the compositional process.", [["CSN", "PROTEIN", 48, 51], ["may be due to", "UNCERTAINTY", 5, 18]]], ["4) CANN-F performs worse than CANN-G, that because CANN-F only considers the semantic-focal contents, which may make some information ignored.", [["CANN-F", "GENE_OR_GENE_PRODUCT", 3, 9], ["CANN-G", "GENE_OR_GENE_PRODUCT", 30, 36], ["CANN-F", "GENE_OR_GENE_PRODUCT", 51, 57], ["CANN", "PROTEIN", 3, 7], ["CANN", "PROTEIN", 30, 34], ["CANN", "PROTEIN", 51, 55], ["the semantic-focal contents", "PROBLEM", 73, 100], ["focal", "OBSERVATION_MODIFIER", 86, 91], ["contents", "OBSERVATION", 92, 100]]], ["Moreover, CANN-G outperforms other methods except for CANN.", [["CANN-G", "GENE_OR_GENE_PRODUCT", 10, 16], ["CANN", "PROTEIN", 10, 14], ["CANN", "PROTEIN", 54, 58]]], ["That enables us to safely draw the conclusion that it is advisable to model the compositional coherence of items on both global and semantic-focal contents.Ablation Study on Focal CoherenceTo further assess the robustness of the model and necessity of the semantic-focal coherence, we set different semantic contents in FCL module and evaluate the performances as the number of candidate collections increases.", [["Ablation Study", "TEST", 156, 170], ["Focal CoherenceTo", "TREATMENT", 174, 191], ["the semantic-focal coherence", "PROBLEM", 252, 280], ["both", "OBSERVATION_MODIFIER", 116, 120], ["global", "OBSERVATION_MODIFIER", 121, 127], ["semantic", "OBSERVATION_MODIFIER", 132, 140], ["focal contents", "OBSERVATION", 141, 155], ["focal", "OBSERVATION_MODIFIER", 265, 270], ["semantic contents", "OBSERVATION", 299, 316], ["collections", "OBSERVATION", 388, 399]]], ["We set the FCL module with only color-focal, texture-focal and hybrid-focal contents and compare these models with all our proposed model CANN which contains all the semantic-focal contents.Ablation Study on Focal CoherenceThe results are shown in the Figure 3 , where the horizontal axis indicates the number of candidate collections.", [["FCL module", "DNA", 11, 21], ["CANN", "DNA", 138, 142], ["color-focal, texture-focal and hybrid-focal contents", "PROBLEM", 32, 84], ["Ablation Study", "TEST", 190, 204], ["FCL module", "OBSERVATION", 11, 21], ["focal", "OBSERVATION_MODIFIER", 38, 43], ["texture", "OBSERVATION_MODIFIER", 45, 52], ["focal", "OBSERVATION_MODIFIER", 53, 58], ["hybrid", "OBSERVATION_MODIFIER", 63, 69], ["focal contents", "OBSERVATION", 70, 84], ["all", "OBSERVATION_MODIFIER", 158, 161], ["semantic", "OBSERVATION_MODIFIER", 166, 174], ["focal contents", "OBSERVATION", 175, 189], ["Focal", "OBSERVATION_MODIFIER", 208, 213], ["collections", "OBSERVATION", 323, 334]]], ["The Color, Texture, Hybrid and ALL represent that CANN uses only color-focal, texture-focal, hybrid-focal and all contents, respectively.", [["ALL", "DISEASE", 31, 34], ["ALL", "CANCER", 31, 34], ["color", "TEST", 65, 70], ["focal, hybrid-focal and all contents", "PROBLEM", 86, 122], ["Color", "OBSERVATION_MODIFIER", 4, 9], ["Texture", "OBSERVATION_MODIFIER", 11, 18], ["focal", "OBSERVATION_MODIFIER", 71, 76], ["texture", "OBSERVATION_MODIFIER", 78, 85], ["focal", "OBSERVATION_MODIFIER", 86, 91], ["hybrid", "OBSERVATION_MODIFIER", 93, 99], ["focal", "OBSERVATION_MODIFIER", 100, 105], ["all", "OBSERVATION_MODIFIER", 110, 113], ["contents", "OBSERVATION", 114, 122]]], ["From the Figure 3 , we can get the following observations: 1) CANN with all the semantic-focal contents has outperformed others, which clearly demonstrate the effectiveness of all components in our proposed CANN.Ablation Study on Focal Coherence2) The CANN with hybrid-focal coherence learning performs better than color-focal and texture-focal methods.", [["CANN", "CANCER", 207, 211], ["CANN", "PROTEIN", 207, 211], ["Ablation Study", "TEST", 212, 226], ["focal methods", "PROBLEM", 339, 352], ["focal", "OBSERVATION_MODIFIER", 89, 94], ["contents", "OBSERVATION", 95, 103], ["focal", "OBSERVATION_MODIFIER", 269, 274], ["focal", "OBSERVATION_MODIFIER", 321, 326], ["texture", "OBSERVATION_MODIFIER", 331, 338], ["focal", "OBSERVATION_MODIFIER", 339, 344]]], ["Meanwhile, the color-focal model outperforms the texture-focal model.", [["the color", "TEST", 11, 20], ["color", "OBSERVATION_MODIFIER", 15, 20], ["focal", "OBSERVATION_MODIFIER", 21, 26], ["model outperforms", "OBSERVATION", 27, 44], ["texture", "OBSERVATION_MODIFIER", 49, 56], ["focal model", "OBSERVATION", 57, 68]]], ["These observations imply that the color is an important factor for content-based complementary item recommendations.Ablation Study on Focal Coherence3) CANN with all semantic-focal contents outperforms other single semantic-focal models on FITB Category with a larger margin than on FITB Random.", [["Ablation Study", "TEST", 116, 130], ["focal contents", "PROBLEM", 175, 189], ["focal", "OBSERVATION_MODIFIER", 175, 180], ["focal", "OBSERVATION_MODIFIER", 224, 229], ["larger", "OBSERVATION_MODIFIER", 261, 267], ["margin", "OBSERVATION_MODIFIER", 268, 274]]], ["These observations imply that semantic-focal contents can help the model to better understand the item compositional relationships and generate the best-matched complementary item suggestions.Visualization of the Attention MechanismTo further illustrate the learning and expression of compositional visual coherence in our model, we visualize the intermediate results of the coherence score \u03b1 i,j in Eq.", [["Attention MechanismTo", "DNA", 213, 234], ["semantic-focal contents", "PROBLEM", 30, 53], ["focal", "OBSERVATION_MODIFIER", 39, 44]]], ["For the better visualization, we select one semantic region generated by our model for each semantic-focal content.", [["focal content", "OBSERVATION", 101, 114]]], ["The color in Figure 4 changes from light to dark while the value of coherence score increases.", [["color", "OBSERVATION_MODIFIER", 4, 9]]], ["From Figure 4 , it is worth noting that the coherence scores between the t-shirt and shorts are higher than others in all coherence spaces.", [["t-shirt", "DNA", 73, 80], ["higher", "OBSERVATION_MODIFIER", 96, 102]]], ["Meanwhile, the scores between shoes and bracelet are also quite high.", [["shoes and bracelet", "TREATMENT", 30, 48], ["high", "OBSERVATION", 64, 68]]], ["That is intuitive that the black t-shirt and dark blue shorts are similar in color.", [["dark blue shorts", "PROBLEM", 45, 61], ["dark", "OBSERVATION_MODIFIER", 45, 49], ["blue shorts", "OBSERVATION", 50, 61]]], ["The shoes and bracelet are similar in leopard print style.", [["The shoes and bracelet", "TREATMENT", 0, 22], ["shoes", "OBSERVATION", 4, 9], ["similar", "OBSERVATION_MODIFIER", 27, 34], ["leopard print", "OBSERVATION", 38, 51]]], ["These observations imply that our proposed CANN can provide a good way to capture the visual coherence for the complementary items from both global and semantic-focal views.ConclusionIn this paper, we proposed a novel framework, the Content Attentive Neural Network (CANN), to address the problem of content-based complementary recommendations.", [["CANN", "DNA", 43, 47]]], ["For generating complementary item recommendations, the global and semantic contents (such as color collocations, texture compatibilities) are indispensable parts to understand the comprehensive compositional relationship among items.", [["global", "OBSERVATION_MODIFIER", 55, 61], ["semantic contents", "OBSERVATION", 66, 83]]], ["Along this line, we provided a focused study on the compositional coherence in item visual contents.", [["a focused study", "TEST", 29, 44]]], ["More specifically, we first proposed a Global Coherence Learning (GCL) module based on multi-heads attention to model the global compositional coherence.", [["a Global Coherence Learning (GCL) module", "TREATMENT", 37, 77], ["multi-heads attention", "TREATMENT", 87, 108], ["global", "OBSERVATION_MODIFIER", 122, 128], ["compositional coherence", "OBSERVATION", 129, 152]]], ["Then, we generated the content semantic-focal representations and designed a hierarchical attention module, i.e., Focal Coherence Learning (FCL), to learn the focal coherence from different semantic-focal contents.", [["focal representations", "PROBLEM", 40, 61], ["a hierarchical attention module", "TREATMENT", 75, 106], ["focal", "OBSERVATION_MODIFIER", 40, 45], ["Focal", "OBSERVATION_MODIFIER", 114, 119], ["focal", "OBSERVATION_MODIFIER", 159, 164], ["different", "OBSERVATION_MODIFIER", 180, 189], ["semantic", "OBSERVATION_MODIFIER", 190, 198], ["focal contents", "OBSERVATION", 199, 213]]], ["Next, for simulating users' decision-making process on complementary items, we optimized the CANN in a novel compositional optimization strategy.", [["CANN", "DNA", 93, 97], ["a novel compositional optimization strategy", "TREATMENT", 101, 144]]], ["Finally, we conducted extensive experiments on a real-world dataset and the experimental results clearly demonstrated the effectiveness of CANN compared with several state-of-the-art methods.ConclusionIn the future, we would like to consider multi-modal information, such as item descriptions and categories for the deep exploration of the item complementary relationships.", [["the deep exploration", "TEST", 312, 332]]], ["Moreover, we are also willing to investigate the domain knowledge about aesthetics assessment and make the recommender systems more explainable.", [["aesthetics assessment", "TEST", 72, 93]]]], "dda902a72728faf3f12e96b6765ed4beb0b57961": [["INTRODUCTIONEpithelial cells are positioned strategically to provide barriers to pathogens and other environmental agents.", [["INTRODUCTIONEpithelial cells", "ANATOMY", 0, 28], ["INTRODUCTIONEpithelial cells", "CELL", 0, 28], ["INTRODUCTIONEpithelial cells", "CELL_TYPE", 0, 28], ["INTRODUCTIONEpithelial cells", "TREATMENT", 0, 28], ["barriers to pathogens", "TREATMENT", 69, 90], ["other environmental agents", "TREATMENT", 95, 121]]], ["They are located both on the outside, e.g., in the skin surface, and on the inside, e.g., along the gastrointestinal tract (Ivanov et al., 2010) .", [["skin surface", "ANATOMY", 51, 63], ["gastrointestinal tract", "ANATOMY", 100, 122], ["skin surface", "TISSUE", 51, 63], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 100, 122], ["skin", "ANATOMY", 51, 55], ["surface", "ANATOMY_MODIFIER", 56, 63], ["gastrointestinal tract", "ANATOMY", 100, 122]]], ["The linings of blood and lymphatic vessels of circulatory system are accordingly covered by a specialized form of epithelium, the endothelium (Rodrigues and Granger, 2015) .", [["linings", "ANATOMY", 4, 11], ["blood", "ANATOMY", 15, 20], ["lymphatic vessels", "ANATOMY", 25, 42], ["circulatory system", "ANATOMY", 46, 64], ["epithelium", "ANATOMY", 114, 124], ["endothelium", "ANATOMY", 130, 141], ["linings", "TISSUE", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 25, 42], ["circulatory system", "ANATOMICAL_SYSTEM", 46, 64], ["epithelium", "TISSUE", 114, 124], ["endothelium", "TISSUE", 130, 141], ["linings", "ANATOMY_MODIFIER", 4, 11], ["blood", "ANATOMY", 15, 20], ["lymphatic vessels", "ANATOMY", 25, 42], ["circulatory system", "ANATOMY", 46, 64], ["epithelium", "ANATOMY_MODIFIER", 114, 124], ["endothelium", "ANATOMY", 130, 141]]], ["These barriers display both physical and immune characteristics, where the former are potentiated by epithelial cell-to-cell junctions that prevent passage of pathogens and large molecules, and the latter are maintained via detection of antigens and recruitment for instance of phagocytes to the site of infection, potentially resulting in inflammation and tissue damage (Figure 1 ; Condeelis and Pollard, 2006; Ivanov et al., 2010; Rodrigues and Granger, 2015) .", [["epithelial cell", "ANATOMY", 101, 116], ["cell", "ANATOMY", 120, 124], ["phagocytes", "ANATOMY", 278, 288], ["site", "ANATOMY", 296, 300], ["tissue", "ANATOMY", 357, 363], ["infection", "DISEASE", 304, 313], ["inflammation", "DISEASE", 340, 352], ["epithelial cell", "CELL", 101, 116], ["cell", "CELL", 120, 124], ["phagocytes", "CELL", 278, 288], ["tissue", "TISSUE", 357, 363], ["epithelial cell", "CELL_TYPE", 101, 116], ["antigens", "PROTEIN", 237, 245], ["phagocytes", "CELL_TYPE", 278, 288], ["epithelial cell", "PROBLEM", 101, 116], ["passage of pathogens and large molecules", "PROBLEM", 148, 188], ["antigens", "PROBLEM", 237, 245], ["phagocytes", "PROBLEM", 278, 288], ["infection", "PROBLEM", 304, 313], ["inflammation", "PROBLEM", 340, 352], ["tissue damage", "PROBLEM", 357, 370], ["epithelial cell", "OBSERVATION", 101, 116], ["cell junctions", "OBSERVATION", 120, 134], ["large", "OBSERVATION_MODIFIER", 173, 178], ["molecules", "OBSERVATION", 179, 188], ["infection", "OBSERVATION", 304, 313], ["inflammation", "OBSERVATION", 340, 352], ["tissue damage", "OBSERVATION", 357, 370]]], ["The epithelial cell barrier consists of a monolayer of cells that are constantly moving and renewed normally every 72 h in the gut.", [["epithelial cell", "ANATOMY", 4, 19], ["monolayer", "ANATOMY", 42, 51], ["cells", "ANATOMY", 55, 60], ["gut", "ANATOMY", 127, 130], ["epithelial cell barrier", "TISSUE", 4, 27], ["monolayer", "CELL", 42, 51], ["cells", "CELL", 55, 60], ["gut", "ORGANISM_SUBDIVISION", 127, 130], ["The epithelial cell barrier", "TREATMENT", 0, 27], ["a monolayer of cells", "PROBLEM", 40, 60], ["epithelial cell", "OBSERVATION", 4, 19], ["monolayer", "OBSERVATION_MODIFIER", 42, 51], ["gut", "ANATOMY", 127, 130]]], ["This is controlled by a highly sophisticated interplay between the cytoskeleton, intercellular junctions, extracellular matrix, FIGURE 1 | Epithelial barrier functions at the front line of viral infections.", [["cytoskeleton", "ANATOMY", 67, 79], ["intercellular junctions", "ANATOMY", 81, 104], ["extracellular matrix", "ANATOMY", 106, 126], ["Epithelial barrier", "ANATOMY", 139, 157], ["front line", "ANATOMY", 175, 185], ["viral infections", "DISEASE", 189, 205], ["cytoskeleton", "CELLULAR_COMPONENT", 67, 79], ["intercellular junctions", "CELLULAR_COMPONENT", 81, 104], ["extracellular matrix", "CELLULAR_COMPONENT", 106, 126], ["Epithelial barrier", "TISSUE", 139, 157], ["Epithelial barrier functions", "TREATMENT", 139, 167], ["viral infections", "PROBLEM", 189, 205], ["intercellular junctions", "ANATOMY", 81, 104], ["extracellular matrix", "ANATOMY", 106, 126], ["front line", "OBSERVATION_MODIFIER", 175, 185], ["viral infections", "OBSERVATION", 189, 205]]], ["Epithelial and endothelial cell monolayers (in pink) provide a series of host barriers to pathogens and other environmental agents.", [["Epithelial", "ANATOMY", 0, 10], ["endothelial cell monolayers", "ANATOMY", 15, 42], ["Epithelial", "CELL", 0, 10], ["endothelial cell monolayers", "CELL", 15, 42], ["Epithelial and endothelial cell monolayers", "CELL_TYPE", 0, 42], ["Epithelial and endothelial cell monolayers", "PROBLEM", 0, 42], ["host barriers", "TREATMENT", 73, 86], ["other environmental agents", "TREATMENT", 104, 130], ["endothelial cell monolayers", "OBSERVATION", 15, 42]]], ["Epithelium constantly moving, renewing, and normally undergoes a wound-healing process which is controlled by an interplay between matrix, water homeostasis (in yellow), and cytoskeleton and junctions-associated proteins (ex.", [["Epithelium", "ANATOMY", 0, 10], ["wound", "ANATOMY", 65, 70], ["matrix", "ANATOMY", 131, 137], ["cytoskeleton", "ANATOMY", 174, 186], ["junctions", "ANATOMY", 191, 200], ["Epithelium", "TISSUE", 0, 10], ["wound", "PATHOLOGICAL_FORMATION", 65, 70], ["matrix", "CELLULAR_COMPONENT", 131, 137], ["water", "SIMPLE_CHEMICAL", 139, 144], ["cytoskeleton", "CELLULAR_COMPONENT", 174, 186], ["junctions", "CELLULAR_COMPONENT", 191, 200], ["associated proteins", "PROTEIN", 201, 220], ["Epithelium", "PROBLEM", 0, 10], ["a wound-healing process", "PROBLEM", 63, 86], ["wound", "ANATOMY", 65, 70], ["healing", "OBSERVATION", 71, 78]]], ["IQGAP1 in green).", [["IQGAP1", "GENE_OR_GENE_PRODUCT", 0, 6], ["IQGAP1", "PROTEIN", 0, 6]]], ["Viruses of the Nairovirus genus (red asterisk) can overcome the first host barrier to enter the body and access underlying cells.", [["body", "ANATOMY", 96, 100], ["cells", "ANATOMY", 123, 128], ["Nairovirus genus", "ORGANISM", 15, 31], ["body", "ORGANISM_SUBDIVISION", 96, 100], ["cells", "CELL", 123, 128], ["the Nairovirus genus", "PROBLEM", 11, 31]]], ["Viruses enter host cells by endocytosis, replicates, and assembles in the perinuclear regions of the cytoplasm and leaves the epithelial cell monolayers from the basolateral side (in blue), and further utilize microtubule (light green) and actin (red), the components of host cytoskeleton during the whole life cycle.INTRODUCTIONFrontiers in Cell and Developmental Biology | www.frontiersin.org surface receptors, signal mediators and fluxes of solutes and water (Ivanov et al., 2010; Rodrigues and Granger, 2015; Friedl and Mayor, 2017) .", [["cells", "ANATOMY", 19, 24], ["perinuclear regions", "ANATOMY", 74, 93], ["cytoplasm", "ANATOMY", 101, 110], ["epithelial cell monolayers", "ANATOMY", 126, 152], ["basolateral side", "ANATOMY", 162, 178], ["microtubule", "ANATOMY", 210, 221], ["cytoskeleton", "ANATOMY", 276, 288], ["Cell", "ANATOMY", 342, 346], ["surface", "ANATOMY", 395, 402], ["host cells", "CELL", 14, 24], ["perinuclear regions", "CELLULAR_COMPONENT", 74, 93], ["cytoplasm", "ORGANISM_SUBSTANCE", 101, 110], ["epithelial cell monolayers", "CELL", 126, 152], ["basolateral side", "CELLULAR_COMPONENT", 162, 178], ["microtubule", "CELLULAR_COMPONENT", 210, 221], ["light green)", "GENE_OR_GENE_PRODUCT", 223, 235], ["actin", "GENE_OR_GENE_PRODUCT", 240, 245], ["host cytoskeleton", "CELLULAR_COMPONENT", 271, 288], ["Cell", "CELL", 342, 346], ["frontiersin.org surface receptors", "GENE_OR_GENE_PRODUCT", 379, 412], ["host cells", "CELL_TYPE", 14, 24], ["epithelial cell monolayers", "CELL_TYPE", 126, 152], ["microtubule", "PROTEIN", 210, 221], ["light green", "PROTEIN", 223, 234], ["actin", "PROTEIN", 240, 245], ["red", "PROTEIN", 247, 250], ["frontiersin.org surface receptors", "PROTEIN", 379, 412], ["signal mediators", "PROTEIN", 414, 430], ["the whole life cycle", "TREATMENT", 296, 316], ["frontiersin.org surface receptors", "TEST", 379, 412], ["host cells", "OBSERVATION", 14, 24], ["endocytosis", "OBSERVATION_MODIFIER", 28, 39], ["perinuclear", "ANATOMY_MODIFIER", 74, 85], ["cytoplasm", "ANATOMY_MODIFIER", 101, 110], ["epithelial cell monolayers", "OBSERVATION", 126, 152], ["basolateral", "ANATOMY_MODIFIER", 162, 173], ["host cytoskeleton", "OBSERVATION", 271, 288]]], ["Extensive remodeling of the cytoskeleton is regulated by the Rho family of small GTPases (Zegers and Friedl, 2014) , where the IQ-motif-containing GTPase-activating proteins IQGAP scaffolds a plethora molecules to control diverse cellular processes, including cytoskeletal dynamics, cell migration, cell proliferation and vesicle trafficking (Karlsson et al., 2012; Hedman et al., 2015) .", [["cytoskeleton", "ANATOMY", 28, 40], ["cellular", "ANATOMY", 230, 238], ["cytoskeletal", "ANATOMY", 260, 272], ["cell", "ANATOMY", 283, 287], ["cell", "ANATOMY", 299, 303], ["vesicle", "ANATOMY", 322, 329], ["cytoskeleton", "CELLULAR_COMPONENT", 28, 40], ["Rho", "GENE_OR_GENE_PRODUCT", 61, 64], ["small GTPases", "GENE_OR_GENE_PRODUCT", 75, 88], ["Zegers", "GENE_OR_GENE_PRODUCT", 90, 96], ["IQGAP", "GENE_OR_GENE_PRODUCT", 174, 179], ["cellular", "CELL", 230, 238], ["cytoskeletal", "CELLULAR_COMPONENT", 260, 272], ["cell", "CELL", 283, 287], ["cell", "CELL", 299, 303], ["vesicle", "CELLULAR_COMPONENT", 322, 329], ["Rho family", "PROTEIN", 61, 71], ["small GTPases", "PROTEIN", 75, 88], ["Zegers", "PROTEIN", 90, 96], ["Friedl", "PROTEIN", 101, 107], ["2014", "PROTEIN", 109, 113], ["IQ-motif-containing GTPase-activating proteins", "PROTEIN", 127, 173], ["IQGAP", "PROTEIN", 174, 179], ["plethora molecules", "PROTEIN", 192, 210], ["Extensive remodeling of the cytoskeleton", "PROBLEM", 0, 40], ["GTPase-activating proteins IQGAP scaffolds", "TREATMENT", 147, 189], ["a plethora molecules", "TREATMENT", 190, 210], ["diverse cellular processes", "PROBLEM", 222, 248], ["cytoskeletal dynamics", "PROBLEM", 260, 281], ["cell migration", "TREATMENT", 283, 297], ["cell proliferation", "TREATMENT", 299, 317], ["remodeling", "OBSERVATION", 10, 20], ["cytoskeleton", "OBSERVATION", 28, 40], ["small", "OBSERVATION_MODIFIER", 75, 80], ["GTPases", "OBSERVATION", 81, 88], ["diverse", "OBSERVATION_MODIFIER", 222, 229], ["cellular processes", "OBSERVATION", 230, 248], ["cytoskeletal dynamics", "OBSERVATION", 260, 281], ["cell migration", "OBSERVATION", 283, 297], ["cell proliferation", "OBSERVATION", 299, 317]]], ["We have thus provided an evidence that water fluxes through aquaporins (AQP) play a pivotal role in cell migration (Loitto et al., 2009; Karlsson et al., 2013) , besides selectively facilitating the transport of water and small uncharged solutes like glycerol both over the cell membrane (Verkman, 2005; Benga, 2012) and intracellular membranes (Molinas et al., 2016) .", [["cell", "ANATOMY", 100, 104], ["cell membrane", "ANATOMY", 274, 287], ["intracellular membranes", "ANATOMY", 321, 344], ["glycerol", "CHEMICAL", 251, 259], ["glycerol", "CHEMICAL", 251, 259], ["water", "SIMPLE_CHEMICAL", 39, 44], ["aquaporins", "GENE_OR_GENE_PRODUCT", 60, 70], ["AQP", "GENE_OR_GENE_PRODUCT", 72, 75], ["cell", "CELL", 100, 104], ["water", "SIMPLE_CHEMICAL", 212, 217], ["glycerol", "SIMPLE_CHEMICAL", 251, 259], ["cell membrane", "CELLULAR_COMPONENT", 274, 287], ["intracellular membranes", "CELLULAR_COMPONENT", 321, 344], ["aquaporins", "PROTEIN", 60, 70], ["AQP", "PROTEIN", 72, 75], ["water fluxes through aquaporins (AQP)", "TREATMENT", 39, 76], ["small uncharged solutes like glycerol", "TREATMENT", 222, 259], ["cell migration", "OBSERVATION", 100, 114], ["cell membrane", "ANATOMY", 274, 287], ["intracellular membranes", "ANATOMY", 321, 344]]], ["By such interplay with the cytoskeleton and signaling cascades, the AQP do assist directly and indirectly distinct processes, such as cell volume, signal transduction, metabolism, cell migration, and organelle physiology (Saadoun et al., 2005; Verkman, 2005; Loitto et al., 2009; Karlsson et al., 2013; Holm et al., 2016; Molinas et al., 2016) .INTRODUCTIONViruses can be inhaled or ingested as free viruses, be contained in droplets shed from an infected host, or be injected via arthropods.", [["cytoskeleton", "ANATOMY", 27, 39], ["cell", "ANATOMY", 134, 138], ["cell", "ANATOMY", 180, 184], ["organelle", "ANATOMY", 200, 209], ["cytoskeleton", "CELLULAR_COMPONENT", 27, 39], ["AQP", "GENE_OR_GENE_PRODUCT", 68, 71], ["cell", "CELL", 134, 138], ["cell", "CELL", 180, 184], ["organelle", "CELLULAR_COMPONENT", 200, 209], ["AQP", "PROTEIN", 68, 71], ["signaling cascades", "PROBLEM", 44, 62], ["cell volume", "TEST", 134, 145], ["signal transduction", "TEST", 147, 166], ["free viruses", "PROBLEM", 395, 407], ["an infected host", "TREATMENT", 444, 460], ["cell migration", "OBSERVATION", 180, 194], ["infected", "OBSERVATION", 447, 455]]], ["When they have overcome the first host barrier and enter the body, they get access to underlying permissive cells and can establish an infection (Figure 1) .INTRODUCTIONSome of these arthropod-borne viruses belong to the Nairovirus genus of the Bunyaviridae family and include pathogens that cause infectious diseases in both animals and humans.", [["body", "ANATOMY", 61, 65], ["cells", "ANATOMY", 108, 113], ["infection", "DISEASE", 135, 144], ["Bunyaviridae", "DISEASE", 245, 257], ["infectious diseases", "DISEASE", 298, 317], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["cells", "CELL", 108, 113], ["arthropod-borne viruses", "ORGANISM", 183, 206], ["Nairovirus genus", "ORGANISM", 221, 237], ["humans", "ORGANISM", 338, 344], ["permissive cells", "CELL_TYPE", 97, 113], ["humans", "SPECIES", 338, 344], ["humans", "SPECIES", 338, 344], ["the first host barrier", "TREATMENT", 24, 46], ["underlying permissive cells", "PROBLEM", 86, 113], ["an infection", "PROBLEM", 132, 144], ["these arthropod-borne viruses", "TREATMENT", 177, 206], ["pathogens", "PROBLEM", 277, 286], ["infectious diseases", "PROBLEM", 298, 317], ["body", "ANATOMY", 61, 65], ["permissive cells", "OBSERVATION", 97, 113], ["infection", "OBSERVATION", 135, 144]]], ["The most well-known among them, Crimean-Congo hemorrhagic fever virus (CCHFV) is a human high-fatality rate pathogen causing fever, hemorrhagic symptoms and gastrointestinal disorders, such as nausea, vomiting, and diarrhea (Ergonul, 2012; Bente et al., 2013) .", [["gastrointestinal", "ANATOMY", 157, 173], ["Crimean-Congo hemorrhagic fever", "DISEASE", 32, 63], ["CCHFV", "DISEASE", 71, 76], ["fever", "DISEASE", 125, 130], ["hemorrhagic symptoms", "DISEASE", 132, 152], ["gastrointestinal disorders", "DISEASE", 157, 183], ["nausea, vomiting", "DISEASE", 193, 209], ["diarrhea", "DISEASE", 215, 223], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 32, 69], ["CCHFV", "ORGANISM", 71, 76], ["human", "ORGANISM", 83, 88], ["gastrointestinal", "ORGAN", 157, 173], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 32, 69], ["human", "SPECIES", 83, 88], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 32, 69], ["CCHFV", "SPECIES", 71, 76], ["human", "SPECIES", 83, 88], ["Congo hemorrhagic fever virus", "PROBLEM", 40, 69], ["a human high-fatality rate pathogen", "PROBLEM", 81, 116], ["fever", "PROBLEM", 125, 130], ["hemorrhagic symptoms", "PROBLEM", 132, 152], ["gastrointestinal disorders", "PROBLEM", 157, 183], ["nausea", "PROBLEM", 193, 199], ["vomiting", "PROBLEM", 201, 209], ["diarrhea", "PROBLEM", 215, 223], ["hemorrhagic", "OBSERVATION_MODIFIER", 132, 143], ["gastrointestinal", "ANATOMY", 157, 173]]], ["It is an enveloped virus, with three negative-stranded RNA, designated as small, medium and large, which encode the nucleocapsid protein (N), surface glycoproteins, and a RNA-dependent polymerase, respectively (Morikawa et al., 2007) .", [["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 116, 140], ["surface glycoproteins", "GENE_OR_GENE_PRODUCT", 142, 163], ["negative-stranded RNA", "RNA", 37, 58], ["nucleocapsid protein", "PROTEIN", 116, 136], ["N", "PROTEIN", 138, 139], ["surface glycoproteins", "PROTEIN", 142, 163], ["RNA-dependent polymerase", "PROTEIN", 171, 195], ["an enveloped virus", "PROBLEM", 6, 24], ["stranded RNA", "PROBLEM", 46, 58], ["small, medium and large", "PROBLEM", 74, 97], ["the nucleocapsid protein", "TEST", 112, 136], ["surface glycoproteins", "TEST", 142, 163], ["a RNA-dependent polymerase", "TEST", 169, 195], ["enveloped", "OBSERVATION_MODIFIER", 9, 18], ["virus", "OBSERVATION", 19, 24], ["stranded RNA", "OBSERVATION_MODIFIER", 46, 58], ["small", "OBSERVATION_MODIFIER", 74, 79], ["medium", "OBSERVATION_MODIFIER", 81, 87], ["large", "OBSERVATION_MODIFIER", 92, 97], ["nucleocapsid protein", "OBSERVATION", 116, 136]]], ["The N is a multifunctional structural protein that plays a key role in the biology of RNA viruses, as it binds to the viral RNA genome and forms a ribonucleoprotein in mature virions.", [["virions", "ANATOMY", 175, 182], ["N", "PROTEIN", 4, 5], ["multifunctional structural protein", "PROTEIN", 11, 45], ["viral RNA genome", "RNA", 118, 134], ["a multifunctional structural protein", "PROBLEM", 9, 45], ["RNA viruses", "PROBLEM", 86, 97], ["a ribonucleoprotein in mature virions", "PROBLEM", 145, 182], ["RNA viruses", "OBSERVATION", 86, 97], ["viral RNA genome", "OBSERVATION", 118, 134], ["mature virions", "OBSERVATION", 168, 182]]], ["It also interacts with host cell proteins to facilitate the virus life cycle (Wulan et al., 2015) , and localizes in the perinuclear region (Andersson et al., 2004) and in the nuclei of infected cells (Cohen et al., 2011) .", [["cell", "ANATOMY", 28, 32], ["perinuclear region", "ANATOMY", 121, 139], ["nuclei", "ANATOMY", 176, 182], ["cells", "ANATOMY", 195, 200], ["host cell", "CELL", 23, 32], ["perinuclear region", "CELLULAR_COMPONENT", 121, 139], ["nuclei", "CELLULAR_COMPONENT", 176, 182], ["cells", "CELL", 195, 200], ["host cell proteins", "PROTEIN", 23, 41], ["infected cells", "CELL_TYPE", 186, 200], ["host cell proteins", "TREATMENT", 23, 41], ["host cell", "OBSERVATION", 23, 32], ["perinuclear", "ANATOMY_MODIFIER", 121, 132], ["nuclei", "ANATOMY", 176, 182], ["infected cells", "OBSERVATION", 186, 200]]], ["Since N is present in high amounts early during infection, it is useful for clinical diagnosis (Dowall et al., 2012b) .INTRODUCTIONWorking with the extremely pathogenic CCHFV requires a high biosafety level 4 laboratory, which has limited the research on specific virus-host interactions and development of antiviral therapies (Whitehouse, 2004; Dowall et al., 2015) .", [["infection", "DISEASE", 48, 57], ["CCHFV", "DISEASE", 169, 174], ["CCHFV", "ORGANISM", 169, 174], ["CCHFV", "SPECIES", 169, 174], ["infection", "PROBLEM", 48, 57], ["specific virus", "TREATMENT", 255, 269], ["antiviral therapies", "TREATMENT", 307, 326], ["high amounts", "OBSERVATION_MODIFIER", 22, 34], ["infection", "OBSERVATION", 48, 57], ["CCHFV", "OBSERVATION", 169, 174], ["antiviral therapies", "OBSERVATION", 307, 326]]], ["The related Hazara virus is classified as a hazard group 2 pathogen and it is not associated with serious diseases in humans, although infections of interferon-knockout mice with either Hazara virus or CCHFV result in similar disease progression (Dowall et al., 2012a) .", [["infections", "DISEASE", 135, 145], ["CCHFV", "DISEASE", 202, 207], ["Hazara virus", "ORGANISM", 12, 24], ["humans", "ORGANISM", 118, 124], ["interferon", "GENE_OR_GENE_PRODUCT", 149, 159], ["mice", "ORGANISM", 169, 173], ["Hazara virus", "ORGANISM", 186, 198], ["CCHFV", "ORGANISM", 202, 207], ["interferon", "PROTEIN", 149, 159], ["humans", "SPECIES", 118, 124], ["mice", "SPECIES", 169, 173], ["Hazara virus", "SPECIES", 12, 24], ["humans", "SPECIES", 118, 124], ["mice", "SPECIES", 169, 173], ["Hazara virus", "SPECIES", 186, 198], ["CCHFV", "SPECIES", 202, 207], ["The related Hazara virus", "PROBLEM", 0, 24], ["a hazard group 2 pathogen", "PROBLEM", 42, 67], ["serious diseases in humans", "PROBLEM", 98, 124], ["interferon", "TREATMENT", 149, 159], ["knockout mice", "TREATMENT", 160, 173], ["Hazara virus", "PROBLEM", 186, 198], ["CCHFV", "PROBLEM", 202, 207], ["similar disease progression", "PROBLEM", 218, 245], ["Hazara virus", "OBSERVATION", 12, 24], ["not associated with", "UNCERTAINTY", 78, 97], ["serious", "OBSERVATION_MODIFIER", 98, 105], ["diseases", "OBSERVATION", 106, 114]]], ["Hazara virus and CCHFV exhibit about 70 and 86% nucleotide and amino acid sequence similarity, respectively (Honig et al., 2004) , correlating well with virus serology and pathogenicity.", [["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 48, 58], ["amino acid", "CHEMICAL", 63, 73], ["Hazara virus", "ORGANISM", 0, 12], ["CCHFV", "ORGANISM", 17, 22], ["amino acid", "AMINO_ACID", 63, 73], ["Hazara virus", "SPECIES", 0, 12], ["CCHFV", "SPECIES", 17, 22], ["Hazara virus", "PROBLEM", 0, 12], ["CCHFV", "PROBLEM", 17, 22], ["amino acid sequence similarity", "TEST", 63, 93], ["virus serology", "TEST", 153, 167], ["pathogenicity", "PROBLEM", 172, 185]]], ["Hazara virus has thus been used as a valid alternative experimental model for a CCHFV infection (Ergonul, 2006; Dowall et al., 2012a) , enabling the investigation of Nairovirus and the development of antivirals without having access to a biosafety level 4 laboratory.INTRODUCTIONOur previous investigations have shown that Hazara virus and CCHFV enter host cells by endocytosis, replicate and assemble in the perinuclear regions of the cytoplasm and leave the epithelial cell from the basolateral side (Figure 1 ; Connolly-Andersen et al., 2007) , and further utilize microtubule and actin, the key components of host cytoskeleton during the whole life cycle (Simon et al., 2009) .", [["cells", "ANATOMY", 357, 362], ["perinuclear regions", "ANATOMY", 409, 428], ["cytoplasm", "ANATOMY", 436, 445], ["epithelial cell", "ANATOMY", 460, 475], ["basolateral side", "ANATOMY", 485, 501], ["microtubule", "ANATOMY", 568, 579], ["cytoskeleton", "ANATOMY", 618, 630], ["CCHFV infection", "DISEASE", 80, 95], ["Nairovirus", "CHEMICAL", 166, 176], ["Hazara virus", "ORGANISM", 0, 12], ["CCHFV", "ORGANISM", 80, 85], ["Hazara virus", "ORGANISM", 323, 335], ["CCHFV", "ORGANISM", 340, 345], ["host cells", "CELL", 352, 362], ["cytoplasm", "ORGANISM_SUBSTANCE", 436, 445], ["epithelial cell", "CELL", 460, 475], ["microtubule", "CELLULAR_COMPONENT", 568, 579], ["actin", "GENE_OR_GENE_PRODUCT", 584, 589], ["cytoskeleton", "CELLULAR_COMPONENT", 618, 630], ["epithelial cell", "CELL_TYPE", 460, 475], ["microtubule", "PROTEIN", 568, 579], ["actin", "PROTEIN", 584, 589], ["Hazara virus", "SPECIES", 0, 12], ["CCHFV", "SPECIES", 80, 85], ["Hazara virus", "SPECIES", 323, 335], ["CCHFV", "SPECIES", 340, 345], ["Hazara virus", "PROBLEM", 0, 12], ["a CCHFV infection", "PROBLEM", 78, 95], ["Nairovirus", "TREATMENT", 166, 176], ["antivirals", "TREATMENT", 200, 210], ["previous investigations", "TEST", 283, 306], ["Hazara virus", "PROBLEM", 323, 335], ["the whole life cycle", "TREATMENT", 638, 658], ["CCHFV", "OBSERVATION", 80, 85], ["host cells", "OBSERVATION", 352, 362], ["epithelial cell", "OBSERVATION", 460, 475], ["basolateral", "ANATOMY_MODIFIER", 485, 496], ["host cytoskeleton", "OBSERVATION", 613, 630]]], ["Here, the cytoskeleton regulator and scaffold protein IQ-motif-containing GTPaseactivating protein 1 (IQGAP1) seems essential for virus virulence and completion of invasion, replication and egress in some viruses including Ebola, Moloney murine leukemia and swine fever (Hedman et al., 2015) .", [["cytoskeleton", "ANATOMY", 10, 22], ["leukemia", "ANATOMY", 245, 253], ["Ebola", "DISEASE", 223, 228], ["Moloney murine leukemia", "DISEASE", 230, 253], ["swine fever", "DISEASE", 258, 269], ["cytoskeleton", "CELLULAR_COMPONENT", 10, 22], ["IQ-motif-containing GTPaseactivating protein 1", "GENE_OR_GENE_PRODUCT", 54, 100], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 102, 108], ["Ebola", "ORGANISM", 223, 228], ["Moloney murine leukemia", "ORGANISM", 230, 253], ["swine", "ORGANISM", 258, 263], ["cytoskeleton regulator", "PROTEIN", 10, 32], ["scaffold protein IQ-motif-containing GTPaseactivating protein 1", "PROTEIN", 37, 100], ["IQGAP1", "PROTEIN", 102, 108], ["Ebola", "SPECIES", 223, 228], ["murine", "SPECIES", 238, 244], ["swine fever", "SPECIES", 258, 269], ["the cytoskeleton regulator", "TEST", 6, 32], ["scaffold protein IQ", "TEST", 37, 56], ["motif-containing GTPaseactivating protein", "TREATMENT", 57, 98], ["IQGAP1", "TEST", 102, 108], ["virus virulence", "PROBLEM", 130, 145], ["invasion", "PROBLEM", 164, 172], ["replication", "TREATMENT", 174, 185], ["some viruses", "PROBLEM", 200, 212], ["Ebola", "PROBLEM", 223, 228], ["Moloney murine leukemia", "PROBLEM", 230, 253], ["swine fever", "PROBLEM", 258, 269], ["essential for", "UNCERTAINTY", 116, 129], ["invasion", "OBSERVATION", 164, 172], ["Moloney murine leukemia", "OBSERVATION", 230, 253]]], ["We also showed recently that aquaporin 6 (AQP6), a water transporter and cytoskeleton interactor linked to an intracellular anion channel and involved in vesicle trafficking and sorting (Beitz et al., 2006; Nozaki et al., 2008) , seems to have a protective role against Hazara virus infections (Molinas et al., 2016) (Figure 1 , shown in yellow).INTRODUCTIONThe aim of this study was to assess in greater detail consequences of virus-host cell interactions, focusing on whether and how the virus infection impacts wound-healing, cytoskeleton organization, IQGAP1 and AQP6 characteristics, and the cellular protein interactome associated specifically with the viral N. To achieve this, we used a Caco-2 epithelial cell migration assay, immunofluorescence imaging, immunoprecipitation, proteomics and bioinformatics.", [["cytoskeleton", "ANATOMY", 73, 85], ["intracellular", "ANATOMY", 110, 123], ["vesicle", "ANATOMY", 154, 161], ["cell", "ANATOMY", 439, 443], ["wound", "ANATOMY", 514, 519], ["cytoskeleton", "ANATOMY", 529, 541], ["cellular", "ANATOMY", 597, 605], ["Caco-2 epithelial cell", "ANATOMY", 695, 717], ["Hazara virus infections", "DISEASE", 270, 293], ["infection", "DISEASE", 496, 505], ["aquaporin 6", "GENE_OR_GENE_PRODUCT", 29, 40], ["AQP6", "GENE_OR_GENE_PRODUCT", 42, 46], ["cytoskeleton", "CELLULAR_COMPONENT", 73, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["vesicle", "CELLULAR_COMPONENT", 154, 161], ["Hazara virus", "ORGANISM", 270, 282], ["host cell", "CELL", 434, 443], ["wound", "PATHOLOGICAL_FORMATION", 514, 519], ["cytoskeleton", "CELLULAR_COMPONENT", 529, 541], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 556, 562], ["AQP6", "GENE_OR_GENE_PRODUCT", 567, 571], ["cellular", "CELL", 597, 605], ["Caco-2 epithelial cell", "CELL", 695, 717], ["aquaporin 6", "PROTEIN", 29, 40], ["AQP6", "PROTEIN", 42, 46], ["water transporter", "PROTEIN", 51, 68], ["cytoskeleton interactor", "PROTEIN", 73, 96], ["intracellular anion channel", "PROTEIN", 110, 137], ["IQGAP1", "PROTEIN", 556, 562], ["AQP6", "PROTEIN", 567, 571], ["Hazara virus", "SPECIES", 270, 282], ["a water transporter", "TREATMENT", 49, 68], ["an intracellular anion channel", "TREATMENT", 107, 137], ["Hazara virus infections", "PROBLEM", 270, 293], ["this study", "TEST", 369, 379], ["virus", "PROBLEM", 428, 433], ["the virus infection impacts wound", "PROBLEM", 486, 519], ["IQGAP1 and AQP6 characteristics", "PROBLEM", 556, 587], ["the cellular protein interactome", "PROBLEM", 593, 625], ["a Caco-2 epithelial cell migration", "TREATMENT", 693, 727], ["immunofluorescence imaging", "TEST", 735, 761], ["immunoprecipitation", "TEST", 763, 782], ["proteomics", "TEST", 784, 794], ["anion channel", "OBSERVATION", 124, 137], ["host cell interactions", "OBSERVATION", 434, 456], ["healing", "OBSERVATION_MODIFIER", 520, 527], ["protein interactome", "OBSERVATION", 606, 625], ["epithelial cell migration", "OBSERVATION", 702, 727]]], ["We found here that the virus load and infection duration strongly impacted on epithelial cell structure, signaling and the repair potential.Epithelial Cell CultureHuman epithelial colorectal adenocarcinoma Caco-2 cells (86010202 obtained directly from Sigma Aldrich, St. Louis, MO) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 \u00b5g/ml streptomycin, 1% non-essential amino acids and 2 mM L-glutamine (Life Technologies, Grand Island, NY) at 37 \u2022 C in 5% CO 2 .", [["epithelial cell", "ANATOMY", 78, 93], ["Epithelial Cell CultureHuman epithelial colorectal adenocarcinoma Caco-2 cells", "ANATOMY", 140, 218], ["fetal calf serum", "ANATOMY", 377, 393], ["infection", "DISEASE", 38, 47], ["penicillin", "CHEMICAL", 404, 414], ["streptomycin", "CHEMICAL", 426, 438], ["amino acids", "CHEMICAL", 457, 468], ["L-glutamine", "CHEMICAL", 478, 489], ["penicillin", "CHEMICAL", 404, 414], ["streptomycin", "CHEMICAL", 426, 438], ["amino acids", "CHEMICAL", 457, 468], ["L-glutamine", "CHEMICAL", 478, 489], ["CO 2", "CHEMICAL", 544, 548], ["epithelial cell", "CELL", 78, 93], ["Epithelial Cell CultureHuman epithelial colorectal adenocarcinoma Caco-2 cells", "CELL", 140, 218], ["86010202", "CELL", 220, 228], ["Sigma Aldrich", "ORGANISM", 252, 265], ["St. Louis", "ORGANISM", 267, 276], ["MO", "ORGANISM", 278, 280], ["calf", "ORGANISM", 383, 387], ["serum", "ORGANISM_SUBSTANCE", 388, 393], ["penicillin", "SIMPLE_CHEMICAL", 404, 414], ["streptomycin", "SIMPLE_CHEMICAL", 426, 438], ["amino acids", "AMINO_ACID", 457, 468], ["L-glutamine", "SIMPLE_CHEMICAL", 478, 489], ["Epithelial Cell CultureHuman epithelial colorectal adenocarcinoma Caco-2 cells", "CELL_LINE", 140, 218], ["calf", "SPECIES", 383, 387], ["the virus load", "PROBLEM", 19, 33], ["infection duration", "PROBLEM", 38, 56], ["epithelial cell structure", "PROBLEM", 78, 103], ["the repair", "TREATMENT", 119, 129], ["Epithelial Cell", "TEST", 140, 155], ["epithelial colorectal adenocarcinoma", "PROBLEM", 169, 205], ["fetal calf serum", "TEST", 377, 393], ["penicillin", "TREATMENT", 404, 414], ["streptomycin", "TREATMENT", 426, 438], ["non-essential amino acids", "TREATMENT", 443, 468], ["2 mM L-glutamine (Life Technologies", "TREATMENT", 473, 508], ["infection", "OBSERVATION", 38, 47], ["epithelial cell structure", "OBSERVATION", 78, 103], ["repair", "OBSERVATION_MODIFIER", 123, 129], ["potential", "OBSERVATION_MODIFIER", 130, 139], ["epithelial", "ANATOMY_MODIFIER", 169, 179], ["colorectal adenocarcinoma", "OBSERVATION", 180, 205], ["calf", "ANATOMY", 383, 387]]], ["This was done for 7-10 days to allow the cells to become mature, differentiated and establish polarized epithelial monolayers.Virus StockThe stock for Hazara virus strain JC280 (GenBank accession number M86624.1) was produced in human adrenal cortex adeno carcinoma SW-13 cells (CCL-105 obtained directly from American Type Culture Collection, Manassas, VA) maintained in Leibovitz's L15 medium (L15) supplemented with 10% heat-inactivated fetal bovine serum, 25 mM HEPES, 100 U/ml penicillin, 100 \u00b5g/ml streptomycin (Life Technologies) at 37 \u2022 C in 5% CO 2 .Virus InfectionCaco-2 cell monolayers were starved in serum-free DMEM overnight and then infected with Hazara virus at three multiplicities of infection (MOI) 0.02, 1 and 2 for 1 h at 37 \u2022 C in 5% CO 2 in DMEM supplemented with 2% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 \u00b5g/ml streptomycin.", [["cells", "ANATOMY", 41, 46], ["epithelial monolayers", "ANATOMY", 104, 125], ["adrenal cortex adeno carcinoma SW-13 cells", "ANATOMY", 235, 277], ["CCL-105", "ANATOMY", 279, 286], ["fetal bovine serum", "ANATOMY", 440, 458], ["InfectionCaco-2 cell monolayers", "ANATOMY", 565, 596], ["serum", "ANATOMY", 613, 618], ["fetal bovine serum", "ANATOMY", 807, 825], ["JC280", "CHEMICAL", 171, 176], ["CCL-105", "CHEMICAL", 279, 286], ["penicillin", "CHEMICAL", 482, 492], ["streptomycin", "CHEMICAL", 504, 516], ["infection", "DISEASE", 702, 711], ["penicillin", "CHEMICAL", 836, 846], ["streptomycin", "CHEMICAL", 858, 870], ["HEPES", "CHEMICAL", 466, 471], ["penicillin", "CHEMICAL", 482, 492], ["streptomycin", "CHEMICAL", 504, 516], ["CO 2", "CHEMICAL", 756, 760], ["penicillin", "CHEMICAL", 836, 846], ["streptomycin", "CHEMICAL", 858, 870], ["cells", "CELL", 41, 46], ["epithelial monolayers", "CELL", 104, 125], ["Virus", "ORGANISM", 126, 131], ["Hazara virus strain", "ORGANISM", 151, 170], ["JC280", "ORGANISM", 171, 176], ["human", "ORGANISM", 229, 234], ["adrenal cortex adeno carcinoma SW-13 cells", "CELL", 235, 277], ["CCL-105", "CELL", 279, 286], ["bovine", "ORGANISM", 446, 452], ["serum", "ORGANISM_SUBSTANCE", 453, 458], ["penicillin", "SIMPLE_CHEMICAL", 482, 492], ["streptomycin", "SIMPLE_CHEMICAL", 504, 516], ["InfectionCaco-2 cell monolayers", "CELL", 565, 596], ["serum", "ORGANISM_SUBSTANCE", 613, 618], ["Hazara virus", "ORGANISM", 662, 674], ["bovine", "ORGANISM", 813, 819], ["serum", "ORGANISM_SUBSTANCE", 820, 825], ["penicillin", "SIMPLE_CHEMICAL", 836, 846], ["streptomycin", "SIMPLE_CHEMICAL", 858, 870], ["polarized epithelial monolayers", "CELL_TYPE", 94, 125], ["human adrenal cortex adeno carcinoma SW-13 cells", "CELL_LINE", 229, 277], ["CCL-105", "CELL_LINE", 279, 286], ["Virus InfectionCaco-2 cell monolayers", "CELL_LINE", 559, 596], ["Hazara virus", "SPECIES", 151, 163], ["human", "SPECIES", 229, 234], ["bovine", "SPECIES", 446, 452], ["bovine", "SPECIES", 813, 819], ["Hazara virus strain JC280", "SPECIES", 151, 176], ["human", "SPECIES", 229, 234], ["bovine", "SPECIES", 446, 452], ["Hazara virus", "SPECIES", 662, 674], ["bovine", "SPECIES", 813, 819], ["the cells", "PROBLEM", 37, 46], ["Virus StockThe stock", "TREATMENT", 126, 146], ["Hazara virus strain", "PROBLEM", 151, 170], ["human adrenal cortex adeno carcinoma", "PROBLEM", 229, 265], ["CCL", "TEST", 279, 282], ["Culture Collection", "TEST", 324, 342], ["Manassas", "TEST", 344, 352], ["Leibovitz", "TEST", 372, 381], ["fetal bovine serum", "TEST", 440, 458], ["HEPES", "TEST", 466, 471], ["penicillin", "TREATMENT", 482, 492], ["streptomycin", "TREATMENT", 504, 516], ["C", "TEST", 545, 546], ["CO", "TEST", 553, 555], ["Virus InfectionCaco", "TEST", 559, 578], ["cell monolayers", "TEST", 581, 596], ["serum", "TEST", 613, 618], ["Hazara virus", "PROBLEM", 662, 674], ["infection", "PROBLEM", 702, 711], ["2% heat", "TREATMENT", 787, 794], ["fetal bovine serum", "TREATMENT", 807, 825], ["penicillin", "TREATMENT", 836, 846], ["streptomycin", "TREATMENT", 858, 870], ["polarized epithelial monolayers", "OBSERVATION", 94, 125], ["adrenal cortex", "ANATOMY", 235, 249], ["adeno carcinoma", "OBSERVATION", 250, 265], ["infection", "OBSERVATION", 702, 711]]], ["After 1-h infection, cells were rinsed and maintained for 24 or 48 h post infection (hpi) at 37 \u2022 C in 5% CO 2 in serum free DMEM supplemented with 100 U/ml penicillin, 100 \u00b5g/ml streptomycin.", [["cells", "ANATOMY", 21, 26], ["serum", "ANATOMY", 114, 119], ["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 74, 83], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 179, 191], ["CO 2", "CHEMICAL", 106, 110], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 179, 191], ["cells", "CELL", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["penicillin", "SIMPLE_CHEMICAL", 157, 167], ["streptomycin", "SIMPLE_CHEMICAL", 179, 191], ["1-h infection", "PROBLEM", 6, 19], ["infection", "PROBLEM", 74, 83], ["serum free DMEM", "TREATMENT", 114, 129], ["penicillin", "TREATMENT", 157, 167], ["streptomycin", "TREATMENT", 179, 191], ["infection", "OBSERVATION", 10, 19], ["infection", "OBSERVATION", 74, 83]]], ["Then, the cells were processed for migration assay, imaging, and proteomics.Migration AssayCaco-2 cells were seeded in \u00b5-dishes with inserts (Ibidi GmbM, Martinsried, Germany) and cultured for 10-12 days to allow the cells to become 100% confluent, mature, differentiated and polarized epithelial monolayers.", [["cells", "ANATOMY", 10, 15], ["AssayCaco-2 cells", "ANATOMY", 86, 103], ["\u00b5-dishes", "ANATOMY", 119, 127], ["cells", "ANATOMY", 217, 222], ["epithelial monolayers", "ANATOMY", 286, 307], ["cells", "CELL", 10, 15], ["AssayCaco-2 cells", "CELL", 86, 103], ["cells", "CELL", 217, 222], ["epithelial monolayers", "CELL", 286, 307], ["AssayCaco-2 cells", "CELL_LINE", 86, 103], ["polarized epithelial monolayers", "CELL_TYPE", 276, 307], ["migration assay", "TEST", 35, 50], ["imaging", "TEST", 52, 59], ["proteomics", "TEST", 65, 75], ["Migration", "TREATMENT", 76, 85], ["AssayCaco", "TEST", 86, 95], ["the cells", "TEST", 213, 222], ["polarized epithelial monolayers", "OBSERVATION", 276, 307]]], ["Then, cells were serum-starved overnight and either non-infected or infected with Hazara virus at MOI 0.02 and 2.0 for 1 h at 37 \u2022 C in 5% CO 2 in serum free DMEM supplemented with 100 U/ml penicillin, 100 \u00b5g/ml streptomycin.", [["cells", "ANATOMY", 6, 11], ["serum", "ANATOMY", 17, 22], ["serum", "ANATOMY", 147, 152], ["penicillin", "CHEMICAL", 190, 200], ["streptomycin", "CHEMICAL", 212, 224], ["CO 2", "CHEMICAL", 139, 143], ["penicillin", "CHEMICAL", 190, 200], ["streptomycin", "CHEMICAL", 212, 224], ["cells", "CELL", 6, 11], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["Hazara virus", "ORGANISM", 82, 94], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["penicillin", "SIMPLE_CHEMICAL", 190, 200], ["streptomycin", "SIMPLE_CHEMICAL", 212, 224], ["Hazara virus", "SPECIES", 82, 94], ["serum", "TEST", 17, 22], ["Hazara virus", "PROBLEM", 82, 94], ["MOI", "TEST", 98, 101], ["serum free DMEM", "TREATMENT", 147, 162], ["penicillin", "TREATMENT", 190, 200], ["streptomycin", "TREATMENT", 212, 224]]], ["After 1-h infection, the cells were rinsed and maintained for 0, 24, or 48 hpi (Figure 2 ).", [["cells", "ANATOMY", 25, 30], ["infection", "DISEASE", 10, 19], ["cells", "CELL", 25, 30], ["1-h infection", "PROBLEM", 6, 19], ["infection", "OBSERVATION", 10, 19]]], ["At 0, 24 and 48 hpi, the insert was removed to get two cell patches with a 500 \u00b1 50 \u00b5m cell-free gap in between allowing the cells to migrate and heal the wound.", [["cell", "ANATOMY", 55, 59], ["cell", "ANATOMY", 87, 91], ["cells", "ANATOMY", 125, 130], ["wound", "ANATOMY", 155, 160], ["cell", "CELL", 55, 59], ["cell", "CELL", 87, 91], ["cells", "CELL", 125, 130], ["wound", "PATHOLOGICAL_FORMATION", 155, 160], ["the insert", "TREATMENT", 21, 31], ["two cell patches", "TREATMENT", 51, 67], ["a 500 \u00b1 50 \u00b5m cell-free gap", "TREATMENT", 73, 100], ["the cells", "TREATMENT", 121, 130], ["heal the wound", "PROBLEM", 146, 160], ["wound", "OBSERVATION", 155, 160]]], ["For each dish, the images of cells migrating into the gap area were taken at indicated time points (Figure 2 ) using the benchtop microscope JuLI (NanoEnTek Inc., Seoul, South Korea); between imaging, cells were returned to the incubator.", [["cells", "ANATOMY", 29, 34], ["gap area", "ANATOMY", 54, 62], ["cells", "ANATOMY", 201, 206], ["cells", "CELL", 29, 34], ["cells", "CELL", 201, 206], ["the images of cells", "TEST", 15, 34], ["the benchtop microscope", "TEST", 117, 140], ["imaging", "TEST", 192, 199]]], ["Migration activity was calculated by measuring the relative area of the image occupied by cells on each dish at each time point with the Image J software (NIH, Bethesda, MD https://imagej. nih.gov/ij/).", [["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["Migration activity", "PROBLEM", 0, 18], ["ij", "TREATMENT", 197, 199], ["ij", "ANATOMY", 197, 199]]], ["At least 3 independent experiments were performed on separate days on different cell passages.Determination of Virus with Immunofluorescence MicroscopyDetermination of the concentration of Hazara virus in the virus stock and in the monolayers after migration experiments was performed as described previously (Andersson et al., 2004) .", [["cell", "ANATOMY", 80, 84], ["monolayers", "ANATOMY", 232, 242], ["cell", "CELL", 80, 84], ["Virus", "ORGANISM", 111, 116], ["Hazara virus", "ORGANISM", 189, 201], ["monolayers", "CELL", 232, 242], ["Hazara virus", "SPECIES", 189, 201], ["different cell passages", "TREATMENT", 70, 93], ["Virus", "PROBLEM", 111, 116], ["Immunofluorescence", "TEST", 122, 140], ["Hazara virus", "PROBLEM", 189, 201], ["the virus stock", "TREATMENT", 205, 220], ["cell passages", "OBSERVATION", 80, 93], ["Virus", "OBSERVATION", 111, 116], ["virus stock", "OBSERVATION", 209, 220]]], ["Briefly, SW-13, or Caco-2 cells in 96-well plates were infected with 10-fold serial dilutions of the virus stock for 1 h at 37 \u2022 C in 5% CO 2 .", [["SW-13", "ANATOMY", 9, 14], ["Caco-2 cells", "ANATOMY", 19, 31], ["CO 2", "CHEMICAL", 137, 141], ["SW-13", "CELL", 9, 14], ["Caco-2 cells", "CELL", 19, 31], ["SW-13", "CELL_LINE", 9, 14], ["Caco-2 cells", "CELL_LINE", 19, 31], ["SW", "TEST", 9, 11], ["Caco-2 cells", "TREATMENT", 19, 31], ["the virus stock", "TREATMENT", 97, 112]]], ["Alternatively, Caco-2 monolayers in \u00b5-dishes after closure of the wound were used.", [["Caco-2 monolayers", "ANATOMY", 15, 32], ["wound", "ANATOMY", 66, 71], ["Caco-2 monolayers", "CELL", 15, 32], ["wound", "PATHOLOGICAL_FORMATION", 66, 71], ["Caco-2 monolayers", "CELL_LINE", 15, 32], ["Caco-2 monolayers", "TREATMENT", 15, 32], ["closure", "TREATMENT", 51, 58], ["the wound", "PROBLEM", 62, 71], ["wound", "OBSERVATION", 66, 71]]], ["Cells were fixed, permeabilized, labeled with polyclonal rabbit anti-CCHFV/Hazara N antibodies (Andersson et al., 2004) and Alexa Fluor 488-conjugated polyclonal goat anti-rabbit antibodies (A11008, Life Technologies).", [["Cells", "ANATOMY", 0, 5], ["Alexa Fluor 488", "CHEMICAL", 124, 139], ["Cells", "CELL", 0, 5], ["rabbit", "ORGANISM", 57, 63], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 124, 139], ["anti-CCHFV", "PROTEIN", 64, 74], ["Hazara N antibodies", "PROTEIN", 75, 94], ["Alexa Fluor 488-conjugated polyclonal goat anti-rabbit antibodies", "PROTEIN", 124, 189], ["A11008", "PROTEIN", 191, 197], ["rabbit", "SPECIES", 57, 63], ["goat", "SPECIES", 162, 166], ["anti-rabbit", "SPECIES", 167, 178], ["rabbit", "SPECIES", 57, 63], ["Alexa Fluor 488", "SPECIES", 124, 139], ["goat", "SPECIES", 162, 166], ["polyclonal rabbit anti-CCHFV", "TREATMENT", 46, 74], ["Hazara N antibodies", "TREATMENT", 75, 94], ["Alexa Fluor", "TEST", 124, 135], ["conjugated polyclonal goat anti-rabbit antibodies", "TREATMENT", 140, 189]]], ["Fluorescent foci were counted in an Axiovert 35 fluorescence microscope (Carl Zeiss, Jena, Germany) equipped with a ProgResC camera (Jenoptik, Jena, Germany).", [["foci", "ANATOMY", 12, 16], ["foci", "CELL", 12, 16], ["Fluorescent foci", "PROBLEM", 0, 16], ["foci", "OBSERVATION", 12, 16]]], ["This allowed the determination of the infectious virus titer in focus forming units per ml (FFU/ml).Laser Scanning Confocal ImagingCaco-2 monolayers grown on glass coverslips (thickness 0.17 \u00b1 0.01, 13 mm-diameter; Karl Hecht Assistent, Sondheim, Germany) were washed with PBS pH 7.3 and pretreated with 0.2% Triton X-100 (Sigma Aldrich) in PBS for 2 min on ice.Laser Scanning Confocal ImagingThe samples were then fixed in 2.5% paraformaldehyde (Sigma Aldrich) in PBS pH 7.3 for 20 min at room temperature.", [["samples", "ANATOMY", 397, 404], ["Triton X-100", "CHEMICAL", 309, 321], ["Triton X-100", "CHEMICAL", 309, 321], ["paraformaldehyde", "CHEMICAL", 429, 445], ["ImagingCaco-2 monolayers", "CELL", 124, 148], ["Triton X-100", "SIMPLE_CHEMICAL", 309, 321], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 323, 336], ["paraformaldehyde", "SIMPLE_CHEMICAL", 429, 445], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 447, 460], ["the infectious virus titer", "PROBLEM", 34, 60], ["Laser Scanning", "TEST", 100, 114], ["ImagingCaco", "TEST", 124, 135], ["glass coverslips", "TEST", 158, 174], ["thickness", "TEST", 176, 185], ["PBS pH", "TEST", 273, 279], ["Laser Scanning", "TEST", 362, 376], ["Confocal Imaging", "TEST", 377, 393], ["The samples", "TEST", 393, 404], ["PBS pH", "TEST", 465, 471], ["infectious", "OBSERVATION_MODIFIER", 38, 48]]], ["The pre-treatment with 0.2% Triton X-100 was important for a clear labeling of proteins.", [["Triton X-100", "CHEMICAL", 28, 40], ["Triton X-100", "CHEMICAL", 28, 40], ["Triton X-100", "SIMPLE_CHEMICAL", 28, 40], ["The pre-treatment", "TREATMENT", 0, 17], ["0.2% Triton", "TREATMENT", 23, 34]]], ["After washing with PBS cells were further permeabilized in 0.05% Triton X-100 in PBS for 5 min and washed again.", [["cells", "ANATOMY", 23, 28], ["Triton X-100", "CHEMICAL", 65, 77], ["cells", "CELL", 23, 28], ["Triton X-100", "SIMPLE_CHEMICAL", 65, 77], ["PBS cells", "CELL_LINE", 19, 28], ["PBS cells", "TREATMENT", 19, 28]]], ["Non-specific background staining was blocked for 10 min in PBS containing 1% BSA and 10 mM glycine.", [["BSA", "CHEMICAL", 77, 80], ["glycine", "CHEMICAL", 91, 98], ["glycine", "CHEMICAL", 91, 98], ["BSA", "SIMPLE_CHEMICAL", 77, 80], ["glycine", "SIMPLE_CHEMICAL", 91, 98], ["Non-specific background staining", "PROBLEM", 0, 32], ["PBS", "TEST", 59, 62], ["staining", "OBSERVATION", 24, 32]]], ["The washing was repeated, and polyclonal rabbit or monoclonal mouse antibodies against CCHFV/Hazara N (Andersson et al., 2004) , monoclonal mouse antibodies against IQGAP1 or polyclonal rabbit antibodies against AQP6 (05-504, AB3073, Millipore, Temecula, CA), diluted 1:200 in blocking buffer were then applied for 1 h at 37 \u2022 C in a moist chamber.", [["rabbit", "ORGANISM", 41, 47], ["mouse", "ORGANISM", 62, 67], ["CCHFV", "ORGANISM", 87, 92], ["mouse", "ORGANISM", 140, 145], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 165, 171], ["polyclonal rabbit", "PROTEIN", 30, 47], ["monoclonal mouse antibodies", "PROTEIN", 51, 78], ["monoclonal mouse antibodies", "PROTEIN", 129, 156], ["IQGAP1", "PROTEIN", 165, 171], ["polyclonal rabbit antibodies", "PROTEIN", 175, 203], ["AQP6", "PROTEIN", 212, 216], ["rabbit", "SPECIES", 41, 47], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 140, 145], ["rabbit", "SPECIES", 186, 192], ["rabbit", "SPECIES", 41, 47], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 140, 145], ["rabbit", "SPECIES", 186, 192], ["The washing", "TEST", 0, 11], ["polyclonal rabbit", "TREATMENT", 30, 47], ["monoclonal mouse antibodies", "TEST", 51, 78], ["CCHFV", "PROBLEM", 87, 92], ["monoclonal mouse antibodies", "TEST", 129, 156], ["IQGAP1", "TEST", 165, 171], ["polyclonal rabbit antibodies", "TEST", 175, 203], ["AQP6", "TEST", 212, 216], ["AB", "TEST", 226, 228], ["Millipore", "TEST", 234, 243], ["blocking buffer", "TREATMENT", 277, 292], ["moist chamber", "OBSERVATION", 334, 347]]], ["After washing, Alexa 568-conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-mouse antibodies (A11036, A11029, Life Technologies) diluted 1:400 were added and incubated for 1 h at 37 \u2022 C in a moist dark chamber.", [["Alexa 568", "CHEMICAL", 15, 24], ["Alexa 568", "CHEMICAL", 15, 24], ["Alexa 488", "CHEMICAL", 57, 66], ["Alexa 568", "SIMPLE_CHEMICAL", 15, 24], ["goat", "ORGANISM", 36, 40], ["anti-rabbit", "SIMPLE_CHEMICAL", 41, 52], ["Alexa 488", "SIMPLE_CHEMICAL", 57, 66], ["goat", "ORGANISM", 78, 82], ["Alexa 568-conjugated goat anti-rabbit", "PROTEIN", 15, 52], ["Alexa 488-conjugated goat anti-mouse antibodies", "PROTEIN", 57, 104], ["goat", "SPECIES", 36, 40], ["anti-rabbit", "SPECIES", 41, 52], ["goat", "SPECIES", 78, 82], ["anti-mouse", "SPECIES", 83, 93], ["goat", "SPECIES", 36, 40], ["anti-rabbit", "SPECIES", 41, 52], ["goat", "SPECIES", 78, 82], ["Alexa", "TEST", 15, 20], ["Alexa", "TEST", 57, 62], ["conjugated goat anti-mouse antibodies", "TREATMENT", 67, 104], ["Life Technologies", "TREATMENT", 122, 139]]], ["To detect F-actin, cells were stained with Alexa 488-conjugated phalloidin (A12379, Life Technologies).", [["cells", "ANATOMY", 19, 24], ["Alexa 488", "CHEMICAL", 43, 52], ["phalloidin", "CHEMICAL", 64, 74], ["F-actin", "GENE_OR_GENE_PRODUCT", 10, 17], ["cells", "CELL", 19, 24], ["Alexa 488", "SIMPLE_CHEMICAL", 43, 52], ["conjugated phalloidin", "SIMPLE_CHEMICAL", 53, 74], ["A12379", "SIMPLE_CHEMICAL", 76, 82], ["F-actin", "PROTEIN", 10, 17], ["Alexa 488", "PROTEIN", 43, 52], ["Alexa", "TEST", 43, 48]]], ["Nuclei were labeled with DAPI (Life Technologies), according to the manufacturer's instructions.", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 25, 29], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["DAPI", "SIMPLE_CHEMICAL", 25, 29], ["DAPI (Life Technologies", "TREATMENT", 25, 48]]], ["The specimens were examined through 63x oil immersion objectives with NA 1.40 in a fluorescence microscope Zeiss Axio Observer Z1 with the confocal system Zeiss LSM700 and Zeiss ZEN software (Carl Zeiss, Jena, Germany).", [["specimens", "ANATOMY", 4, 13], ["NA", "CHEMICAL", 70, 72], ["specimens", "CELL", 4, 13], ["The specimens", "TEST", 0, 13], ["NA", "TEST", 70, 72]]], ["Fluorescence intensity in juxta-membrane regions in the cell monolayers and intensity profile plots across the cell monolayers were measures and quantified using the ImageJ software (NIH).", [["juxta-membrane", "ANATOMY", 26, 40], ["cell monolayers", "ANATOMY", 56, 71], ["cell monolayers", "ANATOMY", 111, 126], ["cell monolayers", "CELL", 56, 71], ["cell monolayers", "CELL", 111, 126], ["juxta-membrane regions", "DNA", 26, 48], ["Fluorescence intensity", "TEST", 0, 22], ["the cell monolayers", "TEST", 52, 71], ["intensity profile plots", "TEST", 76, 99], ["intensity", "OBSERVATION_MODIFIER", 13, 22], ["membrane", "ANATOMY_MODIFIER", 32, 40], ["regions", "ANATOMY_MODIFIER", 41, 48], ["cell monolayers", "OBSERVATION", 56, 71], ["cell monolayers", "OBSERVATION", 111, 126]]], ["At least 3 independent experiments were done on separate days on different cell passages.Total Cell Lysates, SDS-PAGE and ImmunoblottingCaco-2 monolayers grown on 6-well plates or flasks were washed with PBS, pH 7.6 and lysed with ice-cold RIPA buffer (150 mM NaCl, 1% deoxycholic acid sodium salt, 1% N-40, 0.1% SDS, 10 mM EDTA pH 8.0, 10 mM Tris pH 7.4 dissolved in PBS) supplemented with 25U nuclease (Thermo Scientific, Rockford, IL), 1 mM phenyl-methyl-sulfonyl-fluoride, 1 mM Na 3 VaO 4 , 25 mM NaF (Sigma Aldrich), protein inhibitors Complete (Roche Diagnostics, Mannheim, Germany).", [["cell", "ANATOMY", 75, 79], ["Cell Lysates", "ANATOMY", 95, 107], ["Caco-2 monolayers", "ANATOMY", 136, 153], ["NaCl", "CHEMICAL", 260, 264], ["deoxycholic acid sodium salt", "CHEMICAL", 269, 297], ["N-40", "CHEMICAL", 302, 306], ["phenyl-methyl-sulfonyl-fluoride", "CHEMICAL", 444, 475], ["Na", "CHEMICAL", 482, 484], ["NaF", "CHEMICAL", 501, 504], ["NaCl", "CHEMICAL", 260, 264], ["deoxycholic acid sodium salt", "CHEMICAL", 269, 297], ["EDTA", "CHEMICAL", 324, 328], ["phenyl-methyl-sulfonyl-fluoride", "CHEMICAL", 444, 475], ["Na 3 VaO 4", "CHEMICAL", 482, 492], ["NaF", "CHEMICAL", 501, 504], ["cell", "CELL", 75, 79], ["Cell Lysates", "CELL", 95, 107], ["Caco-2 monolayers", "CELL", 136, 153], ["deoxycholic acid sodium salt", "SIMPLE_CHEMICAL", 269, 297], ["N-40", "SIMPLE_CHEMICAL", 302, 306], ["phenyl-methyl-sulfonyl-fluoride", "SIMPLE_CHEMICAL", 444, 475], ["Na 3 VaO 4", "SIMPLE_CHEMICAL", 482, 492], ["NaF", "SIMPLE_CHEMICAL", 501, 504], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 506, 519], ["Caco-2 monolayers", "CELL_LINE", 136, 153], ["different cell passages", "TREATMENT", 65, 88], ["Total Cell Lysates", "TEST", 89, 107], ["SDS", "TEST", 109, 112], ["Immunoblotting", "TEST", 122, 136], ["Caco", "TEST", 136, 140], ["PBS", "TEST", 204, 207], ["pH", "TEST", 209, 211], ["ice", "TEST", 231, 234], ["cold RIPA buffer", "TREATMENT", 235, 251], ["NaCl", "TEST", 260, 264], ["deoxycholic acid sodium", "TEST", 269, 292], ["salt", "TEST", 293, 297], ["SDS", "TEST", 313, 316], ["EDTA", "TEST", 324, 328], ["pH", "TEST", 329, 331], ["mM Tris pH", "TEST", 340, 350], ["25U nuclease", "TREATMENT", 391, 403], ["1 mM phenyl", "TREATMENT", 439, 450], ["methyl", "TREATMENT", 451, 457], ["sulfonyl-fluoride", "TREATMENT", 458, 475], ["VaO", "TEST", 487, 490], ["protein inhibitors", "TREATMENT", 522, 540], ["cell passages", "OBSERVATION", 75, 88], ["Cell Lysates", "OBSERVATION", 95, 107]]], ["Cell suspensions were homogenized through a 21-gauge needle and centrifuged at 18,000 g for 30 min at 4 \u2022 C, and the supernatants were collected.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 117, 129], ["Cell", "CELL", 0, 4], ["Cell suspensions", "TREATMENT", 0, 16], ["a 21-gauge needle", "TREATMENT", 42, 59]]], ["The protein concentration in cell lysates was measured with the Bio-Rad D C protein assay (Bio-Rad Laboratories, Hercules, CA).", [["cell lysates", "ANATOMY", 29, 41], ["cell lysates", "ORGANISM_SUBSTANCE", 29, 41], ["Rad D C", "GENE_OR_GENE_PRODUCT", 68, 75], ["Rad D C protein", "PROTEIN", 68, 83], ["The protein concentration in cell lysates", "TEST", 0, 41], ["the Bio", "TEST", 60, 67], ["protein assay", "TEST", 76, 89], ["Bio-Rad Laboratories", "TEST", 91, 111], ["cell lysates", "OBSERVATION", 29, 41]]], ["The samples were further diluted in Laemmli sample buffer at equal protein concentrations, heated for 5 min at 95 \u2022 C and then subjected to electrophoresis.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["Laemmli sample buffer", "TREATMENT", 36, 57], ["electrophoresis", "TEST", 140, 155]]], ["They were loaded on 8-16% SDS-polyacrylamide gels (Lonza, Rockland, ME), and after separation, proteins were electrophoretically transferred to a PVDF Immobilon-FL membrane (Millipore); the quality of the transfer was controlled by Ponceau S staining (Sigma Aldrich).", [["SDS", "CHEMICAL", 26, 29], ["polyacrylamide", "CHEMICAL", 30, 44], ["PVDF", "CHEMICAL", 146, 150], ["Ponceau S", "CHEMICAL", 232, 241], ["SDS-polyacrylamide gels", "SIMPLE_CHEMICAL", 26, 49], ["polyacrylamide gels", "TREATMENT", 30, 49], ["a PVDF Immobilon-FL membrane (Millipore", "TREATMENT", 144, 183]]], ["Non-specific binding was blocked by 1-h incubation in 5% non-fat milk in PBS, pH 7.6 containing 0.18% Tween 20 at room temperature.", [["fat milk", "ANATOMY", 61, 69], ["Tween 20", "CHEMICAL", 102, 110], ["Tween 20", "CHEMICAL", 102, 110], ["fat milk", "ORGANISM_SUBSTANCE", 61, 69], ["Non-specific binding", "PROBLEM", 0, 20], ["pH", "TEST", 78, 80]]], ["The membranes were then incubated with antibodies against CCHFV/Hazara N (Andersson et al., 2004) , IQGAP1, AQP6, and GAPDH (05-504, AB3073, MAB374 FIGURE 2 | Schematic layout of wound healing assays.", [["membranes", "ANATOMY", 4, 13], ["wound", "ANATOMY", 179, 184], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 100, 106], ["AQP6", "GENE_OR_GENE_PRODUCT", 108, 112], ["GAPDH", "GENE_OR_GENE_PRODUCT", 118, 123], ["wound", "PATHOLOGICAL_FORMATION", 179, 184], ["antibodies", "PROTEIN", 39, 49], ["IQGAP1", "PROTEIN", 100, 106], ["antibodies", "TEST", 39, 49], ["CCHFV", "TEST", 58, 63], ["IQGAP1", "TEST", 100, 106], ["AQP6", "TEST", 108, 112], ["GAPDH", "TEST", 118, 123], ["wound healing assays", "PROBLEM", 179, 199], ["wound", "ANATOMY", 179, 184], ["healing", "OBSERVATION", 185, 192]]], ["Caco-2 cells were cultured in \u00b5-dishes with Ibidi inserts until monolayers were confluent.", [["Caco-2 cells", "ANATOMY", 0, 12], ["monolayers", "ANATOMY", 64, 74], ["Caco-2 cells", "CELL", 0, 12], ["monolayers", "CELL", 64, 74], ["Caco-2 cells", "CELL_LINE", 0, 12], ["Caco-2 cells", "TREATMENT", 0, 12], ["Ibidi inserts", "TREATMENT", 44, 57], ["confluent", "OBSERVATION_MODIFIER", 80, 89]]], ["Cells were then either untreated (Control) or infected with Hazara virus at different MOI for 1 h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Hazara virus", "ORGANISM", 60, 72], ["Hazara virus", "SPECIES", 60, 72], ["Hazara virus", "PROBLEM", 60, 72]]], ["After 1-h infection, the cells were rinsed and maintained for 0, 24, or 48 hpi as shown in (A-C) respectively.", [["cells", "ANATOMY", 25, 30], ["infection", "DISEASE", 10, 19], ["cells", "CELL", 25, 30], ["A-C", "SIMPLE_CHEMICAL", 92, 95], ["1-h infection", "PROBLEM", 6, 19], ["the cells", "TEST", 21, 30], ["infection", "OBSERVATION", 10, 19]]], ["To create a wound, the inserts were removed at 0, 24, or 48 hpi, and the cells were thereafter allowed to migrate.", [["wound", "ANATOMY", 12, 17], ["cells", "ANATOMY", 73, 78], ["wound", "PATHOLOGICAL_FORMATION", 12, 17], ["cells", "CELL", 73, 78], ["a wound", "PROBLEM", 10, 17], ["wound", "OBSERVATION", 12, 17]]], ["To monitor the wound healing, the images of cells migrating into the gap area of the wound were taken at indicated time using the benchtop microscope.Total Cell Lysates, SDS-PAGE and ImmunoblottingMillipore) diluted 1:1000 in blocking buffer overnight at 4 \u2022 C. After washing, they were treated for 1 h at room temperature with IRDye 800CW goat anti-rabbit or IRDye 680CW goat antimouse antibodies (926-32,211, 926-68,070, LI-COR Biosciences, Cambridge, UK), diluted 1:10,000 and washed extensively.", [["wound", "ANATOMY", 15, 20], ["cells", "ANATOMY", 44, 49], ["wound", "ANATOMY", 85, 90], ["Cell", "ANATOMY", 156, 160], ["IRDye", "CHEMICAL", 328, 333], ["wound", "PATHOLOGICAL_FORMATION", 15, 20], ["cells", "CELL", 44, 49], ["wound", "PATHOLOGICAL_FORMATION", 85, 90], ["Cell", "CELL", 156, 160], ["IRDye", "SIMPLE_CHEMICAL", 328, 333], ["IRDye", "GENE_OR_GENE_PRODUCT", 360, 365], ["IRDye 800CW goat anti-rabbit", "PROTEIN", 328, 356], ["IRDye 680CW goat antimouse antibodies", "PROTEIN", 360, 397], ["goat", "SPECIES", 340, 344], ["anti-rabbit", "SPECIES", 345, 356], ["goat", "SPECIES", 372, 376], ["goat", "SPECIES", 340, 344], ["goat", "SPECIES", 372, 376], ["the wound healing", "PROBLEM", 11, 28], ["the images of cells", "TEST", 30, 49], ["the wound", "PROBLEM", 81, 90], ["the benchtop microscope", "TEST", 126, 149], ["Total Cell Lysates", "TREATMENT", 150, 168], ["SDS", "TREATMENT", 170, 173], ["ImmunoblottingMillipore)", "TREATMENT", 183, 207], ["IRDye 800CW goat anti-rabbit", "TREATMENT", 328, 356], ["IRDye", "TREATMENT", 360, 365], ["antimouse antibodies", "TEST", 377, 397], ["wound", "ANATOMY", 15, 20], ["healing", "OBSERVATION", 21, 28], ["wound", "ANATOMY", 85, 90]]], ["The signals were detected and the density ratio was quantified using the Odyssey CLx and the Image Studio software (LI-COR).", [["the density ratio", "TEST", 30, 47], ["the Odyssey CLx", "TEST", 69, 84]]], ["At least 4 independent experiments were performed on separate days on different cell passages.ImmunoprecipitationTotal-cell lysates were pre-cleared for 30 min at 4 \u2022 C with of protein G-Sepharose \"4 fast flow\" (GE Healthcare, Uppsala, Sweden) and centrifuged before the protein concentration in the supernatants was determined with the Bio-Rad D C protein assay.", [["cell", "ANATOMY", 80, 84], ["Total-cell lysates", "ANATOMY", 113, 131], ["supernatants", "ANATOMY", 300, 312], ["cell", "CELL", 80, 84], ["cell lysates", "ORGANISM_SUBSTANCE", 119, 131], ["Rad D C", "GENE_OR_GENE_PRODUCT", 341, 348], ["different cell passages", "TREATMENT", 70, 93], ["Immunoprecipitation", "TEST", 94, 113], ["Total-cell lysates", "TREATMENT", 113, 131], ["protein G", "TEST", 177, 186], ["the protein concentration", "TREATMENT", 267, 292], ["the Bio-Rad D C protein assay", "TEST", 333, 362], ["cell passages", "OBSERVATION", 80, 93]]], ["Samples with equal protein concentrations were then precipitated overnight at 4 \u2022 C with 1 \u00b5g antibodies against CCHFV/Hazara N (Andersson et al., 2004) .", [["Samples", "ANATOMY", 0, 7], ["CCHFV", "ORGANISM", 113, 118], ["Samples", "TEST", 0, 7], ["equal protein concentrations", "PROBLEM", 13, 41]]], ["Immune complexes were captured at 4 \u2022 C overnight using protein G-Sepharose \"4 fast flow.\"", [["Immune complexes", "PROTEIN", 0, 16], ["protein G", "PROTEIN", 56, 65], ["Immune complexes", "PROBLEM", 0, 16], ["protein G-Sepharose", "TREATMENT", 56, 75]]], ["The beads were collected by pulse centrifugation and washed three times with cold PBS, pH 7.6.", [["beads", "ANATOMY", 4, 9], ["The beads", "TREATMENT", 0, 9], ["pulse centrifugation", "TREATMENT", 28, 48], ["cold PBS", "TEST", 77, 85], ["pH", "TEST", 87, 89], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["Sepharose beads were re-suspended in Laemmli sample buffer, boiled for 5 min at 95 \u2022 C, collected by centrifugation, and the supernatant was subjected to 8-16% SDS-PAGE (Lonza).", [["supernatant", "ANATOMY", 125, 136], ["Sepharose beads", "TREATMENT", 0, 15]]], ["The gels were stained with Coomassie Blue (Thermo Scientific).", [["Coomassie Blue", "CHEMICAL", 27, 41], ["Coomassie Blue", "SIMPLE_CHEMICAL", 27, 41]]], ["At least 4 independent experiments were done on separate days on different cell passages.Protein Identification by In-Gel Digestion and LC-MS/MSCoomassie Blue-stained protein bands were excised, reduced, alkylated and digested as described previously (Shevchenko et al., 2006) ; generated peptides were dried, dissolved in 0.1% (v/v) formic acid in water and analyzed by LC-MS/MS. Peptides were separated by reverse phase chromatography on a 20 mm \u00d7 100 \u00b5m C18 pre column followed by a 100 mm \u00d7 75 \u00b5m C18 column with particle size 5 \u00b5m (NanoSeparatoons, Nieuwkoop, Netherlands) at a flow rate 300 nL/min.", [["cell", "ANATOMY", 75, 79], ["formic acid", "CHEMICAL", 334, 345], ["formic acid", "CHEMICAL", 334, 345], ["cell", "CELL", 75, 79], ["v/v) formic acid", "SIMPLE_CHEMICAL", 329, 345], ["water", "SIMPLE_CHEMICAL", 349, 354], ["different cell passages", "TREATMENT", 65, 88], ["Protein Identification", "TEST", 89, 111], ["Gel Digestion", "TEST", 118, 131], ["LC", "TEST", 136, 138], ["MS", "TEST", 139, 141], ["MSCoomassie", "PROBLEM", 142, 153], ["Blue-stained protein bands", "PROBLEM", 154, 180], ["formic acid in water", "TREATMENT", 334, 354], ["MS", "PROBLEM", 377, 379], ["Peptides", "TEST", 381, 389], ["reverse phase chromatography", "TEST", 408, 436], ["a 100 mm \u00d7 75 \u00b5m C18 column", "TREATMENT", 484, 511], ["a flow rate", "TEST", 581, 592], ["cell passages", "OBSERVATION", 75, 88], ["LC", "ANATOMY", 136, 138]]], ["EASY-nLC II (Thermo Scientific) by gradient of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) as follows: 0-30% B in 50 min, 30-100% B in 40 min.", [["EASY-nLC II", "CHEMICAL", 0, 11], ["formic acid", "CHEMICAL", 52, 63], ["formic acid", "CHEMICAL", 86, 97], ["acetonitrile", "CHEMICAL", 101, 113], ["formic acid", "CHEMICAL", 52, 63], ["formic acid", "CHEMICAL", 86, 97], ["acetonitrile", "CHEMICAL", 101, 113], ["formic acid", "SIMPLE_CHEMICAL", 52, 63], ["water", "SIMPLE_CHEMICAL", 67, 72], ["formic acid", "SIMPLE_CHEMICAL", 86, 97], ["acetonitrile", "SIMPLE_CHEMICAL", 101, 113], ["formic acid in water (A)", "TREATMENT", 52, 76], ["0.1% formic acid in acetonitrile", "TREATMENT", 81, 113]]], ["Automated online analyses were performed with a LTQ Orbitrap Velos Pro hybrid mass spectrometer (Thermo Scientific) with a nano-electrospray source.Database SearchingRaw files were analyzed using Sequest HT in Proteome Discoverer (Thermo Fisher Scientific, San Jose, CS version 1.4.0.288) against a Uniprot Human database available at UniProtKB website (http://www.uniprot. org/taxonomy/9606) with the following parameters: trypsin as a digestion enzyme; maximum number of missed cleavages 2; fragment ion mass tolerance 0.60 Da; parent ion mass tolerance 10.0 ppm; fixed modification, carbamidomethylation of cysteine; variable modifications, methionine oxidation.Data Evaluation and Label-Free QuantificationIdentified proteins were validated using SCAFFOLD (Version 4.4.8; Proteome Software Inc., Portland, OR).", [["HT", "DISEASE", 204, 206], ["cysteine", "CHEMICAL", 610, 618], ["methionine", "CHEMICAL", 644, 654], ["cysteine", "CHEMICAL", 610, 618], ["methionine", "CHEMICAL", 644, 654], ["Human", "ORGANISM", 307, 312], ["trypsin", "GENE_OR_GENE_PRODUCT", 424, 431], ["cysteine", "AMINO_ACID", 610, 618], ["methionine", "SIMPLE_CHEMICAL", 644, 654], ["Raw files", "DNA", 166, 175], ["trypsin", "PROTEIN", 424, 431], ["digestion enzyme", "PROTEIN", 437, 453], ["Human", "SPECIES", 307, 312], ["Automated online analyses", "TEST", 0, 25], ["a LTQ Orbitrap Velos Pro hybrid mass spectrometer", "TREATMENT", 46, 95], ["a nano-electrospray source", "TREATMENT", 121, 147], ["trypsin", "TREATMENT", 424, 431], ["a digestion enzyme", "TEST", 435, 453], ["missed cleavages", "PROBLEM", 473, 489], ["fragment ion mass tolerance", "PROBLEM", 493, 520], ["parent ion mass tolerance", "TREATMENT", 530, 555], ["fixed modification", "TREATMENT", 566, 584], ["carbamidomethylation of cysteine", "TREATMENT", 586, 618], ["variable modifications", "TREATMENT", 620, 642], ["methionine oxidation", "TREATMENT", 644, 664], ["Data Evaluation", "TEST", 665, 680], ["SCAFFOLD (Version", "TREATMENT", 751, 768]]], ["Identifications were based on a minimum of 2 unique peptides, minimum 80% peptide identification probability (using the Scaffold Local FDR algorithm), and minimum 95% protein identification probability (using the Protein Prophet algorithm (Nesvizhskii et al., 2003) , resulting in a 0.0% decoy FDR).", [["the Protein Prophet algorithm", "TREATMENT", 209, 238]]], ["Proteins that contained similar peptides and which could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.", [["MS/MS analysis", "TEST", 88, 102], ["similar peptides", "OBSERVATION", 24, 40], ["could not be", "UNCERTAINTY", 51, 63]]], ["The label-free quantitative analysis of peptides was performed by spectral counting analysis using normalized spectral abundance factor (NSAF) calculated for each protein to normalize run-to-run variations (Zybailov et al., 2006) , and quantitative differences were statistically analyzed by two-tailed Student's t-test.", [["spectral abundance factor", "PROTEIN", 110, 135], ["NSAF", "PROTEIN", 137, 141], ["spectral counting analysis", "TEST", 66, 92], ["each protein", "TEST", 158, 170]]], ["Identified proteins were categorized according to gene ontology terms.Bioinformatics AnalysisThe interactions between the identified cellular proteins were analyzed by the Search Tool for the Retrieval of Interacting Genes and Proteins, STRING 10.0 (http://www.ncbi.nlm. nih.gov/pubmed/18940858) using medium confidence score 0.4 and all active interaction sources (Franceschini et al., 2013) .", [["cellular", "ANATOMY", 133, 141], ["cellular", "CELL", 133, 141], ["cellular proteins", "PROTEIN", 133, 150], ["Interacting Genes", "DNA", 205, 222], ["Bioinformatics Analysis", "TEST", 70, 93], ["medium confidence score", "TEST", 302, 325], ["active", "OBSERVATION_MODIFIER", 338, 344]]], ["STRING and NCBI GO annotations by SCAFFOLD analyses were used to group proteins into functional classes.Statistical AnalysisData in the graphs are presented as mean \u00b1 SE.", [["SE", "DISEASE", 167, 169], ["SCAFFOLD analyses", "TEST", 34, 51]]], ["Statistical analyses are based on two-tailed Student's t-test.", [["Statistical analyses", "TEST", 0, 20], ["Student's t-test", "TEST", 45, 61]]], ["The experiments on migration and imaging were done at least 3 times on separate days on different cell passages.", [["cell", "ANATOMY", 98, 102], ["cell", "CELL", 98, 102], ["imaging", "TEST", 33, 40], ["different cell passages", "TREATMENT", 88, 111], ["cell passages", "OBSERVATION", 98, 111]]], ["The experiments for immunoblotting, immunoprecipitation, proteome and interactome were repeated 4 times on separate days.", [["immunoblotting", "TREATMENT", 20, 34], ["immunoprecipitation", "TEST", 36, 55], ["proteome", "TEST", 57, 65]]], ["Data evaluation and quantification for proteome and interactome experiments are described above.Hazara Virus Modulates Migration and Wound-Healing Capacity of Epithelial Cell MonolayersWhen viruses target and enter epithelial cells (Connolly-Andersen et al., 2007) , a further perturbation of cell properties and wound-healing process may occur.", [["Epithelial Cell Monolayers", "ANATOMY", 159, 185], ["epithelial cells", "ANATOMY", 215, 231], ["cell", "ANATOMY", 293, 297], ["wound", "ANATOMY", 313, 318], ["Epithelial Cell Monolayers", "CELL", 159, 185], ["epithelial cells", "CELL", 215, 231], ["cell", "CELL", 293, 297], ["wound", "PATHOLOGICAL_FORMATION", 313, 318], ["epithelial cells", "CELL_TYPE", 215, 231], ["Data evaluation", "TEST", 0, 15], ["quantification", "TEST", 20, 34], ["proteome and interactome experiments", "PROBLEM", 39, 75], ["Hazara Virus Modulates Migration", "PROBLEM", 96, 128], ["Wound", "PROBLEM", 133, 138], ["Epithelial Cell Monolayers", "PROBLEM", 159, 185], ["a further perturbation of cell properties", "TREATMENT", 267, 308], ["wound-healing process", "PROBLEM", 313, 334], ["interactome experiments", "OBSERVATION", 52, 75], ["Migration", "OBSERVATION_MODIFIER", 119, 128], ["Wound", "ANATOMY", 133, 138], ["Healing Capacity", "OBSERVATION_MODIFIER", 139, 155], ["Epithelial Cell Monolayers", "OBSERVATION", 159, 185], ["epithelial cells", "OBSERVATION", 215, 231], ["cell properties", "OBSERVATION", 293, 308], ["wound", "OBSERVATION", 313, 318], ["healing", "OBSERVATION", 319, 326]]], ["Therefore, we investigated whether an infection with Hazara virus affected epithelial cell migration, using Ibidi wound-healing chambers (Figure 2) .", [["epithelial cell", "ANATOMY", 75, 90], ["wound", "ANATOMY", 114, 119], ["infection", "DISEASE", 38, 47], ["Hazara virus", "ORGANISM", 53, 65], ["epithelial cell", "CELL", 75, 90], ["wound", "PATHOLOGICAL_FORMATION", 114, 119], ["Hazara virus", "SPECIES", 53, 65], ["an infection", "PROBLEM", 35, 47], ["Hazara virus affected epithelial cell migration", "PROBLEM", 53, 100], ["Ibidi wound", "TREATMENT", 108, 119], ["infection", "OBSERVATION", 38, 47], ["epithelial cell migration", "OBSERVATION", 75, 100], ["healing", "OBSERVATION_MODIFIER", 120, 127], ["chambers", "OBSERVATION_MODIFIER", 128, 136]]], ["The mature differentiated and polarized epithelial monolayers were infected with Hazara virus at two multiplicities of infection (MOI), 0.02 and 2.0 for 1 h, and wounds were then created at 0, i.e., immediately, or at 24 and 48 h post infection (hpi), allowing the cells to migrate and heal the wound for up to 52 h (Figures 2, 3) .", [["epithelial monolayers", "ANATOMY", 40, 61], ["wounds", "ANATOMY", 162, 168], ["cells", "ANATOMY", 265, 270], ["wound", "ANATOMY", 295, 300], ["infection", "DISEASE", 119, 128], ["infection", "DISEASE", 235, 244], ["epithelial monolayers", "CELL", 40, 61], ["Hazara virus", "ORGANISM", 81, 93], ["wounds", "PATHOLOGICAL_FORMATION", 162, 168], ["cells", "CELL", 265, 270], ["wound", "PATHOLOGICAL_FORMATION", 295, 300], ["polarized epithelial monolayers", "CELL_LINE", 30, 61], ["Hazara virus", "SPECIES", 81, 93], ["polarized epithelial monolayers", "PROBLEM", 30, 61], ["Hazara virus", "PROBLEM", 81, 93], ["infection", "PROBLEM", 119, 128], ["wounds", "PROBLEM", 162, 168], ["infection", "PROBLEM", 235, 244], ["the cells", "TREATMENT", 261, 270], ["heal the wound", "PROBLEM", 286, 300], ["mature", "OBSERVATION_MODIFIER", 4, 10], ["differentiated", "OBSERVATION_MODIFIER", 11, 25], ["polarized", "OBSERVATION_MODIFIER", 30, 39], ["epithelial monolayers", "OBSERVATION", 40, 61], ["multiplicities", "OBSERVATION_MODIFIER", 101, 115], ["infection", "OBSERVATION", 119, 128], ["wounds", "ANATOMY", 162, 168], ["infection", "OBSERVATION", 235, 244], ["wound", "ANATOMY", 295, 300]]], ["For the 0-hpi wound, we observed that the migration rates of virus-infected cells were similar to the control, i.e., untreated cells ( Figure 3A) .", [["wound", "ANATOMY", 14, 19], ["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 127, 132], ["wound", "PATHOLOGICAL_FORMATION", 14, 19], ["cells", "CELL", 76, 81], ["cells", "CELL", 127, 132], ["virus-infected cells", "CELL_TYPE", 61, 81], ["untreated cells", "CELL_TYPE", 117, 132], ["the 0-hpi wound", "PROBLEM", 4, 19], ["the migration rates of virus", "PROBLEM", 38, 66], ["infected cells", "PROBLEM", 67, 81], ["infected cells", "OBSERVATION", 67, 81]]], ["For the wounds created at 24 hpi, the rates of healing for cells infected with Hazara virus at MOI 2.0 were significantly suppressed at 30-52 h.", [["wounds", "ANATOMY", 8, 14], ["cells", "ANATOMY", 59, 64], ["wounds", "PATHOLOGICAL_FORMATION", 8, 14], ["cells", "CELL", 59, 64], ["Hazara virus", "ORGANISM", 79, 91], ["Hazara virus", "SPECIES", 79, 91], ["Hazara virus", "SPECIES", 79, 91], ["the wounds", "PROBLEM", 4, 14], ["cells infected", "PROBLEM", 59, 73], ["Hazara virus", "PROBLEM", 79, 91], ["wounds", "OBSERVATION", 8, 14], ["healing", "OBSERVATION_MODIFIER", 47, 54]]], ["By contrast, the MOI 0.02 resulted in significantly promoted migration between 24 and 30 h after creation of wounds, as compared to the untreated control ( Figure 3B ).", [["wounds", "ANATOMY", 109, 115], ["wounds", "PATHOLOGICAL_FORMATION", 109, 115], ["wounds", "PROBLEM", 109, 115], ["migration", "OBSERVATION_MODIFIER", 61, 70], ["wounds", "OBSERVATION", 109, 115]]], ["When the wounds were created at 48 hpi, the migration rates of cells infected with Hazara virus at both MOI 0.02 and 2.0 and 0.02 were significantly inhibited around 24-28 h ( Figure 3C) ; the control non-infected wounds were closed at that time and for this reason the study was not continued longer.", [["wounds", "ANATOMY", 9, 15], ["cells", "ANATOMY", 63, 68], ["wounds", "ANATOMY", 214, 220], ["wounds", "PATHOLOGICAL_FORMATION", 9, 15], ["cells", "CELL", 63, 68], ["Hazara virus", "ORGANISM", 83, 95], ["wounds", "PATHOLOGICAL_FORMATION", 214, 220], ["Hazara virus", "SPECIES", 83, 95], ["the wounds", "PROBLEM", 5, 15], ["Hazara virus", "PROBLEM", 83, 95], ["the control non-infected wounds", "PROBLEM", 189, 220], ["the study", "TEST", 266, 275], ["wounds", "ANATOMY", 9, 15], ["non-infected", "OBSERVATION_MODIFIER", 201, 213], ["wounds", "OBSERVATION", 214, 220]]], ["In this set of experiments, no signs of Caco-2 cell death or apoptosis were seen.Hazara Virus Modulates Migration and Wound-Healing Capacity of Epithelial Cell MonolayersTo conclude, Hazara virus can perturb the normal physiology of epithelial cell monolayers and modulate their migration and wound-healing capacity in a dose-and time-dependent manner.Hazara Virus Infection Reduces the Expression of Cytoskeleton-Associated ProteinsIndividual and collective cell migration and restitution of epithelium are driven by actin cytoskeleton reorganization, primarily by dynamic polymerization of monomeric G-actin to F-actin (Ivanov et al., 2010; Friedl and Mayor, 2017) and are regulated by an ensemble of interacting proteins, including IQGAP1 (Karlsson et al., 2012; Hedman et al., 2015) and water fluxes via AQP (Karlsson et al., 2013) , which facilitate Factin formation.", [["Caco-2 cell", "ANATOMY", 40, 51], ["Epithelial Cell Monolayers", "ANATOMY", 144, 170], ["epithelial cell monolayers", "ANATOMY", 233, 259], ["wound", "ANATOMY", 293, 298], ["cell", "ANATOMY", 459, 463], ["epithelium", "ANATOMY", 493, 503], ["cytoskeleton", "ANATOMY", 524, 536], ["death", "DISEASE", 52, 57], ["Caco-2 cell", "CELL", 40, 51], ["Epithelial Cell Monolayers", "CELL", 144, 170], ["Hazara virus", "ORGANISM", 183, 195], ["epithelial cell monolayers", "CELL", 233, 259], ["wound", "PATHOLOGICAL_FORMATION", 293, 298], ["Hazara Virus", "ORGANISM", 352, 364], ["Cytoskeleton-Associated Proteins", "GENE_OR_GENE_PRODUCT", 401, 433], ["cell", "CELL", 459, 463], ["epithelium", "TISSUE", 493, 503], ["actin", "GENE_OR_GENE_PRODUCT", 518, 523], ["cytoskeleton", "CELLULAR_COMPONENT", 524, 536], ["G-actin", "GENE_OR_GENE_PRODUCT", 602, 609], ["F-actin", "CELLULAR_COMPONENT", 613, 620], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 735, 741], ["AQP", "GENE_OR_GENE_PRODUCT", 808, 811], ["Factin", "GENE_OR_GENE_PRODUCT", 855, 861], ["epithelial cell monolayers", "CELL_TYPE", 233, 259], ["Cytoskeleton-Associated Proteins", "PROTEIN", 401, 433], ["actin", "PROTEIN", 518, 523], ["monomeric G-actin", "PROTEIN", 592, 609], ["F-actin", "PROTEIN", 613, 620], ["interacting proteins", "PROTEIN", 703, 723], ["IQGAP1", "PROTEIN", 735, 741], ["Factin", "PROTEIN", 855, 861], ["Hazara virus", "SPECIES", 183, 195], ["Caco-2 cell death", "PROBLEM", 40, 57], ["apoptosis", "PROBLEM", 61, 70], ["Hazara Virus Modulates Migration", "PROBLEM", 81, 113], ["Wound", "PROBLEM", 118, 123], ["Epithelial Cell Monolayers", "PROBLEM", 144, 170], ["Hazara virus", "PROBLEM", 183, 195], ["epithelial cell monolayers", "PROBLEM", 233, 259], ["their migration", "PROBLEM", 273, 288], ["wound", "PROBLEM", 293, 298], ["healing capacity", "PROBLEM", 299, 315], ["Hazara Virus Infection", "PROBLEM", 352, 374], ["Associated ProteinsIndividual", "PROBLEM", 414, 443], ["collective cell migration", "TREATMENT", 448, 473], ["restitution of epithelium", "PROBLEM", 478, 503], ["no signs of", "UNCERTAINTY", 28, 39], ["cell death", "OBSERVATION", 47, 57], ["apoptosis", "OBSERVATION", 61, 70], ["Migration", "OBSERVATION_MODIFIER", 104, 113], ["Wound", "ANATOMY", 118, 123], ["Healing Capacity", "OBSERVATION_MODIFIER", 124, 140], ["Epithelial Cell Monolayers", "OBSERVATION", 144, 170], ["epithelial cell monolayers", "OBSERVATION", 233, 259], ["migration", "OBSERVATION_MODIFIER", 279, 288], ["wound", "OBSERVATION_MODIFIER", 293, 298], ["healing", "OBSERVATION_MODIFIER", 299, 306], ["capacity", "OBSERVATION_MODIFIER", 307, 315], ["Infection", "OBSERVATION", 365, 374], ["ProteinsIndividual", "OBSERVATION_MODIFIER", 425, 443], ["collective cell migration", "OBSERVATION", 448, 473], ["epithelium", "ANATOMY_MODIFIER", 493, 503], ["actin cytoskeleton reorganization", "OBSERVATION", 518, 551], ["monomeric G-actin", "OBSERVATION", 592, 609]]], ["Using confocal imaging, we disclosed dramatic decreases in F-actin as well as redistribution of IQGAP1 and AQP6 in Caco-2 monolayers infected with Hazara virus at MOI 1 for 24 h, in clear contrast to control cells (Figures 4A-C) .", [["Caco-2 monolayers", "ANATOMY", 115, 132], ["cells", "ANATOMY", 208, 213], ["F-actin", "GENE_OR_GENE_PRODUCT", 59, 66], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 96, 102], ["AQP6", "GENE_OR_GENE_PRODUCT", 107, 111], ["Caco-2 monolayers", "CELL", 115, 132], ["Hazara virus", "ORGANISM", 147, 159], ["cells", "CELL", 208, 213], ["F-actin", "PROTEIN", 59, 66], ["IQGAP1", "PROTEIN", 96, 102], ["AQP6", "PROTEIN", 107, 111], ["Caco-2 monolayers", "CELL_LINE", 115, 132], ["control cells", "CELL_TYPE", 200, 213], ["Hazara virus", "SPECIES", 147, 159], ["confocal imaging", "TEST", 6, 22], ["dramatic decreases in F-actin", "PROBLEM", 37, 66], ["IQGAP1", "TEST", 96, 102], ["AQP6", "TEST", 107, 111], ["Caco", "TEST", 115, 119], ["Hazara virus", "PROBLEM", 147, 159], ["dramatic", "OBSERVATION_MODIFIER", 37, 45], ["decreases", "OBSERVATION_MODIFIER", 46, 55], ["redistribution", "OBSERVATION_MODIFIER", 78, 92]]], ["The distribution of these proteins in juxta-membrane regions went from a distinct uniform to a more disorganized and diffuse pattern; AQP6 re-localized to the cytoplasm; IQGAP1 formed cytoplasmic aggregates; and this was observed in more or less all cells in different fields of views.", [["juxta-membrane", "ANATOMY", 38, 52], ["cytoplasm", "ANATOMY", 159, 168], ["cytoplasmic aggregates", "ANATOMY", 184, 206], ["cells", "ANATOMY", 250, 255], ["AQP6", "GENE_OR_GENE_PRODUCT", 134, 138], ["cytoplasm", "ORGANISM_SUBSTANCE", 159, 168], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 170, 176], ["cytoplasmic", "ORGANISM_SUBSTANCE", 184, 195], ["cells", "CELL", 250, 255], ["juxta-membrane regions", "PROTEIN", 38, 60], ["AQP6", "PROTEIN", 134, 138], ["IQGAP1", "PROTEIN", 170, 176], ["these proteins in juxta-membrane regions", "PROBLEM", 20, 60], ["a more disorganized and diffuse pattern", "PROBLEM", 93, 132], ["the cytoplasm", "PROBLEM", 155, 168], ["IQGAP1 formed cytoplasmic aggregates", "PROBLEM", 170, 206], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["proteins", "OBSERVATION", 26, 34], ["membrane", "ANATOMY_MODIFIER", 44, 52], ["distinct", "OBSERVATION_MODIFIER", 73, 81], ["uniform", "OBSERVATION_MODIFIER", 82, 89], ["more disorganized", "OBSERVATION_MODIFIER", 95, 112], ["diffuse", "OBSERVATION_MODIFIER", 117, 124], ["pattern", "OBSERVATION_MODIFIER", 125, 132], ["cytoplasmic aggregates", "OBSERVATION", 184, 206]]], ["The quantification of fluorescence intensities of F-actin, IQGAP1 and AQP6 in juxta-membrane regions revealed a pronounced and significant decrease of intensity in virus-infected cells (Figures 4D-F) , suggesting that cell-to-cell contacts and junctional associations FIGURE 3 | Hazara virus modulates wound healing.", [["juxta-membrane", "ANATOMY", 78, 92], ["cells", "ANATOMY", 179, 184], ["cell", "ANATOMY", 218, 222], ["cell", "ANATOMY", 226, 230], ["junctional", "ANATOMY", 244, 254], ["wound", "ANATOMY", 302, 307], ["F-actin", "GENE_OR_GENE_PRODUCT", 50, 57], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 59, 65], ["AQP6", "GENE_OR_GENE_PRODUCT", 70, 74], ["cells", "CELL", 179, 184], ["Figures 4D-F", "CELL", 186, 198], ["cell", "CELL", 218, 222], ["cell", "CELL", 226, 230], ["Hazara virus", "ORGANISM", 279, 291], ["wound", "PATHOLOGICAL_FORMATION", 302, 307], ["F-actin", "PROTEIN", 50, 57], ["IQGAP1", "PROTEIN", 59, 65], ["AQP6", "PROTEIN", 70, 74], ["juxta-membrane regions", "PROTEIN", 78, 100], ["virus-infected cells", "CELL_TYPE", 164, 184], ["Hazara virus", "SPECIES", 279, 291], ["fluorescence intensities", "TEST", 22, 46], ["F-actin, IQGAP1 and AQP6 in juxta-membrane regions", "TEST", 50, 100], ["significant decrease of intensity in virus", "PROBLEM", 127, 169], ["infected cells", "PROBLEM", 170, 184], ["cell", "TEST", 218, 222], ["cell contacts", "PROBLEM", 226, 239], ["junctional associations FIGURE", "PROBLEM", 244, 274], ["Hazara virus modulates", "TREATMENT", 279, 301], ["wound healing", "PROBLEM", 302, 315], ["pronounced", "OBSERVATION_MODIFIER", 112, 122], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["intensity", "OBSERVATION_MODIFIER", 151, 160], ["infected cells", "OBSERVATION", 170, 184], ["cell", "OBSERVATION", 218, 222], ["healing", "OBSERVATION_MODIFIER", 308, 315]]], ["Wound healing assays were performed as shown in Figure 2 .", [["Wound", "ANATOMY", 0, 5], ["Wound", "PATHOLOGICAL_FORMATION", 0, 5], ["Wound healing assays", "TEST", 0, 20], ["healing", "OBSERVATION", 6, 13]]], ["Cell monolayers were either untreated (Control) or infected with Hazara virus at MOI 2.0 and 0.02 for 1 h.", [["Cell monolayers", "ANATOMY", 0, 15], ["Cell monolayers", "CELL", 0, 15], ["Hazara virus", "ORGANISM", 65, 77], ["Hazara virus", "SPECIES", 65, 77], ["Cell monolayers", "TEST", 0, 15], ["Hazara virus", "PROBLEM", 65, 77]]], ["After 1-h infection, the cells were rinsed and maintained for 0, 24, or 48 hpi, as in (A-C) respectively.", [["cells", "ANATOMY", 25, 30], ["infection", "DISEASE", 10, 19], ["cells", "CELL", 25, 30], ["A-C", "SIMPLE_CHEMICAL", 87, 90], ["1-h infection", "PROBLEM", 6, 19], ["the cells", "TEST", 21, 30], ["infection", "OBSERVATION", 10, 19]]], ["To create a wound, the inserts were removed at 0, 24, or 48 hpi, and the cells were thereafter allowed to migrate as shown in images in in the right panels in (A-C), respectively.", [["wound", "ANATOMY", 12, 17], ["cells", "ANATOMY", 73, 78], ["wound", "PATHOLOGICAL_FORMATION", 12, 17], ["cells", "CELL", 73, 78], ["a wound", "PROBLEM", 10, 17], ["wound", "OBSERVATION", 12, 17], ["right", "ANATOMY_MODIFIER", 143, 148]]], ["The graphs in the left panels represent quantification of wound opening, shown as percent (%) of the original gap.", [["wound", "ANATOMY", 58, 63], ["wound", "PATHOLOGICAL_FORMATION", 58, 63], ["The graphs in the left panels", "TEST", 0, 29], ["wound opening", "PROBLEM", 58, 71], ["left", "ANATOMY_MODIFIER", 18, 22], ["quantification", "OBSERVATION", 40, 54], ["wound opening", "OBSERVATION", 58, 71]]], ["Values are the mean \u00b1 SE based on three independent experiments performed on separate days from different cell passages (n = 3).", [["cell", "ANATOMY", 106, 110], ["cell", "CELL", 106, 110], ["Values", "TEST", 0, 6], ["different cell passages", "TEST", 96, 119], ["cell passages", "OBSERVATION", 106, 119]]], ["Representative images of one of three independent experiments are shown in panels on the right.", [["Representative images", "TEST", 0, 21], ["right", "ANATOMY_MODIFIER", 89, 94]]], ["Bar 200 \u00b5m.Hazara Virus Infection Reduces the Expression of Cytoskeleton-Associated ProteinsFrontiers in Cell and Developmental Biology | www.frontiersin.org FIGURE 4 | Visualization of Hazara virus, F-actin, IQGAP1 and AQP6 in epithelial cells.", [["Cell", "ANATOMY", 105, 109], ["epithelial cells", "ANATOMY", 228, 244], ["Hazara Virus", "ORGANISM", 11, 23], ["Cell", "CELL", 105, 109], ["Hazara virus", "ORGANISM", 186, 198], ["F-actin", "GENE_OR_GENE_PRODUCT", 200, 207], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 209, 215], ["AQP6", "GENE_OR_GENE_PRODUCT", 220, 224], ["epithelial cells", "CELL", 228, 244], ["Cytoskeleton-Associated Proteins", "PROTEIN", 60, 92], ["F-actin", "PROTEIN", 200, 207], ["IQGAP1", "PROTEIN", 209, 215], ["AQP6", "PROTEIN", 220, 224], ["epithelial cells", "CELL_TYPE", 228, 244], ["Hazara virus", "SPECIES", 186, 198], ["Hazara Virus Infection", "PROBLEM", 11, 33], ["Visualization", "TEST", 169, 182], ["Hazara virus", "PROBLEM", 186, 198], ["F-actin", "TEST", 200, 207], ["IQGAP1", "TEST", 209, 215], ["Infection", "OBSERVATION", 24, 33], ["epithelial cells", "OBSERVATION", 228, 244]]], ["Caco-2 cell monolayers were infected with Hazara virus at MOI 1 for 1 h and maintained for 24 hpi.", [["Caco-2 cell monolayers", "ANATOMY", 0, 22], ["Caco-2 cell monolayers", "CELL", 0, 22], ["Hazara virus", "ORGANISM", 42, 54], ["Caco-2 cell monolayers", "CELL_LINE", 0, 22], ["Hazara virus", "SPECIES", 42, 54], ["Caco-2 cell monolayers", "TREATMENT", 0, 22], ["Hazara virus", "PROBLEM", 42, 54], ["cell monolayers", "OBSERVATION", 7, 22]]], ["Untreated non-infected Caco-2 cell monolayers were used as a control.", [["Caco-2 cell monolayers", "ANATOMY", 23, 45], ["Caco-2 cell monolayers", "CELL", 23, 45], ["Caco-2 cell monolayers", "CELL_LINE", 23, 45], ["Untreated non-infected Caco-2 cell monolayers", "TREATMENT", 0, 45], ["non-infected", "OBSERVATION_MODIFIER", 10, 22], ["Caco-2 cell monolayers", "OBSERVATION", 23, 45]]], ["Samples were then fixed and stained for: (A) viral N (red) and F-actin (green); (B) viral N (red) and IQGAP1 (green); (C) viral N (green) and AQP6 (red); nuclei were labeled with DAPI (blue).", [["Samples", "ANATOMY", 0, 7], ["nuclei", "ANATOMY", 154, 160], ["DAPI", "CHEMICAL", 179, 183], ["F-actin", "GENE_OR_GENE_PRODUCT", 63, 70], ["N (red)", "GENE_OR_GENE_PRODUCT", 90, 97], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 102, 108], ["N (green)", "GENE_OR_GENE_PRODUCT", 128, 137], ["AQP6 (red)", "GENE_OR_GENE_PRODUCT", 142, 152], ["nuclei", "CELLULAR_COMPONENT", 154, 160], ["DAPI", "SIMPLE_CHEMICAL", 179, 183], ["actin", "PROTEIN", 65, 70], ["viral N (red)", "PROTEIN", 84, 97], ["IQGAP1", "PROTEIN", 102, 108], ["AQP6", "PROTEIN", 142, 146], ["Samples", "TEST", 0, 7], ["A) viral N", "TEST", 42, 52], ["viral N", "TEST", 84, 91], ["IQGAP1", "TEST", 102, 108], ["viral N (green", "TEST", 122, 136], ["AQP6", "TEST", 142, 146]]], ["Samples were analyzed by confocal microscopy.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["confocal microscopy", "TEST", 25, 44]]], ["Image size is 67.6 \u00d7 67.6 \u00b5m and pixel size is 0.13 \u00b5m.", [["Image size", "TEST", 0, 10], ["pixel size", "TEST", 33, 43], ["size", "OBSERVATION_MODIFIER", 39, 43], ["0.13 \u00b5m", "OBSERVATION_MODIFIER", 47, 54]]], ["Quantification of fluorescence intensities for F-actin (D), IQGAP1 (E) and AQP6 (F) measured in juxta-membrane regions in cell monolayers as indicated by blue (untreated control) and yellow rectangles (virus-infected cells, MOI 1, 24 hpi) in (A-C).", [["juxta-membrane regions", "ANATOMY", 96, 118], ["cell monolayers", "ANATOMY", 122, 137], ["cells", "ANATOMY", 217, 222], ["F-actin", "GENE_OR_GENE_PRODUCT", 47, 54], ["D", "GENE_OR_GENE_PRODUCT", 56, 57], ["IQGAP1 (E)", "GENE_OR_GENE_PRODUCT", 60, 70], ["AQP6 (F)", "GENE_OR_GENE_PRODUCT", 75, 83], ["cell monolayers", "CELL", 122, 137], ["cells", "CELL", 217, 222], ["A-C", "SIMPLE_CHEMICAL", 243, 246], ["F", "PROTEIN", 47, 48], ["actin", "PROTEIN", 49, 54], ["D", "PROTEIN", 56, 57], ["IQGAP1", "PROTEIN", 60, 66], ["E", "PROTEIN", 68, 69], ["AQP6 (F)", "PROTEIN", 75, 83], ["juxta-membrane regions", "DNA", 96, 118], ["virus-infected cells", "CELL_TYPE", 202, 222], ["fluorescence intensities", "TEST", 18, 42], ["F-actin (D), IQGAP1 (E) and AQP6 (F)", "TEST", 47, 83], ["cell monolayers", "TREATMENT", 122, 137], ["blue (untreated control", "TREATMENT", 154, 177], ["yellow rectangles (virus-infected cells", "PROBLEM", 183, 222], ["MOI", "TEST", 224, 227], ["cell monolayers", "OBSERVATION", 122, 137]]], ["Values in graphs represent the mean \u00b1 SE based on 3 independent experiments and 60-63 cells for each condition (same color code as in images).", [["cells", "ANATOMY", 86, 91], ["cells", "CELL", 86, 91], ["Values in graphs", "TEST", 0, 16]]], ["Significant differences were analyzed by Student's t-test and are indicated with *** when P < 0.001 compared to control.Hazara Virus Infection Reduces the Expression of Cytoskeleton-Associated ProteinsFrontiers in Cell and Developmental Biology | www.frontiersin.org are indeed affected.", [["Cell", "ANATOMY", 214, 218], ["Hazara Virus", "ORGANISM", 120, 132], ["Cytoskeleton", "GENE_OR_GENE_PRODUCT", 169, 181], ["Cell", "CELL", 214, 218], ["Cytoskeleton-Associated ProteinsFrontiers", "PROTEIN", 169, 210], ["Student's t-test", "TEST", 41, 57], ["Hazara Virus Infection", "PROBLEM", 120, 142], ["Infection", "OBSERVATION", 133, 142]]], ["To further quantify, intensity profile plots across the cell monolayers were measured (Figures S1-S4) .", [["cell monolayers", "ANATOMY", 56, 71], ["cell monolayers", "CELL", 56, 71], ["intensity profile plots", "TEST", 21, 44], ["the cell monolayers", "TEST", 52, 71], ["cell monolayers", "OBSERVATION", 56, 71]]], ["Here, non-infected controls displayed pronounced distinct assemblies of F-actin, IQGAP1 and AQP6 at cell-to-cell contacts, whereas the virus-infected cells had clearly more smooth profiles.", [["cell", "ANATOMY", 100, 104], ["cell", "ANATOMY", 108, 112], ["cells", "ANATOMY", 150, 155], ["F-actin", "GENE_OR_GENE_PRODUCT", 72, 79], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 81, 87], ["AQP6", "GENE_OR_GENE_PRODUCT", 92, 96], ["cell", "CELL", 100, 104], ["cell contacts", "CELLULAR_COMPONENT", 108, 121], ["cells", "CELL", 150, 155], ["F-actin", "PROTEIN", 72, 79], ["IQGAP1", "PROTEIN", 81, 87], ["AQP6", "PROTEIN", 92, 96], ["virus-infected cells", "CELL_TYPE", 135, 155], ["F-actin, IQGAP1 and AQP6 at cell", "PROBLEM", 72, 104], ["cell contacts", "PROBLEM", 108, 121], ["the virus", "PROBLEM", 131, 140], ["infected cells", "PROBLEM", 141, 155], ["pronounced distinct", "OBSERVATION_MODIFIER", 38, 57], ["infected cells", "OBSERVATION", 141, 155], ["more smooth", "OBSERVATION_MODIFIER", 168, 179]]], ["Viral N was observed in the perinuclear region of infected cells (Figures 4A-C) , which is in line with an earlier report (Andersson et al., 2004) .", [["perinuclear region", "ANATOMY", 28, 46], ["cells", "ANATOMY", 59, 64], ["perinuclear region", "CELLULAR_COMPONENT", 28, 46], ["cells", "CELL", 59, 64], ["infected cells", "CELL_TYPE", 50, 64], ["Viral N", "PROBLEM", 0, 7], ["infected cells", "PROBLEM", 50, 64], ["perinuclear", "ANATOMY_MODIFIER", 28, 39], ["infected cells", "OBSERVATION", 50, 64]]], ["Next, we investigated the effect of Hazara virus on the expression levels of IQGAP1 and AQP6 in epithelial cells with immunoblotting ( Figure 5A ) and further quantification of the density of the bands (Figures 5B,C) .", [["epithelial cells", "ANATOMY", 96, 112], ["Hazara virus", "ORGANISM", 36, 48], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 77, 83], ["AQP6", "GENE_OR_GENE_PRODUCT", 88, 92], ["epithelial cells", "CELL", 96, 112], ["IQGAP1", "PROTEIN", 77, 83], ["AQP6", "PROTEIN", 88, 92], ["epithelial cells", "CELL_TYPE", 96, 112], ["Hazara virus", "SPECIES", 36, 48], ["Hazara virus", "PROBLEM", 36, 48], ["IQGAP1", "TEST", 77, 83], ["AQP6 in epithelial cells", "PROBLEM", 88, 112], ["immunoblotting ( Figure 5A", "TREATMENT", 118, 144], ["the bands", "TEST", 192, 201], ["epithelial cells", "ANATOMY", 96, 112], ["density", "OBSERVATION", 181, 188]]], ["Here, the infection with Hazara virus at MOI 1 for 24 h caused a significant decrease in the expression level of either protein.Hazara Virus Infection Reduces the Expression of Cytoskeleton-Associated ProteinsThus, the Hazara virus infection resulted in less cytoskeletal F-actin, altered distribution and reduced expression of IQGAP1 and AQP6 appealing for perturbed organization of the cytoskeleton.Alterations in the Human Cellular Interactome of the Viral NSince Hazara virus challenges resulted in modified epithelial migration (Figure 3 ) and reduced expression of several proteins important for cytoskeletal dynamics and homeostasis (Figures 4, 5) , other parallel manipulations of cellular processes and programs might be of significance.", [["cytoskeletal", "ANATOMY", 259, 271], ["cytoskeleton", "ANATOMY", 388, 400], ["Cellular", "ANATOMY", 426, 434], ["epithelial", "ANATOMY", 512, 522], ["cytoskeletal", "ANATOMY", 602, 614], ["cellular", "ANATOMY", 689, 697], ["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 232, 241], ["Hazara virus", "ORGANISM", 25, 37], ["Hazara Virus", "ORGANISM", 128, 140], ["Cytoskeleton-Associated Proteins", "GENE_OR_GENE_PRODUCT", 177, 209], ["Hazara virus", "ORGANISM", 219, 231], ["cytoskeletal F-actin", "CELLULAR_COMPONENT", 259, 279], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 328, 334], ["AQP6", "GENE_OR_GENE_PRODUCT", 339, 343], ["cytoskeleton", "CELLULAR_COMPONENT", 388, 400], ["Human", "ORGANISM", 420, 425], ["Viral NSince Hazara virus", "ORGANISM", 454, 479], ["epithelial", "TISSUE", 512, 522], ["cytoskeletal", "CELLULAR_COMPONENT", 602, 614], ["cellular", "CELL", 689, 697], ["Cytoskeleton-Associated Proteins", "PROTEIN", 177, 209], ["cytoskeletal F-actin", "PROTEIN", 259, 279], ["IQGAP1", "PROTEIN", 328, 334], ["AQP6", "PROTEIN", 339, 343], ["Human", "SPECIES", 420, 425], ["Hazara virus", "SPECIES", 25, 37], ["Hazara virus", "SPECIES", 219, 231], ["Hazara virus", "SPECIES", 467, 479], ["the infection", "PROBLEM", 6, 19], ["Hazara virus", "PROBLEM", 25, 37], ["a significant decrease in the expression level", "PROBLEM", 63, 109], ["Hazara Virus Infection", "PROBLEM", 128, 150], ["Associated Proteins", "PROBLEM", 190, 209], ["the Hazara virus infection", "PROBLEM", 215, 241], ["altered distribution", "PROBLEM", 281, 301], ["reduced expression of IQGAP1 and AQP6", "PROBLEM", 306, 343], ["perturbed organization of the cytoskeleton", "PROBLEM", 358, 400], ["the Viral NSince Hazara virus challenges", "TREATMENT", 450, 490], ["modified epithelial migration", "PROBLEM", 503, 532], ["several proteins", "PROBLEM", 571, 587], ["cytoskeletal dynamics", "TEST", 602, 623], ["cellular processes", "TREATMENT", 689, 707], ["infection", "OBSERVATION", 10, 19], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["decrease", "OBSERVATION", 77, 85], ["Infection", "OBSERVATION", 141, 150], ["less", "OBSERVATION_MODIFIER", 254, 258], ["cytoskeletal F-actin", "OBSERVATION", 259, 279], ["altered", "OBSERVATION_MODIFIER", 281, 288], ["distribution", "OBSERVATION_MODIFIER", 289, 301], ["reduced", "OBSERVATION_MODIFIER", 306, 313], ["expression", "OBSERVATION_MODIFIER", 314, 324], ["cytoskeleton", "OBSERVATION_MODIFIER", 388, 400], ["epithelial migration", "OBSERVATION", 512, 532], ["cellular processes", "OBSERVATION", 689, 707]]], ["We thus further aimed to identify partners of Hazara virus nucleocapsid protein (N) in the cellular proteome of human epithelia upon infection.", [["cellular proteome", "ANATOMY", 91, 108], ["epithelia", "ANATOMY", 118, 127], ["infection", "DISEASE", 133, 142], ["Hazara virus", "ORGANISM", 46, 58], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 59, 83], ["cellular", "CELL", 91, 99], ["human", "ORGANISM", 112, 117], ["epithelia", "TISSUE", 118, 127], ["Hazara virus nucleocapsid protein", "PROTEIN", 46, 79], ["N", "PROTEIN", 81, 82], ["Hazara virus nucleocapsid", "SPECIES", 46, 71], ["human", "SPECIES", 112, 117], ["Hazara virus", "SPECIES", 46, 58], ["human", "SPECIES", 112, 117], ["Hazara virus nucleocapsid protein", "PROBLEM", 46, 79], ["human epithelia upon infection", "PROBLEM", 112, 142], ["human epithelia", "OBSERVATION", 112, 127], ["infection", "OBSERVATION", 133, 142]]], ["To do so, epithelial monolayers were kept non-infected, or infected with Hazara virus at MOI 1 for 1 h, and at 24 hpi, total cell lysate samples were obtained and further immunoprecipitated using the antibodies against CCHFV/Hazara N. The N-enriched immune complexes, as well as total cell lysate samples were separated on SDS-PAGE and stained with Coomassie Blue (Figure 6) .", [["epithelial monolayers", "ANATOMY", 10, 31], ["cell lysate samples", "ANATOMY", 125, 144], ["cell lysate samples", "ANATOMY", 285, 304], ["Coomassie Blue", "CHEMICAL", 349, 363], ["epithelial monolayers", "CELL", 10, 31], ["Hazara virus", "ORGANISM", 73, 85], ["cell lysate samples", "ORGANISM_SUBSTANCE", 125, 144], ["CCHFV", "ORGANISM", 219, 224], ["Hazara N.", "ORGANISM", 225, 234], ["cell", "CELL", 285, 289], ["Coomassie Blue", "SIMPLE_CHEMICAL", 349, 363], ["epithelial monolayers", "CELL_TYPE", 10, 31], ["antibodies", "PROTEIN", 200, 210], ["N-enriched immune complexes", "PROTEIN", 239, 266], ["Hazara virus", "SPECIES", 73, 85], ["epithelial monolayers", "PROBLEM", 10, 31], ["Hazara virus", "PROBLEM", 73, 85], ["total cell lysate samples", "TEST", 119, 144], ["the antibodies", "TEST", 196, 210], ["CCHFV/Hazara", "TREATMENT", 219, 231], ["The N-enriched immune complexes", "TREATMENT", 235, 266], ["total cell lysate samples", "TEST", 279, 304], ["epithelial", "ANATOMY", 10, 20]]], ["For the latter, no significant difference in protein patterns of infected and non-infected cells was observed (Figure 6 , right panel).", [["cells", "ANATOMY", 91, 96], ["cells", "CELL", 91, 96], ["infected and non-infected cells", "CELL_TYPE", 65, 96], ["significant difference in protein patterns of infected and non-infected cells", "PROBLEM", 19, 96], ["Figure", "TEST", 111, 117], ["right panel", "TEST", 122, 133], ["no", "UNCERTAINTY", 16, 18], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["difference", "OBSERVATION_MODIFIER", 31, 41], ["protein patterns", "OBSERVATION", 45, 61], ["infected", "OBSERVATION_MODIFIER", 65, 73], ["non-infected cells", "OBSERVATION", 78, 96]]], ["For the samples with N-enriched immune complexes, one additional protein band was reproducibly seen in the sample corresponding cells infected with Hazara virus (Figure 6 , left panel).Alterations in the Human Cellular Interactome of the Viral NEach gel line was cut into 10 slices, digested and analyzed by liquid chromatography and mass spectrometry (LC-MS/MS), where spectrum counts were used for quantitative comparisons of samples.", [["samples", "ANATOMY", 8, 15], ["sample", "ANATOMY", 107, 113], ["cells", "ANATOMY", 128, 133], ["Cellular", "ANATOMY", 210, 218], ["slices", "ANATOMY", 275, 281], ["samples", "ANATOMY", 428, 435], ["N", "CHEMICAL", 21, 22], ["cells", "CELL", 128, 133], ["Hazara virus", "ORGANISM", 148, 160], ["Human", "ORGANISM", 204, 209], ["N-enriched immune complexes", "PROTEIN", 21, 48], ["Human", "SPECIES", 204, 209], ["Hazara virus", "SPECIES", 148, 160], ["the samples", "TEST", 4, 15], ["N-enriched immune complexes", "TREATMENT", 21, 48], ["additional protein band", "TEST", 54, 77], ["Hazara virus", "PROBLEM", 148, 160], ["left panel", "TEST", 173, 183], ["the Viral NEach gel line", "TREATMENT", 234, 258], ["liquid chromatography", "TEST", 308, 329], ["mass spectrometry", "TEST", 334, 351], ["LC", "TEST", 353, 355], ["spectrum counts", "TEST", 370, 385], ["quantitative comparisons of samples", "TEST", 400, 435], ["left", "ANATOMY_MODIFIER", 173, 177]]], ["The additional visible band detected in the sample corresponding cells infected with Hazara virus was identified as the viral N (Figure 6, left panel) , which served as a control to confirm both infection and immunoprecipitation.", [["sample", "ANATOMY", 44, 50], ["cells", "ANATOMY", 65, 70], ["infection", "DISEASE", 195, 204], ["cells", "CELL", 65, 70], ["Hazara virus", "ORGANISM", 85, 97], ["Hazara virus", "SPECIES", 85, 97], ["The additional visible band", "PROBLEM", 0, 27], ["Hazara virus", "PROBLEM", 85, 97], ["the viral N (Figure", "TEST", 116, 135], ["left panel", "TEST", 139, 149], ["both infection", "PROBLEM", 190, 204], ["immunoprecipitation", "PROBLEM", 209, 228], ["visible", "OBSERVATION_MODIFIER", 15, 22], ["band", "OBSERVATION_MODIFIER", 23, 27], ["cells", "OBSERVATION_MODIFIER", 65, 70], ["infected", "OBSERVATION_MODIFIER", 71, 79], ["infection", "OBSERVATION", 195, 204]]], ["Furthermore, 36 out of around 500 cellular proteins were typically identified in the N-enriched immune complexes and exhibited significant differences in affinity ( Table 1) .Alterations in the Human Cellular Interactome of the Viral NTen N-associated proteins were detected in virus-infected cells only, and 13 proteins displayed at least 2-fold increased binding to N-enriched immune complexes upon viral infection in comparison to the non-infected control ( Table 1) .", [["cellular", "ANATOMY", 34, 42], ["Cellular", "ANATOMY", 200, 208], ["cells", "ANATOMY", 293, 298], ["viral infection", "DISEASE", 401, 416], ["N", "CHEMICAL", 368, 369], ["cellular", "CELL", 34, 42], ["Human", "ORGANISM", 194, 199], ["Viral", "ORGANISM", 228, 233], ["NTen N-associated proteins", "GENE_OR_GENE_PRODUCT", 234, 260], ["cells", "CELL", 293, 298], ["cellular proteins", "PROTEIN", 34, 51], ["N-enriched immune complexes", "PROTEIN", 85, 112], ["Viral NTen N-associated proteins", "PROTEIN", 228, 260], ["virus-infected cells", "CELL_TYPE", 278, 298], ["13 proteins", "PROTEIN", 309, 320], ["N-enriched immune complexes", "PROTEIN", 368, 395], ["Human", "SPECIES", 194, 199], ["cellular proteins", "TEST", 34, 51], ["significant differences in affinity", "PROBLEM", 127, 162], ["the Viral NTen N-associated proteins", "TEST", 224, 260], ["infected cells", "PROBLEM", 284, 298], ["13 proteins", "TEST", 309, 320], ["N-enriched immune complexes", "TREATMENT", 368, 395], ["viral infection", "PROBLEM", 401, 416], ["immune complexes", "OBSERVATION", 96, 112], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["differences", "OBSERVATION_MODIFIER", 139, 150], ["infected cells", "OBSERVATION", 284, 298], ["viral infection", "OBSERVATION", 401, 416]]], ["These 23 proteins were considered as potential N partners in the Hazara infection.", [["infection", "DISEASE", 72, 81], ["the Hazara infection", "PROBLEM", 61, 81], ["infection", "OBSERVATION", 72, 81]]], ["Twelve proteins displayed decreased binding to N-enriched immune complexes upon viral infection in comparison to non-infected control ( Table 1) .", [["viral infection", "DISEASE", 80, 95], ["N", "CHEMICAL", 47, 48], ["N-enriched immune complexes", "PROTEIN", 47, 74], ["Twelve proteins", "TEST", 0, 15], ["decreased binding", "PROBLEM", 26, 43], ["viral infection", "PROBLEM", 80, 95], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["viral infection", "OBSERVATION", 80, 95]]], ["All 36 cellular proteins, typically identified in N-associated immune complexes and exhibited significant differences in affinity (Table 1) , were included in the further bioinformatics analyses.Alterations in the Human Cellular Interactome of the Viral NBioinformatics analyses, using the search tool for the retrieval of interacting genes and proteins (STRING) and NCBI GO annotations by SCAFFOLD, were performed to investigate whether the identified N-associated cellular proteins could be placed into distinct functional classes.", [["cellular", "ANATOMY", 7, 15], ["cellular", "ANATOMY", 466, 474], ["cellular", "CELL", 7, 15], ["Human", "ORGANISM", 214, 219], ["cellular", "CELL", 466, 474], ["cellular proteins", "PROTEIN", 7, 24], ["N-associated immune complexes", "PROTEIN", 50, 79], ["interacting genes", "DNA", 323, 340], ["STRING", "PROTEIN", 355, 361], ["NCBI GO annotations", "DNA", 367, 386], ["N-associated cellular proteins", "PROTEIN", 453, 483], ["Human", "SPECIES", 214, 219], ["All 36 cellular proteins", "TEST", 0, 24], ["significant differences in affinity", "PROBLEM", 94, 129], ["the further bioinformatics analyses", "TEST", 159, 194], ["the Viral NBioinformatics analyses", "TEST", 244, 278], ["the search tool", "TEST", 286, 301], ["the identified N-associated cellular proteins", "PROBLEM", 438, 483], ["cellular proteins", "OBSERVATION", 7, 24], ["significant", "OBSERVATION_MODIFIER", 94, 105]]], ["This revealed that they could be put in a groups being involved in: RNA and DNA processes, formation of membrane-bound vesicles, cell morphology, migration, differentiation, proliferation and apoptosis, metabolism, cellular defense and response to stress and pathogens, virus growth and chaperone activity ( Table 1) .Alterations in the Human Cellular Interactome of the Viral NIndependent analyses of network interactions, using STRING, disclosed that out of the 36 host proteins, which were typically identified in N-enriched immune complexes, at least 24 were connected through distinct types of actions (Figure 7) , as previously being established experimentally and from curated databases and predicted by gene neighborhood and co-occurrence or by protein co-expressions and homologies ( Figure S5 ).", [["membrane", "ANATOMY", 104, 112], ["vesicles", "ANATOMY", 119, 127], ["cell", "ANATOMY", 129, 133], ["cellular", "ANATOMY", 215, 223], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["vesicles", "CELLULAR_COMPONENT", 119, 127], ["cell", "CELL", 129, 133], ["cellular", "CELL", 215, 223], ["Human", "ORGANISM", 337, 342], ["N-enriched immune complexes", "PROTEIN", 517, 544], ["Human", "SPECIES", 337, 342], ["RNA and DNA processes", "PROBLEM", 68, 89], ["membrane-bound vesicles", "PROBLEM", 104, 127], ["proliferation", "PROBLEM", 174, 187], ["apoptosis", "PROBLEM", 192, 201], ["metabolism, cellular defense", "PROBLEM", 203, 231], ["stress and pathogens", "PROBLEM", 248, 268], ["virus growth", "PROBLEM", 270, 282], ["bound vesicles", "ANATOMY", 113, 127], ["cell morphology", "OBSERVATION", 129, 144], ["migration", "OBSERVATION_MODIFIER", 146, 155], ["cellular defense", "OBSERVATION", 215, 231]]], ["The distinct, large node cluster of N-associated proteins having a rich network of protein-protein interactions (Figure 7) contained proteins with chaperone activity ( Table 1 , depicted in blue): calnexin, mitochondrial Hsp60 and Hsp70, stress-induced phosphoprotein 1, elongation factor 1-\u03b4, \u03b1enolase, hsc70-interacting protein and two members of the protein disulfide isomerase family.", [["node", "ANATOMY", 20, 24], ["mitochondrial", "ANATOMY", 207, 220], ["disulfide", "CHEMICAL", 361, 370], ["Table 1", "GENE_OR_GENE_PRODUCT", 168, 175], ["calnexin", "GENE_OR_GENE_PRODUCT", 197, 205], ["mitochondrial", "CELLULAR_COMPONENT", 207, 220], ["Hsp60", "GENE_OR_GENE_PRODUCT", 221, 226], ["Hsp70", "GENE_OR_GENE_PRODUCT", 231, 236], ["stress-induced phosphoprotein 1", "GENE_OR_GENE_PRODUCT", 238, 269], ["elongation factor 1-\u03b4", "GENE_OR_GENE_PRODUCT", 271, 292], ["\u03b1enolase", "GENE_OR_GENE_PRODUCT", 294, 302], ["hsc70", "GENE_OR_GENE_PRODUCT", 304, 309], ["protein disulfide isomerase", "GENE_OR_GENE_PRODUCT", 353, 380], ["N-associated proteins", "PROTEIN", 36, 57], ["calnexin", "PROTEIN", 197, 205], ["mitochondrial Hsp60", "PROTEIN", 207, 226], ["Hsp70", "PROTEIN", 231, 236], ["stress-induced phosphoprotein 1", "PROTEIN", 238, 269], ["elongation factor 1", "PROTEIN", 271, 290], ["\u03b4", "PROTEIN", 291, 292], ["\u03b1enolase", "PROTEIN", 294, 302], ["hsc70", "PROTEIN", 304, 309], ["interacting protein", "PROTEIN", 310, 329], ["protein disulfide isomerase family", "PROTEIN", 353, 387], ["The distinct, large node cluster of N-associated proteins", "PROBLEM", 0, 57], ["calnexin", "TREATMENT", 197, 205], ["mitochondrial Hsp60", "TEST", 207, 226], ["Hsp70", "TEST", 231, 236], ["stress", "TEST", 238, 244], ["phosphoprotein", "TEST", 253, 267], ["elongation factor", "TEST", 271, 288], ["\u03b1enolase", "TEST", 294, 302], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["large", "OBSERVATION_MODIFIER", 14, 19], ["node", "OBSERVATION", 20, 24], ["cluster", "OBSERVATION_MODIFIER", 25, 32]]], ["Other proteins with a rich network were ribosomal receptor of activated protein C kinase 1 and cytoplasmic heterogeneous nuclear ribonucleoprotein Q (Figure 7) .", [["ribosomal", "ANATOMY", 40, 49], ["cytoplasmic", "ANATOMY", 95, 106], ["ribosomal receptor of activated protein C kinase 1", "GENE_OR_GENE_PRODUCT", 40, 90], ["cytoplasmic", "ORGANISM_SUBSTANCE", 95, 106], ["ribosomal receptor of activated protein C kinase 1", "PROTEIN", 40, 90], ["cytoplasmic heterogeneous nuclear ribonucleoprotein Q", "PROTEIN", 95, 148], ["Figure 7", "PROTEIN", 150, 158], ["activated protein C kinase", "TEST", 62, 88], ["cytoplasmic heterogeneous nuclear ribonucleoprotein", "PROBLEM", 95, 146], ["heterogeneous", "OBSERVATION_MODIFIER", 107, 120], ["nuclear ribonucleoprotein", "OBSERVATION", 121, 146]]], ["Further bioinformatics analyses revealed clusters of proteins involved in RNA and DNA processes ( Table 1 , noted in red, Figure S6A ), in membrane-bound vesicle communication ( Table 1 , shown in violet, Figure S6B) , and in key cellular processes, such as cell morphology, migration, differentiation, proliferation and apoptosis (Table 1, shown in green).Alterations in the Human Cellular Interactome of the Viral NThus, epithelial cellular protein networks are strongly perturbed by a Hazara virus infection, where the viral structural N associates and interacts with an array of cellular proteins.DISCUSSIONA fundamental feature of epithelial linings of multicellular organisms is their ability to repair wounds via regeneration and collective cellular movement (Friedl and Mayor, 2017) .", [["membrane", "ANATOMY", 139, 147], ["vesicle", "ANATOMY", 154, 161], ["cellular", "ANATOMY", 230, 238], ["cell", "ANATOMY", 258, 262], ["Cellular", "ANATOMY", 382, 390], ["epithelial cellular", "ANATOMY", 423, 442], ["cellular", "ANATOMY", 583, 591], ["epithelial linings", "ANATOMY", 636, 654], ["multicellular organisms", "ANATOMY", 658, 681], ["wounds", "ANATOMY", 709, 715], ["cellular", "ANATOMY", 748, 756], ["infection", "DISEASE", 501, 510], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["Table 1", "GENE_OR_GENE_PRODUCT", 98, 105], ["red, Figure S6A", "GENE_OR_GENE_PRODUCT", 117, 132], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["vesicle", "CELLULAR_COMPONENT", 154, 161], ["violet, Figure S6B", "GENE_OR_GENE_PRODUCT", 197, 215], ["cellular", "CELL", 230, 238], ["cell", "CELL", 258, 262], ["Human", "ORGANISM", 376, 381], ["epithelial cellular", "CELL", 423, 442], ["Hazara virus", "ORGANISM", 488, 500], ["cellular", "CELL", 583, 591], ["epithelial linings", "TISSUE", 636, 654], ["wounds", "PATHOLOGICAL_FORMATION", 709, 715], ["cellular", "CELL", 748, 756], ["Viral NThus", "PROTEIN", 410, 421], ["epithelial cellular protein networks", "PROTEIN", 423, 459], ["viral structural N", "PROTEIN", 522, 540], ["cellular proteins", "PROTEIN", 583, 600], ["Human", "SPECIES", 376, 381], ["Hazara virus", "SPECIES", 488, 500], ["Further bioinformatics analyses", "TEST", 0, 31], ["clusters of proteins", "PROBLEM", 41, 61], ["DNA processes", "PROBLEM", 82, 95], ["proliferation", "PROBLEM", 303, 316], ["apoptosis", "PROBLEM", 321, 330], ["the Viral NThus", "TEST", 406, 421], ["epithelial cellular protein networks", "PROBLEM", 423, 459], ["a Hazara virus infection", "PROBLEM", 486, 510], ["cellular proteins", "PROBLEM", 583, 600], ["epithelial linings of multicellular organisms", "PROBLEM", 636, 681], ["repair wounds", "PROBLEM", 702, 715], ["regeneration", "PROBLEM", 720, 732], ["bound vesicle", "ANATOMY", 148, 161], ["cellular processes", "OBSERVATION", 230, 248], ["migration", "OBSERVATION_MODIFIER", 275, 284], ["proliferation", "OBSERVATION_MODIFIER", 303, 316], ["apoptosis", "OBSERVATION_MODIFIER", 321, 330], ["epithelial cellular", "OBSERVATION", 423, 442], ["protein networks", "OBSERVATION", 443, 459], ["cellular proteins", "OBSERVATION", 583, 600], ["epithelial linings", "OBSERVATION", 636, 654], ["multicellular organisms", "OBSERVATION", 658, 681], ["wounds", "OBSERVATION", 709, 715], ["cellular movement", "OBSERVATION", 748, 765]]], ["Both properties are crucial for the maintenance of the structural and functional integrity and homeostasis of tissues (Figure 1 ).", [["tissues", "ANATOMY", 110, 117], ["tissues", "TISSUE", 110, 117], ["functional integrity", "OBSERVATION", 70, 90]]], ["Employing the model of epithelial wound healing (Figure 2) , we show that the repair was perturbed upon Hazara virus infection (Figure 3) .", [["epithelial wound", "ANATOMY", 23, 39], ["infection", "DISEASE", 117, 126], ["epithelial wound", "PATHOLOGICAL_FORMATION", 23, 39], ["Hazara virus", "ORGANISM", 104, 116], ["Hazara virus", "SPECIES", 104, 116], ["epithelial wound healing", "PROBLEM", 23, 47], ["the repair", "TREATMENT", 74, 84], ["Hazara virus infection", "PROBLEM", 104, 126], ["epithelial", "ANATOMY_MODIFIER", 23, 33], ["wound", "ANATOMY", 34, 39], ["healing", "OBSERVATION_MODIFIER", 40, 47], ["repair", "OBSERVATION", 78, 84]]], ["At early stages of infection, the migration rates of virus-infected cells were either similar to the control or even promoted (Figures 3A,B) .", [["cells", "ANATOMY", 68, 73], ["infection", "DISEASE", 19, 28], ["cells", "CELL", 68, 73], ["virus-infected cells", "CELL_TYPE", 53, 73], ["infection", "PROBLEM", 19, 28], ["the migration rates of virus", "PROBLEM", 30, 58], ["infected cells", "PROBLEM", 59, 73], ["infection", "OBSERVATION", 19, 28], ["infected cells", "OBSERVATION", 59, 73]]], ["This probably reflects the very short time for establishment of infection.", [["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["probably reflects", "UNCERTAINTY", 5, 22], ["infection", "OBSERVATION", 64, 73]]], ["Indeed, in CCHFV, RNA synthesis in the infected cells likely starts at 6-16 h after infection (Simon et al., 2009) .", [["cells", "ANATOMY", 48, 53], ["infection", "DISEASE", 84, 93], ["CCHFV", "ORGANISM", 11, 16], ["cells", "CELL", 48, 53], ["infected cells", "CELL_TYPE", 39, 53], ["CCHFV", "SPECIES", 11, 16], ["CCHFV", "PROBLEM", 11, 16], ["RNA synthesis", "PROBLEM", 18, 31], ["the infected cells", "PROBLEM", 35, 53], ["infection", "PROBLEM", 84, 93], ["CCHFV", "OBSERVATION", 11, 16], ["infected cells", "OBSERVATION", 39, 53]]], ["Later, we observed consistently significantly Values are the mean \u00b1 SE based on four independent experiments performed on separate days from different cell passages (n = 4).", [["cell", "ANATOMY", 151, 155], ["cell", "CELL", 151, 155], ["different cell passages", "TEST", 141, 164], ["cell passages", "OBSERVATION", 151, 164]]], ["Significant differences were analyzed by Student's t-test and are indicated with * or ** when P < 0.05 or P < 0.01 compared to control.DISCUSSIONdecreased repair of the wounds, e.g., after longer presence of the virus (Figures 4, 5) and associated disturbances in the cellular proteome.", [["wounds", "ANATOMY", 169, 175], ["cellular", "ANATOMY", 268, 276], ["wounds", "PATHOLOGICAL_FORMATION", 169, 175], ["cellular", "CELL", 268, 276], ["Student's t-test", "TEST", 41, 57], ["repair", "TREATMENT", 155, 161], ["the wounds", "PROBLEM", 165, 175], ["the virus", "PROBLEM", 208, 217], ["associated disturbances in the cellular proteome", "PROBLEM", 237, 285], ["repair", "OBSERVATION", 155, 161], ["wounds", "OBSERVATION", 169, 175], ["virus", "OBSERVATION", 212, 217], ["cellular proteome", "OBSERVATION", 268, 285]]], ["During virus infection, a plethora of factors released from the cells may also have some impact on epithelial repair and barrier function (Bente et al., 2013) .DISCUSSIONSuccessful wound closure requires extensive remodeling of the cytoskeleton, which is controlled by a plethora molecules (Yang et al., 2009; Ivanov et al., 2010; Friedl and Mayor, 2017) , and among them, scaffold IQGAP1 (Karlsson et al., 2012; Hedman #Functional groups of human proteins: X, RNA and DNA processes; X, metabolism; X, cell defense and response to stress and pathogens; X, virus growth; X, cell morphology, migration, differentiation, proliferation and apoptosis; X, chaperone activity; X-membrane-bound vesicle communication.", [["cells", "ANATOMY", 64, 69], ["epithelial", "ANATOMY", 99, 109], ["barrier", "ANATOMY", 121, 128], ["wound", "ANATOMY", 181, 186], ["cytoskeleton", "ANATOMY", 232, 244], ["cell", "ANATOMY", 502, 506], ["cell", "ANATOMY", 573, 577], ["vesicle", "ANATOMY", 687, 694], ["infection", "DISEASE", 13, 22], ["cells", "CELL", 64, 69], ["epithelial", "TISSUE", 99, 109], ["barrier", "TISSUE", 121, 128], ["wound", "PATHOLOGICAL_FORMATION", 181, 186], ["cytoskeleton", "CELLULAR_COMPONENT", 232, 244], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 382, 388], ["human", "ORGANISM", 442, 447], ["proteins: X", "GENE_OR_GENE_PRODUCT", 448, 459], ["DNA", "CELLULAR_COMPONENT", 469, 472], ["cell", "CELL", 502, 506], ["cell", "CELL", 573, 577], ["vesicle", "CELLULAR_COMPONENT", 687, 694], ["IQGAP1", "PROTEIN", 382, 388], ["human proteins", "PROTEIN", 442, 456], ["human", "SPECIES", 442, 447], ["human", "SPECIES", 442, 447], ["virus infection", "PROBLEM", 7, 22], ["epithelial repair", "TREATMENT", 99, 116], ["wound closure", "TREATMENT", 181, 194], ["extensive remodeling of the cytoskeleton", "TREATMENT", 204, 244], ["human proteins", "PROBLEM", 442, 456], ["RNA and DNA processes", "PROBLEM", 461, 482], ["stress and pathogens", "PROBLEM", 531, 551], ["virus growth", "PROBLEM", 556, 568], ["apoptosis", "PROBLEM", 636, 645], ["infection", "OBSERVATION", 13, 22], ["epithelial repair", "OBSERVATION", 99, 116], ["wound", "ANATOMY", 181, 186], ["closure", "OBSERVATION", 187, 194], ["extensive", "OBSERVATION_MODIFIER", 204, 213], ["remodeling", "OBSERVATION", 214, 224]]], ["STRING and SCAFFOLD analyses were used to group proteins into functional classes.", [["SCAFFOLD", "PROTEIN", 11, 19], ["STRING and SCAFFOLD analyses", "TEST", 0, 28]]], ["Data are from 4 independent experiments.DISCUSSIONFIGURE 7 | Bioinformatic assessment of the human cellular interactome of the Hazara virus N shown in Table 1 .", [["cellular", "ANATOMY", 99, 107], ["human", "ORGANISM", 93, 98], ["cellular", "CELL", 99, 107], ["Hazara virus", "ORGANISM", 127, 139], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["Hazara virus", "SPECIES", 127, 139], ["Bioinformatic assessment", "TEST", 61, 85], ["the Hazara virus N", "TREATMENT", 123, 141]]], ["Network nodes represent human proteins pooled into two units.", [["Network nodes", "ANATOMY", 0, 13], ["Network nodes", "MULTI-TISSUE_STRUCTURE", 0, 13], ["human", "ORGANISM", 24, 29], ["human proteins", "PROTEIN", 24, 38], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["human proteins", "PROBLEM", 24, 38], ["nodes", "OBSERVATION", 8, 13]]], ["The upper unit with gray nodes represent 23 proteins suggested as potential N partners upon Hazara infection.", [["gray nodes", "ANATOMY", 20, 30], ["infection", "DISEASE", 99, 108], ["gray nodes", "MULTI-TISSUE_STRUCTURE", 20, 30], ["gray nodes", "TEST", 20, 30], ["23 proteins", "PROBLEM", 41, 52], ["Hazara infection", "PROBLEM", 92, 108], ["upper unit", "OBSERVATION_MODIFIER", 4, 14], ["gray", "ANATOMY", 20, 24], ["nodes", "OBSERVATION", 25, 30], ["23 proteins", "OBSERVATION_MODIFIER", 41, 52], ["infection", "OBSERVATION", 99, 108]]], ["These include 10 N-associated proteins detected only in virus-infected cells and 13 proteins displayed at least 2-fold increased binding to N-enriched immune complexes upon viral infection in comparison to non-infected control ( Table 1) .", [["cells", "ANATOMY", 71, 76], ["viral infection", "DISEASE", 173, 188], ["N", "CHEMICAL", 140, 141], ["cells", "CELL", 71, 76], ["N-associated proteins", "PROTEIN", 17, 38], ["virus-infected cells", "CELL_TYPE", 56, 76], ["13 proteins", "PROTEIN", 81, 92], ["N-enriched immune complexes", "PROTEIN", 140, 167], ["10 N-associated proteins", "PROBLEM", 14, 38], ["virus", "PROBLEM", 56, 61], ["infected cells", "PROBLEM", 62, 76], ["13 proteins", "TEST", 81, 92], ["fold increased binding", "PROBLEM", 114, 136], ["enriched immune complexes", "PROBLEM", 142, 167], ["viral infection", "PROBLEM", 173, 188], ["infected cells", "OBSERVATION", 62, 76], ["enriched immune complexes", "OBSERVATION", 142, 167], ["viral infection", "OBSERVATION", 173, 188]]], ["The lower unit with white nodes represent 12 proteins displayed decreased binding to N-enriched immune complexes upon viral infection in comparison to non-infected control ( Table 1) .", [["white nodes", "ANATOMY", 20, 31], ["viral infection", "DISEASE", 118, 133], ["N", "CHEMICAL", 85, 86], ["white nodes", "MULTI-TISSUE_STRUCTURE", 20, 31], ["N-enriched immune complexes", "PROTEIN", 85, 112], ["white nodes", "PROBLEM", 20, 31], ["12 proteins", "PROBLEM", 42, 53], ["decreased binding", "PROBLEM", 64, 81], ["enriched immune complexes", "PROBLEM", 87, 112], ["viral infection", "PROBLEM", 118, 133], ["lower unit", "OBSERVATION_MODIFIER", 4, 14], ["white nodes", "OBSERVATION", 20, 31], ["viral infection", "OBSERVATION", 118, 133]]], ["Edges represent protein-protein interactions where line thickness indicates the strength of data support.", [["protein-protein interactions", "TREATMENT", 16, 44], ["line thickness", "TEST", 51, 65], ["protein", "OBSERVATION", 16, 23], ["protein interactions", "OBSERVATION", 24, 44]]], ["The assessment is based on STRING analysis shown in Figure S1 and LC-MS/MS analysis and quantification of alterations in cellular proteome and interactome of N shown in Table 1 . et al., 2015) and AQP (Loitto et al., 2009; Karlsson et al., 2013) , playing a pivotal role in regulation of cell migration, cytoskeleton dynamics, water homeostasis and vesicle communication.", [["cellular", "ANATOMY", 121, 129], ["cell", "ANATOMY", 288, 292], ["cytoskeleton", "ANATOMY", 304, 316], ["vesicle", "ANATOMY", 349, 356], ["cellular", "CELL", 121, 129], ["AQP", "GENE_OR_GENE_PRODUCT", 197, 200], ["cell", "CELL", 288, 292], ["cytoskeleton", "CELLULAR_COMPONENT", 304, 316], ["water", "SIMPLE_CHEMICAL", 327, 332], ["vesicle", "CELLULAR_COMPONENT", 349, 356], ["The assessment", "TEST", 0, 14], ["STRING analysis", "TEST", 27, 42], ["Figure S1", "TEST", 52, 61], ["LC", "TEST", 66, 68], ["MS", "PROBLEM", 69, 71], ["MS analysis", "TEST", 72, 83], ["alterations in cellular proteome", "PROBLEM", 106, 138], ["cell migration", "TREATMENT", 288, 302], ["water homeostasis", "TREATMENT", 327, 344], ["cell migration", "OBSERVATION", 288, 302], ["vesicle communication", "OBSERVATION", 349, 370]]], ["We therefore further focused our investigations on the mechanisms whereby Hazara virus could have on epithelial cell migration.DISCUSSIONUsing confocal imaging and immunoblotting, we observed that the F-actin was disrupted and the expression and distribution of IQGAP1 and AQP6 were reduced upon Hazara infection (Figures 4, 5) .", [["epithelial cell", "ANATOMY", 101, 116], ["Hazara infection", "DISEASE", 296, 312], ["Hazara virus", "ORGANISM", 74, 86], ["epithelial cell", "CELL", 101, 116], ["F-actin", "GENE_OR_GENE_PRODUCT", 201, 208], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 262, 268], ["AQP6", "GENE_OR_GENE_PRODUCT", 273, 277], ["F-actin", "PROTEIN", 201, 208], ["IQGAP1", "PROTEIN", 262, 268], ["AQP6", "PROTEIN", 273, 277], ["Hazara virus", "SPECIES", 74, 86], ["our investigations", "TEST", 29, 47], ["Hazara virus", "PROBLEM", 74, 86], ["epithelial cell migration", "PROBLEM", 101, 126], ["confocal imaging", "TEST", 143, 159], ["immunoblotting", "TEST", 164, 178], ["IQGAP1 and AQP6", "PROBLEM", 262, 277], ["Hazara infection", "PROBLEM", 296, 312], ["epithelial cell migration", "OBSERVATION", 101, 126]]], ["This may allow virus to maintain long-term infections in the host and perturb the repair of epithelia by interfering with cytoskeletal structure and water homeostasis.", [["epithelia", "ANATOMY", 92, 101], ["cytoskeletal", "ANATOMY", 122, 134], ["infections", "DISEASE", 43, 53], ["epithelia", "TISSUE", 92, 101], ["water", "SIMPLE_CHEMICAL", 149, 154], ["virus", "PROBLEM", 15, 20], ["long-term infections", "PROBLEM", 33, 53], ["the repair of epithelia", "TREATMENT", 78, 101], ["water homeostasis", "TREATMENT", 149, 166], ["long-term", "OBSERVATION_MODIFIER", 33, 42], ["infections", "OBSERVATION", 43, 53], ["repair", "OBSERVATION", 82, 88], ["cytoskeletal structure", "OBSERVATION", 122, 144], ["water homeostasis", "OBSERVATION", 149, 166]]], ["Our findings corroborate several reports on how microbial pathogens may manipulate signaling pathways of the host cells, particularly cytoskeletal dynamics, to help them invade, replicate and maintain infections (Chazal and Gerlier, 2003; Sewald et al., 2016) .", [["cells", "ANATOMY", 114, 119], ["cytoskeletal", "ANATOMY", 134, 146], ["infections", "DISEASE", 201, 211], ["cells", "CELL", 114, 119], ["cytoskeletal", "CELLULAR_COMPONENT", 134, 146], ["host cells", "CELL_TYPE", 109, 119], ["how microbial pathogens", "PROBLEM", 44, 67], ["the host cells", "PROBLEM", 105, 119], ["host cells", "OBSERVATION", 109, 119], ["infections", "OBSERVATION", 201, 211]]], ["Thus, IQGAP1 regulates egress of Ebola virus (Lu et al., 2013) , invasion and replication of Moloney leukemia virus (Leung et al., 2006) and virulence of swine fever virus (Gladue et al., 2011) .", [["Ebola", "DISEASE", 33, 38], ["Moloney leukemia virus", "DISEASE", 93, 115], ["swine fever", "DISEASE", 154, 165], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 6, 12], ["Ebola virus", "ORGANISM", 33, 44], ["Moloney leukemia virus", "ORGANISM", 93, 115], ["swine fever virus", "ORGANISM", 154, 171], ["IQGAP1", "PROTEIN", 6, 12], ["Ebola virus", "SPECIES", 33, 44], ["Moloney leukemia virus", "SPECIES", 93, 115], ["swine fever virus", "SPECIES", 154, 171], ["Ebola virus", "SPECIES", 33, 44], ["Moloney leukemia virus", "SPECIES", 93, 115], ["swine fever virus", "SPECIES", 154, 171], ["Ebola virus", "PROBLEM", 33, 44], ["invasion", "PROBLEM", 65, 73], ["Moloney leukemia virus", "PROBLEM", 93, 115], ["swine fever virus", "PROBLEM", 154, 171], ["Ebola virus", "OBSERVATION", 33, 44], ["invasion", "OBSERVATION", 65, 73], ["Moloney leukemia virus", "OBSERVATION", 93, 115]]], ["Moreover, CCHFV did perturb strongly the microtubule and actin filaments during entry, growth and release to the surroundings (Andersson et al., 2004; Simon et al., 2009) .", [["microtubule", "ANATOMY", 41, 52], ["filaments", "ANATOMY", 63, 72], ["CCHFV", "ORGANISM", 10, 15], ["microtubule", "CELLULAR_COMPONENT", 41, 52], ["actin", "GENE_OR_GENE_PRODUCT", 57, 62], ["microtubule", "PROTEIN", 41, 52], ["actin", "PROTEIN", 57, 62], ["CCHFV", "SPECIES", 10, 15], ["CCHFV", "OBSERVATION", 10, 15], ["actin filaments", "OBSERVATION", 57, 72]]], ["Additionally, other studies have proposed a new role for AQP as important proteins during viral infections and inflammation.", [["viral infections", "DISEASE", 90, 106], ["inflammation", "DISEASE", 111, 123], ["AQP", "GENE_OR_GENE_PRODUCT", 57, 60], ["AQP", "PROTEIN", 57, 60], ["other studies", "TEST", 14, 27], ["AQP", "PROBLEM", 57, 60], ["viral infections", "PROBLEM", 90, 106], ["inflammation", "PROBLEM", 111, 123], ["viral infections", "OBSERVATION", 90, 106], ["inflammation", "OBSERVATION", 111, 123]]], ["Thus, the levels of AQP1 and 5 were low during pulmonary, adenoviral infection (Towne et al., 2000) .", [["pulmonary", "ANATOMY", 47, 56], ["pulmonary, adenoviral infection", "DISEASE", 47, 78], ["AQP1", "GENE_OR_GENE_PRODUCT", 20, 24], ["5", "GENE_OR_GENE_PRODUCT", 29, 30], ["pulmonary", "ORGAN", 47, 56], ["adenoviral", "ORGANISM", 58, 68], ["AQP1", "PROTEIN", 20, 24], ["the levels", "TEST", 6, 16], ["AQP1", "TEST", 20, 24], ["pulmonary, adenoviral infection", "PROBLEM", 47, 78], ["pulmonary", "ANATOMY", 47, 56], ["adenoviral", "ANATOMY", 58, 68], ["infection", "OBSERVATION", 69, 78]]], ["AQP4 was decreased in the acute phase of a Herpes simplex virus infection, but increased in the long-term of disease (Martinez Torres et al., 2007) .", [["Herpes simplex virus infection", "DISEASE", 43, 73], ["AQP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["Herpes simplex virus", "ORGANISM", 43, 63], ["AQP4", "PROTEIN", 0, 4], ["Herpes simplex virus", "SPECIES", 43, 63], ["Herpes simplex virus", "SPECIES", 43, 63], ["AQP4", "PROBLEM", 0, 4], ["a Herpes simplex virus infection", "PROBLEM", 41, 73], ["disease", "PROBLEM", 109, 116], ["decreased", "OBSERVATION_MODIFIER", 9, 18], ["acute phase", "OBSERVATION_MODIFIER", 26, 37], ["Herpes simplex virus infection", "OBSERVATION", 43, 73], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["long-term", "OBSERVATION_MODIFIER", 96, 105]]], ["An infection of human cells with CCHFV strain IbAR 10200 downregulated the AQP6 mRNA expression (Molinas et al., 2016) .", [["cells", "ANATOMY", 22, 27], ["infection", "DISEASE", 3, 12], ["IbAR 10200", "CHEMICAL", 46, 56], ["human", "ORGANISM", 16, 21], ["cells", "CELL", 22, 27], ["CCHFV strain IbAR 10200", "ORGANISM", 33, 56], ["AQP6", "GENE_OR_GENE_PRODUCT", 75, 79], ["human cells", "CELL_TYPE", 16, 27], ["AQP6 mRNA", "RNA", 75, 84], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["CCHFV strain IbAR 10200", "SPECIES", 33, 56], ["An infection of human cells", "PROBLEM", 0, 27], ["CCHFV strain IbAR", "TEST", 33, 50], ["infection", "OBSERVATION", 3, 12], ["human cells", "OBSERVATION", 16, 27]]], ["Furthermore, with Hazara virus as a model, we have recently provided an evidence for a protective role of AQP6 against virus infection (Molinas et al., 2016) .DISCUSSIONTo further elucidate details on how the virus affects the cells, we aimed to identify potential partners of Hazara virus N in the epithelial cellular proteome upon infection.", [["cells", "ANATOMY", 227, 232], ["epithelial cellular", "ANATOMY", 299, 318], ["AQP6", "CHEMICAL", 106, 110], ["infection", "DISEASE", 125, 134], ["infection", "DISEASE", 333, 342], ["Hazara virus", "ORGANISM", 18, 30], ["AQP6", "GENE_OR_GENE_PRODUCT", 106, 110], ["cells", "CELL", 227, 232], ["Hazara virus N", "ORGANISM", 277, 291], ["epithelial cellular", "CELL", 299, 318], ["AQP6", "PROTEIN", 106, 110], ["Hazara virus", "SPECIES", 18, 30], ["Hazara virus", "SPECIES", 277, 289], ["Hazara virus", "PROBLEM", 18, 30], ["virus infection", "PROBLEM", 119, 134], ["Hazara virus N", "PROBLEM", 277, 291], ["infection", "PROBLEM", 333, 342], ["epithelial cellular proteome", "OBSERVATION", 299, 327], ["infection", "OBSERVATION", 333, 342]]], ["To do this, we employed immunoprecipitation, SDS-PAGE (Figure 6) , LC-MS/MS (Table 1 ) and bioinformatics analyses (Figure 7) .", [["immunoprecipitation", "TEST", 24, 43], ["SDS", "TEST", 45, 48], ["LC", "TEST", 67, 69], ["MS", "PROBLEM", 73, 75], ["bioinformatics analyses", "TEST", 91, 114]]], ["Upon virus infection, 36 out of around 500 cellular proteins were typically identified in N-enriched immune complexes and exhibited significant difference in in connectivity to viral N ( Table 1) .", [["cellular", "ANATOMY", 43, 51], ["infection", "DISEASE", 11, 20], ["cellular", "CELL", 43, 51], ["cellular proteins", "PROTEIN", 43, 60], ["N-enriched immune complexes", "PROTEIN", 90, 117], ["virus infection", "PROBLEM", 5, 20], ["cellular proteins", "TEST", 43, 60], ["significant difference", "PROBLEM", 132, 154], ["virus", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["difference", "OBSERVATION", 144, 154]]], ["Among them, 10 proteins were detected only in virus-infected cells, and further 13 and 12 proteins displayed either increased or decreased binding to N-enriched immune complexes, respectively, upon viral infection in comparison to non-infected control ( Table 1) .DISCUSSIONWe identified proteins with chaperone activity (Figure 7 , Table 1 , noted in blue).", [["cells", "ANATOMY", 61, 66], ["viral infection", "DISEASE", 198, 213], ["cells", "CELL", 61, 66], ["virus-infected cells", "CELL_TYPE", 46, 66], ["13 and 12 proteins", "PROTEIN", 80, 98], ["N-enriched immune complexes", "PROTEIN", 150, 177], ["infected cells", "PROBLEM", 52, 66], ["12 proteins", "TEST", 87, 98], ["decreased binding", "PROBLEM", 129, 146], ["viral infection", "PROBLEM", 198, 213], ["infected cells", "OBSERVATION", 52, 66], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["decreased", "OBSERVATION_MODIFIER", 129, 138], ["viral", "OBSERVATION_MODIFIER", 198, 203], ["infection", "OBSERVATION", 204, 213]]], ["They can interact with viral proteins, including N, and favor viral replication and block actin binding (Mirazimi et al., 1998; Horna-Terron et al., 2014; Abbas et al., 2015; Khachatoorian and French, 2016) .", [["actin", "GENE_OR_GENE_PRODUCT", 90, 95], ["viral proteins", "PROTEIN", 23, 37], ["N", "PROTEIN", 49, 50], ["actin", "PROTEIN", 90, 95], ["viral replication", "TREATMENT", 62, 79], ["viral replication", "OBSERVATION", 62, 79]]], ["Both Hsp60 and Hsp70, may also directly bind virus RNA (Nanda et al., 2004) and thereby control viral infection (Lahaye et al., 2012) .", [["viral infection", "DISEASE", 96, 111], ["Hsp60", "GENE_OR_GENE_PRODUCT", 5, 10], ["Hsp70", "GENE_OR_GENE_PRODUCT", 15, 20], ["Hsp60", "PROTEIN", 5, 10], ["Hsp70", "PROTEIN", 15, 20], ["Both Hsp60", "TEST", 0, 10], ["Hsp70", "TEST", 15, 20], ["directly bind virus RNA", "PROBLEM", 31, 54], ["thereby control viral infection", "PROBLEM", 80, 111], ["viral infection", "OBSERVATION", 96, 111]]], ["Consistent with this scenario, Hsp70 association with Nairovirus N was required for viral replication (Surtees et al., 2016) .DISCUSSIONWe also recognized the ribosomal receptor of activated protein C kinase 1 and cytoplasmic heterogeneous nuclear ribonucleoprotein Q (Figure 7) , earlier being implicated in viral replication and release (Liu et al., 2009; Demirov et al., 2012) .DISCUSSIONA cluster of the proteins is involved in RNA and DNA processes ( Table 1 , noted in red).", [["ribosomal", "ANATOMY", 159, 168], ["cytoplasmic", "ANATOMY", 214, 225], ["Hsp70", "GENE_OR_GENE_PRODUCT", 31, 36], ["Nairovirus N", "GENE_OR_GENE_PRODUCT", 54, 66], ["ribosomal", "CELLULAR_COMPONENT", 159, 168], ["receptor of activated protein C kinase 1", "GENE_OR_GENE_PRODUCT", 169, 209], ["cytoplasmic", "ORGANISM_SUBSTANCE", 214, 225], ["heterogeneous nuclear ribonucleoprotein Q (Figure 7", "GENE_OR_GENE_PRODUCT", 226, 277], ["DNA", "CELLULAR_COMPONENT", 440, 443], ["Table 1", "GENE_OR_GENE_PRODUCT", 456, 463], ["Hsp70", "PROTEIN", 31, 36], ["Nairovirus N", "PROTEIN", 54, 66], ["ribosomal receptor of activated protein C kinase 1", "PROTEIN", 159, 209], ["cytoplasmic heterogeneous nuclear ribonucleoprotein Q", "PROTEIN", 214, 267], ["Figure 7", "PROTEIN", 269, 277], ["Nairovirus N", "TREATMENT", 54, 66], ["viral replication", "PROBLEM", 84, 101], ["activated protein C kinase", "TEST", 181, 207], ["cytoplasmic heterogeneous nuclear ribonucleoprotein Q", "PROBLEM", 214, 267], ["heterogeneous", "OBSERVATION_MODIFIER", 226, 239], ["viral replication", "OBSERVATION", 309, 326]]], ["Viral N has several RNA binding domains that facilitate ribonucleoprotein formation in mature virions.", [["virions", "ANATOMY", 94, 101], ["RNA binding domains", "PROTEIN", 20, 39], ["Viral N", "PROBLEM", 0, 7], ["several RNA binding domains", "PROBLEM", 12, 39], ["ribonucleoprotein formation", "PROBLEM", 56, 83], ["ribonucleoprotein formation", "OBSERVATION", 56, 83], ["mature virions", "OBSERVATION", 87, 101]]], ["This should also give a basis for molecular mimicry allowing N to associate with host cellular RNA-binding proteins, to be transported to the nuclear region and to utilize host protein machinery for virus production (Rowland and Yoo, 2003; Wulan et al., 2015) .DISCUSSIONA group of N-binding proteins orchestrates membrane-bound vesicle communication (Table 1 , shown in violet).", [["cellular", "ANATOMY", 86, 94], ["nuclear region", "ANATOMY", 142, 156], ["membrane", "ANATOMY", 314, 322], ["vesicle", "ANATOMY", 329, 336], ["cellular", "CELL", 86, 94], ["nuclear", "CELLULAR_COMPONENT", 142, 149], ["N-binding proteins", "GENE_OR_GENE_PRODUCT", 282, 300], ["membrane", "CELLULAR_COMPONENT", 314, 322], ["vesicle", "CELLULAR_COMPONENT", 329, 336], ["violet", "SIMPLE_CHEMICAL", 371, 377], ["host cellular RNA-binding proteins", "PROTEIN", 81, 115], ["N-binding proteins", "PROTEIN", 282, 300], ["host cellular RNA-binding proteins", "PROBLEM", 81, 115], ["host protein machinery", "TREATMENT", 172, 194], ["N-binding proteins", "TREATMENT", 282, 300]]], ["Extracellular membrane vesicles (EMV) are membrane-bound structures shedding from cells into the environment and playing a role in cell-cell communication through protein, lipid and nucleic acid transfer.", [["Extracellular membrane vesicles", "ANATOMY", 0, 31], ["EMV", "ANATOMY", 33, 36], ["membrane", "ANATOMY", 42, 50], ["structures", "ANATOMY", 57, 67], ["cells", "ANATOMY", 82, 87], ["cell", "ANATOMY", 131, 135], ["cell", "ANATOMY", 136, 140], ["nucleic acid", "CHEMICAL", 182, 194], ["Extracellular", "CELLULAR_COMPONENT", 0, 13], ["membrane vesicles", "CELLULAR_COMPONENT", 14, 31], ["EMV", "CELLULAR_COMPONENT", 33, 36], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["cells", "CELL", 82, 87], ["cell", "CELL", 131, 135], ["cell", "CELL", 136, 140], ["lipid", "SIMPLE_CHEMICAL", 172, 177], ["nucleic acid", "SIMPLE_CHEMICAL", 182, 194], ["Extracellular membrane vesicles", "PROBLEM", 0, 31], ["nucleic acid transfer", "TREATMENT", 182, 203], ["membrane vesicles", "OBSERVATION", 14, 31]]], ["Both pathogenic bacteria and viruses can hijack FIGURE 8 | Schematic model.", [["Both pathogenic bacteria", "PROBLEM", 0, 24], ["pathogenic", "OBSERVATION_MODIFIER", 5, 15], ["bacteria", "OBSERVATION", 16, 24], ["viruses", "OBSERVATION", 29, 36]]], ["Epithelial wound healing process and cellular protein networks (shown as arrows) in human epithelial cells (in pink) are perturbed by Hazara virus infection.", [["Epithelial wound", "ANATOMY", 0, 16], ["cellular", "ANATOMY", 37, 45], ["epithelial cells", "ANATOMY", 90, 106], ["infection", "DISEASE", 147, 156], ["Epithelial wound", "PATHOLOGICAL_FORMATION", 0, 16], ["cellular", "CELL", 37, 45], ["human", "ORGANISM", 84, 89], ["epithelial cells", "CELL", 90, 106], ["Hazara virus", "ORGANISM", 134, 146], ["cellular protein networks", "PROTEIN", 37, 62], ["human epithelial cells", "CELL_TYPE", 84, 106], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["Hazara virus", "SPECIES", 134, 146], ["Epithelial wound healing process", "PROBLEM", 0, 32], ["cellular protein networks", "PROBLEM", 37, 62], ["human epithelial cells", "PROBLEM", 84, 106], ["Hazara virus infection", "PROBLEM", 134, 156], ["wound", "OBSERVATION_MODIFIER", 11, 16], ["healing", "OBSERVATION", 17, 24], ["cellular protein networks", "OBSERVATION", 37, 62], ["epithelial cells", "OBSERVATION", 90, 106], ["virus infection", "OBSERVATION", 141, 156]]], ["This is paralleled by disruption in the organization of actin cytoskeleton (in red) and reduction of the expression and distribution of IQGAP1 (in green) and AQP6 (in yellow), events that influence homeostasis in the intestine and along blood vessel walls and integrity of an individual. host EMV and thereby enhance their pathogenicity (Schwab et al., 2015; Turkina et al., 2015) .", [["cytoskeleton", "ANATOMY", 62, 74], ["intestine", "ANATOMY", 217, 226], ["blood vessel walls", "ANATOMY", 237, 255], ["actin", "GENE_OR_GENE_PRODUCT", 56, 61], ["cytoskeleton", "CELLULAR_COMPONENT", 62, 74], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 136, 142], ["green)", "GENE_OR_GENE_PRODUCT", 147, 153], ["AQP6", "GENE_OR_GENE_PRODUCT", 158, 162], ["intestine", "ORGAN", 217, 226], ["blood vessel walls", "MULTI-TISSUE_STRUCTURE", 237, 255], ["actin", "PROTEIN", 56, 61], ["IQGAP1", "PROTEIN", 136, 142], ["AQP6", "PROTEIN", 158, 162], ["IQGAP1 (in green) and AQP6 (in yellow", "PROBLEM", 136, 173], ["influence homeostasis in the intestine", "PROBLEM", 188, 226], ["disruption", "OBSERVATION", 22, 32], ["actin cytoskeleton", "OBSERVATION", 56, 74], ["reduction", "OBSERVATION_MODIFIER", 88, 97], ["expression", "OBSERVATION_MODIFIER", 105, 115], ["distribution", "OBSERVATION_MODIFIER", 120, 132], ["IQGAP1", "OBSERVATION_MODIFIER", 136, 142], ["intestine", "ANATOMY", 217, 226], ["blood vessel", "ANATOMY", 237, 249], ["walls", "ANATOMY_MODIFIER", 250, 255], ["integrity", "OBSERVATION_MODIFIER", 260, 269]]], ["Coxsackie virus disseminates within host EMV upon stem cell migration and differentiation and thereby spreads to new cells (Robinson et al., 2014) .", [["EMV", "ANATOMY", 41, 44], ["stem cell", "ANATOMY", 50, 59], ["cells", "ANATOMY", 117, 122], ["Coxsackie virus", "ORGANISM", 0, 15], ["EMV", "CELL", 41, 44], ["stem cell", "CELL", 50, 59], ["cells", "CELL", 117, 122], ["Coxsackie virus", "SPECIES", 0, 15], ["Coxsackie virus", "SPECIES", 0, 15], ["EMV", "SPECIES", 41, 44], ["Coxsackie virus disseminates", "PROBLEM", 0, 28], ["stem cell migration", "TREATMENT", 50, 69], ["stem cell migration", "OBSERVATION", 50, 69]]], ["Severe fever with thrombocytopenia syndrome virus (SFTS), which is a new Bunyaviridae family member, incorporates itself into EMV and use them as a delivery system for its own spreading (Silvas et al., 2016) .", [["fever", "DISEASE", 7, 12], ["thrombocytopenia syndrome", "DISEASE", 18, 43], ["SFTS", "DISEASE", 51, 55], ["Bunyaviridae", "DISEASE", 73, 85], ["EMV", "CANCER", 126, 129], ["Severe fever with thrombocytopenia syndrome virus", "SPECIES", 0, 49], ["EMV", "SPECIES", 126, 129], ["Severe fever", "PROBLEM", 0, 12], ["thrombocytopenia syndrome virus", "PROBLEM", 18, 49], ["a delivery system", "TREATMENT", 146, 163], ["fever", "OBSERVATION", 7, 12], ["thrombocytopenia", "OBSERVATION", 18, 34]]], ["We suggest that Hazara virus may also take the advantage of host EMV to promote spreading through cell-tocell contacts and thereby the establishment and progression of infection.DISCUSSIONA large group of proteins is required for regulation of cell morphology, migration, differentiation, proliferation and apoptosis ( Table 1 , shown in green).", [["cell", "ANATOMY", 98, 102], ["tocell contacts", "ANATOMY", 103, 118], ["cell", "ANATOMY", 244, 248], ["infection", "DISEASE", 168, 177], ["Hazara virus", "ORGANISM", 16, 28], ["EMV", "GENE_OR_GENE_PRODUCT", 65, 68], ["cell", "CELL", 98, 102], ["cell", "CELL", 244, 248], ["Hazara virus", "SPECIES", 16, 28], ["EMV", "SPECIES", 65, 68], ["Hazara virus", "PROBLEM", 16, 28], ["host EMV", "TREATMENT", 60, 68], ["cell-tocell contacts", "TREATMENT", 98, 118], ["infection", "PROBLEM", 168, 177], ["large group of proteins", "PROBLEM", 190, 213], ["proliferation", "PROBLEM", 289, 302], ["apoptosis", "PROBLEM", 307, 316], ["progression", "OBSERVATION_MODIFIER", 153, 164], ["infection", "OBSERVATION", 168, 177], ["cell morphology", "OBSERVATION", 244, 259], ["migration", "OBSERVATION_MODIFIER", 261, 270], ["proliferation", "OBSERVATION_MODIFIER", 289, 302], ["apoptosis", "OBSERVATION_MODIFIER", 307, 316]]], ["Indeed, virus can target and manipulate host cytoskeleton dynamics and organization which may ensure virus replication and spread (Sewald et al., 2016) .", [["cytoskeleton", "ANATOMY", 45, 57], ["virus", "PROBLEM", 8, 13], ["virus replication", "PROBLEM", 101, 118], ["virus", "OBSERVATION", 8, 13]]], ["Dendritic cells (Cunningham et al., 2010) , monocytes (Daley-Bauer et al., 2014) , and T-cells (Murooka et al., 2012) can be hijacked by varicella zoster virus, cytomegalovirus and HIV, and thereby used as migratory vehicles for viral dissemination.DISCUSSIONIn many RNA viruses, N is known not only as a structural but also as a functionally important protein.", [["Dendritic cells", "ANATOMY", 0, 15], ["monocytes", "ANATOMY", 44, 53], ["T-cells", "ANATOMY", 87, 94], ["varicella zoster", "DISEASE", 137, 153], ["Dendritic cells", "CELL", 0, 15], ["monocytes", "CELL", 44, 53], ["T-cells", "CELL", 87, 94], ["varicella zoster virus", "ORGANISM", 137, 159], ["cytomegalovirus", "ORGANISM", 161, 176], ["HIV", "ORGANISM", 181, 184], ["Dendritic cells", "CELL_TYPE", 0, 15], ["monocytes", "CELL_TYPE", 44, 53], ["T-cells", "CELL_TYPE", 87, 94], ["varicella zoster virus", "SPECIES", 137, 159], ["HIV", "SPECIES", 181, 184], ["varicella zoster virus", "SPECIES", 137, 159], ["HIV", "SPECIES", 181, 184], ["Dendritic cells", "TEST", 0, 15], ["Cunningham et al.", "TEST", 17, 34], ["monocytes", "TEST", 44, 53], ["Daley", "TEST", 55, 60], ["Bauer et al.", "TEST", 61, 73], ["varicella zoster virus", "PROBLEM", 137, 159], ["cytomegalovirus", "PROBLEM", 161, 176], ["HIV", "PROBLEM", 181, 184], ["viral dissemination", "PROBLEM", 229, 248], ["many RNA viruses", "PROBLEM", 262, 278], ["monocytes", "ANATOMY", 44, 53], ["varicella zoster", "ANATOMY", 137, 153], ["cytomegalovirus", "OBSERVATION", 161, 176], ["RNA viruses", "OBSERVATION", 267, 278]]], ["Thus, N binds to the viral RNA genome and forms ribonucleoproteins in mature virions, which is seen in severe acute respiratory syndrome coronavirus (Huang et al., 2004) , infectious bronchitis virus (Spencer and Hiscox, 2006) , and CCHFV (Morikawa et al., 2007) .", [["virions", "ANATOMY", 77, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 110, 148], ["infectious bronchitis virus", "DISEASE", 172, 199], ["CCHFV", "DISEASE", 233, 238], ["infectious bronchitis virus", "ORGANISM", 172, 199], ["N", "PROTEIN", 6, 7], ["viral RNA genome", "DNA", 21, 37], ["infectious bronchitis virus", "SPECIES", 172, 199], ["severe acute respiratory syndrome coronavirus", "SPECIES", 103, 148], ["infectious bronchitis virus", "SPECIES", 172, 199], ["CCHFV", "SPECIES", 233, 238], ["the viral RNA genome", "PROBLEM", 17, 37], ["ribonucleoproteins in mature virions", "PROBLEM", 48, 84], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 103, 148], ["infectious bronchitis virus", "PROBLEM", 172, 199], ["viral RNA genome", "OBSERVATION", 21, 37], ["mature virions", "OBSERVATION", 70, 84], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory syndrome coronavirus", "OBSERVATION", 116, 148], ["infectious", "OBSERVATION_MODIFIER", 172, 182], ["bronchitis", "OBSERVATION", 183, 193], ["CCHFV", "ANATOMY", 233, 238]]], ["Viral N interferes with immune system to enhance virus virulence, arrest host cell cycle and inactivate chaperons (Emmott et al., 2013; McBride et al., 2014) .", [["immune system", "ANATOMY", 24, 37], ["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["Viral N", "PROBLEM", 0, 7], ["immune system", "TREATMENT", 24, 37], ["virus virulence", "PROBLEM", 49, 64], ["arrest host cell cycle", "TREATMENT", 66, 88]]], ["By such a broader interaction with host cell proteins, directly or in-directly, N may manipulate host cytoskeleton dynamics and other distinct cellular processes that potentially affect the virus life cycle.DISCUSSIONIn summary, our study demonstrates that Hazara virus can modulate migration of human epithelial cells, disrupt their actin cytoskeleton organization, cellular distribution and reduce the expression of IQGAP1 and AQP6, which help regulate cytoskeleton dynamics and water homeostasis.", [["cell", "ANATOMY", 40, 44], ["cytoskeleton", "ANATOMY", 102, 114], ["cellular", "ANATOMY", 143, 151], ["epithelial cells", "ANATOMY", 302, 318], ["cytoskeleton", "ANATOMY", 340, 352], ["cellular", "ANATOMY", 367, 375], ["cytoskeleton", "ANATOMY", 455, 467], ["host cell", "CELL", 35, 44], ["cellular", "CELL", 143, 151], ["Hazara virus", "ORGANISM", 257, 269], ["human", "ORGANISM", 296, 301], ["epithelial cells", "CELL", 302, 318], ["actin", "GENE_OR_GENE_PRODUCT", 334, 339], ["cytoskeleton", "CELLULAR_COMPONENT", 340, 352], ["cellular", "CELL", 367, 375], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 418, 424], ["AQP6", "GENE_OR_GENE_PRODUCT", 429, 433], ["cytoskeleton", "CELLULAR_COMPONENT", 455, 467], ["water", "SIMPLE_CHEMICAL", 481, 486], ["host cell proteins", "PROTEIN", 35, 53], ["human epithelial cells", "CELL_TYPE", 296, 318], ["actin", "PROTEIN", 334, 339], ["IQGAP1", "PROTEIN", 418, 424], ["AQP6", "PROTEIN", 429, 433], ["human", "SPECIES", 296, 301], ["Hazara virus", "SPECIES", 257, 269], ["human", "SPECIES", 296, 301], ["host cell proteins", "TREATMENT", 35, 53], ["other distinct cellular processes", "PROBLEM", 128, 161], ["our study", "TEST", 229, 238], ["Hazara virus", "PROBLEM", 257, 269], ["human epithelial cells", "PROBLEM", 296, 318], ["IQGAP1 and AQP6", "PROBLEM", 418, 433], ["cellular processes", "OBSERVATION", 143, 161], ["migration", "OBSERVATION_MODIFIER", 283, 292], ["human epithelial cells", "OBSERVATION", 296, 318], ["actin cytoskeleton organization", "OBSERVATION", 334, 365], ["cellular", "OBSERVATION_MODIFIER", 367, 375], ["distribution", "OBSERVATION_MODIFIER", 376, 388]]], ["Moreover, upon infection, Hazara virus structural N is engaged with an array of cellular protein interactions (Figure 8 ).", [["cellular", "ANATOMY", 80, 88], ["infection", "DISEASE", 15, 24], ["Hazara virus", "ORGANISM", 26, 38], ["cellular", "CELL", 80, 88], ["Hazara virus", "SPECIES", 26, 38], ["infection", "PROBLEM", 15, 24], ["Hazara virus structural N", "PROBLEM", 26, 51], ["cellular protein interactions", "PROBLEM", 80, 109], ["infection", "OBSERVATION", 15, 24], ["cellular protein interactions", "OBSERVATION", 80, 109]]], ["Our interactome data provide a foundation for future work on mechanistic insights into biology of an infection.", [["infection", "DISEASE", 101, 110], ["an infection", "PROBLEM", 98, 110], ["infection", "OBSERVATION", 101, 110]]], ["Taken together, these events interfere with many cellular processes that potentially facilitate the virus life cycle, but they are also deleterious to cell renewal and wound healing at epithelial and endothelial linings being so essential to organism homeostasis under normal physiological situation and after bacterial or virus injury and infection.SUPPLEMENTARY MATERIALThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2017.", [["cellular", "ANATOMY", 49, 57], ["cell", "ANATOMY", 151, 155], ["wound", "ANATOMY", 168, 173], ["epithelial", "ANATOMY", 185, 195], ["endothelial linings", "ANATOMY", 200, 219], ["infection", "DISEASE", 340, 349], ["SUPPLEMENTARY", "DISEASE", 350, 363], ["cellular", "CELL", 49, 57], ["cell", "CELL", 151, 155], ["wound", "PATHOLOGICAL_FORMATION", 168, 173], ["epithelial", "TISSUE", 185, 195], ["endothelial linings", "TISSUE", 200, 219], ["many cellular processes", "PROBLEM", 44, 67], ["the virus life cycle", "TREATMENT", 96, 116], ["cell renewal", "TREATMENT", 151, 163], ["wound healing", "PROBLEM", 168, 181], ["epithelial and endothelial linings", "TREATMENT", 185, 219], ["bacterial or virus injury", "PROBLEM", 310, 335], ["infection", "PROBLEM", 340, 349], ["wound", "OBSERVATION_MODIFIER", 168, 173], ["healing", "OBSERVATION_MODIFIER", 174, 181], ["endothelial", "ANATOMY", 200, 211], ["virus", "OBSERVATION", 323, 328], ["infection", "OBSERVATION", 340, 349]]], ["00098/full#supplementary-material Figure S1 | Visualization of Hazara virus, F-actin, IQGAP1 and AQP6 in epithelial cells.", [["epithelial cells", "ANATOMY", 105, 121], ["Hazara virus", "ORGANISM", 63, 75], ["F-actin", "GENE_OR_GENE_PRODUCT", 77, 84], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 86, 92], ["AQP6", "GENE_OR_GENE_PRODUCT", 97, 101], ["epithelial cells", "CELL", 105, 121], ["F-actin", "PROTEIN", 77, 84], ["IQGAP1", "PROTEIN", 86, 92], ["AQP6", "PROTEIN", 97, 101], ["epithelial cells", "CELL_TYPE", 105, 121], ["Hazara virus", "SPECIES", 63, 75], ["Hazara virus", "PROBLEM", 63, 75], ["F-actin", "TEST", 77, 84], ["IQGAP1", "TEST", 86, 92], ["epithelial cells", "OBSERVATION", 105, 121]]], ["Cells were untreated (Control) or infected with Hazara virus at MOI 1 for 1 h and maintained for 24 hpi.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Hazara virus", "ORGANISM", 48, 60], ["Hazara virus", "SPECIES", 48, 60], ["Hazara virus", "PROBLEM", 48, 60]]], ["Samples were then fixed and stained for: (A) viral N (red) and F-actin (green); (B) viral N (red) and IQGAP1 (green); (C) viral N (green) and AQP6 (red); nuclei were labeled with DAPI (blue).", [["Samples", "ANATOMY", 0, 7], ["nuclei", "ANATOMY", 154, 160], ["DAPI", "CHEMICAL", 179, 183], ["F-actin", "GENE_OR_GENE_PRODUCT", 63, 70], ["N (red)", "GENE_OR_GENE_PRODUCT", 90, 97], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 102, 108], ["N (green)", "GENE_OR_GENE_PRODUCT", 128, 137], ["AQP6 (red)", "GENE_OR_GENE_PRODUCT", 142, 152], ["nuclei", "CELLULAR_COMPONENT", 154, 160], ["DAPI", "SIMPLE_CHEMICAL", 179, 183], ["actin", "PROTEIN", 65, 70], ["viral N (red)", "PROTEIN", 84, 97], ["IQGAP1", "PROTEIN", 102, 108], ["AQP6", "PROTEIN", 142, 146], ["Samples", "TEST", 0, 7], ["A) viral N", "TEST", 42, 52], ["viral N", "TEST", 84, 91], ["IQGAP1", "TEST", 102, 108], ["viral N (green", "TEST", 122, 136], ["AQP6", "TEST", 142, 146]]], ["Samples were analyzed by confocal microscopy.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["confocal microscopy", "TEST", 25, 44]]], ["Image size is 67.6 \u00d7 67.6 \u00b5m and pixel size is 0.13 \u00b5m.", [["Image size", "TEST", 0, 10], ["pixel size", "TEST", 33, 43], ["size", "OBSERVATION_MODIFIER", 39, 43], ["0.13 \u00b5m", "OBSERVATION_MODIFIER", 47, 54]]], ["Quantification of immunofluorescence intensity profiles for F-actin (D), IQGAP1 (E) and AQP6 (F) measured across the cell monolayers as indicated by blue arrows (control) and yellow arrows (virus-infected cells, MOI 1, 24 hpi).", [["cell monolayers", "ANATOMY", 117, 132], ["cells", "ANATOMY", 205, 210], ["F-actin", "GENE_OR_GENE_PRODUCT", 60, 67], ["D", "GENE_OR_GENE_PRODUCT", 69, 70], ["IQGAP1 (E)", "GENE_OR_GENE_PRODUCT", 73, 83], ["AQP6 (F)", "GENE_OR_GENE_PRODUCT", 88, 96], ["cell monolayers", "CELL", 117, 132], ["cells", "CELL", 205, 210], ["F", "PROTEIN", 60, 61], ["actin", "PROTEIN", 62, 67], ["D", "PROTEIN", 69, 70], ["IQGAP1", "PROTEIN", 73, 79], ["E", "PROTEIN", 81, 82], ["AQP6 (F)", "PROTEIN", 88, 96], ["virus-infected cells", "CELL_TYPE", 190, 210], ["immunofluorescence intensity profiles", "TEST", 18, 55], ["F-actin (D), IQGAP1 (E) and AQP6 (F)", "TEST", 60, 96], ["the cell monolayers", "TREATMENT", 113, 132], ["yellow arrows (virus-infected cells", "PROBLEM", 175, 210], ["MOI", "TEST", 212, 215], ["cell monolayers", "OBSERVATION", 117, 132]]], ["The length of arrows reflects the distance of 60 \u00b5m.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Figure S2 | Additional quantification of F-actin fluorescence intensity profiles.", [["F-actin", "GENE_OR_GENE_PRODUCT", 41, 48], ["F-actin", "PROTEIN", 41, 48], ["F-actin fluorescence intensity profiles", "PROBLEM", 41, 80], ["F-actin fluorescence", "OBSERVATION", 41, 61]]], ["The set of experiments were performed and quantification of fluorescence intensity profiles were done as in Figure 4A and Figures S1A,D. Non-infected cells are indicated by blue arrows (control) and virus-infected cells are coded by yellow arrows (MOI 1, 24 hpi).", [["cells", "ANATOMY", 150, 155], ["cells", "ANATOMY", 214, 219], ["cells", "CELL", 150, 155], ["cells", "CELL", 214, 219], ["Non-infected cells", "CELL_TYPE", 137, 155], ["virus-infected cells", "CELL_TYPE", 199, 219], ["fluorescence intensity profiles", "TEST", 60, 91], ["Non-infected cells", "PROBLEM", 137, 155], ["blue arrows", "PROBLEM", 173, 184], ["virus", "PROBLEM", 199, 204], ["infected cells", "PROBLEM", 205, 219], ["blue arrows", "OBSERVATION", 173, 184], ["infected cells", "OBSERVATION", 205, 219]]], ["The length of arrows reflects the distance of 60 \u00b5m.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Shown are F-actin intensity profiles measured across the cell monolayers from 6 representative cell regions and three independent experiments performed on separate days from different cell passages.", [["cell monolayers", "ANATOMY", 57, 72], ["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 184, 188], ["F-actin", "GENE_OR_GENE_PRODUCT", 10, 17], ["cell monolayers", "CELL", 57, 72], ["cell", "CELL", 95, 99], ["cell", "CELL", 184, 188], ["F-actin", "PROTEIN", 10, 17], ["F-actin intensity profiles", "PROBLEM", 10, 36], ["F-actin intensity", "OBSERVATION", 10, 27], ["cell monolayers", "OBSERVATION", 57, 72], ["cell passages", "OBSERVATION", 184, 197]]], ["Figure S3 | Additional quantification of IQGAP1 fluorescence intensity profiles.", [["IQGAP1", "GENE_OR_GENE_PRODUCT", 41, 47], ["IQGAP1", "PROTEIN", 41, 47], ["IQGAP1 fluorescence intensity profiles", "PROBLEM", 41, 79], ["IQGAP1 fluorescence", "OBSERVATION", 41, 60]]], ["The set of experiments were performed and quantification of fluorescence intensity profiles were done as in Figure 4B and Figures S1B,E. Non-infected cells are indicated by blue arrows (control) and virus-infected cells are coded by yellow arrows (MOI 1, 24 hpi).", [["cells", "ANATOMY", 150, 155], ["cells", "ANATOMY", 214, 219], ["cells", "CELL", 150, 155], ["cells", "CELL", 214, 219], ["Non-infected cells", "CELL_TYPE", 137, 155], ["virus-infected cells", "CELL_TYPE", 199, 219], ["fluorescence intensity profiles", "TEST", 60, 91], ["Non-infected cells", "PROBLEM", 137, 155], ["blue arrows", "PROBLEM", 173, 184], ["virus", "PROBLEM", 199, 204], ["infected cells", "PROBLEM", 205, 219], ["blue arrows", "OBSERVATION", 173, 184], ["infected cells", "OBSERVATION", 205, 219]]], ["The length of arrows reflects the distance of 60 \u00b5m.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Shown are IQGAP1 intensity profiles measured across the cell monolayers from 6 representative cell regions and three independent experiments performed on separate days from different cell passages.", [["cell monolayers", "ANATOMY", 56, 71], ["cell", "ANATOMY", 94, 98], ["cell", "ANATOMY", 183, 187], ["IQGAP1", "GENE_OR_GENE_PRODUCT", 10, 16], ["cell monolayers", "CELL", 56, 71], ["cell", "CELL", 94, 98], ["cell", "CELL", 183, 187], ["IQGAP1", "PROTEIN", 10, 16], ["IQGAP1 intensity profiles", "PROBLEM", 10, 35], ["IQGAP1", "OBSERVATION", 10, 16], ["intensity", "OBSERVATION_MODIFIER", 17, 26], ["cell monolayers", "OBSERVATION", 56, 71], ["cell passages", "OBSERVATION", 183, 196]]], ["Figure S4 | Additional quantification of AQP6 fluorescence intensity profiles.", [["AQP6", "GENE_OR_GENE_PRODUCT", 41, 45], ["AQP6", "PROTEIN", 41, 45], ["AQP6 fluorescence intensity profiles", "PROBLEM", 41, 77]]], ["The set of experiments were performed and quantification of fluorescence intensity profiles were done as in Figure 4C and Figures S1C,F. Non-infected cells are indicated by blue arrows (control) and virus-infected cells are coded by yellow arrows (MOI 1, 24 hpi).", [["cells", "ANATOMY", 150, 155], ["cells", "ANATOMY", 214, 219], ["cells", "CELL", 150, 155], ["cells", "CELL", 214, 219], ["Non-infected cells", "CELL_TYPE", 137, 155], ["virus-infected cells", "CELL_TYPE", 199, 219], ["fluorescence intensity profiles", "TEST", 60, 91], ["Non-infected cells", "PROBLEM", 137, 155], ["blue arrows", "PROBLEM", 173, 184], ["virus", "PROBLEM", 199, 204], ["infected cells", "PROBLEM", 205, 219], ["blue arrows", "OBSERVATION", 173, 184], ["infected cells", "OBSERVATION", 205, 219]]], ["The length of arrows reflects the distance of 60 \u00b5m.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Shown are AQP6 intensity profiles measured across the cell monolayers from 6 representative cell regions and three independent experiments performed on separate days from different cell passages.", [["cell monolayers", "ANATOMY", 54, 69], ["cell", "ANATOMY", 92, 96], ["cell", "ANATOMY", 181, 185], ["AQP6", "GENE_OR_GENE_PRODUCT", 10, 14], ["cell monolayers", "CELL", 54, 69], ["cell", "CELL", 92, 96], ["cell", "CELL", 181, 185], ["AQP6", "PROTEIN", 10, 14], ["AQP6 intensity profiles", "PROBLEM", 10, 33], ["different cell passages", "TREATMENT", 171, 194], ["cell monolayers", "OBSERVATION", 54, 69], ["cell passages", "OBSERVATION", 181, 194]]], ["Colored network nodes represent query proteins.", [["network nodes", "ANATOMY", 8, 21], ["network nodes", "MULTI-TISSUE_STRUCTURE", 8, 21], ["Colored network nodes", "PROBLEM", 0, 21], ["query proteins", "PROBLEM", 32, 46], ["network nodes", "OBSERVATION", 8, 21], ["query proteins", "OBSERVATION", 32, 46]]], ["Edges represent protein-protein interactions and include different type of actions depicted by the colored lines.", [["lines", "CELL", 107, 112], ["colored lines", "CELL_LINE", 99, 112], ["protein-protein interactions", "TREATMENT", 16, 44], ["protein", "OBSERVATION", 16, 23], ["protein interactions", "OBSERVATION", 24, 44], ["colored lines", "OBSERVATION", 99, 112]]], ["For known interactions: pink, experimentally determined; turquoise, from curated databases.", [["pink", "OBSERVATION", 24, 28]]], ["Network nodes represent proteins.", [["Network nodes", "ANATOMY", 0, 13], ["Network nodes", "MULTI-TISSUE_STRUCTURE", 0, 13], ["nodes", "OBSERVATION", 8, 13]]], ["Red nodes, query proteins and first shell of interaction for those involved in (A) RNA and DNA processes and those associated to (B) membrane bond vesicles.", [["Red nodes", "ANATOMY", 0, 9], ["membrane bond vesicles", "ANATOMY", 133, 155], ["Red nodes", "MULTI-TISSUE_STRUCTURE", 0, 9], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["vesicles", "CELLULAR_COMPONENT", 147, 155], ["Red nodes", "PROBLEM", 0, 9], ["DNA processes", "PROBLEM", 91, 104], ["nodes", "OBSERVATION", 4, 9], ["first shell", "OBSERVATION_MODIFIER", 30, 41]]], ["White nodes, second shell of interaction.", [["White nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["White nodes", "PROBLEM", 0, 11], ["nodes", "OBSERVATION", 6, 11], ["second shell", "OBSERVATION_MODIFIER", 13, 25]]], ["Edges represent protein-protein interactions and include different type of actions depicted by the colored lines as in Figure S1 .", [["colored lines", "CELL_LINE", 99, 112], ["protein-protein interactions", "TREATMENT", 16, 44], ["the colored lines", "TREATMENT", 95, 112], ["protein", "OBSERVATION", 16, 23], ["protein interactions", "OBSERVATION", 24, 44], ["colored lines", "OBSERVATION", 99, 112]]]], "PMC7110610": [["IntroductionSevere acute respiratory syndrome (SARS) has recently emerged as a new severe human disease that resulted in 774 deaths and more than 8000 reported probable cases worldwide.1 The SARS epidemic began in the Guangdong province in southern China, where several cases of atypical pneumonia of unknown etiology were reported in November 2002.IntroductionA novel member of the Coronaviridae family has been identified as the causative agent of this pulmonary disease.2, 3, 4, 5, 6 The SARS-coronavirus (SARS-CoV) is a new coronavirus type, of which the morphology and genome organization are very similar to those of other coronaviruses.", [["pulmonary", "ANATOMY", 455, 464], ["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["deaths", "DISEASE", 125, 131], ["SARS", "DISEASE", 191, 195], ["pneumonia", "DISEASE", 288, 297], ["pulmonary disease", "DISEASE", 455, 472], ["SARS-coronavirus", "DISEASE", 491, 507], ["SARS", "DISEASE", 509, 513], ["human", "ORGANISM", 90, 95], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 383, 396], ["pulmonary", "ORGAN", 455, 464], ["SARS-coronavirus", "ORGANISM", 491, 507], ["SARS-CoV", "ORGANISM", 509, 517], ["coronavirus", "ORGANISM", 528, 539], ["coronaviruses", "ORGANISM", 629, 642], ["Coronaviridae family", "PROTEIN", 383, 403], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["SARS-coronavirus", "SPECIES", 491, 507], ["SARS-CoV", "SPECIES", 509, 517], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a new severe human disease", "PROBLEM", 77, 103], ["The SARS epidemic", "PROBLEM", 187, 204], ["atypical pneumonia", "PROBLEM", 279, 297], ["this pulmonary disease", "PROBLEM", 450, 472], ["The SARS", "TEST", 487, 495], ["a new coronavirus type", "PROBLEM", 522, 544], ["other coronaviruses", "PROBLEM", 623, 642], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["new", "OBSERVATION_MODIFIER", 79, 82], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["SARS", "OBSERVATION_MODIFIER", 191, 195], ["epidemic", "OBSERVATION_MODIFIER", 196, 204], ["atypical", "OBSERVATION_MODIFIER", 279, 287], ["pneumonia", "OBSERVATION", 288, 297], ["pulmonary", "ANATOMY", 455, 464], ["disease", "OBSERVATION", 465, 472], ["new", "OBSERVATION_MODIFIER", 524, 527], ["coronavirus type", "OBSERVATION", 528, 544], ["morphology", "OBSERVATION_MODIFIER", 559, 569], ["genome organization", "OBSERVATION", 574, 593], ["coronaviruses", "OBSERVATION", 629, 642]]], ["Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closely related to any of the previously characterized coronaviruses.6, 7", [["SARS", "DISEASE", 59, 63], ["SARS-CoV", "ORGANISM", 59, 67], ["coronaviruses", "ORGANISM", 130, 143], ["SARS-CoV", "SPECIES", 59, 67], ["Phylogenetic analyses", "TEST", 0, 21], ["sequence comparisons", "TEST", 26, 46], ["SARS-CoV", "PROBLEM", 59, 67], ["the previously characterized coronaviruses", "PROBLEM", 101, 143], ["coronaviruses", "OBSERVATION", 130, 143]]]], "b022afc799e4faea03c71335a62fbda966751dcf": [["Introduction And BackgroundSix Coronavirus species are culprits of human ailments [1] .", [["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Introduction", "TREATMENT", 0, 12], ["BackgroundSix Coronavirus species", "PROBLEM", 17, 50]]], ["The emergence of the severe acute respiratory syndrome (SARS) in 2002-2003 and the Middle East respiratory syndrome (MERS) in 2012 showed the transferal of virus between animal-to-human and human-to-human [2] [3] .", [["acute respiratory syndrome", "DISEASE", 28, 54], ["SARS", "DISEASE", 56, 60], ["Middle East respiratory syndrome", "DISEASE", 83, 115], ["MERS", "DISEASE", 117, 121], ["human", "ORGANISM", 180, 185], ["human", "ORGANISM", 190, 195], ["human", "ORGANISM", 199, 204], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 199, 204], ["the severe acute respiratory syndrome", "PROBLEM", 17, 54], ["SARS", "PROBLEM", 56, 60], ["the Middle East respiratory syndrome", "PROBLEM", 79, 115], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory syndrome", "OBSERVATION", 34, 54], ["Middle", "ANATOMY_MODIFIER", 83, 89], ["respiratory syndrome", "OBSERVATION", 95, 115]]], ["In December 2019, a new virus named COVID-19 surfaced in Wuhan [4] .", [["a new virus named COVID", "TREATMENT", 18, 41]]], ["It has rapidly disseminated across China and several other countries [5] [6] [7] [8] [9] [10] [11] .", [["[5] [6] [7] [8] [9] [10]", "CHEMICAL", 69, 93], ["[5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 69, 98], ["rapidly", "OBSERVATION_MODIFIER", 7, 14], ["disseminated", "OBSERVATION", 15, 27]]], ["These cases of mysterious pneumonia in Wuhan were communicated to the World Health Organization (WHO) on the last day of 2019 [13] .", [["pneumonia", "DISEASE", 26, 35], ["mysterious pneumonia", "PROBLEM", 15, 35], ["mysterious", "OBSERVATION_MODIFIER", 15, 25], ["pneumonia", "OBSERVATION", 26, 35]]], ["Later, on January 7, 2020, Chinese health authorities asserted that this was due to a novel coronavirus, 2019-nCoV [14] .", [["coronavirus", "ORGANISM", 92, 103], ["a novel coronavirus", "PROBLEM", 84, 103]]], ["The blaze has since then escalated, involving the whole of China and 27 other countries, raising the number of cases to 70,000 on Feb 17, 2020 [16] .", [["escalated", "OBSERVATION_MODIFIER", 25, 34]]], ["In March, it was reported that COVID-19 has dispersed in Europe.", [["COVID-19", "CHEMICAL", 31, 39], ["COVID", "TEST", 31, 36]]], ["China, on the other hand, enforced robust measures to fight against COVID-19 by social distancing, early detection of the cases, immense lazaretto, and seclusion of infected individuals.", [["infected individuals", "PROBLEM", 165, 185], ["infected", "OBSERVATION", 165, 173]]], ["All these measures helped flatten the curve of spread in China, Hong Kong, and Singapore.", [["flatten", "OBSERVATION_MODIFIER", 26, 33], ["curve", "OBSERVATION_MODIFIER", 38, 43], ["spread", "OBSERVATION_MODIFIER", 47, 53]]], ["South Korea used digital technology to trace the contacts thus containing the virus without the lockdown.", [["the virus", "PROBLEM", 74, 83]]], ["According to the John Hopkins University case dashboard, the prevalence cases as of March 19, 2020, mounted to 81,155 in China alone ( Figure 1 ).Review SymptomsThe COVID-19 infection has an incubation period varying between two and 14 days, with an average of roughly five days [17] .", [["COVID-19", "CHEMICAL", 165, 173], ["infection", "DISEASE", 174, 183], ["COVID-19", "SPECIES", 165, 173], ["Review Symptoms", "PROBLEM", 146, 161], ["The COVID", "TEST", 161, 170], ["infection", "PROBLEM", 174, 183], ["infection", "OBSERVATION", 174, 183]]], ["The spectrum of disease manifestation is variable, thus complicating the diagnosis of the infected.", [["disease manifestation", "PROBLEM", 16, 37], ["the infected", "PROBLEM", 86, 98], ["spectrum", "OBSERVATION_MODIFIER", 4, 12], ["disease", "OBSERVATION", 16, 23], ["infected", "OBSERVATION", 90, 98]]], ["The majority of patients with COVID-19 are either asymptomatic or have mild symptoms consistent with upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 101, 124], ["upper respiratory tract infection", "DISEASE", 101, 134], ["patients", "ORGANISM", 16, 24], ["upper respiratory", "ORGANISM_SUBDIVISION", 101, 118], ["tract", "ORGANISM_SUBDIVISION", 119, 124], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 30, 35], ["asymptomatic", "PROBLEM", 50, 62], ["mild symptoms", "PROBLEM", 71, 84], ["upper respiratory tract infection", "PROBLEM", 101, 134], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["consistent with", "UNCERTAINTY", 85, 100], ["upper", "ANATOMY_MODIFIER", 101, 106], ["respiratory tract", "ANATOMY", 107, 124], ["infection", "OBSERVATION", 125, 134]]], ["The most typical symptoms of COVID-19 illness are fever, dry cough, and malaise.", [["COVID", "DISEASE", 29, 34], ["illness", "DISEASE", 38, 45], ["fever", "DISEASE", 50, 55], ["dry cough", "DISEASE", 57, 66], ["COVID", "TEST", 29, 34], ["fever", "PROBLEM", 50, 55], ["dry cough", "PROBLEM", 57, 66], ["malaise", "PROBLEM", 72, 79], ["most typical", "OBSERVATION_MODIFIER", 4, 16], ["cough", "OBSERVATION", 61, 66], ["malaise", "OBSERVATION", 72, 79]]], ["Other symptoms include headache, productive cough, shortness of breath, hemoptysis, diarrhea, and decreased lymphocytes on complete blood count [18] [19] [20] .", [["lymphocytes", "ANATOMY", 108, 119], ["blood", "ANATOMY", 132, 137], ["headache", "DISEASE", 23, 31], ["cough", "DISEASE", 44, 49], ["shortness of breath", "DISEASE", 51, 70], ["hemoptysis", "DISEASE", 72, 82], ["diarrhea", "DISEASE", 84, 92], ["lymphocytes", "CELL", 108, 119], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["lymphocytes", "CELL_TYPE", 108, 119], ["Other symptoms", "PROBLEM", 0, 14], ["headache", "PROBLEM", 23, 31], ["productive cough", "PROBLEM", 33, 49], ["shortness of breath", "PROBLEM", 51, 70], ["hemoptysis", "PROBLEM", 72, 82], ["diarrhea", "PROBLEM", 84, 92], ["decreased lymphocytes", "PROBLEM", 98, 119], ["complete blood count", "TEST", 123, 143], ["productive", "OBSERVATION_MODIFIER", 33, 43], ["cough", "OBSERVATION", 44, 49], ["hemoptysis", "OBSERVATION", 72, 82], ["diarrhea", "OBSERVATION", 84, 92], ["decreased", "OBSERVATION_MODIFIER", 98, 107], ["lymphocytes", "OBSERVATION", 108, 119]]], ["A study on the spread of SARS-CoV in health care workers showed 7.5% were SARSpositive cases with no symptoms at all.", [["SARS", "DISEASE", 25, 29], ["SARS-CoV", "ORGANISM", 25, 33], ["SARS-CoV", "SPECIES", 25, 33], ["A study", "TEST", 0, 7], ["symptoms", "PROBLEM", 101, 109]]], ["They were linked with a smaller number of SARS antibody titers and the higher use of face masks [21] .", [["SARS", "DISEASE", 42, 46], ["SARS antibody titers", "TREATMENT", 42, 62], ["face masks", "TREATMENT", 85, 95]]], ["Another study revealing a toddler with no symptoms of the disease but still carrying the COVID-19 virus highly suggested that asymptomatic patients are active carriers of the infections [22] .A study showed that 33 (52%) of 64 patients were interrogated, with 26 (79%) of them confirming at least one respiratory symptom [23] .", [["respiratory", "ANATOMY", 301, 312], ["infections", "DISEASE", 175, 185], ["COVID-19 virus", "ORGANISM", 89, 103], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 227, 235], ["COVID-19 virus", "SPECIES", 89, 103], ["Another study", "TEST", 0, 13], ["symptoms", "PROBLEM", 42, 50], ["the disease", "PROBLEM", 54, 65], ["the COVID", "TEST", 85, 94], ["the infections", "PROBLEM", 171, 185], ["A study", "TEST", 192, 199], ["one respiratory symptom", "PROBLEM", 297, 320], ["disease", "OBSERVATION", 58, 65], ["active", "OBSERVATION_MODIFIER", 152, 158]]], ["Serious symptoms, such as respiratory failure, septic shock, and multiple system involvement, were present in 5% of the cases [24] .TransmissionCOVID-19 owns strong pathogenicity and transmissibility, even more than the other members of the family (SARS-CoV and MERS-CoV) [25] .", [["respiratory", "ANATOMY", 26, 37], ["respiratory failure", "DISEASE", 26, 45], ["septic shock", "DISEASE", 47, 59], ["SARS-CoV", "ORGANISM", 249, 257], ["MERS-CoV", "ORGANISM", 262, 270], ["SARS-CoV", "SPECIES", 249, 257], ["MERS-CoV", "SPECIES", 262, 270], ["Serious symptoms", "PROBLEM", 0, 16], ["respiratory failure", "PROBLEM", 26, 45], ["septic shock", "PROBLEM", 47, 59], ["multiple system involvement", "PROBLEM", 65, 92], ["TransmissionCOVID", "TEST", 132, 149], ["respiratory", "ANATOMY", 26, 37], ["failure", "OBSERVATION", 38, 45], ["septic shock", "OBSERVATION", 47, 59], ["multiple", "OBSERVATION_MODIFIER", 65, 73], ["19 owns", "OBSERVATION_MODIFIER", 150, 157], ["strong", "OBSERVATION_MODIFIER", 158, 164], ["pathogenicity", "OBSERVATION", 165, 178]]], ["Wrapp et al. stated that COVID-19 binds to angiotensinconverting enzyme 2 (ACE2) receptors [26] [27] [28] .", [["COVID-19", "CHEMICAL", 25, 33], ["COVID-19", "CHEMICAL", 25, 33], ["COVID-19", "GENE_OR_GENE_PRODUCT", 25, 33], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 43, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["[26] [27] [28]", "SIMPLE_CHEMICAL", 91, 105], ["COVID-19", "DNA", 25, 33], ["angiotensinconverting enzyme 2 (ACE2) receptors", "PROTEIN", 43, 90], ["COVID", "TEST", 25, 30], ["angiotensinconverting enzyme", "TEST", 43, 71]]], ["Another hypothesis put forward by Zou L et al. states that the shedding pattern of viral nucleic acid in patients infected with COVID-19 is homogenous to influenza [29] .", [["nucleic acid", "CHEMICAL", 89, 101], ["COVID-19", "CHEMICAL", 128, 136], ["influenza", "DISEASE", 154, 163], ["patients", "ORGANISM", 105, 113], ["COVID-19", "ORGANISM", 128, 136], ["patients", "SPECIES", 105, 113], ["COVID-19", "SPECIES", 128, 136], ["viral nucleic acid", "PROBLEM", 83, 101], ["COVID", "TEST", 128, 133], ["influenza", "PROBLEM", 154, 163], ["viral nucleic acid", "OBSERVATION", 83, 101]]], ["Other modes of transmission are being studied as COVID-19 can be detected in the gastrointestinal tract, saliva, and urine, comparing it to the influenza virus, which has the same mode of transmission [30] .", [["gastrointestinal tract", "ANATOMY", 81, 103], ["saliva", "ANATOMY", 105, 111], ["urine", "ANATOMY", 117, 122], ["COVID-19", "CHEMICAL", 49, 57], ["COVID-19", "GENE_OR_GENE_PRODUCT", 49, 57], ["gastrointestinal tract", "ORGAN", 81, 103], ["saliva", "ORGANISM_SUBSTANCE", 105, 111], ["urine", "ORGANISM_SUBSTANCE", 117, 122], ["influenza virus", "ORGANISM", 144, 159], ["influenza virus", "SPECIES", 144, 159], ["COVID", "TEST", 49, 54], ["saliva, and urine", "TEST", 105, 122], ["the influenza virus", "PROBLEM", 140, 159], ["gastrointestinal tract", "ANATOMY", 81, 103]]], ["Despite this, to the present, there has been no definitive evidence of coronavirus reservoirs other than mammals and birds [31] [32] .", [["coronavirus", "ORGANISM", 71, 82], ["coronavirus reservoirs", "PROBLEM", 71, 93], ["no definitive evidence of", "UNCERTAINTY", 45, 70], ["coronavirus reservoirs", "OBSERVATION", 71, 93]]], ["The genomic sequence analysis of COVID-19 identified 88% similarity with two bat-derived SARS-like coronaviruses [33] [34] .", [["SARS", "DISEASE", 89, 93], ["SARS-like coronaviruses", "ORGANISM", 89, 112], ["COVID-19", "DNA", 33, 41], ["The genomic sequence analysis", "TEST", 0, 29], ["COVID", "TEST", 33, 38], ["two bat", "TEST", 73, 80]]], ["Person-to-person transmission is the most likely mode of transmission of COVID-19 infection, as some cases were detected in people who never visited the wet market of Wuhan but were residents of the area or visited the city and still contracted the virus [35] .", [["COVID-19", "CHEMICAL", 73, 81], ["infection", "DISEASE", 82, 91], ["COVID-19", "ORGANISM", 73, 81], ["people", "ORGANISM", 124, 130], ["person", "SPECIES", 10, 16], ["people", "SPECIES", 124, 130], ["COVID-19", "SPECIES", 73, 81], ["COVID-19 infection", "PROBLEM", 73, 91], ["infection", "OBSERVATION", 82, 91]]], ["The virus is highly transmissible, with viral shedding from nasopharyngeal aspirates for at least 24 days after the first presentation of symptoms, which is longer than the one previously reported in China [36] .", [["nasopharyngeal aspirates", "ANATOMY", 60, 84], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 60, 84], ["The virus", "PROBLEM", 0, 9], ["viral shedding from nasopharyngeal aspirates", "PROBLEM", 40, 84], ["symptoms", "PROBLEM", 138, 146], ["virus", "OBSERVATION", 4, 9], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["nasopharyngeal", "ANATOMY", 60, 74], ["aspirates", "OBSERVATION", 75, 84]]], ["The virus is highly resistant, staying on surfaces for days and in the air for hours.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["resistant", "OBSERVATION_MODIFIER", 20, 29]]], ["Lancet also reminded doctors not to ignore that COVID-19 can also spread through the ocular medium, as the infected droplets might contaminate conjunctiva and cause infection [31] .", [["ocular", "ANATOMY", 85, 91], ["droplets", "ANATOMY", 116, 124], ["conjunctiva", "ANATOMY", 143, 154], ["COVID-19", "CHEMICAL", 48, 56], ["infection", "DISEASE", 165, 174], ["COVID-19", "CHEMICAL", 48, 56], ["conjunctiva", "ORGAN", 143, 154], ["the infected droplets", "PROBLEM", 103, 124], ["infection", "PROBLEM", 165, 174], ["ocular", "ANATOMY", 85, 91], ["infection", "OBSERVATION", 165, 174]]], ["A single infected person can spread the disease to at least two to three other individuals.", [["person", "ORGANISM", 18, 24], ["person", "SPECIES", 18, 24], ["A single infected person", "PROBLEM", 0, 24], ["the disease", "PROBLEM", 36, 47], ["single", "OBSERVATION_MODIFIER", 2, 8], ["infected", "OBSERVATION", 9, 17], ["disease", "OBSERVATION", 40, 47]]], ["The drastically increasing number of cases points towards more of a human-to-human spread of the disease.Treatment optionsCurrently, COVID-19 infection has no treatment or vaccine available for the potential cure of humans.", [["COVID-19", "CHEMICAL", 133, 141], ["infection", "DISEASE", 142, 151], ["human", "ORGANISM", 68, 73], ["human", "ORGANISM", 77, 82], ["COVID-19", "ORGANISM", 133, 141], ["humans", "ORGANISM", 216, 222], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 77, 82], ["humans", "SPECIES", 216, 222], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 77, 82], ["COVID-19", "SPECIES", 133, 141], ["humans", "SPECIES", 216, 222], ["the disease", "PROBLEM", 93, 104], ["Treatment options", "TREATMENT", 105, 122], ["COVID", "TEST", 133, 138], ["infection", "PROBLEM", 142, 151], ["treatment", "TREATMENT", 159, 168], ["vaccine", "TREATMENT", 172, 179], ["drastically", "OBSERVATION_MODIFIER", 4, 15], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["number", "OBSERVATION_MODIFIER", 27, 33], ["disease", "OBSERVATION", 97, 104], ["infection", "OBSERVATION", 142, 151]]], ["Antiviral drugs, such as nucleoside analogs and human immunodeficiency virus (HIV) protease inhibitors can be used to weaken the virus until a particular drug becomes available [37] .", [["nucleoside", "CHEMICAL", 25, 35], ["human immunodeficiency virus (HIV)", "DISEASE", 48, 82], ["nucleoside", "CHEMICAL", 25, 35], ["nucleoside analogs", "SIMPLE_CHEMICAL", 25, 43], ["human immunodeficiency virus", "ORGANISM", 48, 76], ["HIV", "ORGANISM", 78, 81], ["human immunodeficiency virus", "SPECIES", 48, 76], ["human immunodeficiency virus", "SPECIES", 48, 76], ["HIV", "SPECIES", 78, 81], ["Antiviral drugs", "TREATMENT", 0, 15], ["nucleoside analogs", "TREATMENT", 25, 43], ["human immunodeficiency virus (HIV) protease inhibitors", "TREATMENT", 48, 102], ["the virus", "PROBLEM", 125, 134]]], ["Clinical studies state that Remdesivir (GS5734) (that hinders ribonucleic acid (RNA) polymerase) could be used against coronavirus infections [38] .", [["Remdesivir", "CHEMICAL", 28, 38], ["GS5734", "CHEMICAL", 40, 46], ["ribonucleic acid", "CHEMICAL", 62, 78], ["coronavirus infections", "DISEASE", 119, 141], ["Remdesivir", "CHEMICAL", 28, 38], ["GS5734", "CHEMICAL", 40, 46], ["Remdesivir", "SIMPLE_CHEMICAL", 28, 38], ["GS5734", "SIMPLE_CHEMICAL", 40, 46], ["ribonucleic acid", "GENE_OR_GENE_PRODUCT", 62, 78], ["coronavirus", "ORGANISM", 119, 130], ["ribonucleic acid (RNA) polymerase", "PROTEIN", 62, 95], ["Clinical studies", "TEST", 0, 16], ["ribonucleic acid (RNA) polymerase", "PROBLEM", 62, 95], ["coronavirus infections", "PROBLEM", 119, 141]]], ["Another study states the importance of chloroquine in reducing the morbidity of COVID-19 pneumonia [39] [40] .", [["chloroquine", "CHEMICAL", 39, 50], ["COVID-19", "CHEMICAL", 80, 88], ["pneumonia", "DISEASE", 89, 98], ["chloroquine", "CHEMICAL", 39, 50], ["COVID-19", "CHEMICAL", 80, 88], ["chloroquine", "SIMPLE_CHEMICAL", 39, 50], ["Another study", "TEST", 0, 13], ["chloroquine", "TREATMENT", 39, 50], ["COVID", "TEST", 80, 85], ["pneumonia", "PROBLEM", 89, 98], ["pneumonia", "OBSERVATION", 89, 98]]], ["Another study tried treating 75 patients twice a day with the oral administration of 75 mg oseltamivir, 500 mg lopinavir, 500 mg ritonavir, and intravenous (IV) 0.25 g ganciclovir for three to 14 days [41] .", [["oral", "ANATOMY", 62, 66], ["oseltamivir", "CHEMICAL", 91, 102], ["lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 129, 138], ["ganciclovir", "CHEMICAL", 168, 179], ["oseltamivir", "CHEMICAL", 91, 102], ["lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 129, 138], ["ganciclovir", "CHEMICAL", 168, 179], ["patients", "ORGANISM", 32, 40], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["oseltamivir", "SIMPLE_CHEMICAL", 91, 102], ["lopinavir", "SIMPLE_CHEMICAL", 111, 120], ["ritonavir", "SIMPLE_CHEMICAL", 129, 138], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 155], ["ganciclovir", "SIMPLE_CHEMICAL", 168, 179], ["patients", "SPECIES", 32, 40], ["Another study", "TEST", 0, 13], ["oseltamivir", "TREATMENT", 91, 102], ["lopinavir", "TREATMENT", 111, 120], ["ritonavir", "TREATMENT", 129, 138], ["intravenous (IV)", "TREATMENT", 144, 160], ["ganciclovir", "TREATMENT", 168, 179]]], ["A randomized control trial was conducted in Wuhan, China, to determine the effectiveness of lopinavir-ritonavir against COVID-19 but the results were pretty discouraging [42] .", [["lopinavir-ritonavir", "CHEMICAL", 92, 111], ["COVID-19", "CHEMICAL", 120, 128], ["lopinavir", "CHEMICAL", 92, 101], ["ritonavir", "CHEMICAL", 102, 111], ["COVID-19", "CHEMICAL", 120, 128], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 92, 111], ["A randomized control trial", "TREATMENT", 0, 26], ["lopinavir", "TREATMENT", 92, 101], ["ritonavir", "TREATMENT", 102, 111], ["COVID", "TEST", 120, 125]]], ["A phase 1 trial for an investigational vaccine has also begun in Seattle.", [["an investigational vaccine", "TREATMENT", 20, 46]]], ["Multiple therapeutic treatments are still under investigation and further trials are necessary in this time of distress.Future prognosisThere is currently no information available regarding virus mutation [43] .", [["Multiple therapeutic treatments", "TREATMENT", 0, 31], ["further trials", "TREATMENT", 66, 80], ["distress", "PROBLEM", 111, 119], ["virus mutation", "PROBLEM", 190, 204]]], ["The current time requires studying the virus mutations with respect to their geography and pliability to human hosts [44] .", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["the virus mutations", "PROBLEM", 35, 54]]], ["Children may suffer from mild disease.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["mild disease", "PROBLEM", 25, 37], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["disease", "OBSERVATION", 30, 37]]], ["Fatality is high in elderly people with accompanying chronic underlying diseases [45] .", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34], ["accompanying chronic underlying diseases", "PROBLEM", 40, 80], ["high", "OBSERVATION_MODIFIER", 12, 16], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["diseases", "OBSERVATION", 72, 80]]], ["To reduce the havoc caused by COVID-19, public health and infection control should take actions drastically [46] .", [["havoc", "DISEASE", 14, 19], ["COVID-19", "CHEMICAL", 30, 38], ["infection", "DISEASE", 58, 67], ["infection control", "TREATMENT", 58, 75]]], ["Travel history should highly be taken into account for the early detection and isolation of COVID-19 cases [47] .", [["the early detection", "TEST", 55, 74], ["COVID", "TEST", 92, 97]]], ["Every measure should be taken to reduce the progression of the malady until health care authorities find appropriate therapeutics and vaccines [48] .", [["malady", "DISEASE", 63, 69], ["the malady", "PROBLEM", 59, 69]]], ["People in the United States and from around the world have decided to self-quarantine.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Flattening the curve amidst the chaos is vital.", [["Flattening the curve", "PROBLEM", 0, 20], ["curve", "OBSERVATION_MODIFIER", 15, 20]]], ["Testing for the virus should be readily available.", [["the virus", "PROBLEM", 12, 21]]], ["Further studies should be conducted studying the virus course.", [["Further studies", "TEST", 0, 15]]], ["A vaccine against the virus should be made as soon as possible.", [["A vaccine", "TREATMENT", 0, 9], ["the virus", "TREATMENT", 18, 27]]], ["All the countries should make a conjoint effort, crossing borders in inventing the specific antiviral and vaccine against the evil COVID-19.ConclusionsThe last pandemic to hit the world before COVID-19 was the H1N1 pandemic of 2009, which claimed almost 12,469 lives in the United States alone.", [["the specific antiviral and vaccine", "TREATMENT", 79, 113], ["the evil COVID", "TEST", 122, 136], ["COVID", "TEST", 193, 198]]], ["COVID-19 is a similar pandemic and specific measures should be administered to halt the spread of the disease, especially taking into account the high-risk population that includes children, health care professionals, and the elderly population.", [["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["COVID", "TEST", 0, 5], ["the disease", "PROBLEM", 98, 109], ["disease", "OBSERVATION", 102, 109]]], ["Social distancing, avoiding gatherings, wearing a mask, and washing hands with soap and water can help halt the spread to some extent.", [["a mask", "TREATMENT", 48, 54], ["soap and water", "TREATMENT", 79, 93], ["some extent", "OBSERVATION_MODIFIER", 122, 133]]], ["Strong, multifaceted action should be embarked against COVID-19 so that the deceleration phase of the disease begins.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID", "TEST", 55, 60], ["the disease", "PROBLEM", 98, 109], ["disease", "OBSERVATION", 102, 109]]], ["The Chinese approach to the disease has worked and all countries should have a similar approach by limiting social gatherings, shutting down schools and malls and urging people to work from home.", [["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176]]], ["Countries should allow adequate testing, the isolation of people with COVID-19, contact tracing, and forcing quarantine of all contacts.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["adequate testing", "TEST", 23, 39], ["COVID", "TEST", 70, 75], ["contact tracing", "TEST", 80, 95]]], ["Since asymptomatic patients can spread the disease, its transmission should be studied in much more detail.Conflicts of interest:In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["the disease", "PROBLEM", 39, 50], ["financial support", "TREATMENT", 275, 292], ["disease", "OBSERVATION", 43, 50]]]], "89f4bda6c479ca9b60a25181359cfac1f44fef47": [["IntroductionPlants are confronted with sugar accumulation in their leaf mesophyll cells if their photoassimilate production exceeds their utilization in sink tissues.", [["leaf mesophyll cells", "ANATOMY", 67, 87], ["sink tissues", "ANATOMY", 153, 165], ["photoassimilate", "CHEMICAL", 97, 112], ["sugar", "CHEMICAL", 39, 44], ["sugar", "SIMPLE_CHEMICAL", 39, 44], ["leaf mesophyll cells", "CELL", 67, 87], ["photoassimilate", "SIMPLE_CHEMICAL", 97, 112], ["tissues", "TISSUE", 158, 165], ["leaf mesophyll cells", "CELL_TYPE", 67, 87], ["sugar accumulation", "PROBLEM", 39, 57], ["their leaf mesophyll cells", "TREATMENT", 61, 87], ["mesophyll cells", "OBSERVATION", 72, 87], ["sink tissues", "OBSERVATION", 153, 165]]], ["This situation may arise when they are exposed to high light, elevated levels of atmospheric CO2 and/or when they suffer from sink limitations as under nitrogen deficiency or cold stress [34] .", [["CO2", "CHEMICAL", 93, 96], ["nitrogen", "CHEMICAL", 152, 160], ["CO2", "CHEMICAL", 93, 96], ["nitrogen", "CHEMICAL", 152, 160], ["CO2", "SIMPLE_CHEMICAL", 93, 96], ["nitrogen", "SIMPLE_CHEMICAL", 152, 160], ["atmospheric CO2", "TREATMENT", 81, 96], ["nitrogen deficiency", "PROBLEM", 152, 171], ["cold stress", "PROBLEM", 175, 186]]], ["As a result of sugar accumulation the rate of sucrose synthesis decreases, starch accumulates and photosynthesis is inhibited.", [["sucrose", "CHEMICAL", 46, 53], ["starch", "CHEMICAL", 75, 81], ["sugar", "CHEMICAL", 15, 20], ["sucrose", "CHEMICAL", 46, 53], ["sugar", "SIMPLE_CHEMICAL", 15, 20], ["sucrose", "SIMPLE_CHEMICAL", 46, 53], ["starch", "SIMPLE_CHEMICAL", 75, 81], ["sugar accumulation", "PROBLEM", 15, 33], ["sucrose synthesis", "TREATMENT", 46, 63], ["starch accumulates", "PROBLEM", 75, 93], ["sugar accumulation", "OBSERVATION", 15, 33], ["decreases", "OBSERVATION_MODIFIER", 64, 73]]], ["In contrast to the well studied biochemical mechanisms in response to sugar accumulation the underlying molecular mechanisms are largely unknown.", [["sugar", "CHEMICAL", 70, 75], ["sugar", "SIMPLE_CHEMICAL", 70, 75], ["sugar accumulation", "PROBLEM", 70, 88], ["sugar accumulation", "OBSERVATION", 70, 88], ["molecular mechanisms", "OBSERVATION", 104, 124]]], ["Systems used to cause an increase of assimilates in photosynthetically active plant cells are girdling (cold or hot wax collar, respectively) of source leaves, the removal of sink tissues and sugar feeding experiments using detached leaves, cell suspension cultures or protoplasts [6, 12, 13, 24] .", [["cells", "ANATOMY", 84, 89], ["leaves", "ANATOMY", 152, 158], ["tissues", "ANATOMY", 180, 187], ["leaves", "ANATOMY", 233, 239], ["cell", "ANATOMY", 241, 245], ["cultures", "ANATOMY", 257, 265], ["protoplasts", "ANATOMY", 269, 280], ["sugar", "CHEMICAL", 192, 197], ["plant cells", "CELL", 78, 89], ["tissues", "TISSUE", 180, 187], ["sugar", "SIMPLE_CHEMICAL", 192, 197], ["cell", "CELL", 241, 245], ["photosynthetically active plant cells", "CELL_LINE", 52, 89], ["cell suspension cultures", "CELL_LINE", 241, 265], ["an increase of assimilates in photosynthetically active plant cells", "PROBLEM", 22, 89], ["hot wax collar", "TREATMENT", 112, 126], ["the removal of sink tissues", "TREATMENT", 160, 187], ["sugar feeding experiments", "TREATMENT", 192, 217], ["detached leaves", "TREATMENT", 224, 239], ["cell suspension cultures", "TEST", 241, 265], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["plant cells", "OBSERVATION", 78, 89], ["sink tissues", "OBSERVATION", 175, 187]]], ["All these experimental systems, however, are restricted to investigations of the short-term response to sugar accumulation.", [["sugar", "CHEMICAL", 104, 109], ["sugar", "SIMPLE_CHEMICAL", 104, 109], ["sugar accumulation", "PROBLEM", 104, 122], ["experimental", "OBSERVATION", 10, 22], ["sugar accumulation", "OBSERVATION", 104, 122]]], ["An alternative to study long-term adaptation of plant cells to elevated levels of sugars would be the use of transgenic plants.IntroductionTransgenic tobacco plants expressing E. coli pyrophosphatase behind the constitutive CaMV 35 S promoter (ppa-1 plants) accumulate high levels of carbohydrates in their source leaves [27, 9] .", [["cells", "ANATOMY", 54, 59], ["sugars", "CHEMICAL", 82, 88], ["carbohydrates", "CHEMICAL", 284, 297], ["plant cells", "CELL", 48, 59], ["sugars", "SIMPLE_CHEMICAL", 82, 88], ["Transgenic tobacco plants", "ORGANISM", 139, 164], ["E. coli", "ORGANISM", 176, 183], ["pyrophosphatase", "GENE_OR_GENE_PRODUCT", 184, 199], ["CaMV 35 S", "GENE_OR_GENE_PRODUCT", 224, 233], ["ppa-1", "GENE_OR_GENE_PRODUCT", 244, 249], ["plant cells", "CELL_TYPE", 48, 59], ["E. coli pyrophosphatase", "PROTEIN", 176, 199], ["constitutive CaMV 35 S promoter", "DNA", 211, 242], ["ppa", "DNA", 244, 247], ["tobacco", "SPECIES", 150, 157], ["E. coli", "SPECIES", 176, 183], ["tobacco", "SPECIES", 150, 157], ["E. coli", "SPECIES", 176, 183], ["plant cells", "PROBLEM", 48, 59], ["elevated levels of sugars", "PROBLEM", 63, 88], ["transgenic plants", "TREATMENT", 109, 126], ["E. coli pyrophosphatase", "PROBLEM", 176, 199], ["the constitutive CaMV 35 S promoter (ppa-1 plants", "TREATMENT", 207, 256], ["high levels of carbohydrates", "PROBLEM", 269, 297], ["plant cells", "OBSERVATION", 48, 59], ["high levels", "OBSERVATION_MODIFIER", 269, 280]]], ["These biochemical changes have been explained to be due to increased sucrose synthesis and inhibited loading of sucrose into the phloem [27, 15, 5] .", [["phloem", "ANATOMY", 129, 135], ["sucrose", "CHEMICAL", 69, 76], ["sucrose", "CHEMICAL", 112, 119], ["sucrose", "CHEMICAL", 69, 76], ["sucrose", "CHEMICAL", 112, 119], ["sucrose", "SIMPLE_CHEMICAL", 69, 76], ["sucrose", "SIMPLE_CHEMICAL", 112, 119], ["increased sucrose synthesis", "TREATMENT", 59, 86]]], ["In addition to the expected biochemical alterations in plant metabolism caused by the E. coli transgene a number of other phenotypical changes were observed in the transgenic tobacco plants.", [["E. coli", "ORGANISM", 86, 93], ["tobacco", "ORGANISM", 175, 182], ["E. coli", "SPECIES", 86, 93], ["tobacco", "SPECIES", 175, 182], ["E. coli", "SPECIES", 86, 93], ["tobacco", "SPECIES", 175, 182], ["the expected biochemical alterations", "PROBLEM", 15, 51], ["the E. coli transgene", "TREATMENT", 82, 103], ["other phenotypical changes", "PROBLEM", 116, 142], ["biochemical alterations", "OBSERVATION", 28, 51], ["plant metabolism", "OBSERVATION", 55, 71], ["E. coli transgene", "OBSERVATION", 86, 103], ["tobacco plants", "OBSERVATION", 175, 189]]], ["The high sugar levels in the source leaves lead to an increase in turgor pressure by a factor of about 9 in the transgenic as compared to wild-type plants while the water potential was essentially not changed [28] .", [["leaves", "ANATOMY", 36, 42], ["sugar", "CHEMICAL", 9, 14], ["sugar", "SIMPLE_CHEMICAL", 9, 14], ["leaves", "ORGANISM_SUBDIVISION", 36, 42], ["The high sugar levels", "PROBLEM", 0, 21], ["an increase in turgor pressure", "PROBLEM", 51, 81], ["high", "OBSERVATION_MODIFIER", 4, 8], ["sugar levels", "OBSERVATION_MODIFIER", 9, 21], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["turgor pressure", "OBSERVATION", 66, 81]]], ["Presumably as a consequence of the elevated turgor, the mesophyll cell enlarged two-fold as compared to wild-type cells and cell walls were found to contain 14~o and 43~o more pectin and uronic acids, respectively [28] .IntroductionTo study the long-term adaptation of gene expression of plants that are continuously confronted with high levels of endogenous soluble sugars we have chosen the transgenic ppa-1 plants as a tool.", [["mesophyll cell", "ANATOMY", 56, 70], ["cells", "ANATOMY", 114, 119], ["cell walls", "ANATOMY", 124, 134], ["uronic acids", "CHEMICAL", 187, 199], ["uronic acids", "CHEMICAL", 187, 199], ["sugars", "CHEMICAL", 367, 373], ["mesophyll cell", "CELL", 56, 70], ["cells", "CELL", 114, 119], ["cell walls", "CELL", 124, 134], ["pectin", "SIMPLE_CHEMICAL", 176, 182], ["uronic acids", "SIMPLE_CHEMICAL", 187, 199], ["ppa-1", "GENE_OR_GENE_PRODUCT", 404, 409], ["wild-type cells", "CELL_TYPE", 104, 119], ["the elevated turgor", "PROBLEM", 31, 50], ["the mesophyll cell enlarged two-fold", "PROBLEM", 52, 88], ["cell walls", "TEST", 124, 134], ["uronic acids", "TEST", 187, 199], ["gene expression of plants", "TREATMENT", 269, 294], ["endogenous soluble sugars", "TREATMENT", 348, 373], ["the transgenic ppa", "TREATMENT", 389, 407], ["elevated", "OBSERVATION_MODIFIER", 35, 43], ["turgor", "OBSERVATION_MODIFIER", 44, 50], ["mesophyll cell", "OBSERVATION", 56, 70], ["enlarged", "OBSERVATION_MODIFIER", 71, 79], ["two", "OBSERVATION_MODIFIER", 80, 83], ["-fold", "OBSERVATION_MODIFIER", 83, 88], ["cell walls", "OBSERVATION", 124, 134]]], ["Here we describe the cloning and description of cDNAs from a subtractive library enriched for transcripts present in the sugaraccumulating ppa-1 plants.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 139, 144], ["cDNAs", "DNA", 48, 53], ["ppa", "PROTEIN", 139, 142], ["a subtractive library", "TREATMENT", 59, 80]]], ["An efficient and simpined procedure for the establishment of subtractive cDNA libraries will be presented.", [["subtractive cDNA libraries", "DNA", 61, 87], ["An efficient and simpined procedure", "TREATMENT", 0, 35], ["subtractive cDNA libraries", "TREATMENT", 61, 87]]], ["One of the cDNAs that could not be identified by sequence homology will be characterized in more detail and is suggested to code for a new class of pathogenesis-related proteins (PR proteins).Recombinant DNA techniques and bacterial strainsStandard procedures were used for recombinant DNA work [23] .", [["PR", "GENE_OR_GENE_PRODUCT", 179, 181], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["DNA", "CELLULAR_COMPONENT", 286, 289], ["cDNAs", "DNA", 11, 16], ["pathogenesis-related proteins", "PROTEIN", 148, 177], ["PR proteins", "PROTEIN", 179, 190], ["pathogenesis", "PROBLEM", 148, 160], ["related proteins (PR proteins)", "PROBLEM", 161, 191], ["Recombinant DNA techniques", "TREATMENT", 192, 218], ["bacterial strains", "PROBLEM", 223, 240], ["Standard procedures", "TREATMENT", 240, 259], ["could not be", "UNCERTAINTY", 22, 34], ["bacterial strains", "OBSERVATION", 223, 240]]], ["Bacterial transformation were done into E. coli XLl-blue (Stratagene, La Jolla, CA).RNA preparationTotal RNA was extracted from frozen plant material [ 16] .", [["E. coli", "ORGANISM", 40, 47], ["RNA preparationTotal RNA", "RNA", 84, 108], ["E. coli", "SPECIES", 40, 47], ["E. coli", "SPECIES", 40, 47], ["Bacterial transformation", "PROBLEM", 0, 24], ["E. coli XLl", "TEST", 40, 51], ["blue", "PROBLEM", 52, 56], ["RNA preparationTotal RNA", "TREATMENT", 84, 108], ["E. coli", "OBSERVATION_MODIFIER", 40, 47]]], ["Poly(A) RNA was isolated by means of oligo(dT) cellulose type 7 (Pharmacia) according to the manufacturer's instructions.Preparation of cDNA librariesPoly(A) RNA was prepared from source leaves of wildtype and ppa-1 plants.", [["leaves", "ANATOMY", 187, 193], ["Poly", "CHEMICAL", 0, 4], ["oligo(dT", "CHEMICAL", 37, 45], ["Poly", "CHEMICAL", 150, 154], ["Poly(A)", "CHEMICAL", 0, 7], ["Poly(A)", "GENE_OR_GENE_PRODUCT", 0, 7], ["Poly(A)", "GENE_OR_GENE_PRODUCT", 150, 157], ["ppa-1 plants", "ORGANISM", 210, 222], ["Poly(A) RNA", "RNA", 0, 11], ["cDNA libraries", "DNA", 136, 150], ["Poly(A) RNA", "RNA", 150, 161], ["ppa-1", "SPECIES", 210, 215], ["Poly(A) RNA", "PROBLEM", 0, 11], ["oligo(dT) cellulose type", "TREATMENT", 37, 61], ["cDNA librariesPoly(A) RNA", "TREATMENT", 136, 161]]], ["5/zg were transcribed into double-stranded cDNA using the cDNA synthesis kit from Pharmacia.", [["zg", "GENE_OR_GENE_PRODUCT", 2, 4], ["double-stranded cDNA", "DNA", 27, 47]]], ["Eco RI-Not I adaptors (Pharmacia) were ligated to the cDNAs which were then cloned into Eco RI-digested 2ZAP II vector arms (Stratagene).", [["Eco RI-Not I", "GENE_OR_GENE_PRODUCT", 0, 12], ["Pharmacia", "GENE_OR_GENE_PRODUCT", 23, 32], ["2ZAP II", "GENE_OR_GENE_PRODUCT", 104, 111], ["Eco RI-Not I adaptors", "DNA", 0, 21], ["cDNAs", "DNA", 54, 59], ["Eco RI-digested 2ZAP II vector arms", "DNA", 88, 123]]], ["After in vitro packaging using the Gigapack II packaging extract (Stratagene) recombinant lambda DNA was transfected into E. coli XL1-Blue cells (Strategene) and the titer of the cDNA libraries determined by counting the plaques.", [["XL1-Blue cells", "ANATOMY", 130, 144], ["plaques", "ANATOMY", 221, 228], ["Gigapack II", "CHEMICAL", 35, 46], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["E. coli", "ORGANISM", 122, 129], ["XL1-Blue cells", "CELL", 130, 144], ["Strategene", "CELL", 146, 156], ["plaques", "PATHOLOGICAL_FORMATION", 221, 228], ["Gigapack II packaging extract (Stratagene) recombinant lambda DNA", "DNA", 35, 100], ["E. coli XL1-Blue cells", "CELL_LINE", 122, 144], ["Strategene", "CELL_LINE", 146, 156], ["cDNA libraries", "DNA", 179, 193], ["E. coli", "SPECIES", 122, 129], ["E. coli", "SPECIES", 122, 129], ["vitro packaging", "TREATMENT", 9, 24], ["the Gigapack II packaging extract (Stratagene) recombinant lambda DNA", "TREATMENT", 31, 100], ["E. coli", "TEST", 122, 129], ["the cDNA libraries", "TEST", 175, 193], ["the plaques", "PROBLEM", 217, 228], ["Blue cells", "OBSERVATION", 134, 144], ["plaques", "OBSERVATION", 221, 228]]], ["Thereafter the cDNA libraries were amplified according to the amplification protocol of Stratagene.Preparation of a subtractive cDNA libraryThe preparation of the subtractive library is schematically drawn in Fig. 1 .", [["cDNA libraries", "DNA", 15, 29], ["subtractive cDNA library", "DNA", 116, 140], ["the cDNA libraries", "TREATMENT", 11, 29], ["the amplification protocol", "TEST", 58, 84], ["Stratagene", "TREATMENT", 88, 98], ["a subtractive cDNA library", "TREATMENT", 114, 140]]], ["The wild-type and the ppa-1 cDNA libraries prepared as described above were in vivo excised according to the in vivo excision protocol of Stratagene.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["ppa-1 cDNA libraries", "DNA", 22, 42], ["the ppa-1 cDNA libraries", "TREATMENT", 18, 42], ["Stratagene", "TREATMENT", 138, 148]]], ["Obtained bacterial colonies were ampfified and their recombinant plasmid DNA isolated using standard procedures.", [["colonies", "ANATOMY", 19, 27], ["plasmid", "ANATOMY", 65, 72], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["recombinant plasmid DNA", "DNA", 53, 76], ["bacterial colonies", "PROBLEM", 9, 27], ["their recombinant plasmid DNA", "TREATMENT", 47, 76], ["standard procedures", "TREATMENT", 92, 111], ["bacterial colonies", "OBSERVATION", 9, 27]]], ["200 ktg of the wild-type plasmid cDNA library was digested with Not I while plasmids of the ppa-1 cDNA library were cut with Eco RI. cDNA fragments were then separated in agarose gels and fragments between 0.5 kb and 1.5 kb eluted.", [["plasmids", "ANATOMY", 76, 84], ["ppa-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["wild-type plasmid cDNA library", "DNA", 15, 45], ["Not I", "DNA", 64, 69], ["ppa-1 cDNA library", "DNA", 92, 110], ["Eco RI", "DNA", 125, 131], ["cDNA fragments", "DNA", 133, 147], ["the wild-type plasmid cDNA library", "TREATMENT", 11, 45], ["the ppa", "TEST", 88, 95], ["cDNA library", "TEST", 98, 110], ["cDNA fragments", "PROBLEM", 133, 147], ["agarose gels", "TREATMENT", 171, 183], ["fragments", "OBSERVATION_MODIFIER", 138, 147]]], ["Wild-type cDNA was photobiotinylated (Clontech) according to the protocol by Strauss and Ausubel [30] .", [["Wild-type cDNA", "DNA", 0, 14]]], ["Photobiotinylated wild-type cDNA and ppa-1 cDNA fragments were mixed in a ratio 10:1, denatured at 95 \u00b0C and renatured by slowly decreasing the temperature to 25 \u00b0C. Avidin (Vectrex Avidin) was added to the mixture and wild-type and hybrid cDNA molecules removed by centrifugation.", [["Avidin", "CHEMICAL", 166, 172], ["Vectrex Avidin", "CHEMICAL", 174, 188], ["Avidin", "CHEMICAL", 166, 172], ["ppa-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["Avidin", "SIMPLE_CHEMICAL", 166, 172], ["Vectrex Avidin", "SIMPLE_CHEMICAL", 174, 188], ["Photobiotinylated wild-type cDNA", "DNA", 0, 32], ["ppa-1 cDNA fragments", "DNA", 37, 57], ["hybrid cDNA molecules", "PROTEIN", 233, 254], ["type cDNA", "TREATMENT", 23, 32], ["ppa", "TEST", 37, 40], ["1 cDNA fragments", "TREATMENT", 41, 57], ["the temperature", "TEST", 140, 155], ["Avidin (Vectrex Avidin", "TREATMENT", 166, 188], ["the mixture", "TREATMENT", 203, 214], ["wild-type and hybrid cDNA molecules", "TREATMENT", 219, 254]]], ["PPa-1 enriched cDNA fragments were cloned into EcoRI-digested 2ZAP II vector arms, packaged, transfected into XLl-blue cells, the titer determined and the subtractive cDNA library amplified as described above.Differential screening of the subtractive libraryScreening of cDNA libraries followed the DNA screening protocol by Stratagene.", [["fragments", "ANATOMY", 20, 29], ["XLl-blue cells", "ANATOMY", 110, 124], ["PPa-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["EcoRI", "GENE_OR_GENE_PRODUCT", 47, 52], ["XLl-blue cells", "CELL", 110, 124], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["PPa-1 enriched cDNA fragments", "DNA", 0, 29], ["EcoRI-digested 2ZAP II vector arms", "DNA", 47, 81], ["XLl-blue cells", "CELL_LINE", 110, 124], ["subtractive cDNA library", "DNA", 155, 179], ["cDNA libraries", "DNA", 271, 285], ["PPa", "TEST", 0, 3], ["1 enriched cDNA fragments", "PROBLEM", 4, 29], ["EcoRI", "TEST", 47, 52], ["the titer", "TEST", 126, 135], ["the subtractive cDNA library", "TREATMENT", 151, 179], ["Differential screening", "TEST", 209, 231], ["cDNA libraries", "TREATMENT", 271, 285], ["the DNA screening protocol", "TEST", 295, 321], ["cDNA fragments", "OBSERVATION", 15, 29], ["blue cells", "OBSERVATION", 114, 124]]], ["DNA of 2 x 104 plaque-forming units of the subtractive library were transferred onto nylon filters (Hybond N, Amersham Buchler) and hybridized to radioactively labelled wild-type cDNA.", [["plaque", "ANATOMY", 15, 21], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["radioactively labelled wild-type cDNA", "DNA", 146, 183], ["DNA", "TEST", 0, 3], ["the subtractive library", "TREATMENT", 39, 62], ["nylon filters", "TREATMENT", 85, 98]]], ["Hybridizing phage DNAs were visualized by autoradiography before the filters were hybridized to radioactively labelled ppa-1 cDNA.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 119, 124], ["phage DNAs", "DNA", 12, 22], ["radioactively labelled ppa-1 cDNA", "DNA", 96, 129], ["Hybridizing phage DNAs", "TREATMENT", 0, 22], ["the filters", "TREATMENT", 65, 76], ["radioactively labelled ppa", "TEST", 96, 122]]], ["After autoradiographic exposure the two autoradiographies were compared to identify phage DNAs specific to ppa-1.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["phage DNAs", "DNA", 84, 94], ["ppa-1", "DNA", 107, 112], ["ppa", "TEST", 107, 110]]], ["Purified clones were in vivo excised and characterized by sequencing.Plant materialNicotiana tabacum L. cv.", [["clones", "ANATOMY", 9, 15], ["clones", "CELL", 9, 15], ["Nicotiana tabacum", "ORGANISM", 83, 100], ["L. cv", "ORGANISM", 101, 106], ["Nicotiana tabacum", "SPECIES", 83, 100], ["L. cv", "SPECIES", 101, 106], ["Nicotiana tabacum L. cv", "SPECIES", 83, 106], ["Purified clones", "PROBLEM", 0, 15], ["clones", "OBSERVATION", 9, 15], ["material", "OBSERVATION_MODIFIER", 75, 83]]], ["The transgenic ppa-1 tobacco plants have been described [27] .Northern blot experimentsTotal RNA was denatured in 40% formamide, subjected to agarose gel electrophoresis (1.5% agarose, 15% formaldehyde) and blotted onto nylon membranes (Hybond N; Amersham Buchler, Braunschweig, Germany).Labelling of probes and hybridization of membranesIf not otherwise stated, membranes were hybridized at 42 \u00b0C in a buffer containing polyethylene glycol and 25 ~o formamide [1 ] .", [["nylon membranes", "ANATOMY", 220, 235], ["membranes", "ANATOMY", 329, 338], ["membranes", "ANATOMY", 363, 372], ["formamide", "CHEMICAL", 118, 127], ["formaldehyde", "CHEMICAL", 189, 201], ["polyethylene glycol", "CHEMICAL", 421, 440], ["25 ~o formamide", "CHEMICAL", 445, 460], ["formamide", "CHEMICAL", 118, 127], ["formaldehyde", "CHEMICAL", 189, 201], ["polyethylene glycol", "CHEMICAL", 421, 440], ["formamide", "CHEMICAL", 451, 460], ["ppa-1", "ORGANISM", 15, 20], ["tobacco", "ORGANISM", 21, 28], ["formamide", "SIMPLE_CHEMICAL", 118, 127], ["agarose", "SIMPLE_CHEMICAL", 142, 149], ["agarose", "SIMPLE_CHEMICAL", 176, 183], ["formaldehyde", "SIMPLE_CHEMICAL", 189, 201], ["membranes", "CELLULAR_COMPONENT", 329, 338], ["membranes", "CELLULAR_COMPONENT", 363, 372], ["polyethylene glycol", "SIMPLE_CHEMICAL", 421, 440], ["tobacco", "SPECIES", 21, 28], ["tobacco", "SPECIES", 21, 28], ["The transgenic ppa", "TREATMENT", 0, 18], ["Total RNA", "TEST", 87, 96], ["40% formamide", "TREATMENT", 114, 127], ["agarose gel electrophoresis", "TREATMENT", 142, 169], ["1.5% agarose", "TREATMENT", 171, 183], ["Labelling of probes", "TREATMENT", 288, 307], ["hybridization of membranes", "TREATMENT", 312, 338], ["membranes", "PROBLEM", 363, 372], ["a buffer containing polyethylene glycol", "TREATMENT", 401, 440]]], ["Radioactive labelling of DNA probes was performed using a random-primed DNA labeling kit (Boehringer, Mannheim, Germany).", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["DNA probes", "DNA", 25, 35], ["Radioactive labelling of DNA probes", "TREATMENT", 0, 35]]], ["Filters were washed three times for 20 min at 42 \u00b0C w i t h 2 x S S C ( I \u00d7 SSC is 0.15 M NaC1, 0.015 M sodium citrate).", [["sodium citrate", "CHEMICAL", 104, 118], ["NaC1", "CHEMICAL", 90, 94], ["sodium citrate", "CHEMICAL", 104, 118], ["sodium citrate", "SIMPLE_CHEMICAL", 104, 118], ["Filters", "TREATMENT", 0, 7], ["NaC1", "TREATMENT", 90, 94], ["0.015 M sodium citrate", "TREATMENT", 96, 118]]], ["Radioactive probes for screening the subtractive library were prepared as follows: 0.5 #g mRNA of wildtype and ppa-1 plants, respectively, were transcribed into double-stranded cDNA (cDNA synthesis kit, Pharmacia).", [["ppa-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["0.5 #g mRNA", "RNA", 83, 94], ["ppa", "PROTEIN", 111, 114], ["double-stranded cDNA", "DNA", 161, 181], ["cDNA", "DNA", 183, 187], ["Radioactive probes", "TREATMENT", 0, 18], ["ppa", "TEST", 111, 114], ["double-stranded cDNA (cDNA synthesis kit", "TREATMENT", 161, 201]]], ["This cDNA was radioactively labelled using the random primed DNA labeling kit as described above.Infection of tobacco leaves with potato virus Y (PVY N)PVY N was obtained from the Bundesanstalt far Ztichtungsforschung an Kulturpflanzen (Aschersleben, Germany).", [["cDNA", "CELLULAR_COMPONENT", 5, 9], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["tobacco", "ORGANISM", 110, 117], ["leaves", "ORGANISM_SUBDIVISION", 118, 124], ["potato virus Y", "ORGANISM", 130, 144], ["cDNA", "DNA", 5, 9], ["tobacco", "SPECIES", 110, 117], ["potato virus", "SPECIES", 130, 142], ["tobacco", "SPECIES", 110, 117], ["potato virus Y (PVY N)PVY", "SPECIES", 130, 155], ["the random primed DNA labeling kit", "TREATMENT", 43, 77]]], ["Leaves of infected tobacco plants were homogenized in 100 mM potassium phosphate buffer, pH 7.0 (ca.", [["Leaves", "ANATOMY", 0, 6], ["potassium phosphate", "CHEMICAL", 61, 80], ["potassium phosphate", "CHEMICAL", 61, 80], ["Leaves", "ORGANISM", 0, 6], ["tobacco", "ORGANISM", 19, 26], ["potassium", "SIMPLE_CHEMICAL", 61, 70], ["tobacco", "SPECIES", 19, 26], ["tobacco", "SPECIES", 19, 26], ["potassium phosphate buffer", "TREATMENT", 61, 87], ["pH", "TEST", 89, 91], ["infected", "OBSERVATION_MODIFIER", 10, 18], ["tobacco plants", "OBSERVATION", 19, 33]]], ["1 g leaf material in 20 ml buffer) to obtain viral extract.", [["leaf", "ANATOMY", 4, 8], ["extract", "ANATOMY", 51, 58], ["1 g leaf material", "TREATMENT", 0, 17], ["viral extract", "PROBLEM", 45, 58]]], ["Leaves to be infection were dusted with carborundum (SIC) and the viral extract applied by gently rubbing the upper face of the respective leaves with a pistil.", [["Leaves", "ANATOMY", 0, 6], ["extract", "ANATOMY", 72, 79], ["leaves", "ANATOMY", 139, 145], ["pistil", "ANATOMY", 153, 159], ["infection", "DISEASE", 13, 22], ["Leaves", "ORGAN", 0, 6], ["carborundum", "SIMPLE_CHEMICAL", 40, 51], ["upper face", "ORGANISM_SUBDIVISION", 110, 120], ["pistil", "ORGANISM_SUBDIVISION", 153, 159], ["infection", "PROBLEM", 13, 22], ["carborundum (SIC)", "TREATMENT", 40, 57], ["the viral extract", "TREATMENT", 62, 79], ["a pistil", "TREATMENT", 151, 159], ["infection", "OBSERVATION", 13, 22], ["upper", "ANATOMY_MODIFIER", 110, 115]]], ["A few minutes later the treated leaves were rinsed with water.", [["leaves", "ANATOMY", 32, 38], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["Mature source leaves were used to apply the viral extract.", [["leaves", "ANATOMY", 14, 20], ["extract", "ANATOMY", 50, 57], ["the viral extract", "TREATMENT", 40, 57]]], ["8 to 12 days after infection symptoms appeared on the plants.Immunological detection of virus coat proteinPlant material was homogenized with PB S buffer [23] containing 0.05% Tween-20, 2% polyvinylpyrollidone 25000, 0.2~o bovine serum albumin (1 g plant material/20 ml buffer).", [["serum", "ANATOMY", 230, 235], ["infection", "DISEASE", 19, 28], ["Tween-20", "CHEMICAL", 176, 184], ["polyvinylpyrollidone 25000", "CHEMICAL", 189, 215], ["Tween-20", "CHEMICAL", 176, 184], ["polyvinylpyrollidone", "CHEMICAL", 189, 209], ["Tween-20", "SIMPLE_CHEMICAL", 176, 184], ["polyvinylpyrollidone 25000", "SIMPLE_CHEMICAL", 189, 215], ["bovine", "ORGANISM", 223, 229], ["serum", "ORGANISM_SUBSTANCE", 230, 235], ["albumin", "SIMPLE_CHEMICAL", 236, 243], ["bovine", "SPECIES", 223, 229], ["bovine", "SPECIES", 223, 229], ["infection symptoms", "PROBLEM", 19, 37], ["Immunological detection", "TEST", 61, 84], ["virus coat proteinPlant material", "TREATMENT", 88, 120], ["PB S buffer", "TREATMENT", 142, 153], ["polyvinylpyrollidone", "TREATMENT", 189, 209], ["bovine serum albumin", "TREATMENT", 223, 243]]], ["Serial dilutions of homogenized extract were analysed by means of the 'Double Antibody Sandwich' test using monoclonal antibodies against PVY (Bioreba, Reinach, Schweiz).", [["extract", "ANATOMY", 32, 39], ["PVY", "ORGANISM", 138, 141], ["monoclonal antibodies", "PROTEIN", 108, 129], ["PVY", "SPECIES", 138, 141], ["Serial dilutions of homogenized extract", "TREATMENT", 0, 39], ["the 'Double Antibody Sandwich' test", "TREATMENT", 66, 101], ["monoclonal antibodies", "TREATMENT", 108, 129], ["PVY", "PROBLEM", 138, 141]]], ["The ELISA procedure was performed accordir/g to the protocol by Bioreba.Preparation of a ppa-1 subtractive cDNA library by restriction site exclusionIn order to get ppa-l-specific cDNA clones a subtractive library enriched for transcripts present in ppa-1 plants was prepared ( Fig. 1) .", [["ppa-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["ppa-1", "GENE_OR_GENE_PRODUCT", 250, 255], ["ppa-1 subtractive cDNA library", "DNA", 89, 119], ["ppa-l-specific cDNA clones", "DNA", 165, 191], ["ppa", "PROTEIN", 250, 253], ["The ELISA procedure", "TREATMENT", 0, 19], ["a ppa-1 subtractive cDNA library", "TREATMENT", 87, 119], ["a subtractive library", "TREATMENT", 192, 213]]], ["RNA was isolated from ppa-l-10 plants which is the best characterized ppa-1 plant line [27] .", [["ppa-l-10 plants", "ORGANISM", 22, 37], ["RNA", "RNA", 0, 3], ["RNA", "TEST", 0, 3], ["ppa-l", "TEST", 22, 27], ["plant line", "OBSERVATION", 76, 86]]], ["To avoid multiple cycles of subtraction with subsequent PCR amplification as developed by Straus and Ausubel for genomic subtraction [30] , the subtractive eDNA library was made by only one cycle of subtraction with subsequent selective cloning of transcripts from ppa-1 plants (Fig. 1 ).", [["ppa-1", "GENE_OR_GENE_PRODUCT", 265, 270], ["subtractive eDNA library", "DNA", 144, 168], ["ppa", "PROTEIN", 265, 268], ["multiple cycles of subtraction", "TREATMENT", 9, 39], ["subsequent PCR amplification", "TREATMENT", 45, 73], ["genomic subtraction", "TEST", 113, 132], ["the subtractive eDNA library", "TREATMENT", 140, 168], ["subtraction", "TREATMENT", 199, 210], ["ppa", "TEST", 265, 268]]], ["To this end the recombinant plasmids of the original cDNA libraries made from mRNA of wild-type and ppa-1 plants, respectively, were digested with different restriction enzymes, i.e. wild-type cDNA with Not I and ppa-1 cDNA with Eco RI.", [["plasmids", "ANATOMY", 28, 36], ["ppa-1", "GENE_OR_GENE_PRODUCT", 100, 105], ["Not I", "GENE_OR_GENE_PRODUCT", 203, 208], ["ppa-1", "GENE_OR_GENE_PRODUCT", 213, 218], ["Eco RI", "GENE_OR_GENE_PRODUCT", 229, 235], ["recombinant plasmids", "DNA", 16, 36], ["cDNA libraries", "DNA", 53, 67], ["mRNA", "RNA", 78, 82], ["restriction enzymes", "PROTEIN", 157, 176], ["wild-type cDNA", "DNA", 183, 197], ["Not I and ppa-1 cDNA", "DNA", 203, 223], ["Eco RI", "DNA", 229, 235], ["the original cDNA libraries", "TREATMENT", 40, 67], ["different restriction enzymes", "TEST", 147, 176], ["ppa", "TEST", 213, 216]]], ["The respective cDNAs were eluted from agarose gels and the wild-type cDNA fragments were then photobiotinylated and hybridized to the ppa-1 cDNA.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 134, 139], ["cDNAs", "DNA", 15, 20], ["wild-type cDNA fragments", "DNA", 59, 83], ["ppa-1 cDNA", "DNA", 134, 144], ["The respective cDNAs", "PROBLEM", 0, 20], ["agarose gels", "TREATMENT", 38, 50], ["type cDNA fragments", "PROBLEM", 64, 83], ["the ppa", "TEST", 130, 137]]], ["After addition of avidin wild-type as well as hybrid cDNAs were removed by centrifugation.", [["avidin", "GENE_OR_GENE_PRODUCT", 18, 24], ["hybrid cDNAs", "CELL", 46, 58], ["avidin", "PROTEIN", 18, 24], ["hybrid cDNAs", "DNA", 46, 58], ["avidin wild", "TREATMENT", 18, 29], ["hybrid cDNAs", "TREATMENT", 46, 58]]], ["The remaining cDNA fragments -already enriched for ppa-1 clones -were inserted into the Eco RI restriction site of the 2ZAP II vector thereby excluding the cloning of Not I-digested wild-type cDNAs.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["Eco RI", "GENE_OR_GENE_PRODUCT", 88, 94], ["2ZAP II", "GENE_OR_GENE_PRODUCT", 119, 126], ["Not I", "GENE_OR_GENE_PRODUCT", 167, 172], ["cDNA fragments", "DNA", 14, 28], ["ppa-1 clones", "DNA", 51, 63], ["Eco RI restriction site", "DNA", 88, 111], ["2ZAP II vector", "DNA", 119, 133], ["Not I-digested wild-type cDNAs", "DNA", 167, 197], ["The remaining cDNA fragments", "PROBLEM", 0, 28], ["ppa-1 clones", "TREATMENT", 51, 63], ["the 2ZAP II vector", "TREATMENT", 115, 133], ["cDNA fragments", "OBSERVATION", 14, 28]]], ["By hybridizing the same number of plaque-forming units of the subtractive library and the original ppa-1 cDNA library with the E. coli pyrophosphatase DNA (present only in the transgenic ppa-1 plants) it was found that this procedure had resulted in a ten-fold increase of ppa-1-specific clones in the subtractive library.Preparation of a ppa-1 subtractive cDNA library by restriction site exclusionThe main advantage of this method is that amplification of the library in vivo largely excludes artifacts which are commonly found in PCRamplified cDNA libraries.", [["plaque", "ANATOMY", 34, 40], ["ppa-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["E. coli", "ORGANISM", 127, 134], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["ppa-1", "GENE_OR_GENE_PRODUCT", 187, 192], ["ppa-1", "GENE_OR_GENE_PRODUCT", 273, 278], ["ppa-1", "GENE_OR_GENE_PRODUCT", 339, 344], ["ppa-1 cDNA library", "DNA", 99, 117], ["E. coli pyrophosphatase DNA", "DNA", 127, 154], ["transgenic ppa", "PROTEIN", 176, 190], ["ppa-1", "PROTEIN", 273, 278], ["ppa-1 subtractive cDNA library", "DNA", 339, 369], ["PCRamplified cDNA libraries", "DNA", 533, 560], ["E. coli", "SPECIES", 127, 134], ["E. coli", "SPECIES", 127, 134], ["the subtractive library", "TREATMENT", 58, 81], ["the original ppa", "TEST", 86, 102], ["the E. coli pyrophosphatase DNA", "PROBLEM", 123, 154], ["this procedure", "TREATMENT", 219, 233], ["a ten-fold increase of ppa-1", "PROBLEM", 250, 278], ["a ppa-1 subtractive cDNA library", "TREATMENT", 337, 369], ["artifacts", "PROBLEM", 495, 504], ["plaque", "OBSERVATION", 34, 40], ["coli pyrophosphatase DNA", "OBSERVATION", 130, 154], ["subtractive library", "OBSERVATION", 302, 321], ["main", "OBSERVATION_MODIFIER", 403, 407]]], ["One step of subtraction was performed in order not to lose cDNA clones which are only moderately induced in ppa-1 plants.Preparation of a ppa-1 subtractive cDNA library by restriction site exclusionhomologous to the ribosomal protein L19 from man [14] while the remaining six could not be identified by sequence homologies in the databanks.", [["ribosomal", "ANATOMY", 216, 225], ["ppa-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["ppa-1", "GENE_OR_GENE_PRODUCT", 138, 143], ["ribosomal", "CELLULAR_COMPONENT", 216, 225], ["cDNA clones", "DNA", 59, 70], ["ppa", "PROTEIN", 108, 111], ["ppa-1 subtractive cDNA library", "DNA", 138, 168], ["restriction site", "DNA", 172, 188], ["ribosomal protein L19", "PROTEIN", 216, 237], ["man", "SPECIES", 243, 246], ["subtraction", "TEST", 12, 23], ["a ppa-1 subtractive cDNA library", "TREATMENT", 136, 168], ["the ribosomal protein", "TEST", 212, 233], ["moderately", "OBSERVATION_MODIFIER", 86, 96]]], ["Because of their responsiveness to sugar accumulation in the transgenic ppa-1 plants these cDNAs were designated PAR (1 to 6) which stands for photoassimilate-responsive genes.Induction of the PAR-1 cDNA by sucrose, glucose and salicylateTo get a clue about possible functions we started to analyse the expression pattern of one of the isolated unknown cDNA clones (PAR-l).", [["sucrose", "CHEMICAL", 207, 214], ["glucose", "CHEMICAL", 216, 223], ["salicylate", "CHEMICAL", 228, 238], ["sugar", "CHEMICAL", 35, 40], ["sucrose", "CHEMICAL", 207, 214], ["glucose", "CHEMICAL", 216, 223], ["salicylate", "CHEMICAL", 228, 238], ["sugar", "SIMPLE_CHEMICAL", 35, 40], ["ppa-1 plants", "ORGANISM", 72, 84], ["PAR", "GENE_OR_GENE_PRODUCT", 113, 116], ["photoassimilate", "GENE_OR_GENE_PRODUCT", 143, 158], ["PAR-1", "GENE_OR_GENE_PRODUCT", 193, 198], ["sucrose", "SIMPLE_CHEMICAL", 207, 214], ["glucose", "SIMPLE_CHEMICAL", 216, 223], ["salicylate", "SIMPLE_CHEMICAL", 228, 238], ["PAR-l", "GENE_OR_GENE_PRODUCT", 366, 371], ["transgenic ppa-1 plants", "DNA", 61, 84], ["cDNAs", "DNA", 91, 96], ["PAR (1 to 6", "DNA", 113, 124], ["photoassimilate-responsive genes", "DNA", 143, 175], ["PAR-1 cDNA", "DNA", 193, 203], ["cDNA clones", "DNA", 353, 364], ["PAR", "PROTEIN", 366, 369], ["sugar accumulation", "PROBLEM", 35, 53], ["photoassimilate-responsive genes", "TREATMENT", 143, 175], ["the PAR", "TREATMENT", 189, 196], ["glucose", "TEST", 216, 223], ["salicylate", "TREATMENT", 228, 238], ["the isolated unknown cDNA clones", "PROBLEM", 332, 364], ["responsive genes", "OBSERVATION", 159, 175], ["cDNA clones", "OBSERVATION", 353, 364]]], ["In ppa-l-10 plants the steady-state RNA levels hybridizing to this unidentified cDNA increased in the order from sink to source leaves (Fig. 2b , lanes 1 to 6) which are characterized by increasing sugar levels in the same order [27] .", [["sugar", "CHEMICAL", 198, 203], ["ppa-l-10", "GENE_OR_GENE_PRODUCT", 3, 11], ["sugar", "SIMPLE_CHEMICAL", 198, 203], ["cDNA", "DNA", 80, 84], ["this unidentified cDNA", "PROBLEM", 62, 84], ["increasing sugar levels", "PROBLEM", 187, 210]]], ["Much weaker hybridization signals were detected in source leaves of wild-type plants (Fig. 2a, lane 6) .", [["Much weaker hybridization signals", "PROBLEM", 0, 33]]], ["Signal strengths in leaves of ppa-1 plants were approximately four times more intense than in the corresponding leaves of wild-type plants as deter-Isolation of ppa-l-specific cDNA from the subtractive library by differential screeningInduction of the PAR-1 cDNA by sucrose, glucose and salicylateThe subtractive library was successively hybridized to radioactively labelled cDNA prepared from mRNA of wild-type and ppa-1 plants.", [["leaves", "ANATOMY", 20, 26], ["leaves", "ANATOMY", 112, 118], ["sucrose", "CHEMICAL", 266, 273], ["glucose", "CHEMICAL", 275, 282], ["salicylate", "CHEMICAL", 287, 297], ["sucrose", "CHEMICAL", 266, 273], ["glucose", "CHEMICAL", 275, 282], ["salicylate", "CHEMICAL", 287, 297], ["ppa-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["PAR-1", "GENE_OR_GENE_PRODUCT", 252, 257], ["sucrose", "SIMPLE_CHEMICAL", 266, 273], ["glucose", "SIMPLE_CHEMICAL", 275, 282], ["salicylate", "SIMPLE_CHEMICAL", 287, 297], ["ppa-1", "GENE_OR_GENE_PRODUCT", 416, 421], ["ppa-l-specific cDNA", "DNA", 161, 180], ["PAR-1 cDNA", "DNA", 252, 262], ["cDNA", "DNA", 375, 379], ["mRNA", "RNA", 394, 398], ["ppa-1", "SPECIES", 30, 35], ["ppa", "TEST", 30, 33], ["the PAR", "TEST", 248, 255], ["glucose", "TEST", 275, 282], ["salicylate", "TREATMENT", 287, 297], ["ppa", "TEST", 416, 419]]], ["12 differentially hybridizing clones were purified and sequenced.", [["clones", "ANATOMY", 30, 36], ["clones", "CELL", 30, 36], ["12 differentially hybridizing clones", "PROBLEM", 0, 36], ["hybridizing clones", "OBSERVATION", 18, 36]]], ["By homology to known sequences four cDNAs could be identified as coding for 1-aminocyclopropane-l-carboxylic acid oxidase [7] and for three different pathogenesis-related proteins (PR proteins), PR-lb [4] , PR-Q [20] and SARS.2 [35] .", [["1-aminocyclopropane-l-carboxylic acid", "CHEMICAL", 76, 113], ["1-aminocyclopropane-l-carboxylic acid", "CHEMICAL", 76, 113], ["1-aminocyclopropane-l-carboxylic acid oxidase", "GENE_OR_GENE_PRODUCT", 76, 121], ["PR proteins", "GENE_OR_GENE_PRODUCT", 181, 192], ["PR-lb", "GENE_OR_GENE_PRODUCT", 195, 200], ["PR-Q", "GENE_OR_GENE_PRODUCT", 207, 211], ["cDNAs", "DNA", 36, 41], ["1-aminocyclopropane-l-carboxylic acid oxidase", "PROTEIN", 76, 121], ["pathogenesis-related proteins", "PROTEIN", 150, 179], ["PR proteins", "PROTEIN", 181, 192], ["PR", "PROTEIN", 195, 197], ["lb", "PROTEIN", 198, 200], ["PR", "PROTEIN", 207, 209], ["aminocyclopropane", "TREATMENT", 78, 95], ["l-carboxylic acid oxidase", "TREATMENT", 96, 121], ["three different pathogenesis", "PROBLEM", 134, 162], ["proteins", "TEST", 171, 179], ["proteins", "TEST", 184, 192], ["PR", "TEST", 195, 197], ["PR", "TEST", 207, 209], ["SARS.2", "TEST", 221, 227]]], ["The DNA sequence of one cDNA clone shares homology with a calmodulinlike protein from Arabidopsis [2] and one is mined using a phosphoimager.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA sequence", "DNA", 4, 16], ["cDNA clone", "DNA", 24, 34], ["calmodulinlike protein", "PROTEIN", 58, 80], ["Arabidopsis", "SPECIES", 86, 97], ["The DNA sequence", "TEST", 0, 16], ["a calmodulinlike protein", "PROBLEM", 56, 80], ["a phosphoimager", "TREATMENT", 125, 140]]], ["The results were confirmed by analysing RNA from two other independent ppa-1 lines (ppa-l-5 and ppa-l-30) [27] .", [["ppa-l-5", "GENE_OR_GENE_PRODUCT", 84, 91], ["ppa-1 lines", "CELL_LINE", 71, 82], ["ppa", "TEST", 84, 87]]], ["The unknown cDNA which was 950 bp in length hybridized to two mRNA transcripts being ca.", [["cDNA", "DNA", 12, 16], ["mRNA transcripts", "RNA", 62, 78], ["bp", "TEST", 31, 33]]], ["1.2 kb and 1.0 kb in length.Induction of the PAR-1 cDNA by sucrose, glucose and salicylateBecause the accumulation of transcript levels appeared to be correlated with corresponding steady-state levels of soluble sugar (Fig. 2) we wondered whether the m R N A transcripts would accumulate in wild-type leaves upon incubation with soluble sugars.", [["leaves", "ANATOMY", 301, 307], ["sucrose", "CHEMICAL", 59, 66], ["glucose", "CHEMICAL", 68, 75], ["salicylate", "CHEMICAL", 80, 90], ["sucrose", "CHEMICAL", 59, 66], ["glucose", "CHEMICAL", 68, 75], ["salicylate", "CHEMICAL", 80, 90], ["sugar", "CHEMICAL", 212, 217], ["sugars", "CHEMICAL", 337, 343], ["PAR-1", "GENE_OR_GENE_PRODUCT", 45, 50], ["sucrose", "SIMPLE_CHEMICAL", 59, 66], ["glucose", "SIMPLE_CHEMICAL", 68, 75], ["salicylate", "SIMPLE_CHEMICAL", 80, 90], ["sugar", "SIMPLE_CHEMICAL", 212, 217], ["R N A", "GENE_OR_GENE_PRODUCT", 253, 258], ["PAR-1 cDNA", "DNA", 45, 55], ["m R N A transcripts", "RNA", 251, 270], ["length", "TEST", 21, 27], ["the PAR", "TREATMENT", 41, 48], ["glucose", "TEST", 68, 75], ["salicylate", "TREATMENT", 80, 90], ["transcript levels", "TEST", 118, 135], ["soluble sugar", "TEST", 204, 217], ["soluble sugars", "TEST", 329, 343], ["length", "OBSERVATION_MODIFIER", 21, 27]]], ["Leaf discs from mature leaves of wild-type tobacco plants were therefore floated on water, glucose and sucrose (50, 100, 200, 300, 400, 500 mM) for 24 h and the RNA was analysed (Fig. 3) .", [["Leaf discs", "ANATOMY", 0, 10], ["leaves", "ANATOMY", 23, 29], ["glucose", "CHEMICAL", 91, 98], ["sucrose", "CHEMICAL", 103, 110], ["glucose", "CHEMICAL", 91, 98], ["sucrose", "CHEMICAL", 103, 110], ["Leaf discs", "TISSUE", 0, 10], ["leaves", "ORGANISM_SUBDIVISION", 23, 29], ["tobacco", "ORGANISM", 43, 50], ["water", "SIMPLE_CHEMICAL", 84, 89], ["glucose", "SIMPLE_CHEMICAL", 91, 98], ["sucrose", "SIMPLE_CHEMICAL", 103, 110], ["tobacco", "SPECIES", 43, 50], ["tobacco", "SPECIES", 43, 50], ["Leaf discs", "PROBLEM", 0, 10], ["the RNA", "TEST", 157, 164], ["discs", "OBSERVATION_MODIFIER", 5, 10], ["mature", "OBSERVATION_MODIFIER", 16, 22], ["leaves", "OBSERVATION_MODIFIER", 23, 29]]], ["The PAR-1 m R N A transcripts accumulated in response to sucrose at a concentration of 200 mM and levels increased with higher concentrations of sucrose (Fig. 3, lanes 8-14) .", [["sucrose", "CHEMICAL", 57, 64], ["sucrose", "CHEMICAL", 145, 152], ["sucrose", "CHEMICAL", 57, 64], ["sucrose", "CHEMICAL", 145, 152], ["PAR-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["R N A", "GENE_OR_GENE_PRODUCT", 12, 17], ["sucrose", "SIMPLE_CHEMICAL", 57, 64], ["sucrose", "SIMPLE_CHEMICAL", 145, 152], ["PAR-1 m R N A transcripts", "RNA", 4, 29], ["sucrose", "TREATMENT", 57, 64], ["sucrose (Fig.", "TREATMENT", 145, 158]]], ["Floating on glucose at concentrations of 200 mM to 500 mM also lead to accumulating levels of PAR-1 mRNA although less strongly (Fig. 3, lanes 1-7) .", [["glucose", "CHEMICAL", 12, 19], ["glucose", "CHEMICAL", 12, 19], ["glucose", "SIMPLE_CHEMICAL", 12, 19], ["PAR-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["PAR-1 mRNA", "RNA", 94, 104], ["glucose", "TEST", 12, 19], ["PAR", "TEST", 94, 97], ["lanes", "TEST", 137, 142], ["levels", "OBSERVATION_MODIFIER", 84, 90]]], ["At a glucose concentration of 500 mM levels of PAR-I transcripts had increased 12-fold while floating on sucrose resulted in an increase of about 29-fold compared to the water control as quantified by phosphoimaging.Induction of the PAR-1 cDNA by sucrose, glucose and salicylateThere are multiple ways by which sugars may possibly exert their effect on gene expression.", [["glucose", "CHEMICAL", 5, 12], ["sucrose", "CHEMICAL", 105, 112], ["sucrose", "CHEMICAL", 247, 254], ["glucose", "CHEMICAL", 256, 263], ["salicylate", "CHEMICAL", 268, 278], ["glucose", "CHEMICAL", 5, 12], ["sucrose", "CHEMICAL", 105, 112], ["sucrose", "CHEMICAL", 247, 254], ["glucose", "CHEMICAL", 256, 263], ["salicylate", "CHEMICAL", 268, 278], ["sugars", "CHEMICAL", 311, 317], ["glucose", "SIMPLE_CHEMICAL", 5, 12], ["PAR-I", "GENE_OR_GENE_PRODUCT", 47, 52], ["sucrose", "SIMPLE_CHEMICAL", 105, 112], ["PAR-1", "GENE_OR_GENE_PRODUCT", 233, 238], ["sucrose", "SIMPLE_CHEMICAL", 247, 254], ["glucose", "SIMPLE_CHEMICAL", 256, 263], ["salicylate", "SIMPLE_CHEMICAL", 268, 278], ["sugars", "SIMPLE_CHEMICAL", 311, 317], ["PAR", "PROTEIN", 47, 50], ["I transcripts", "PROTEIN", 51, 64], ["PAR-1 cDNA", "DNA", 233, 243], ["a glucose concentration", "TEST", 3, 26], ["PAR-I transcripts", "TEST", 47, 64], ["sucrose", "TREATMENT", 105, 112], ["the water control", "TREATMENT", 166, 183], ["the PAR", "TREATMENT", 229, 236], ["glucose", "TEST", 256, 263], ["salicylate", "TREATMENT", 268, 278], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["multiple", "OBSERVATION_MODIFIER", 288, 296]]], ["Alternatively, the water household may be perturbed (osmotic potential, water potential and resulting turgor pressure) or metabolic changes such as alterations in the C/N ratio may occur in response to sugar accumulation.", [["sugar", "CHEMICAL", 202, 207], ["C/N", "GENE_OR_GENE_PRODUCT", 167, 170], ["sugar", "SIMPLE_CHEMICAL", 202, 207], ["turgor pressure", "TEST", 102, 117], ["metabolic changes", "PROBLEM", 122, 139], ["alterations in the C/N ratio", "PROBLEM", 148, 176], ["sugar accumulation", "PROBLEM", 202, 220], ["sugar accumulation", "OBSERVATION", 202, 220]]], ["Alternatively, sugars might induce a state of general stress resulting in changed levels of phytohormones which would regulate gene expression.", [["sugars", "CHEMICAL", 15, 21], ["sugars", "SIMPLE_CHEMICAL", 15, 21], ["sugars", "TEST", 15, 21], ["general stress", "PROBLEM", 46, 60], ["phytohormones", "TREATMENT", 92, 105]]], ["To study whether the accumulation of PAR-1 transcripts was due to osmotic effects caused by an increase in the levels of soluble sugars, leaf discs were incubated in different osmolytes and the RNA was analysed.", [["leaf discs", "ANATOMY", 137, 147], ["sugars", "CHEMICAL", 129, 135], ["PAR-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["sugars", "SIMPLE_CHEMICAL", 129, 135], ["leaf discs", "ORGANISM_SUBSTANCE", 137, 147], ["PAR", "PROTEIN", 37, 40], ["the accumulation of PAR", "PROBLEM", 17, 40], ["osmotic effects", "PROBLEM", 66, 81], ["an increase", "PROBLEM", 92, 103], ["soluble sugars", "TREATMENT", 121, 135], ["leaf discs", "PROBLEM", 137, 147], ["different osmolytes", "TEST", 166, 185], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["Sorbitol at concentrations of 80 and 250 mM (measured to correspond to 98 and 260 mmol/ kg), did not cause PAR-1 transcript accumulation in floating experiments (Fig. 4, lanes 3 and 4) .", [["Sorbitol", "CHEMICAL", 0, 8], ["Sorbitol", "CHEMICAL", 0, 8], ["Sorbitol", "SIMPLE_CHEMICAL", 0, 8], ["PAR-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["PAR", "PROTEIN", 107, 110], ["Sorbitol", "TREATMENT", 0, 8], ["PAR", "PROBLEM", 107, 110], ["floating experiments", "OBSERVATION", 140, 160]]], ["These concentrations were used as they were about equal in osmolality to 50 mM and 200 mM glucose (measured to be 84 and 247 mmol/kg, respectively).", [["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["mM glucose", "TEST", 87, 97]]], ["As expected, floating on 200 mM glucose resulted in the accumulation of PAR-1 transcripts (Fig. 4, lane 2) .", [["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 32, 39], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["PAR-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["PAR", "PROTEIN", 72, 75], ["200 mM glucose", "TEST", 25, 39], ["the accumulation of PAR", "PROBLEM", 52, 75], ["floating", "OBSERVATION_MODIFIER", 13, 21]]], ["No induction was observed after floating leaf discs on 7 ~o polyethylene glycol 6000 (Fig. 4, lane 5) .", [["leaf discs", "ANATOMY", 41, 51], ["polyethylene glycol", "CHEMICAL", 60, 79], ["polyethylene glycol", "CHEMICAL", 60, 79], ["polyethylene glycol", "SIMPLE_CHEMICAL", 60, 79], ["floating leaf discs", "PROBLEM", 32, 51], ["7 ~o polyethylene glycol", "TREATMENT", 55, 79], ["leaf discs", "OBSERVATION", 41, 51]]], ["Altogether the data suggest that the induction of the PAR-1 transcripts by glucose and sucrose cannot be caused by osmotic changes alone.", [["glucose", "CHEMICAL", 75, 82], ["sucrose", "CHEMICAL", 87, 94], ["glucose", "CHEMICAL", 75, 82], ["sucrose", "CHEMICAL", 87, 94], ["PAR-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["glucose", "SIMPLE_CHEMICAL", 75, 82], ["sucrose", "SIMPLE_CHEMICAL", 87, 94], ["PAR-1 transcripts", "RNA", 54, 71], ["the PAR", "TREATMENT", 50, 57], ["glucose and sucrose", "TREATMENT", 75, 94], ["osmotic changes", "PROBLEM", 115, 130]]], ["Glutamine used in floating experiments to perturb the cellular C/N ratio by increasing the level of amino acids did not lead to enhanced levels of PAR-1 transcripts either (Fig. 4, lane 6) .Induction of the PAR-1 cDNA by sucrose, glucose and salicylateAs cDNAs coding for PR-proteins had been isolated from the ppa-l-specific library supporting the hypothesis that sugar accumulation in leaves would result in a general stress response we wondered whether PAR-1 also possessed any features of stress-related genes.", [["cellular", "ANATOMY", 54, 62], ["leaves", "ANATOMY", 387, 393], ["Glutamine", "CHEMICAL", 0, 9], ["amino acids", "CHEMICAL", 100, 111], ["sucrose", "CHEMICAL", 221, 228], ["glucose", "CHEMICAL", 230, 237], ["salicylate", "CHEMICAL", 242, 252], ["Glutamine", "CHEMICAL", 0, 9], ["amino acids", "CHEMICAL", 100, 111], ["sucrose", "CHEMICAL", 221, 228], ["glucose", "CHEMICAL", 230, 237], ["salicylate", "CHEMICAL", 242, 252], ["sugar", "CHEMICAL", 365, 370], ["Glutamine", "AMINO_ACID", 0, 9], ["cellular", "CELL", 54, 62], ["amino acids", "AMINO_ACID", 100, 111], ["PAR-1", "GENE_OR_GENE_PRODUCT", 147, 152], ["PAR-1", "GENE_OR_GENE_PRODUCT", 207, 212], ["sucrose", "SIMPLE_CHEMICAL", 221, 228], ["glucose", "SIMPLE_CHEMICAL", 230, 237], ["salicylate", "SIMPLE_CHEMICAL", 242, 252], ["PR", "GENE_OR_GENE_PRODUCT", 272, 274], ["sugar", "SIMPLE_CHEMICAL", 365, 370], ["PAR-1", "GENE_OR_GENE_PRODUCT", 456, 461], ["PAR", "PROTEIN", 147, 150], ["PAR-1 cDNA", "DNA", 207, 217], ["cDNAs", "DNA", 255, 260], ["PR", "PROTEIN", 272, 274], ["PAR", "PROTEIN", 456, 459], ["Glutamine", "TREATMENT", 0, 9], ["the cellular C/N ratio", "TEST", 50, 72], ["amino acids", "TEST", 100, 111], ["enhanced levels of PAR", "PROBLEM", 128, 150], ["the PAR", "TREATMENT", 203, 210], ["glucose", "TEST", 230, 237], ["salicylate", "TREATMENT", 242, 252], ["PR", "TEST", 272, 274], ["sugar accumulation", "PROBLEM", 365, 383], ["a general stress response", "PROBLEM", 410, 435], ["stress-related genes", "PROBLEM", 493, 513]]], ["To this end the expression of the PAR-1 transcripts was studied in response to hormones associated with stress in plants by means of floating experiments (Fig. 4) .", [["PAR-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["PAR-1 transcripts", "PROTEIN", 34, 51], ["stress in plants", "PROBLEM", 104, 120]]], ["No substantial differences in transcript levels were observed after floating leaf discs on water, methyl jasmonate and abscisic acid (Fig. 4 , lanes 8 to 10)whereas levels of PAR-1 transcripts rose significantly as a result of floating leaf discs on 1 mM salicylate for 24 h (Fig. 4, lane 7) .Induction of the PAR-1 cDNA by sucrose, glucose and salicylateFloating leaves on gibberellic acid and indole acetic acid as well as spraying plants with ethephon did not induce PAR-1 transcripts (data not shown).Local and systemic induction of the PAR-l-specific transcripts in tobacco plants after infection with potato virus Y (PVY)Because of their induction by salicylate the levels o f m R N A transcripts corresponding to the PAR-1 cDNA were analysed in response to virus infection.", [["leaf discs", "ANATOMY", 77, 87], ["leaf discs", "ANATOMY", 236, 246], ["leaves", "ANATOMY", 364, 370], ["methyl jasmonate", "CHEMICAL", 98, 114], ["abscisic acid", "CHEMICAL", 119, 132], ["salicylate", "CHEMICAL", 255, 265], ["sucrose", "CHEMICAL", 324, 331], ["glucose", "CHEMICAL", 333, 340], ["salicylate", "CHEMICAL", 345, 355], ["gibberellic acid", "CHEMICAL", 374, 390], ["indole acetic acid", "CHEMICAL", 395, 413], ["ethephon", "CHEMICAL", 446, 454], ["infection", "DISEASE", 592, 601], ["salicylate", "CHEMICAL", 657, 667], ["infection", "DISEASE", 770, 779], ["methyl jasmonate", "CHEMICAL", 98, 114], ["abscisic acid", "CHEMICAL", 119, 132], ["salicylate", "CHEMICAL", 255, 265], ["sucrose", "CHEMICAL", 324, 331], ["glucose", "CHEMICAL", 333, 340], ["salicylate", "CHEMICAL", 345, 355], ["gibberellic acid", "CHEMICAL", 374, 390], ["indole acetic acid", "CHEMICAL", 395, 413], ["ethephon", "CHEMICAL", 446, 454], ["salicylate", "CHEMICAL", 657, 667], ["water", "SIMPLE_CHEMICAL", 91, 96], ["methyl jasmonate", "SIMPLE_CHEMICAL", 98, 114], ["abscisic acid", "SIMPLE_CHEMICAL", 119, 132], ["PAR-1", "GENE_OR_GENE_PRODUCT", 175, 180], ["leaf discs", "TISSUE", 236, 246], ["salicylate", "SIMPLE_CHEMICAL", 255, 265], ["PAR-1", "GENE_OR_GENE_PRODUCT", 310, 315], ["sucrose", "SIMPLE_CHEMICAL", 324, 331], ["glucose", "SIMPLE_CHEMICAL", 333, 340], ["salicylate", "SIMPLE_CHEMICAL", 345, 355], ["gibberellic acid", "SIMPLE_CHEMICAL", 374, 390], ["indole acetic acid", "SIMPLE_CHEMICAL", 395, 413], ["ethephon", "SIMPLE_CHEMICAL", 446, 454], ["PAR-1", "GENE_OR_GENE_PRODUCT", 470, 475], ["PAR-l-", "GENE_OR_GENE_PRODUCT", 541, 547], ["tobacco", "ORGANISM", 571, 578], ["potato virus Y (PVY", "ORGANISM", 607, 626], ["salicylate", "SIMPLE_CHEMICAL", 657, 667], ["R N A", "GENE_OR_GENE_PRODUCT", 685, 690], ["PAR-1", "GENE_OR_GENE_PRODUCT", 724, 729], ["PAR", "PROTEIN", 175, 178], ["PAR-1 cDNA", "DNA", 310, 320], ["PAR", "PROTEIN", 470, 473], ["PAR", "PROTEIN", 541, 544], ["f m R N A transcripts", "RNA", 681, 702], ["PAR-1 cDNA", "DNA", 724, 734], ["tobacco", "SPECIES", 571, 578], ["potato virus", "SPECIES", 607, 619], ["tobacco", "SPECIES", 571, 578], ["potato virus", "SPECIES", 607, 619], ["PVY", "SPECIES", 623, 626], ["transcript levels", "TEST", 30, 47], ["floating leaf discs", "PROBLEM", 68, 87], ["water, methyl jasmonate", "TREATMENT", 91, 114], ["abscisic acid", "TEST", 119, 132], ["PAR", "TEST", 175, 178], ["floating leaf discs", "PROBLEM", 227, 246], ["1 mM salicylate", "TREATMENT", 250, 265], ["the PAR", "TREATMENT", 306, 313], ["glucose", "TEST", 333, 340], ["salicylate", "TREATMENT", 345, 355], ["Floating leaves", "PROBLEM", 355, 370], ["gibberellic acid", "TREATMENT", 374, 390], ["indole acetic acid", "TREATMENT", 395, 413], ["ethephon", "TREATMENT", 446, 454], ["the PAR", "TREATMENT", 537, 544], ["infection", "PROBLEM", 592, 601], ["potato virus Y (PVY", "TREATMENT", 607, 626], ["A transcripts", "PROBLEM", 689, 702], ["the PAR", "TEST", 720, 727], ["virus infection", "PROBLEM", 764, 779], ["substantial", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["leaf discs", "OBSERVATION", 77, 87], ["abscisic acid", "OBSERVATION", 119, 132], ["leaf discs", "OBSERVATION", 236, 246], ["gibberellic acid", "OBSERVATION", 374, 390], ["systemic", "OBSERVATION", 515, 523], ["virus infection", "OBSERVATION", 764, 779]]], ["To this end tobacco plants cv.", [["tobacco", "ORGANISM", 12, 19], ["tobacco", "SPECIES", 12, 19], ["cv", "SPECIES", 27, 29]]], ["Samsun NN were infected with PVY which on this cultivar gives rise to systemic infections (unpublished data).", [["systemic infections", "DISEASE", 70, 89], ["PVY", "ORGANISM", 29, 32], ["PVY", "SPECIES", 29, 32], ["Samsun NN", "TREATMENT", 0, 9], ["PVY", "PROBLEM", 29, 32], ["this cultivar", "TREATMENT", 42, 55], ["systemic infections", "PROBLEM", 70, 89], ["infected", "OBSERVATION", 15, 23], ["systemic", "OBSERVATION_MODIFIER", 70, 78], ["infections", "OBSERVATION", 79, 89]]], ["First symptoms of infected leaves are the browning of veins which is followed by a crinkly and finally necrotic appearance of the leaves.", [["leaves", "ANATOMY", 27, 33], ["veins", "ANATOMY", 54, 59], ["leaves", "ANATOMY", 130, 136], ["infected leaves", "DISEASE", 18, 33], ["necrotic", "DISEASE", 103, 111], ["leaves", "ORGANISM_SUBDIVISION", 27, 33], ["veins", "MULTI-TISSUE_STRUCTURE", 54, 59], ["First symptoms", "PROBLEM", 0, 14], ["infected leaves", "PROBLEM", 18, 33], ["the browning of veins", "PROBLEM", 38, 59], ["infected", "OBSERVATION", 18, 26], ["browning", "OBSERVATION_MODIFIER", 42, 50], ["veins", "ANATOMY", 54, 59], ["necrotic", "OBSERVATION_MODIFIER", 103, 111]]], ["In plants with 6 to 8 leaves PVY spreads systemically to all leaves above the directly infected one while in elder plants -depending on the number of leaves at the time of infection -the first to the fourth above the infected leaf does not get infected (unpublished observation).Local and systemic induction of the PAR-l-specific transcripts in tobacco plants after infection with potato virus Y (PVY)The expression of PAR-1 transcripts was studied after treatment of tobacco plants with PVY from 2 to 12 days after infection (dpi).", [["leaves", "ANATOMY", 61, 67], ["leaves", "ANATOMY", 150, 156], ["leaf", "ANATOMY", 226, 230], ["infection", "DISEASE", 172, 181], ["infection", "DISEASE", 366, 375], ["infection", "DISEASE", 516, 525], ["PVY", "ORGANISM", 29, 32], ["leaves", "ORGANISM_SUBDIVISION", 150, 156], ["leaf", "ORGAN", 226, 230], ["PAR-l-", "GENE_OR_GENE_PRODUCT", 315, 321], ["tobacco", "ORGANISM", 345, 352], ["potato virus Y (PVY", "ORGANISM", 381, 400], ["PAR-1", "GENE_OR_GENE_PRODUCT", 419, 424], ["tobacco", "ORGANISM", 468, 475], ["PVY", "ORGANISM", 488, 491], ["PAR", "PROTEIN", 315, 318], ["PAR", "PROTEIN", 419, 422], ["tobacco", "SPECIES", 345, 352], ["potato virus", "SPECIES", 381, 393], ["tobacco", "SPECIES", 468, 475], ["PVY", "SPECIES", 29, 32], ["tobacco", "SPECIES", 345, 352], ["potato virus", "SPECIES", 381, 393], ["PVY", "SPECIES", 397, 400], ["tobacco", "SPECIES", 468, 475], ["PVY", "SPECIES", 488, 491], ["infection", "PROBLEM", 172, 181], ["the PAR", "TREATMENT", 311, 318], ["infection", "PROBLEM", 366, 375], ["potato virus Y", "TREATMENT", 381, 395], ["PAR-1 transcripts", "TREATMENT", 419, 436], ["PVY", "PROBLEM", 488, 491], ["infection", "PROBLEM", 516, 525], ["infected", "OBSERVATION", 87, 95], ["infection", "OBSERVATION", 172, 181], ["infected", "OBSERVATION", 217, 225], ["infected", "OBSERVATION", 244, 252], ["systemic", "OBSERVATION", 289, 297]]], ["Samples were taken for RNA analysis as well as for detection of PVY by the ELISA technique from the directly infected as well as from the systemic noninfected and infected leaves.", [["Samples", "ANATOMY", 0, 7], ["leaves", "ANATOMY", 172, 178], ["PVY", "ORGANISM", 64, 67], ["leaves", "ORGAN", 172, 178], ["PVY", "DNA", 64, 67], ["PVY", "SPECIES", 64, 67], ["Samples", "TEST", 0, 7], ["RNA analysis", "TEST", 23, 35], ["PVY", "PROBLEM", 64, 67], ["the ELISA technique", "TEST", 71, 90], ["the systemic noninfected and infected leaves", "PROBLEM", 134, 178], ["infected", "OBSERVATION", 109, 117], ["systemic", "OBSERVATION_MODIFIER", 138, 146], ["noninfected", "OBSERVATION", 147, 158], ["infected", "OBSERVATION", 163, 171]]], ["Four days after mechanical treatment of leaves with PVY a weak induction of the PAR-1 transcripts could be observed (Fig. 5a, lane 3) .", [["leaves", "ANATOMY", 40, 46], ["leaves", "ORGANISM_SUBDIVISION", 40, 46], ["PAR-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["PAR-1 transcripts", "RNA", 80, 97], ["PVY", "SPECIES", 52, 55], ["mechanical treatment", "TREATMENT", 16, 36], ["PVY", "PROBLEM", 52, 55], ["the PAR", "TREATMENT", 76, 83]]], ["Transcript levels increased up to 9 dpi (Fig. 5a, lanes 3-8) .", [["Transcript levels", "TEST", 0, 17]]], ["A moderate accumulation of transcripts was also found in the systemically uninfected leaves (Fig. 5b, lanes 7-9) .", [["leaves", "ANATOMY", 85, 91], ["A moderate accumulation of transcripts", "PROBLEM", 0, 38], ["moderate", "OBSERVATION_MODIFIER", 2, 10], ["accumulation of transcripts", "OBSERVATION", 11, 38]]], ["At no time virus could be detected in these leaves using monoclonal antibodies against PVY coat protein or by hybridizing northern blots with cDNA encoding PVY coat protein (data not shown).", [["leaves", "ANATOMY", 44, 50], ["PVY coat protein", "GENE_OR_GENE_PRODUCT", 87, 103], ["PVY coat protein", "GENE_OR_GENE_PRODUCT", 156, 172], ["monoclonal antibodies", "PROTEIN", 57, 78], ["PVY coat protein", "PROTEIN", 87, 103], ["cDNA", "DNA", 142, 146], ["PVY coat protein", "PROTEIN", 156, 172], ["PVY", "SPECIES", 87, 90], ["time virus", "PROBLEM", 6, 16], ["monoclonal antibodies", "TREATMENT", 57, 78], ["PVY coat protein", "PROBLEM", 87, 103], ["hybridizing northern blots", "PROBLEM", 110, 136], ["PVY coat protein", "TEST", 156, 172]]], ["Systemic leaves which got infected accumulated high levels of PAR-1 transcripts starting 8 dpi (Fig. 5c, lanes 7-9) .", [["leaves", "ANATOMY", 9, 15], ["PAR-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["PAR", "PROTEIN", 62, 65], ["Systemic leaves", "PROBLEM", 0, 15], ["infected", "PROBLEM", 26, 34], ["lanes", "TEST", 105, 110], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["accumulated", "OBSERVATION_MODIFIER", 35, 46], ["high", "OBSERVATION_MODIFIER", 47, 51], ["levels", "OBSERVATION_MODIFIER", 52, 58]]], ["PVY coat protein could be detected 2 dpi after PVY treatment in locally infected leaves and 6 dpi in systemically infected leaves.", [["leaves", "ANATOMY", 81, 87], ["leaves", "ANATOMY", 123, 129], ["PVY", "ORGANISM", 0, 3], ["PVY", "ORGANISM", 47, 50], ["leaves", "DEVELOPING_ANATOMICAL_STRUCTURE", 81, 87], ["leaves", "ORGANISM_SUBDIVISION", 123, 129], ["PVY coat protein", "PROTEIN", 0, 16], ["PVY", "SPECIES", 0, 3], ["PVY", "SPECIES", 47, 50], ["PVY coat protein", "TEST", 0, 16], ["PVY treatment", "TREATMENT", 47, 60]]], ["The data prove that the PAR-1 transcripts are inducible by virus both locally and systemically.", [["PAR-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["PAR-1 transcripts", "RNA", 24, 41], ["the PAR", "TREATMENT", 20, 27]]], ["The expression of the PAR-1 transcripts in response to PVY occurred co-ordinately with the expression of mRNAs encoding PR-Q and SAR8.2 (data not shown).Isolation of different classes of PAR-1 cDNAsTo find out whether the two differently sized PAR-1 transcripts were due to the expression of homologous genes the original ppa-1 cDNA library was screened with the PAR-1 cDNA fragment.", [["PAR-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["PVY", "ORGANISM", 55, 58], ["PR-Q", "GENE_OR_GENE_PRODUCT", 120, 124], ["SAR8.2", "GENE_OR_GENE_PRODUCT", 129, 135], ["PAR-1", "GENE_OR_GENE_PRODUCT", 187, 192], ["PAR-1", "GENE_OR_GENE_PRODUCT", 244, 249], ["ppa-1", "GENE_OR_GENE_PRODUCT", 322, 327], ["PAR-1", "GENE_OR_GENE_PRODUCT", 363, 368], ["PAR-1 transcripts", "RNA", 22, 39], ["PVY", "DNA", 55, 58], ["mRNAs", "RNA", 105, 110], ["PR", "PROTEIN", 120, 122], ["Q", "PROTEIN", 123, 124], ["SAR8.2", "PROTEIN", 129, 135], ["PAR-1 cDNAs", "DNA", 187, 198], ["PAR", "PROTEIN", 244, 247], ["1 transcripts", "RNA", 248, 261], ["homologous genes", "DNA", 292, 308], ["ppa-1 cDNA library", "DNA", 322, 340], ["PAR-1 cDNA fragment", "DNA", 363, 382], ["PVY", "SPECIES", 55, 58], ["PVY", "PROBLEM", 55, 58], ["the two differently sized PAR", "PROBLEM", 218, 247], ["the original ppa", "TEST", 309, 325], ["cDNA library", "TEST", 328, 340], ["cDNA fragment", "OBSERVATION", 369, 382]]], ["Out of several hundred hybridizing plaques 25 independent clones were purified and after in vivo excision analysed by restriction and sequencing.", [["plaques", "ANATOMY", 35, 42], ["clones", "ANATOMY", 58, 64], ["clones", "CELL", 58, 64], ["several hundred hybridizing plaques", "PROBLEM", 7, 42], ["vivo excision", "TREATMENT", 92, 105], ["hybridizing", "OBSERVATION_MODIFIER", 23, 34], ["plaques", "OBSERVATION", 35, 42]]], ["According to their homology the cDNAs (between 0.6 and 1 kb in length) could be grouped into three different classes (termed PAR-la, b, c).", [["cDNAs", "DNA", 32, 37], ["PAR", "PROTEIN", 125, 128], ["c", "DNA", 136, 137]]], ["The first two classes (a and b) shared 90.6~o homology on the DNA level, while both groups were less related to class c (75.2~o and 70.5~o homology, respectively).", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["the DNA level", "TEST", 58, 71]]], ["The three different cDNAs contained one common open reading frame which would code for a protein with a theoretical molecular mass of ca.", [["cDNAs", "DNA", 20, 25], ["open reading frame", "DNA", 47, 65], ["a theoretical molecular mass of ca", "PROBLEM", 102, 136], ["mass", "OBSERVATION", 126, 130], ["ca", "OBSERVATION", 134, 136]]], ["Comparisons between the putative coding regions of the three PAR-1 proteins essentially reflected the degree of similarity found on the DNA level.", [["PAR-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["PAR-1 proteins", "PROTEIN", 61, 75], ["the DNA level", "TEST", 132, 145]]], ["PAR-la and PAR-Ib proteins would be identical to 90.3 ~o while they would share only 78.1 ~o and 79~o identical amino acids with the PAR-lc pro-tein, respectively.", [["amino acids", "CHEMICAL", 112, 123], ["amino acids", "CHEMICAL", 112, 123], ["PAR", "GENE_OR_GENE_PRODUCT", 0, 3], ["PAR-Ib", "GENE_OR_GENE_PRODUCT", 11, 17], ["amino acids", "AMINO_ACID", 112, 123], ["PAR-lc pro-tein", "GENE_OR_GENE_PRODUCT", 133, 148], ["PAR", "PROTEIN", 0, 3], ["PAR", "PROTEIN", 11, 14], ["Ib proteins", "PROTEIN", 15, 26], ["PAR", "PROTEIN", 133, 136], ["lc pro-tein", "PROTEIN", 137, 148], ["amino acids", "TEST", 112, 123]]], ["The amino acid sequences of the proteins deduced from the open reading frames of the three different PAR cDNAs have been aligned in Fig. 6 .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["PAR", "GENE_OR_GENE_PRODUCT", 101, 104], ["amino acid sequences", "PROTEIN", 4, 24], ["open reading frames", "DNA", 58, 77], ["PAR cDNAs", "DNA", 101, 110], ["The amino acid sequences", "TEST", 0, 24], ["the proteins", "PROBLEM", 28, 40]]], ["The DNA homology in the putative coding region of the three PAR proteins is significantly higher than in the surrounding untranslated regions (data not shown) which additionally argues for this open reading frame as being the coding region.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["PAR", "GENE_OR_GENE_PRODUCT", 60, 63], ["PAR proteins", "PROTEIN", 60, 72], ["surrounding untranslated regions", "DNA", 109, 141], ["open reading frame", "DNA", 194, 212], ["The DNA homology", "TEST", 0, 16], ["the three PAR proteins", "TEST", 50, 72], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["All three PAR proteins have the same hydrophilic profile with a hydrophobic stretch of 28 amino acids at the Nterminus which resembles a signal peptide.", [["amino acids", "CHEMICAL", 90, 101], ["amino acids", "CHEMICAL", 90, 101], ["PAR", "GENE_OR_GENE_PRODUCT", 10, 13], ["amino acids", "AMINO_ACID", 90, 101], ["PAR proteins", "PROTEIN", 10, 22], ["Nterminus", "PROTEIN", 109, 118], ["a hydrophobic stretch", "TEST", 62, 83], ["amino acids", "TEST", 90, 101], ["a signal peptide", "PROBLEM", 135, 151]]], ["It seems likely that the three PARs are targetted into the secretory pathway.Differential expression of PAR mRNAs after virus infectionTo discriminate between the differently sized PAR-1 transcripts DNA fragments were isolated from the putative 3'-untranslated regions of the three PAR-1 cDNAs.", [["infection", "DISEASE", 126, 135], ["PARs", "GENE_OR_GENE_PRODUCT", 31, 35], ["PAR", "GENE_OR_GENE_PRODUCT", 104, 107], ["PAR-1", "GENE_OR_GENE_PRODUCT", 181, 186], ["DNA", "CELLULAR_COMPONENT", 199, 202], ["PAR-1", "GENE_OR_GENE_PRODUCT", 282, 287], ["PARs", "PROTEIN", 31, 35], ["PAR mRNAs", "RNA", 104, 113], ["PAR", "PROTEIN", 181, 184], ["DNA fragments", "DNA", 199, 212], ["putative 3'-untranslated regions", "DNA", 236, 268], ["PAR-1 cDNAs", "DNA", 282, 293], ["the three PARs", "PROBLEM", 21, 35], ["PAR mRNAs", "PROBLEM", 104, 113], ["virus infection", "PROBLEM", 120, 135], ["the differently sized PAR", "PROBLEM", 159, 184], ["DNA fragments", "PROBLEM", 199, 212], ["seems likely", "UNCERTAINTY", 3, 15], ["PAR mRNAs", "OBSERVATION_MODIFIER", 104, 113], ["sized", "OBSERVATION_MODIFIER", 175, 180], ["fragments", "OBSERVATION_MODIFIER", 203, 212]]], ["These were used as probes in northern blots to analyse the accumulation of PAR-1 mRNAs in infected and uninfected leaves of PVY-treated tobacco plants.", [["leaves", "ANATOMY", 114, 120], ["PAR-1", "GENE_OR_GENE_PRODUCT", 75, 80], ["leaves", "ORGANISM_SUBDIVISION", 114, 120], ["PVY", "ORGANISM", 124, 127], ["tobacco", "ORGANISM", 136, 143], ["PAR-1 mRNAs", "RNA", 75, 86], ["tobacco", "SPECIES", 136, 143], ["PVY", "SPECIES", 124, 127], ["tobacco", "SPECIES", 136, 143], ["the accumulation of PAR", "PROBLEM", 55, 78], ["PVY", "PROBLEM", 124, 127], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["tobacco plants", "OBSERVATION", 136, 150]]], ["As shown in Fig. 7 , PAR-la (lanes 5-8) and PAR-lc cDNA fragments (lanes 9-12) differentially hybridized to the 1.2 kb and 1.0 kb mRNA transcript, respectively.", [["PAR", "GENE_OR_GENE_PRODUCT", 21, 24], ["PAR-lc", "GENE_OR_GENE_PRODUCT", 44, 50], ["PAR-la (lanes 5-8", "DNA", 21, 38], ["PAR", "PROTEIN", 44, 47], ["lc cDNA fragments", "DNA", 48, 65], ["lanes 9-12", "DNA", 67, 77], ["1.2 kb and 1.0 kb mRNA transcript", "RNA", 112, 145], ["PAR-la (lanes", "TEST", 21, 34], ["PAR-lc cDNA fragments", "TEST", 44, 65], ["lanes", "TEST", 67, 72]]], ["For comparison, the same blot was hybridized with the full-length PAR-la probe under low-stringent conditions (Fig. 7, lanes 1-4) .Differential expression of PAR mRNAs after virus infectionThe PAR-lb cDNA fragment resulted in a very weak constitutive signal after 2 days exposure.", [["infection", "DISEASE", 180, 189], ["PAR", "GENE_OR_GENE_PRODUCT", 66, 69], ["PAR", "GENE_OR_GENE_PRODUCT", 158, 161], ["PAR", "GENE_OR_GENE_PRODUCT", 193, 196], ["full-length PAR-la probe", "DNA", 54, 78], ["PAR mRNAs", "RNA", 158, 167], ["PAR-lb cDNA fragment", "DNA", 193, 213], ["the full-length PAR-la probe", "TREATMENT", 50, 78], ["PAR mRNAs", "PROBLEM", 158, 167], ["virus infection", "PROBLEM", 174, 189], ["The PAR-lb cDNA fragment", "PROBLEM", 189, 213], ["a very weak constitutive signal", "PROBLEM", 226, 257], ["PAR mRNAs", "OBSERVATION", 158, 167], ["very", "OBSERVATION_MODIFIER", 228, 232], ["weak", "OBSERVATION_MODIFIER", 233, 237], ["constitutive", "OBSERVATION", 238, 250]]], ["PAR-la and c transcripts were induced both in infected and uninfected leaves of PVY-treated plants (Fig. 7 ).DiscussionPlants are faced with photoassimilate accumulation in their cells in a number of natural conditions like elevated levels of atmospheric CO2, nitrogen deficiency, freezing, cold and osmotic stress.", [["leaves", "ANATOMY", 70, 76], ["cells", "ANATOMY", 179, 184], ["CO2", "CHEMICAL", 255, 258], ["nitrogen", "CHEMICAL", 260, 268], ["CO2", "CHEMICAL", 255, 258], ["nitrogen", "CHEMICAL", 260, 268], ["PAR-la", "GENE_OR_GENE_PRODUCT", 0, 6], ["c", "GENE_OR_GENE_PRODUCT", 11, 12], ["PVY", "ORGANISM", 80, 83], ["cells", "CELL", 179, 184], ["CO2", "SIMPLE_CHEMICAL", 255, 258], ["nitrogen", "SIMPLE_CHEMICAL", 260, 268], ["PAR-la and c transcripts", "RNA", 0, 24], ["PVY", "SPECIES", 80, 83], ["PVY", "PROBLEM", 80, 83], ["photoassimilate accumulation", "PROBLEM", 141, 169], ["natural conditions", "PROBLEM", 200, 218], ["elevated levels", "PROBLEM", 224, 239], ["atmospheric CO2", "PROBLEM", 243, 258], ["nitrogen deficiency", "PROBLEM", 260, 279], ["freezing", "PROBLEM", 281, 289], ["cold and osmotic stress", "PROBLEM", 291, 314], ["la", "ANATOMY", 4, 6], ["infected", "OBSERVATION_MODIFIER", 46, 54], ["elevated", "OBSERVATION_MODIFIER", 224, 232], ["atmospheric CO2", "OBSERVATION", 243, 258], ["nitrogen deficiency", "OBSERVATION", 260, 279], ["osmotic stress", "OBSERVATION", 300, 314]]], ["To study long-term adaptation ofgene expression to sugar accumulation we used transgenic photoassimilate-accumulating tobacco plants (ppa-1) [27] as a model system.", [["photoassimilate", "CHEMICAL", 89, 104], ["ppa-1", "CHEMICAL", 134, 139], ["sugar", "CHEMICAL", 51, 56], ["sugar", "SIMPLE_CHEMICAL", 51, 56], ["photoassimilate", "SIMPLE_CHEMICAL", 89, 104], ["tobacco", "ORGANISM", 118, 125], ["ppa-1", "CELL", 134, 139], ["tobacco", "SPECIES", 118, 125], ["tobacco", "SPECIES", 118, 125], ["sugar accumulation", "PROBLEM", 51, 69], ["transgenic photoassimilate", "TREATMENT", 78, 104], ["tobacco plants", "OBSERVATION", 118, 132]]], ["The strategy was to isolate cDNA clones by differential hybridization of a subtractive library enriched for transcript present in the sugaraccumulating ppa-1 plants.", [["cDNA clones", "CELL", 28, 39], ["ppa-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["cDNA clones", "DNA", 28, 39], ["ppa", "PROTEIN", 152, 155], ["a subtractive library", "TREATMENT", 73, 94]]], ["In order to avoid cDNA artifacts frequently resulting from PCR amplifications during the establishment of a subtractive library a novel strategy was employed (Fig. 1) . cDNA libraries were prepared from mRNAs of wild-type and ppa-1 plants allowing the in vivo amplification of the respective cDNAs.", [["ppa-1 plants", "CELL", 226, 238], ["cDNA libraries", "DNA", 169, 183], ["mRNAs", "RNA", 203, 208], ["cDNAs", "DNA", 292, 297], ["ppa-1", "SPECIES", 226, 231], ["cDNA artifacts", "PROBLEM", 18, 32], ["PCR amplifications", "PROBLEM", 59, 77], ["a subtractive library a novel strategy", "TREATMENT", 106, 144], ["cDNA libraries", "PROBLEM", 169, 183]]], ["The eDNA library prepared from mRNA of ppa-1 plants was cut with the same restriction enzyme later used for establishment of the subtractive library.", [["ppa-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["eDNA library", "DNA", 4, 16], ["mRNA", "RNA", 31, 35], ["ppa", "PROTEIN", 39, 42], ["restriction enzyme", "PROTEIN", 74, 92], ["ppa", "TEST", 39, 42], ["the same restriction enzyme", "TREATMENT", 65, 92], ["the subtractive library", "TREATMENT", 125, 148]]], ["On the other hand, the eDNA of the library prepared from mRNA of wild-type plants was excluded from cloning because a different restriction enzyme was used.", [["mRNA", "RNA", 57, 61], ["restriction enzyme", "PROTEIN", 128, 146], ["type plants", "PROBLEM", 70, 81], ["a different restriction enzyme", "TEST", 116, 146]]], ["The exclusion of wild-type eDNA cloning allowed for only one round of subtraction with an enrichment for ppa-l-specific cDNAs by 10-fold.", [["ppa-l", "GENE_OR_GENE_PRODUCT", 105, 110], ["ppa-l", "PROTEIN", 105, 110], ["cDNAs", "DNA", 120, 125], ["subtraction", "TREATMENT", 70, 81], ["an enrichment", "TEST", 87, 100], ["ppa-l", "TEST", 105, 110]]], ["Thus this efficient and simple procedure eliminated the need for multiple rounds of hybridizations/subtractions and subsequent PCR amplifications.DiscussionBy differential screening of the subtractive library 12 different cDNAs were isolated of which four could be identified as encoding 1-aminocyclopropane-1-carboxylate-oxidase (ACC oxidase) and three different PR-proteins (PR-lb, PR-Q and SAR8.2).", [["1-aminocyclopropane-1-carboxylate", "CHEMICAL", 288, 321], ["1-aminocyclopropane-1-carboxylate", "CHEMICAL", 288, 321], ["1-aminocyclopropane-1-carboxylate-oxidase", "GENE_OR_GENE_PRODUCT", 288, 329], ["ACC oxidase", "GENE_OR_GENE_PRODUCT", 331, 342], ["PR-lb", "GENE_OR_GENE_PRODUCT", 377, 382], ["PR-Q", "GENE_OR_GENE_PRODUCT", 384, 388], ["cDNAs", "DNA", 222, 227], ["1-aminocyclopropane-1-carboxylate-oxidase", "PROTEIN", 288, 329], ["ACC oxidase", "PROTEIN", 331, 342], ["PR", "PROTEIN", 364, 366], ["PR", "PROTEIN", 377, 379], ["lb", "PROTEIN", 380, 382], ["PR", "PROTEIN", 384, 386], ["Q", "PROTEIN", 387, 388], ["SAR8.2", "PROTEIN", 393, 399], ["simple procedure", "TREATMENT", 24, 40], ["hybridizations/subtractions", "TREATMENT", 84, 111], ["subsequent PCR amplifications", "TREATMENT", 116, 145], ["different cDNAs", "TEST", 212, 227], ["aminocyclopropane", "TEST", 290, 307], ["carboxylate-oxidase (ACC oxidase", "TREATMENT", 310, 342], ["PR", "TEST", 377, 379], ["PR", "TEST", 384, 386], ["SAR8", "TEST", 393, 397]]], ["Two cDNAs were found to be homologous to a Calmodulin-like protein from Arabidopsis and the human ribosomal protein L19 [ 17] .", [["ribosomal", "ANATOMY", 98, 107], ["Calmodulin-like protein", "GENE_OR_GENE_PRODUCT", 43, 66], ["human", "ORGANISM", 92, 97], ["cDNAs", "DNA", 4, 9], ["Calmodulin-like protein", "PROTEIN", 43, 66], ["human ribosomal protein L19", "PROTEIN", 92, 119], ["Arabidopsis", "SPECIES", 72, 83], ["human", "SPECIES", 92, 97], ["Arabidopsis", "SPECIES", 72, 83], ["human", "SPECIES", 92, 97], ["Two cDNAs", "TEST", 0, 9], ["a Calmodulin-like protein", "PROBLEM", 41, 66], ["Arabidopsis", "PROBLEM", 72, 83], ["the human ribosomal protein L19", "TEST", 88, 119]]], ["The remaining six did not show similarities to sequences in the databanks.Discussion\u2022 One of these unknown cDNAs (termed PAR-1 for photoassimilate-responsive) hybridized to mRNAs of about 1.0 and 1.2 kb.", [["PAR-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["photoassimilate", "GENE_OR_GENE_PRODUCT", 131, 146], ["cDNAs", "DNA", 107, 112], ["PAR", "DNA", 121, 124], ["photoassimilate", "DNA", 131, 146], ["mRNAs", "RNA", 173, 178], ["photoassimilate", "PROBLEM", 131, 146], ["mRNAs", "TEST", 173, 178]]], ["The steadystate levels of PAR-1 transcripts in leaves increased in the order from upper to lower leaves both in wild-type and ppa-1 plants thus being correlated with the levels of endogenous sugars (Fig. 2) [27, 9] .", [["leaves", "ANATOMY", 47, 53], ["sugars", "CHEMICAL", 191, 197], ["PAR-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["leaves", "ORGAN", 47, 53], ["upper", "ORGANISM_SUBDIVISION", 82, 87], ["ppa-1 plants", "ORGANISM", 126, 138], ["sugars", "SIMPLE_CHEMICAL", 191, 197], ["PAR", "PROTEIN", 26, 29], ["The steadystate levels", "TEST", 0, 22], ["PAR", "TEST", 26, 29], ["endogenous sugars", "TEST", 180, 197], ["leaves", "OBSERVATION_MODIFIER", 47, 53], ["increased", "OBSERVATION_MODIFIER", 54, 63]]], ["In ppa-1 plants which accumulate much higher levels of soluble sugars as compared to wild-type plants [27, 9] , PAR-1 transcripts also accumulated to higher levels.", [["sugars", "CHEMICAL", 63, 69], ["ppa-1", "GENE_OR_GENE_PRODUCT", 3, 8], ["sugars", "SIMPLE_CHEMICAL", 63, 69], ["PAR-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["PAR", "PROTEIN", 112, 115], ["soluble sugars", "TEST", 55, 69], ["PAR", "TEST", 112, 115], ["higher levels", "OBSERVATION_MODIFIER", 150, 163]]], ["These correlations strongly indicate that the induction of PAR-1 mRNA may be mediated by an increase in soluble sugars in the plant cells.", [["cells", "ANATOMY", 132, 137], ["sugars", "CHEMICAL", 112, 118], ["PAR-1", "GENE_OR_GENE_PRODUCT", 59, 64], ["cells", "CELL", 132, 137], ["PAR-1 mRNA", "RNA", 59, 69], ["plant cells", "CELL_TYPE", 126, 137], ["PAR-1 mRNA", "TREATMENT", 59, 69], ["an increase in soluble sugars", "PROBLEM", 89, 118], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["soluble sugars", "OBSERVATION", 104, 118], ["plant cells", "OBSERVATION", 126, 137]]], ["This assumption has further been supported by the finding that wild-type leaves floated on different concentrations of glucose and sucrose also accumulated high levels of PAR-1 transcripts (Fig. 3) .", [["leaves", "ANATOMY", 73, 79], ["glucose", "CHEMICAL", 119, 126], ["sucrose", "CHEMICAL", 131, 138], ["glucose", "CHEMICAL", 119, 126], ["sucrose", "CHEMICAL", 131, 138], ["leaves", "ORGANISM", 73, 79], ["glucose", "SIMPLE_CHEMICAL", 119, 126], ["sucrose", "SIMPLE_CHEMICAL", 131, 138], ["PAR-1", "GENE_OR_GENE_PRODUCT", 171, 176], ["PAR", "PROTEIN", 171, 174], ["glucose", "TEST", 119, 126]]], ["Thus the accumulation of PAR-1 eDNA by soluble sugars appears to be the cause for its isolation as a photoassimilate-responding gene.DiscussionBy rescreening the ppa-1 cDNA library using PAR-1 as a probe 25 independent cDNAs were isolated and characterized.", [["sugars", "CHEMICAL", 47, 53], ["PAR-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["PAR-1", "GENE_OR_GENE_PRODUCT", 187, 192], ["PAR", "PROTEIN", 25, 28], ["photoassimilate-responding gene", "DNA", 101, 132], ["ppa-1 cDNA library", "DNA", 162, 180], ["PAR-1", "DNA", 187, 192], ["probe 25 independent cDNAs", "DNA", 198, 224], ["PAR", "PROBLEM", 25, 28], ["soluble sugars", "TEST", 39, 53], ["a photoassimilate", "TREATMENT", 99, 116], ["accumulation", "OBSERVATION_MODIFIER", 9, 21]]], ["By comparison of their respective DNA sequences the cDNAs could be grouped into three different classes of which the first two (PAR-la and b) were 90.6~o homologous while they were less related to the third-group PAR-lc (75.2~o and 70.5 ~o homologous, respectively).", [["DNA", "CELLULAR_COMPONENT", 34, 37], ["PAR", "GENE_OR_GENE_PRODUCT", 128, 131], ["DNA sequences", "DNA", 34, 47], ["cDNAs", "DNA", 52, 57], ["PAR", "PROTEIN", 128, 131], ["PAR-lc", "DNA", 213, 219]]], ["PAR-la and PAR-lc transcripts were found to be strongly inducible by salicylate in floating experiments and were furthermore shown to accumulate in uninfected and infected leaves of tobacco plants treated with PVY ( Fig. 4, 5, 7 ).", [["leaves", "ANATOMY", 172, 178], ["salicylate", "CHEMICAL", 69, 79], ["salicylate", "CHEMICAL", 69, 79], ["PAR", "GENE_OR_GENE_PRODUCT", 0, 3], ["PAR-lc", "GENE_OR_GENE_PRODUCT", 11, 17], ["salicylate", "SIMPLE_CHEMICAL", 69, 79], ["leaves", "ORGANISM_SUBDIVISION", 172, 178], ["tobacco", "ORGANISM", 182, 189], ["PAR-la and PAR-lc transcripts", "RNA", 0, 29], ["tobacco", "SPECIES", 182, 189], ["tobacco", "SPECIES", 182, 189], ["PVY", "SPECIES", 210, 213], ["PVY ( Fig.", "TREATMENT", 210, 220], ["salicylate", "OBSERVATION", 69, 79], ["infected", "OBSERVATION_MODIFIER", 163, 171], ["tobacco plants", "OBSERVATION", 182, 196]]], ["By these characteristics the PAR-1 cDNAs may be classified as cDNAs encoding a novel class of pathogenesis-related proteins.", [["PAR-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["PAR-1 cDNAs", "DNA", 29, 40], ["cDNAs", "DNA", 62, 67], ["pathogenesis-related proteins", "PROTEIN", 94, 123], ["related proteins", "PROBLEM", 107, 123]]], ["The PAR-1 cDNAs would code for proteins with a theoretical molecular mass of 20 kDa which could be targetted into the secretory pathway due to an N-terminal signal peptide (Fig. 6) .DiscussionDifferent sets of PR proteins are known to be induced under a number of stress conditions like viral infection, pathogen invasion, injury, UV light, ozone, chemical treatment, salicylic acid, ethylene and other plant hormones ( [ 3] ; reviewed in [19] ).", [["viral infection", "DISEASE", 287, 302], ["pathogen invasion", "DISEASE", 304, 321], ["ozone", "CHEMICAL", 341, 346], ["salicylic acid", "CHEMICAL", 368, 382], ["ethylene", "CHEMICAL", 384, 392], ["N", "CHEMICAL", 146, 147], ["ozone", "CHEMICAL", 341, 346], ["salicylic acid", "CHEMICAL", 368, 382], ["ethylene", "CHEMICAL", 384, 392], ["PAR-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["PR proteins", "GENE_OR_GENE_PRODUCT", 210, 221], ["ozone", "SIMPLE_CHEMICAL", 341, 346], ["salicylic acid", "SIMPLE_CHEMICAL", 368, 382], ["ethylene", "SIMPLE_CHEMICAL", 384, 392], ["[19]", "SIMPLE_CHEMICAL", 439, 443], ["PAR-1 cDNAs", "DNA", 4, 15], ["PR proteins", "PROTEIN", 210, 221], ["a theoretical molecular mass", "PROBLEM", 45, 73], ["an N-terminal signal peptide", "PROBLEM", 143, 171], ["PR proteins", "TREATMENT", 210, 221], ["stress conditions", "PROBLEM", 264, 281], ["viral infection", "PROBLEM", 287, 302], ["pathogen invasion", "PROBLEM", 304, 321], ["injury", "PROBLEM", 323, 329], ["UV light", "TREATMENT", 331, 339], ["chemical treatment", "TREATMENT", 348, 366], ["salicylic acid", "TREATMENT", 368, 382], ["ethylene and other plant hormones", "TREATMENT", 384, 417], ["mass", "OBSERVATION", 69, 73], ["20 kDa", "OBSERVATION_MODIFIER", 77, 83], ["viral", "OBSERVATION_MODIFIER", 287, 292], ["infection", "OBSERVATION", 293, 302]]], ["Thus the accumulation of at least four different PR proteins under conditions where the plant cells permanently meet high levels of sugars and osmotic stress might have been expected.", [["cells", "ANATOMY", 94, 99], ["sugars", "CHEMICAL", 132, 138], ["PR", "GENE_OR_GENE_PRODUCT", 49, 51], ["cells", "CELL", 94, 99], ["sugars", "SIMPLE_CHEMICAL", 132, 138], ["PR proteins", "PROTEIN", 49, 60], ["plant cells", "CELL_TYPE", 88, 99], ["the plant cells", "TREATMENT", 84, 99], ["high levels of sugars", "PROBLEM", 117, 138], ["osmotic stress", "PROBLEM", 143, 157], ["accumulation", "OBSERVATION_MODIFIER", 9, 21], ["at least", "OBSERVATION_MODIFIER", 25, 33], ["plant cells", "OBSERVATION", 88, 99]]], ["However, PR proteins have attracted attention mainly for their roles in host/pathogen relationships, particularly for their possible involvement in inducing resistance against further development of virus disease in tobacco leaves.", [["leaves", "ANATOMY", 224, 230], ["PR proteins", "GENE_OR_GENE_PRODUCT", 9, 20], ["tobacco", "ORGANISM", 216, 223], ["leaves", "ORGANISM_SUBDIVISION", 224, 230], ["PR proteins", "PROTEIN", 9, 20], ["tobacco", "SPECIES", 216, 223], ["tobacco", "SPECIES", 216, 223], ["PR proteins", "PROBLEM", 9, 20], ["virus disease", "PROBLEM", 199, 212], ["virus disease", "OBSERVATION", 199, 212]]], ["Less consideration has been attributed to PR protein function in response to other physiological conditions like osmotic stress.", [["PR protein", "GENE_OR_GENE_PRODUCT", 42, 52], ["PR", "PROTEIN", 42, 44], ["PR protein function", "PROBLEM", 42, 61], ["other physiological conditions", "PROBLEM", 77, 107], ["osmotic stress", "PROBLEM", 113, 127], ["protein function", "OBSERVATION", 45, 61], ["osmotic stress", "OBSERVATION", 113, 127]]], ["Nevertheless, Pierpoint et al. [22] and Ohashi and Matsuoka [18] reported on the induction of PR proteins under mannitolinduced osmotic stress.", [["PR proteins", "GENE_OR_GENE_PRODUCT", 94, 105], ["PR proteins", "PROTEIN", 94, 105], ["PR proteins", "TREATMENT", 94, 105], ["mannitolinduced osmotic stress", "TREATMENT", 112, 142]]], ["Osmotin, a protein which belongs to the group 5 of PR proteins, had first been studied in cultured tobacco cells osmotically adapted to low water potential [25, 26] .", [["cells", "ANATOMY", 107, 112], ["Osmotin", "CHEMICAL", 0, 7], ["Osmotin", "CHEMICAL", 0, 7], ["Osmotin", "GENE_OR_GENE_PRODUCT", 0, 7], ["PR", "GENE_OR_GENE_PRODUCT", 51, 53], ["tobacco", "ORGANISM", 99, 106], ["cells", "CELL", 107, 112], ["Osmotin", "PROTEIN", 0, 7], ["PR proteins", "PROTEIN", 51, 62], ["cultured tobacco cells", "CELL_LINE", 90, 112], ["tobacco", "SPECIES", 99, 106], ["tobacco", "SPECIES", 99, 106], ["Osmotin", "PROBLEM", 0, 7], ["a protein", "PROBLEM", 9, 18], ["PR proteins", "TEST", 51, 62], ["tobacco cells", "OBSERVATION", 99, 112]]], ["Under comparable osmotic conditions, namely floating leaves on sorbitol and PEG, accumulation of PAR-1 mRNAs was not induced (Fig. 4) .", [["leaves", "ANATOMY", 53, 59], ["sorbitol", "CHEMICAL", 63, 71], ["PEG", "CHEMICAL", 76, 79], ["sorbitol", "CHEMICAL", 63, 71], ["PEG", "CHEMICAL", 76, 79], ["sorbitol", "SIMPLE_CHEMICAL", 63, 71], ["PEG", "SIMPLE_CHEMICAL", 76, 79], ["PAR-1", "GENE_OR_GENE_PRODUCT", 97, 102], ["PAR-1 mRNAs", "RNA", 97, 108], ["sorbitol", "TREATMENT", 63, 71], ["PEG", "TREATMENT", 76, 79], ["accumulation of PAR", "PROBLEM", 81, 100], ["osmotic conditions", "OBSERVATION", 17, 35], ["PEG", "OBSERVATION", 76, 79]]], ["Thus the induction of PAR-1 transcripts in wildtype leaves upon floating on osmolytes cannot be solely attributed to osmotic effects.", [["leaves", "ANATOMY", 52, 58], ["PAR-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["wildtype leaves", "ORGANISM", 43, 58], ["PAR-1 transcripts", "RNA", 22, 39], ["the induction of PAR", "TREATMENT", 5, 25], ["osmolytes", "TREATMENT", 76, 85], ["osmotic effects", "PROBLEM", 117, 132], ["osmotic effects", "OBSERVATION", 117, 132]]], ["Penetrating and possibly metabolizable solutes such as sucrose and glucose (Fig. 3 ) may be required for the response.DiscussionThe question arises how the induction of the PAR-1 mRNAs is mediated and whether there might be induction mechanisms common to other PR protein genes in physiological situations where plants accumulate photoassimilates in their cells.", [["cells", "ANATOMY", 356, 361], ["sucrose", "CHEMICAL", 55, 62], ["glucose", "CHEMICAL", 67, 74], ["sucrose", "CHEMICAL", 55, 62], ["glucose", "CHEMICAL", 67, 74], ["sucrose", "SIMPLE_CHEMICAL", 55, 62], ["glucose", "SIMPLE_CHEMICAL", 67, 74], ["PAR-1", "GENE_OR_GENE_PRODUCT", 173, 178], ["PR protein", "GENE_OR_GENE_PRODUCT", 261, 271], ["cells", "CELL", 356, 361], ["PAR-1 mRNAs", "RNA", 173, 184], ["PR protein genes", "DNA", 261, 277], ["Penetrating", "TREATMENT", 0, 11], ["metabolizable solutes", "TREATMENT", 25, 46], ["sucrose and glucose (Fig.", "TREATMENT", 55, 80], ["other PR protein genes in physiological situations", "PROBLEM", 255, 305], ["possibly", "UNCERTAINTY", 16, 24], ["metabolizable solutes", "OBSERVATION", 25, 46]]], ["Hypothetically, even the induction of PR proteins by pathogens might follow the same mechanism.", [["PR", "GENE_OR_GENE_PRODUCT", 38, 40], ["PR proteins", "PROTEIN", 38, 49], ["PR proteins", "TREATMENT", 38, 49], ["pathogens", "PROBLEM", 53, 62]]], ["Viruses have been described to cause severe perturbations in carbohydrate metabolism in leaves leading to the accumulation of starch [32 and references therein] and/or soluble sugars [36, 29] .", [["leaves", "ANATOMY", 88, 94], ["carbohydrate", "CHEMICAL", 61, 73], ["sugars", "CHEMICAL", 176, 182], ["carbohydrate", "SIMPLE_CHEMICAL", 61, 73], ["leaves", "ORGANISM_SUBDIVISION", 88, 94], ["starch", "SIMPLE_CHEMICAL", 126, 132], ["Viruses", "PROBLEM", 0, 7], ["severe perturbations in carbohydrate metabolism", "PROBLEM", 37, 84], ["the accumulation of starch", "PROBLEM", 106, 132], ["soluble sugars", "TEST", 168, 182], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["perturbations", "OBSERVATION", 44, 57], ["carbohydrate metabolism", "OBSERVATION", 61, 84]]], ["Sturm and Chrispeels [31 ] found that bacterial infection caused rapid induction of extracellular invertase which hydrolyses extracellular sucrose.", [["extracellular", "ANATOMY", 84, 97], ["extracellular", "ANATOMY", 125, 138], ["bacterial infection", "DISEASE", 38, 57], ["sucrose", "CHEMICAL", 139, 146], ["sucrose", "CHEMICAL", 139, 146], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["sucrose", "SIMPLE_CHEMICAL", 139, 146], ["extracellular invertase", "PROTEIN", 84, 107], ["bacterial infection", "PROBLEM", 38, 57], ["extracellular invertase", "TREATMENT", 84, 107], ["hydrolyses extracellular sucrose", "TREATMENT", 114, 146], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["infection", "OBSERVATION", 48, 57]]], ["Glucose and fructose may be taken up which might trigger the induction response.", [["Glucose", "CHEMICAL", 0, 7], ["fructose", "CHEMICAL", 12, 20], ["Glucose", "CHEMICAL", 0, 7], ["fructose", "CHEMICAL", 12, 20], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["fructose", "SIMPLE_CHEMICAL", 12, 20], ["Glucose", "TEST", 0, 7]]], ["Sugars have also been reported to induce other stress-related proteins, such as proteinase inhibitor II [ 10, 11] , cathepsin D inhibitor and leucine aminopeptidase from potato [unpublished data] and chalcone synthase [33] .", [["Sugars", "CHEMICAL", 0, 6], ["leucine", "CHEMICAL", 142, 149], ["chalcone", "CHEMICAL", 200, 208], ["Sugars", "CHEMICAL", 0, 6], ["leucine", "CHEMICAL", 142, 149], ["chalcone", "CHEMICAL", 200, 208], ["Sugars", "SIMPLE_CHEMICAL", 0, 6], ["proteinase inhibitor II", "GENE_OR_GENE_PRODUCT", 80, 103], ["10, 11]", "SIMPLE_CHEMICAL", 106, 113], ["cathepsin D", "SIMPLE_CHEMICAL", 116, 127], ["leucine aminopeptidase", "SIMPLE_CHEMICAL", 142, 164], ["chalcone synthase", "GENE_OR_GENE_PRODUCT", 200, 217], ["proteinase inhibitor II", "PROTEIN", 80, 103], ["cathepsin D inhibitor", "PROTEIN", 116, 137], ["leucine aminopeptidase", "PROTEIN", 142, 164], ["chalcone synthase", "PROTEIN", 200, 217], ["potato", "SPECIES", 170, 176], ["Sugars", "TEST", 0, 6], ["other stress-related proteins", "PROBLEM", 41, 70], ["proteinase inhibitor II", "TREATMENT", 80, 103], ["cathepsin D inhibitor", "TREATMENT", 116, 137], ["leucine aminopeptidase", "TREATMENT", 142, 164], ["chalcone synthase", "TREATMENT", 200, 217]]], ["Thus, as already suggested by J ang and Sheen [8] , there might be a common mechanism of sugar sensing in the repression of photosynthetic genes and the activation of stressrelated/pathogenesis-related genes.", [["sugar", "CHEMICAL", 89, 94], ["sugar", "SIMPLE_CHEMICAL", 89, 94], ["photosynthetic genes", "DNA", 124, 144], ["stressrelated/pathogenesis-related genes", "DNA", 167, 207], ["sugar sensing", "PROBLEM", 89, 102], ["photosynthetic genes", "PROBLEM", 124, 144], ["stressrelated/pathogenesis", "PROBLEM", 167, 193], ["photosynthetic genes", "OBSERVATION", 124, 144]]], ["As the induction of PAR and PR protein-specific transcripts in the ppa-1 plants might be mediated by salicylate we have determined salicylate levels in these plants.", [["salicylate", "CHEMICAL", 101, 111], ["salicylate", "CHEMICAL", 131, 141], ["salicylate", "CHEMICAL", 101, 111], ["salicylate", "CHEMICAL", 131, 141], ["PAR", "GENE_OR_GENE_PRODUCT", 20, 23], ["PR", "GENE_OR_GENE_PRODUCT", 28, 30], ["ppa-1", "GENE_OR_GENE_PRODUCT", 67, 72], ["salicylate", "SIMPLE_CHEMICAL", 101, 111], ["salicylate", "SIMPLE_CHEMICAL", 131, 141], ["PAR", "PROTEIN", 20, 23], ["PR", "PROTEIN", 28, 30], ["PAR and PR protein", "TREATMENT", 20, 38], ["the ppa", "TEST", 63, 70], ["salicylate", "TREATMENT", 101, 111], ["salicylate levels", "TEST", 131, 148]]], ["There was no difference in the levels of salicylic acid or its conjugate between ppa-1 and wild-type plants (Ph. Meuwly, J.-P. M&raux, unpublished data).", [["salicylic acid", "CHEMICAL", 41, 55], ["ppa-1", "CHEMICAL", 81, 86], ["salicylic acid", "CHEMICAL", 41, 55], ["salicylic acid", "SIMPLE_CHEMICAL", 41, 55], ["ppa-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["salicylic acid", "TEST", 41, 55], ["ppa", "TEST", 81, 84], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["This indicates that the accumulation of PR protein-specific transcripts by soluble sugars follows a salicylate-independent pathway.", [["salicylate", "CHEMICAL", 100, 110], ["sugars", "CHEMICAL", 83, 89], ["salicylate", "CHEMICAL", 100, 110], ["PR", "GENE_OR_GENE_PRODUCT", 40, 42], ["sugars", "SIMPLE_CHEMICAL", 83, 89], ["salicylate", "SIMPLE_CHEMICAL", 100, 110], ["PR protein", "PROTEIN", 40, 50], ["the accumulation of PR protein", "PROBLEM", 20, 50], ["soluble sugars", "TEST", 75, 89], ["a salicylate", "TREATMENT", 98, 110]]], ["Other or additional mechanisms for the induction of PR proteins in the photoassimilateaccumulating plants cannot be ruled out.", [["PR proteins", "GENE_OR_GENE_PRODUCT", 52, 63], ["PR proteins", "PROTEIN", 52, 63], ["the induction of PR proteins", "TREATMENT", 35, 63], ["the photoassimilateaccumulating plants", "TREATMENT", 67, 105], ["cannot be ruled", "UNCERTAINTY", 106, 121]]], ["For instance, the accumulation of the mRNA coding for ACC oxidase might indicate a role of ethylene in the induction process.", [["ethylene", "CHEMICAL", 91, 99], ["ethylene", "CHEMICAL", 91, 99], ["ACC oxidase", "GENE_OR_GENE_PRODUCT", 54, 65], ["ethylene", "SIMPLE_CHEMICAL", 91, 99], ["mRNA", "RNA", 38, 42], ["ACC oxidase", "PROTEIN", 54, 65], ["ACC oxidase", "TREATMENT", 54, 65], ["ethylene in the induction process", "TREATMENT", 91, 124]]], ["This is supported by the finding that carbohydrates stimulate ethylene production in tobacco leaf discs [21] .", [["leaf discs", "ANATOMY", 93, 103], ["ethylene", "CHEMICAL", 62, 70], ["carbohydrates", "CHEMICAL", 38, 51], ["ethylene", "CHEMICAL", 62, 70], ["carbohydrates", "SIMPLE_CHEMICAL", 38, 51], ["ethylene", "SIMPLE_CHEMICAL", 62, 70], ["tobacco", "ORGANISM", 85, 92], ["tobacco", "SPECIES", 85, 92], ["tobacco", "SPECIES", 85, 92], ["carbohydrates stimulate ethylene production", "TREATMENT", 38, 81], ["leaf discs", "OBSERVATION", 93, 103]]], ["Current experiments are devoted to studies on the signal transduction mechanisms of stressrelated as well as photosynthetic genes in ppa-1 and other transgenic sugar-accumulating plants (manuscript in preparation).", [["sugar", "CHEMICAL", 160, 165], ["ppa-1", "GENE_OR_GENE_PRODUCT", 133, 138], ["sugar", "SIMPLE_CHEMICAL", 160, 165], ["photosynthetic genes", "DNA", 109, 129], ["ppa", "TEST", 133, 136]]]], "PMC7530857": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "PMC7300811": [["We would like to add some comments, having adapted our technique over the course of treating > 100 patients during the COVID\u201019 pandemic.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["pandemic", "PROBLEM", 128, 136]]]], "e411c54208dfc5d918d46642a7f1694fcc681cf4": [["samples.", [["samples", "ANATOMY", 0, 7], ["samples", "TEST", 0, 7]]], ["Compared to patients aged less than 5 years, older age groups were significantly less infected with RSV.", [["RSV", "DISEASE", 100, 103], ["patients", "ORGANISM", 12, 20], ["RSV", "ORGANISM", 100, 103], ["patients", "SPECIES", 12, 20], ["RSV", "SPECIES", 100, 103], ["RSV", "PROBLEM", 100, 103], ["RSV", "OBSERVATION", 100, 103]]], ["On the other hand, patients aged more than 64 years (OR = 3.66) were at higher risk to be infected with FLUA, while those aged 15-29 years (OR = 3.22) and 30-64 years (OR = 2.39) were more likely to be infected with FLUB (influenza virus B).ConclusionThe frequency of influenza viruses detected among SARI patients aged 65 years and more highlights the need for health authorities to develop strategies to reduce morbidity amongst at-risk population through vaccine recommendation.", [["FLUA", "DISEASE", 104, 108], ["influenza virus B", "DISEASE", 222, 239], ["influenza viruses", "DISEASE", 268, 285], ["SARI", "DISEASE", 301, 305], ["patients", "ORGANISM", 19, 27], ["FLUB", "ORGANISM", 216, 220], ["influenza virus B", "ORGANISM", 222, 239], ["influenza viruses", "ORGANISM", 268, 285], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 19, 27], ["influenza virus", "SPECIES", 222, 237], ["patients", "SPECIES", 306, 314], ["FLUB (influenza virus B", "PROBLEM", 216, 239], ["influenza viruses", "PROBLEM", 268, 285], ["morbidity", "TREATMENT", 413, 422], ["infected", "OBSERVATION", 90, 98], ["more likely to be", "UNCERTAINTY", 184, 201], ["infected", "OBSERVATION", 202, 210], ["influenza viruses", "OBSERVATION", 268, 285]]], ["Amongst young children, the demonstrated burden of RSV should guide clinicians for a better case management of children.", [["RSV", "DISEASE", 51, 54], ["children", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 51, 54], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 111, 119], ["RSV", "SPECIES", 51, 54]]], ["These findings reveal the need to develop point-of-care tests to avoid overuse of antibiotics and to promote vaccine that could reduce drastically the RSV hospitalizations.BackgroundSevere acute respiratory infections (SARI) are among the leading cause of hospitalization and deaths worldwide [1] .", [["respiratory", "ANATOMY", 195, 206], ["RSV", "DISEASE", 151, 154], ["acute respiratory infections", "DISEASE", 189, 217], ["SARI", "DISEASE", 219, 223], ["deaths", "DISEASE", 276, 282], ["RSV", "ORGANISM", 151, 154], ["RSV", "SPECIES", 151, 154], ["care tests", "TEST", 51, 61], ["antibiotics", "TREATMENT", 82, 93], ["vaccine", "TREATMENT", 109, 116], ["the RSV hospitalizations", "PROBLEM", 147, 171], ["BackgroundSevere acute respiratory infections", "PROBLEM", 172, 217], ["RSV", "OBSERVATION", 151, 154], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["respiratory", "ANATOMY", 195, 206], ["infections", "OBSERVATION", 207, 217]]], ["It is estimated that about 4.2 million of deaths are attributed to SARI annually [2] .", [["deaths", "DISEASE", 42, 48], ["SARI", "DISEASE", 67, 71]]], ["Estimation in 2010 have shown that 11 million of children aged less than 5 years were admitted for SARI in developing countries, with an estimated case fatality ratio of 2.3%, compared to 570 000 cases and a case fatality ratio of 0.6% in developed countries [3] .", [["SARI", "DISEASE", 99, 103], ["children", "ORGANISM", 49, 57], ["children", "SPECIES", 49, 57], ["SARI", "PROBLEM", 99, 103], ["a case fatality ratio", "TEST", 206, 227]]], ["In low income countries, the annual incidence of pneumonia is estimated at 151 million children of whom 13% are severe enough to warrant hospitalization [1, 4] .", [["pneumonia", "DISEASE", 49, 58], ["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95], ["pneumonia", "PROBLEM", 49, 58], ["low", "OBSERVATION_MODIFIER", 3, 6], ["pneumonia", "OBSERVATION", 49, 58]]], ["Nearly 2 million children die from pneumonia every year, 70% of which occur in Africa and Southeast Asia [5, 6] .", [["pneumonia", "DISEASE", 35, 44], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["pneumonia", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 35, 44]]], ["SARI may be caused by various pathogens.", [["SARI", "DISEASE", 0, 4], ["SARI", "PROBLEM", 0, 4], ["various pathogens", "PROBLEM", 22, 39], ["may be caused", "UNCERTAINTY", 5, 18], ["various", "OBSERVATION_MODIFIER", 22, 29], ["pathogens", "OBSERVATION", 30, 39]]], ["While bacterial infections play a critical role in causing life-threatening pneumonia [1, [7] [8] [9] , viral infections are associated with significant proportion that range from mild to severe infections [10, 11] .", [["bacterial infections", "DISEASE", 6, 26], ["pneumonia", "DISEASE", 76, 85], ["1, [7] [8] [9", "CHEMICAL", 87, 100], ["viral infections", "DISEASE", 104, 120], ["infections", "DISEASE", 195, 205], ["bacterial infections", "PROBLEM", 6, 26], ["life-threatening pneumonia", "PROBLEM", 59, 85], ["viral infections", "PROBLEM", 104, 120], ["mild to severe infections", "PROBLEM", 180, 205], ["infections", "OBSERVATION", 16, 26], ["pneumonia", "OBSERVATION", 76, 85], ["infections", "OBSERVATION", 110, 120], ["mild", "OBSERVATION_MODIFIER", 180, 184], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["infections", "OBSERVATION", 195, 205]]], ["However, due to the lack of gold standard methods to rapidly differentiate between viral and bacterial infections, most of the patients may be treated empirically with antibiotics [12] .", [["viral and bacterial infections", "DISEASE", 83, 113], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["viral and bacterial infections", "PROBLEM", 83, 113], ["antibiotics", "TREATMENT", 168, 179], ["viral", "OBSERVATION", 83, 88], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["infections", "OBSERVATION", 103, 113]]], ["Rapid etiologic diagnosis is therefore needed to select the most appropriate treatment protocol and to avoid the development of bacterial resistance.BackgroundFollowing the A/H1N1/2009 influenza pandemic that was associated with a high morbidity and an increased risk of mortality among particular groups [13] , a number of countries have strengthened vigilance for the surveillance of severe diseases and deaths in order to rapidly detect new viruses and to provide information in assessing the impact on the population and having operational preparedness plans.", [["influenza pandemic", "DISEASE", 185, 203], ["deaths", "DISEASE", 406, 412], ["A/H1N1", "ORGANISM", 173, 179], ["A/H1N1/2009 influenza pandemic", "SPECIES", 173, 203], ["bacterial resistance", "PROBLEM", 128, 148], ["influenza pandemic", "PROBLEM", 185, 203], ["a high morbidity", "PROBLEM", 229, 245], ["severe diseases", "PROBLEM", 386, 401], ["new viruses", "PROBLEM", 440, 451], ["operational preparedness plans", "TREATMENT", 532, 562], ["bacterial resistance", "OBSERVATION", 128, 148], ["increased", "OBSERVATION_MODIFIER", 253, 262], ["severe", "OBSERVATION_MODIFIER", 386, 392], ["diseases", "OBSERVATION", 393, 401], ["new", "OBSERVATION_MODIFIER", 440, 443], ["viruses", "OBSERVATION", 444, 451]]], ["So far, only few sub-Saharan African countries are collecting data on hospitalization associated to acute respiratory illness [14] [15] [16] .", [["respiratory", "ANATOMY", 106, 117], ["acute respiratory illness", "DISEASE", 100, 125], ["acute respiratory illness", "PROBLEM", 100, 125], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory", "ANATOMY", 106, 117]]], ["In Madagascar, the sentinel syndromic surveillance has been collecting SARI data since 2010.", [["the sentinel syndromic surveillance", "TEST", 15, 50], ["sentinel syndromic", "OBSERVATION", 19, 37]]], ["However, hospitals only collect few data that are not exploitable for analysis.", [["analysis", "TEST", 70, 78]]], ["Thus, data are still scarce regarding the epidemiology of SARI in this country.", [["SARI", "DISEASE", 58, 62], ["SARI", "CANCER", 58, 62], ["SARI", "PROBLEM", 58, 62]]], ["During the last influenza pandemic in 2009, an excess of mortality was observed among inhabitant of the main capital city of Antananarivo [17] .", [["influenza pandemic", "DISEASE", 16, 34]]], ["Following the pandemic, health authorities requested to develop an active surveillance of SARI in order to better understand the epidemiology of this disease in the context of Madagascar.", [["SARI", "PROBLEM", 90, 94], ["this disease", "PROBLEM", 145, 157], ["active", "OBSERVATION_MODIFIER", 67, 73]]], ["The present study aimed to identify etiologies of SARI and to assess clinical features of hospitalization linked to SARI in 2 hospitals during 3 years of surveillance.Study sitesA prospective hospital-based SARI surveillance was conducted from November 2010 to July 2013 in 2 selected sites: the Soavinandriana hospital of Antananarivo and the secondary level public hospital (CHD II) of Moramanga.", [["SARI", "DISEASE", 50, 54], ["SARI", "DISEASE", 116, 120], ["The present study", "TEST", 0, 17], ["SARI", "PROBLEM", 50, 54], ["surveillance", "TEST", 154, 166], ["Antananarivo", "TREATMENT", 323, 335], ["Moramanga", "TREATMENT", 388, 397]]], ["The CENHOSOA is a national referral hospital and is among the 4 largest hospitals that deserve Antananarivo, the main capital city of Madagascar which has around 2.5 million inhabitants.", [["Antananarivo", "TREATMENT", 95, 107], ["main", "OBSERVATION_MODIFIER", 113, 117], ["capital", "OBSERVATION_MODIFIER", 118, 125]]], ["The CHD II in Moramanga is the only local referral hospital for the health district of Moramanga that has 250 000 inhabitants.", [["CHD II", "CHEMICAL", 4, 10]]], ["It is located 115 km east from the capital city.", [["115 km", "OBSERVATION_MODIFIER", 14, 20], ["capital", "ANATOMY_MODIFIER", 35, 42]]], ["Antananarivo and Moramanga present the same climatic profile: hot and rainy in summer and cold and dry in winter, but Moramanga encompasses both semiurban and rural areas.Study subjectsAll patients presenting SARI symptoms at admission were enrolled.", [["Moramanga", "CHEMICAL", 118, 127], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["Antananarivo", "TREATMENT", 0, 12], ["Moramanga", "TREATMENT", 17, 26], ["Study subjects", "TEST", 171, 185], ["SARI symptoms", "PROBLEM", 209, 222], ["dry", "OBSERVATION", 99, 102], ["rural", "ANATOMY_MODIFIER", 159, 164]]], ["SARI case definition was defined according to the WHO case definition as fever (T\ufffd38\u02daC) or history of fever and cough that required hospitalization.", [["fever", "DISEASE", 73, 78], ["fever", "DISEASE", 102, 107], ["cough", "DISEASE", 112, 117], ["fever", "PROBLEM", 73, 78], ["fever", "PROBLEM", 102, 107], ["cough", "PROBLEM", 112, 117], ["fever", "OBSERVATION", 102, 107], ["cough", "OBSERVATION", 112, 117]]], ["For children less than 5 years, the eligibility criteria were suspected sepsis or SARI diagnosed by physician including bronchiolitis, pneumonia, bronchitis, pleural effusion, and cough or difficult breathing as previously published [18] .", [["pleural", "ANATOMY", 158, 165], ["sepsis", "DISEASE", 72, 78], ["SARI", "DISEASE", 82, 86], ["bronchiolitis", "DISEASE", 120, 133], ["pneumonia", "DISEASE", 135, 144], ["bronchitis", "DISEASE", 146, 156], ["pleural effusion", "DISEASE", 158, 174], ["cough", "DISEASE", 180, 185], ["children", "ORGANISM", 4, 12], ["pleural", "ORGAN", 158, 165], ["children", "SPECIES", 4, 12], ["sepsis", "PROBLEM", 72, 78], ["SARI", "PROBLEM", 82, 86], ["bronchiolitis", "PROBLEM", 120, 133], ["pneumonia", "PROBLEM", 135, 144], ["bronchitis", "PROBLEM", 146, 156], ["pleural effusion", "PROBLEM", 158, 174], ["cough", "PROBLEM", 180, 185], ["difficult breathing", "PROBLEM", 189, 208], ["sepsis", "OBSERVATION", 72, 78], ["bronchiolitis", "OBSERVATION", 120, 133], ["pneumonia", "OBSERVATION", 135, 144], ["bronchitis", "OBSERVATION", 146, 156], ["pleural", "ANATOMY", 158, 165], ["effusion", "OBSERVATION", 166, 174], ["cough", "OBSERVATION", 180, 185]]], ["The onset of illness should be less than 7 days before hospitalization.", [["illness", "DISEASE", 13, 20], ["illness", "PROBLEM", 13, 20], ["illness", "OBSERVATION", 13, 20]]], ["For each consented patient, demographic, socio-economic, clinical, and epidemiological data were recorded in case report forms (CRFs).Biological analysisNasopharyngeal, blood, and sputum specimens were collected for each patient enrolled from Monday to Friday and shipped the same day to laboratories located at the Pasteur Institute of Madagascar where they were immediately processed or stored at 4\u02daC until testing (test were performed within 48 hours post-sampling).", [["analysisNasopharyngeal", "ANATOMY", 145, 167], ["blood", "ANATOMY", 169, 174], ["sputum specimens", "ANATOMY", 180, 196], ["patient", "ORGANISM", 19, 26], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["sputum specimens", "CANCER", 180, 196], ["patient", "ORGANISM", 221, 228], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 221, 228], ["epidemiological data", "TEST", 71, 91], ["Biological analysisNasopharyngeal, blood, and sputum specimens", "TEST", 134, 196], ["C until testing (test", "TEST", 401, 422]]], ["All procedures for the biological analyses have been previously described [18, 19] .", [["All procedures", "TREATMENT", 0, 14], ["the biological analyses", "TEST", 19, 42]]], ["Briefly, nasopharyngeal swabs were screened for 14 respiratory viruses using in-house multiplex real-time PCR [19] .", [["nasopharyngeal swabs", "ANATOMY", 9, 29], ["nasopharyngeal swabs", "CANCER", 9, 29], ["nasopharyngeal swabs", "TEST", 9, 29], ["14 respiratory viruses", "PROBLEM", 48, 70], ["nasopharyngeal", "ANATOMY", 9, 23]]], ["Sputum was collected for cytobacteriologic testing while blood samples were used for cell blood count.Data analysisSingle infection was defined as an infection caused by one pathogen (virus or bacteria) and multiple infection as an infection caused by at least 2 pathogens (virus/virus, virus/bacteria or bacteria/bacteria) in a single sample.", [["Sputum", "ANATOMY", 0, 6], ["blood samples", "ANATOMY", 57, 70], ["cell blood", "ANATOMY", 85, 95], ["sample", "ANATOMY", 336, 342], ["analysisSingle infection", "DISEASE", 107, 131], ["infection", "DISEASE", 150, 159], ["infection", "DISEASE", 216, 225], ["infection", "DISEASE", 232, 241], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["blood samples", "ORGANISM_SUBSTANCE", 57, 70], ["cell", "CELL", 85, 89], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["virus/virus", "ORGANISM", 274, 285], ["Sputum", "TEST", 0, 6], ["cytobacteriologic testing", "TEST", 25, 50], ["blood samples", "TEST", 57, 70], ["cell blood count", "TEST", 85, 101], ["Data analysisSingle infection", "PROBLEM", 102, 131], ["an infection", "PROBLEM", 147, 159], ["one pathogen (virus", "PROBLEM", 170, 189], ["bacteria", "PROBLEM", 193, 201], ["multiple infection", "PROBLEM", 207, 225], ["an infection", "PROBLEM", 229, 241], ["2 pathogens (virus/virus", "PROBLEM", 261, 285], ["virus", "PROBLEM", 287, 292], ["bacteria", "PROBLEM", 293, 301], ["bacteria", "PROBLEM", 305, 313], ["bacteria", "PROBLEM", 314, 322], ["a single sample", "TEST", 327, 342], ["infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 150, 159], ["multiple", "OBSERVATION_MODIFIER", 207, 215], ["infection", "OBSERVATION", 216, 225], ["infection", "OBSERVATION", 232, 241]]], ["Patients were divided into 5 age groups: infants and young children (\ufffd 5 years old); children (5-14 years old); adolescent and young adults (15-29 years old); adults , and elderly (\ufffd 65 years old).", [["Patients", "ORGANISM", 0, 8], ["infants", "ORGANISM", 41, 48], ["children", "ORGANISM", 59, 67], ["children", "ORGANISM", 85, 93], ["Patients", "SPECIES", 0, 8], ["infants", "SPECIES", 41, 48], ["children", "SPECIES", 59, 67], ["children", "SPECIES", 85, 93]]], ["Demographic, clinical characteristics, and etiologies were compared by study sites and by age groups.", [["study sites", "TEST", 71, 82]]], ["Univariate analysis and logistic regression were performed using R software.", [["Univariate analysis", "TEST", 0, 19], ["logistic regression", "TEST", 24, 43]]], ["In univariate analysis, qualitative variables were compared with Fisher's exact test and quantitative variables by non-parametric tests (Wilcoxon test).", [["univariate analysis", "TEST", 3, 22], ["qualitative variables", "TEST", 24, 45], ["Fisher's exact test", "TEST", 65, 84], ["non-parametric tests", "TEST", 115, 135], ["Wilcoxon test", "TEST", 137, 150]]], ["Furthermore, logistic regressions were performed to adjust Odds-Ratio (OR) found via maximum-likelihood estimation according to age group for the different variables as dependent variables and to compare each of them according to age group by Wald test.", [["logistic regressions", "TEST", 13, 33], ["Odds", "TEST", 59, 63], ["Wald test", "TEST", 243, 252]]], ["Statistical differences were considered significant for two-sided p-values < = 0.05.Ethics statementAlthough SARI surveillance in Madagascar is not considered as research, this prospective study requested extra sampling and the collection of personal information.", [["two-sided p-values", "TEST", 56, 74], ["SARI surveillance", "TEST", 109, 126], ["this prospective study", "TEST", 172, 194], ["extra sampling", "TREATMENT", 205, 219], ["sided", "ANATOMY_MODIFIER", 60, 65], ["not considered", "UNCERTAINTY", 144, 158]]], ["For that reason, the present study was submitted and approved by the national ethics committee from the ministry of health in Madagascar (Authorization N\u02da068-MSANP/CE).", [["N\u02da068-MSANP/CE", "CHEMICAL", 152, 166], ["the present study", "TEST", 17, 34]]], ["Adult participants or parents were fully informed of the study's objectives and procedures.", [["participants", "ORGANISM", 6, 18], ["participants", "SPECIES", 6, 18], ["the study", "TEST", 53, 62], ["procedures", "TREATMENT", 80, 90]]], ["Written informed consent was obtained from patients enrolled in the study.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["the study", "TEST", 64, 73]]], ["Young participants aged from 7 to 18 years old were asked to sign an informed assent form if they were willing to take part in the study.", [["participants", "ORGANISM", 6, 18], ["participants", "SPECIES", 6, 18], ["the study", "TEST", 127, 136]]], ["For all patients aged less than 18 years, consent was obtained from the parents or legal guardians.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["After obtaining the consent/assent form, the team survey proceeded to collect samples and fill out the CRFs.", [["the CRFs", "PROBLEM", 99, 107]]], ["Refused consent and prior hospitalization within 2 weeks before consultation were reasons for exclusion.Patient's demographic characteristicsFrom November 2010 to July 2013, 876 hospitalized patients completed the established SARI case definition of whom 657 cases (75.0%) were from CENHOSOA and 219 cases (25.0%) from CHD II Moramanga.", [["CHD", "DISEASE", 319, 322], ["patients", "ORGANISM", 191, 199], ["Patient", "SPECIES", 104, 111], ["patients", "SPECIES", 191, 199], ["CENHOSOA", "TEST", 283, 291], ["CHD II Moramanga", "TREATMENT", 319, 335]]], ["The mean age was 8.2 years ranging from 1 day to 89 years and 54.8% of patients were male cases.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["The majority of recruited patients were children aged less than 5 years and accounting for 81% of total inclusion.", [["patients", "ORGANISM", 26, 34], ["children", "ORGANISM", 40, 48], ["patients", "SPECIES", 26, 34], ["children", "SPECIES", 40, 48]]], ["Differences of mean age (2.8 years vs. 9.9 years; p<0.001; Wilcoxon test) and age repartition (p<0.001) of included patients were observed between the 2 study sites with patients hospitalized in CHD II Moramanga being younger than those hospitalized in CENHOSOA (Table 1) .Clinical characteristicsWith exception of dyspnea and fever which are among the principal inclusion criteria, runny nose (69.7%), intercostal recessions (69.9%), productive cough (53.0%), movement of nose wings (52.6%), and anorexia (50.3%) were the most recorded at the time of examination.", [["intercostal", "ANATOMY", 403, 414], ["nose", "ANATOMY", 473, 477], ["CHD", "DISEASE", 195, 198], ["dyspnea", "DISEASE", 315, 322], ["fever", "DISEASE", 327, 332], ["runny nose", "DISEASE", 383, 393], ["intercostal recessions", "DISEASE", 403, 425], ["cough", "DISEASE", 446, 451], ["movement of nose wings", "DISEASE", 461, 483], ["anorexia", "DISEASE", 497, 505], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 170, 178], ["nose", "ORGANISM_SUBDIVISION", 389, 393], ["intercostal recessions", "MULTI-TISSUE_STRUCTURE", 403, 425], ["nose", "ORGANISM_SUBDIVISION", 473, 477], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 170, 178], ["Wilcoxon test", "TEST", 59, 72], ["dyspnea", "PROBLEM", 315, 322], ["fever", "PROBLEM", 327, 332], ["runny nose", "TEST", 383, 393], ["intercostal recessions", "PROBLEM", 403, 425], ["productive cough", "PROBLEM", 435, 451], ["movement of nose wings", "TEST", 461, 483], ["anorexia", "PROBLEM", 497, 505], ["examination", "TEST", 552, 563], ["dyspnea", "OBSERVATION", 315, 322], ["fever", "OBSERVATION", 327, 332], ["intercostal", "ANATOMY", 403, 414], ["productive", "OBSERVATION_MODIFIER", 435, 445], ["cough", "OBSERVATION", 446, 451], ["nose wings", "ANATOMY", 473, 483]]], ["Bronchiolitis (44.5%) was the most clinical diagnostic made by clinicians at admission followed by bronchopneumonia (15.0%) and pneumonia (8.8%).", [["Bronchiolitis", "DISEASE", 0, 13], ["bronchopneumonia", "DISEASE", 99, 115], ["pneumonia", "DISEASE", 128, 137], ["Bronchiolitis", "PROBLEM", 0, 13], ["bronchopneumonia", "PROBLEM", 99, 115], ["pneumonia", "PROBLEM", 128, 137], ["bronchopneumonia", "OBSERVATION", 99, 115], ["pneumonia", "OBSERVATION", 128, 137]]], ["Other low respiratory tract infections (bronchoalveolitis/exacerbation of chronic obstructive pulmonary disease (COPD), pleuropneumonia, and acute lobar pneumonia) were observed in 14.8% of inpatients (S1 Table) .", [["respiratory tract", "ANATOMY", 10, 27], ["pulmonary", "ANATOMY", 94, 103], ["lobar", "ANATOMY", 147, 152], ["low respiratory tract infections", "DISEASE", 6, 38], ["bronchoalveolitis", "DISEASE", 40, 57], ["chronic obstructive pulmonary disease", "DISEASE", 74, 111], ["COPD", "DISEASE", 113, 117], ["pleuropneumonia", "DISEASE", 120, 135], ["pneumonia", "DISEASE", 153, 162], ["tract", "ORGANISM_SUBDIVISION", 22, 27], ["pulmonary", "ORGAN", 94, 103], ["Other low respiratory tract infections", "PROBLEM", 0, 38], ["chronic obstructive pulmonary disease", "PROBLEM", 74, 111], ["COPD)", "PROBLEM", 113, 118], ["pleuropneumonia", "PROBLEM", 120, 135], ["acute lobar pneumonia", "PROBLEM", 141, 162], ["low", "OBSERVATION_MODIFIER", 6, 9], ["respiratory tract", "ANATOMY", 10, 27], ["infections", "OBSERVATION", 28, 38], ["exacerbation", "OBSERVATION_MODIFIER", 58, 70], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["obstructive", "OBSERVATION_MODIFIER", 82, 93], ["pulmonary", "ANATOMY", 94, 103], ["disease", "OBSERVATION", 104, 111], ["COPD", "OBSERVATION", 113, 117], ["pleuropneumonia", "OBSERVATION", 120, 135], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["lobar", "OBSERVATION_MODIFIER", 147, 152], ["pneumonia", "OBSERVATION", 153, 162]]], ["Comparison of clinical symptoms between the 2 sites showed that dry cough (p = 0.026), asthenia (p = 0.001), runny nose (p<0.001), and anorexia (p = 0.001) were statistically frequently observed in patients hospitalized in CHDII Moramanga whereas productive cough (p = 0.026), sore throat (p<0.001), headache (p = 0.014), thrill (p = 0.001), and cyanosis (p<0.001) were significantly associated with patients hospitalized in CENHOSOA (Table 1) .InfectionsAt least one pathogen was found in 83.1% (728/876) of tested patients of which 38.8% (340/ 876) were single infection and 44.3% (388/876) were multiple infections.", [["dry cough", "DISEASE", 64, 73], ["asthenia", "DISEASE", 87, 95], ["runny nose", "DISEASE", 109, 119], ["anorexia", "DISEASE", 135, 143], ["cough", "DISEASE", 258, 263], ["sore throat", "DISEASE", 277, 288], ["headache", "DISEASE", 300, 308], ["cyanosis", "DISEASE", 346, 354], ["Infections", "DISEASE", 445, 455], ["infection", "DISEASE", 563, 572], ["infections", "DISEASE", 607, 617], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 400, 408], ["patients", "ORGANISM", 516, 524], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 400, 408], ["patients", "SPECIES", 516, 524], ["clinical symptoms", "PROBLEM", 14, 31], ["dry cough", "PROBLEM", 64, 73], ["asthenia", "PROBLEM", 87, 95], ["runny nose", "PROBLEM", 109, 119], ["anorexia", "PROBLEM", 135, 143], ["productive cough", "PROBLEM", 247, 263], ["sore throat", "PROBLEM", 277, 288], ["headache", "PROBLEM", 300, 308], ["thrill", "TEST", 322, 328], ["cyanosis", "PROBLEM", 346, 354], ["Infections", "PROBLEM", 445, 455], ["single infection", "PROBLEM", 556, 572], ["multiple infections", "PROBLEM", 598, 617], ["dry", "OBSERVATION_MODIFIER", 64, 67], ["cough", "OBSERVATION", 68, 73], ["cyanosis", "OBSERVATION", 346, 354], ["multiple", "OBSERVATION_MODIFIER", 598, 606], ["infections", "OBSERVATION", 607, 617]]], ["The highest rate of infection was obtained in patients aged less than 5 years (85.2%; 605/710).", [["infection", "DISEASE", 20, 29], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["infection", "PROBLEM", 20, 29], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 20, 29]]], ["For this age group, single and multiple infections were reported in 79.1% (269/340) and 86.6% (336/388) of cases, respectively.", [["infections", "DISEASE", 40, 50], ["single and multiple infections", "PROBLEM", 20, 50], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["infections", "OBSERVATION", 40, 50]]], ["The type of infection (mono-infection vs. multiple infection) differed significantly between age groups (p = 0.03, Fisher's exact test).", [["infection", "DISEASE", 12, 21], ["infection", "DISEASE", 28, 37], ["infection", "DISEASE", 51, 60], ["infection (mono-infection", "PROBLEM", 12, 37], ["multiple infection)", "PROBLEM", 42, 61], ["Fisher's exact test", "TEST", 115, 134], ["infection", "OBSERVATION", 12, 21], ["mono-", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 28, 37], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["infection", "OBSERVATION", 51, 60]]], ["Indeed, patients aged 30-64 years were significantly less likely at risk for being co-infected (OR = 0.4; p = 0.003) compared to those aged less than 5 years (S2 Table) .EtiologiesOverall, viral and bacterial infections occurred in 76.1% (667/876) and 35 Comparison of the prevalence of pathogens by study sites revealed that FLUA (p = 0.04), S. pneumoniae (p = 0.003), and Hib (p = 0.04) were statistically relatively common in patients hospitalized in CENHOSOA (S3 Table) .", [["viral and bacterial infections", "DISEASE", 189, 219], ["patients", "ORGANISM", 8, 16], ["S. pneumoniae", "ORGANISM", 343, 356], ["patients", "ORGANISM", 429, 437], ["patients", "SPECIES", 8, 16], ["S. pneumoniae", "SPECIES", 343, 356], ["patients", "SPECIES", 429, 437], ["S. pneumoniae", "SPECIES", 343, 356], ["co-infected", "PROBLEM", 83, 94], ["EtiologiesOverall", "TEST", 170, 187], ["viral and bacterial infections", "PROBLEM", 189, 219], ["pathogens", "PROBLEM", 287, 296], ["study sites", "TEST", 300, 311], ["FLUA", "TEST", 326, 330], ["p", "TEST", 332, 333], ["S. pneumoniae", "PROBLEM", 343, 356], ["Hib", "TEST", 374, 377], ["co-infected", "OBSERVATION", 83, 94], ["viral", "OBSERVATION_MODIFIER", 189, 194], ["bacterial", "OBSERVATION_MODIFIER", 199, 208], ["infections", "OBSERVATION", 209, 219], ["pneumoniae", "OBSERVATION", 346, 356]]], ["In respect to multiple infections, FLUA (OR = 4. ) .", [["infections", "DISEASE", 23, 33], ["FLUA", "DISEASE", 35, 39], ["multiple infections", "PROBLEM", 14, 33], ["FLUA", "TEST", 35, 39], ["multiple", "OBSERVATION_MODIFIER", 14, 22], ["infections", "OBSERVATION", 23, 33]]], ["Surprisingly, 118 patients were co-infected with 4, 5, and 6 different pathogens (92, 20, and 6, respectively) ( Table 3) .", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["co-infected", "OBSERVATION", 32, 43]]], ["Comparison of demographic and clinical characteristics of SARI patients by age group.", [["SARI", "DISEASE", 58, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["Analysis of data by the age group showed that the frequency of clinical symptoms significantly varied across groups.", [["Analysis of data", "TEST", 0, 16], ["clinical symptoms", "PROBLEM", 63, 80]]], ["Indeed, by multivariate analysis adjusted by age, patients aged \ufffd5 years appeared to suffer chest pain compared to patients aged <5 years while dry cough and GPD were more often observed in the elderly.", [["chest", "ANATOMY", 92, 97], ["chest pain", "DISEASE", 92, 102], ["dry cough", "DISEASE", 144, 153], ["GPD", "DISEASE", 158, 161], ["patients", "ORGANISM", 50, 58], ["chest", "ORGANISM_SUBDIVISION", 92, 97], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 115, 123], ["chest pain", "PROBLEM", 92, 102], ["dry cough", "PROBLEM", 144, 153], ["GPD", "PROBLEM", 158, 161], ["chest", "ANATOMY", 92, 97]]], ["Dyspnea and cyanosis were significantly more common in adults aged 30-64 years.", [["Dyspnea", "DISEASE", 0, 7], ["cyanosis", "DISEASE", 12, 20], ["Dyspnea", "PROBLEM", 0, 7], ["cyanosis", "PROBLEM", 12, 20], ["cyanosis", "OBSERVATION", 12, 20]]], ["Headache, thrill, sweats, anorexia, weight loss, and asthenia were more often observed in the older age groups (15-29 years, 30-64 years and \ufffd65 years).", [["Headache", "DISEASE", 0, 8], ["sweats", "DISEASE", 18, 24], ["anorexia", "DISEASE", 26, 34], ["weight loss", "DISEASE", 36, 47], ["asthenia", "DISEASE", 53, 61], ["Headache", "PROBLEM", 0, 8], ["thrill", "PROBLEM", 10, 16], ["sweats", "PROBLEM", 18, 24], ["anorexia", "PROBLEM", 26, 34], ["weight loss", "PROBLEM", 36, 47], ["asthenia", "PROBLEM", 53, 61], ["anorexia", "OBSERVATION", 26, 34]]], ["Sore throat was frequently reported in the age groups 5-14 years, 15-29 years and 30-64 years.", [["Sore throat", "PROBLEM", 0, 11], ["throat", "ANATOMY", 5, 11]]], ["Runny nose and intercostal recession appeared to be relatively infrequent in the older age groups (15-29 years, 30-64 years and \ufffd65 years) ( Table 4 and S4 Table) .EtiologiesRegarding infection, prevalence of RSV (p<0.001) and influenza viruses (p<0.001) substantially varied depending the age group.", [["nose", "ANATOMY", 6, 10], ["intercostal", "ANATOMY", 15, 26], ["infection", "DISEASE", 184, 193], ["RSV (p<0.001) and influenza viruses", "DISEASE", 209, 244], ["nose", "ORGAN", 6, 10], ["intercostal", "ORGAN", 15, 26], ["RSV", "ORGANISM", 209, 212], ["RSV", "SPECIES", 209, 212], ["Runny nose and intercostal recession", "PROBLEM", 0, 36], ["infection", "PROBLEM", 184, 193], ["RSV", "PROBLEM", 209, 212], ["influenza viruses", "PROBLEM", 227, 244], ["nose", "ANATOMY", 6, 10], ["intercostal", "ANATOMY", 15, 26], ["recession", "OBSERVATION", 27, 36], ["relatively", "OBSERVATION_MODIFIER", 52, 62], ["infrequent", "OBSERVATION_MODIFIER", 63, 73], ["infection", "OBSERVATION", 184, 193], ["RSV", "ANATOMY", 209, 212]]], ["As expected, RSV accounted for the highest proportion of SARI in young children (45.9%; 326/710).", [["SARI", "DISEASE", 57, 61], ["RSV", "ORGANISM", 13, 16], ["SARI", "CANCER", 57, 61], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["RSV", "SPECIES", 13, 16], ["RSV", "PROBLEM", 13, 16], ["RSV", "OBSERVATION", 13, 16]]], ["In fact, the older age groups were significantly less at risk to develop an RSV infection compared to the age group less than 5 years (Table 5) 2) and between 30-64 years (OR = 2.4) were more likely to catch FLUB infection.", [["RSV infection", "DISEASE", 76, 89], ["infection", "DISEASE", 213, 222], ["RSV", "ORGANISM", 76, 79], ["RSV", "SPECIES", 76, 79], ["an RSV infection", "PROBLEM", 73, 89], ["catch FLUB infection", "PROBLEM", 202, 222], ["RSV", "OBSERVATION", 76, 79], ["infection", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 213, 222]]], ["By multivariate analysis, the age group between 30-64 years were less likely to suffer from S. pneumoniae infection (OR = 0.5) than the age group less than 5 years ( Table 5) .EtiologiesPattern of circulation of respiratory pathogens.", [["respiratory", "ANATOMY", 212, 223], ["S. pneumoniae infection", "DISEASE", 92, 115], ["respiratory pathogens", "DISEASE", 212, 233], ["S. pneumoniae", "ORGANISM", 92, 105], ["S. pneumoniae", "SPECIES", 92, 105], ["S. pneumoniae", "SPECIES", 92, 105], ["multivariate analysis", "TEST", 3, 24], ["S. pneumoniae infection", "PROBLEM", 92, 115], ["respiratory pathogens", "PROBLEM", 212, 233], ["pneumoniae", "OBSERVATION", 95, 105], ["circulation", "OBSERVATION_MODIFIER", 197, 208], ["respiratory pathogens", "OBSERVATION", 212, 233]]], ["SARI cases were detected all year around during the 3 years of surveillance with distinct peaks of detection observed each year: between January and March in 2011 and 2013 and between May and July in 2012 (Fig 1) .", [["SARI cases", "PROBLEM", 0, 10], ["surveillance", "TEST", 63, 75]]], ["These peaks coincided with an active circulation of RSV and influenza viruses.", [["influenza viruses", "DISEASE", 60, 77], ["RSV", "ORGANISM", 52, 55], ["influenza viruses", "ORGANISM", 60, 77], ["RSV", "SPECIES", 52, 55], ["RSV", "PROBLEM", 52, 55], ["influenza viruses", "PROBLEM", 60, 77], ["active", "OBSERVATION_MODIFIER", 30, 36], ["circulation", "OBSERVATION", 37, 48], ["RSV", "OBSERVATION", 52, 55], ["influenza viruses", "OBSERVATION", 60, 77]]], ["Nevertheless, peaks of SARI appear to be more correlated to RSV circulation.", [["SARI", "GENE_OR_GENE_PRODUCT", 23, 27], ["RSV", "ORGANISM", 60, 63], ["SARI", "PROTEIN", 23, 27], ["RSV", "SPECIES", 60, 63], ["SARI", "PROBLEM", 23, 27], ["RSV", "OBSERVATION", 60, 63]]], ["Unlike other respiratory pathogens that are detected all year along, RSV seems to circulate once a year and being responsible of an epidemic every year.DiscussionTo the best of our knowledge, this study is the first description of etiologies associated to hospitalized SARI patients from both urban and peri-urban areas in Madagascar.", [["SARI", "DISEASE", 269, 273], ["RSV", "ORGANISM", 69, 72], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 274, 282], ["RSV", "SPECIES", 69, 72], ["other respiratory pathogens", "PROBLEM", 7, 34], ["RSV", "PROBLEM", 69, 72], ["this study", "TEST", 192, 202], ["respiratory", "ANATOMY", 13, 24], ["pathogens", "OBSERVATION", 25, 34]]], ["During the 3 years of surveillance, 867 consented patients meeting the established case definition of SARI were enrolled.", [["SARI", "DISEASE", 102, 106], ["patients", "ORGANISM", 50, 58], ["SARI", "CANCER", 102, 106], ["patients", "SPECIES", 50, 58], ["surveillance", "TEST", 22, 34], ["SARI", "PROBLEM", 102, 106]]], ["The observed different clinical spectrum across age groups may be helpful to avoid misclassification of patients presenting with respiratory illness at the triage level when no standardized protocol is available.DiscussionThe finding that about 82% of inpatients were tested positive for a pathogen is consistent with those reported elsewhere which showed etiologies ranging from 40% to 85% of hospitalized SARI cases depending on case definition or methodology design [14, 20, 21] .", [["respiratory", "ANATOMY", 129, 140], ["respiratory illness", "DISEASE", 129, 148], ["SARI", "DISEASE", 407, 411], ["patients", "ORGANISM", 104, 112], ["inpatients", "ORGANISM", 252, 262], ["patients", "SPECIES", 104, 112], ["respiratory illness", "PROBLEM", 129, 148], ["standardized protocol", "TREATMENT", 177, 198], ["a pathogen", "PROBLEM", 288, 298], ["etiologies", "TEST", 356, 366], ["hospitalized SARI cases", "PROBLEM", 394, 417]]], ["Most of the included patients were children less than 5 years old (78.5%).", [["patients", "ORGANISM", 21, 29], ["children", "ORGANISM", 35, 43], ["patients", "SPECIES", 21, 29], ["children", "SPECIES", 35, 43]]], ["This study confirms that young children are the most vulnerable group to suffer from SARI [22, 23] .", [["SARI", "DISEASE", 85, 89], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["This study", "TEST", 0, 10]]], ["Indeed, parents are keener to seek care for their children while older individuals try to cure themselves at home using self-medication or traditional medicine.DiscussionIn the present study, about 43% of inpatients presented multiple infections by at least 2 pathogens.", [["infections", "DISEASE", 235, 245], ["children", "ORGANISM", 50, 58], ["inpatients", "ORGANISM", 205, 215], ["children", "SPECIES", 50, 58], ["self-medication", "TREATMENT", 120, 135], ["traditional medicine", "TREATMENT", 139, 159], ["the present study", "TEST", 173, 190], ["multiple infections", "PROBLEM", 226, 245], ["multiple", "OBSERVATION_MODIFIER", 226, 234], ["infections", "OBSERVATION", 235, 245]]], ["Here, viral infections were commonly found in 75.4% of tested patients which is similar to what was observed within the community during the influenza-like illness surveillance [19] .", [["viral infections", "DISEASE", 6, 22], ["influenza-like illness", "DISEASE", 141, 163], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["viral infections", "PROBLEM", 6, 22], ["the influenza", "PROBLEM", 137, 150], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infections", "OBSERVATION", 12, 22]]], ["Taken together, the present study clearly demonstrates that respiratory viruses are the leading cause of severe acute respiratory illnesses in Madagascar.", [["respiratory", "ANATOMY", 118, 129], ["respiratory viruses", "DISEASE", 60, 79], ["acute respiratory illnesses", "DISEASE", 112, 139], ["the present study", "TEST", 16, 33], ["respiratory viruses", "PROBLEM", 60, 79], ["severe acute respiratory illnesses in Madagascar", "PROBLEM", 105, 153], ["respiratory viruses", "OBSERVATION", 60, 79], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory illnesses", "OBSERVATION", 118, 139]]], ["Overall, RSV was the most commonly detected followed by S. pneumoniae and influenza viruses.DiscussionSimilar to other studies, substantial rate of RSV infection was observed in young population [14, 24, 25] .", [["influenza viruses", "DISEASE", 74, 91], ["RSV infection", "DISEASE", 148, 161], ["RSV", "ORGANISM", 9, 12], ["S. pneumoniae", "ORGANISM", 56, 69], ["influenza viruses", "ORGANISM", 74, 91], ["RSV", "ORGANISM", 148, 151], ["S. pneumoniae", "SPECIES", 56, 69], ["RSV", "SPECIES", 9, 12], ["S. pneumoniae", "SPECIES", 56, 69], ["RSV", "SPECIES", 148, 151], ["RSV", "PROBLEM", 9, 12], ["S. pneumoniae", "PROBLEM", 56, 69], ["influenza viruses", "PROBLEM", 74, 91], ["other studies", "TEST", 113, 126], ["RSV infection", "PROBLEM", 148, 161], ["RSV", "OBSERVATION", 9, 12], ["pneumoniae", "OBSERVATION", 59, 69], ["influenza viruses", "OBSERVATION", 74, 91], ["substantial", "OBSERVATION_MODIFIER", 128, 139], ["RSV infection", "OBSERVATION", 148, 161]]], ["A meta-analysis of data from Africa reported that the incidence of RSV in lower acute respiratory infections that required hospitalization ranged from 10-18 per 1000 person year for infants and 3-9 per 1000 person year for children under 5 years of age [26] .", [["respiratory", "ANATOMY", 86, 97], ["RSV", "DISEASE", 67, 70], ["acute respiratory infections", "DISEASE", 80, 108], ["RSV", "ORGANISM", 67, 70], ["infants", "ORGANISM", 182, 189], ["children", "ORGANISM", 223, 231], ["person", "SPECIES", 166, 172], ["infants", "SPECIES", 182, 189], ["person", "SPECIES", 207, 213], ["children", "SPECIES", 223, 231], ["RSV", "SPECIES", 67, 70], ["RSV", "PROBLEM", 67, 70], ["lower acute respiratory infections", "PROBLEM", 74, 108], ["RSV", "OBSERVATION", 67, 70], ["lower", "OBSERVATION_MODIFIER", 74, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory", "ANATOMY", 86, 97], ["infections", "OBSERVATION", 98, 108]]], ["The increased circulation of RSV that coincided with the peak of SARI cases may be informative for clinicians to predict an epidemic due to RSV and to choose the most appropriate care for patients in order to avoid overuse of antibiotics.", [["RSV", "DISEASE", 140, 143], ["RSV", "ORGANISM", 29, 32], ["SARI", "GENE_OR_GENE_PRODUCT", 65, 69], ["RSV", "ORGANISM", 140, 143], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["RSV", "SPECIES", 29, 32], ["RSV", "SPECIES", 140, 143], ["The increased circulation of RSV", "PROBLEM", 0, 32], ["RSV", "PROBLEM", 140, 143], ["antibiotics", "TREATMENT", 226, 237], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["circulation", "OBSERVATION_MODIFIER", 14, 25], ["RSV", "OBSERVATION", 29, 32]]], ["In addition, the epidemic pattern of this virus reveals the need to develop rapid diagnostic tests to rapidly manage patients and reduce the number of hospitalization, and to promote effective vaccine to prevent severe infections in high-risk populations.DiscussionThe role of influenza viruses in SARI-associated hospitalization is increasingly defined because of available data from active influenza sentinel surveillance system initiated in several countries including sub-Saharan Africa [27] [28] [29] [30] .", [["infections", "DISEASE", 219, 229], ["influenza viruses", "DISEASE", 277, 294], ["SARI", "DISEASE", 298, 302], ["patients", "ORGANISM", 117, 125], ["influenza viruses", "ORGANISM", 277, 294], ["[27] [28] [29", "SIMPLE_CHEMICAL", 491, 504], ["patients", "SPECIES", 117, 125], ["this virus", "PROBLEM", 37, 47], ["rapid diagnostic tests", "TEST", 76, 98], ["effective vaccine", "TREATMENT", 183, 200], ["severe infections", "PROBLEM", 212, 229], ["high-risk populations", "PROBLEM", 233, 254], ["influenza viruses", "PROBLEM", 277, 294], ["active influenza sentinel surveillance system", "TREATMENT", 385, 430], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["infections", "OBSERVATION", 219, 229]]], ["The proportion of influenza viruses in young population obtained here (20.4%) is much higher than in other African countries were SARI attributable to influenza are around 7% [16] .", [["influenza viruses", "DISEASE", 18, 35], ["SARI", "DISEASE", 130, 134], ["influenza", "DISEASE", 151, 160], ["influenza viruses", "ORGANISM", 18, 35], ["influenza viruses", "PROBLEM", 18, 35], ["SARI", "PROBLEM", 130, 134], ["influenza", "PROBLEM", 151, 160], ["influenza viruses", "OBSERVATION", 18, 35]]], ["As seen elsewhere, the highest rate of hospitalization is obtained with the subtype A/H3N2 virus during its circulation [31, 32] .", [["A/H3N2 virus", "ORGANISM", 84, 96], ["H3N2 virus", "SPECIES", 86, 96], ["A/H3N2 virus", "SPECIES", 84, 96], ["the subtype A/H3N2 virus", "PROBLEM", 72, 96]]], ["In Madagascar despite decades of reliable influenza surveillance, no national policy is implemented regarding vaccination.", [["influenza", "DISEASE", 42, 51], ["reliable influenza surveillance", "TEST", 33, 64]]], ["Moreover, influenza vaccines are not widely accessible and affordable for the whole population.DiscussionIn the present study, about 35.2% of SARI cases were likely due to bacterial infection.", [["SARI", "DISEASE", 142, 146], ["bacterial infection", "DISEASE", 172, 191], ["SARI", "CANCER", 142, 146], ["influenza vaccines", "TREATMENT", 10, 28], ["the present study", "TEST", 108, 125], ["SARI cases", "PROBLEM", 142, 152], ["bacterial infection", "PROBLEM", 172, 191], ["likely due to", "UNCERTAINTY", 158, 171], ["bacterial", "OBSERVATION_MODIFIER", 172, 181], ["infection", "OBSERVATION", 182, 191]]], ["Nevertheless, it is not clear what this high proportion of bacteria means due to the notion of carriage.", [["bacteria", "PROBLEM", 59, 67], ["carriage", "PROBLEM", 95, 103]]], ["The substantial rate of S. pneumoniae detected might be partly explained by the very low pneumococcal vaccination rate among the younger population (estimated at 0.4%) because most of the positive cases were detected before the introduction of pneumococcal vaccine into the expanded program on immunization (EPI) in Madagascar in 2012 [33] .", [["S. pneumoniae", "ORGANISM", 24, 37], ["pneumococcal", "ORGANISM", 244, 256], ["S. pneumoniae", "SPECIES", 24, 37], ["S. pneumoniae", "SPECIES", 24, 37], ["pneumococcal", "SPECIES", 89, 101], ["pneumococcal", "SPECIES", 244, 256], ["S. pneumoniae", "PROBLEM", 24, 37], ["the very low pneumococcal vaccination rate", "PROBLEM", 76, 118], ["the positive cases", "PROBLEM", 184, 202], ["pneumococcal vaccine", "TREATMENT", 244, 264], ["immunization (EPI", "TREATMENT", 294, 311], ["substantial", "OBSERVATION_MODIFIER", 4, 15], ["pneumoniae", "OBSERVATION", 27, 37], ["might be partly explained", "UNCERTAINTY", 47, 72], ["very", "OBSERVATION_MODIFIER", 80, 84], ["low", "OBSERVATION_MODIFIER", 85, 88], ["pneumococcal", "OBSERVATION", 89, 101]]], ["This vaccine is believed to reduce substantially the burden of pneumococcal disease.", [["pneumococcal disease", "DISEASE", 63, 83], ["pneumococcal", "SPECIES", 63, 75], ["This vaccine", "TREATMENT", 0, 12], ["pneumococcal disease", "PROBLEM", 63, 83], ["pneumococcal disease", "OBSERVATION", 63, 83]]], ["Thus, it would be interesting to evaluate the proportion of SARI associated to S. pneumoniae more than 5 years after the introduction of the vaccine in Madagascar.", [["SARI", "DISEASE", 60, 64], ["S. pneumoniae", "DISEASE", 79, 92], ["SARI", "CANCER", 60, 64], ["S. pneumoniae", "ORGANISM", 79, 92], ["S. pneumoniae", "SPECIES", 79, 92], ["S. pneumoniae", "SPECIES", 79, 92], ["SARI", "PROBLEM", 60, 64], ["S. pneumoniae", "PROBLEM", 79, 92], ["the vaccine", "TREATMENT", 137, 148], ["pneumoniae", "OBSERVATION", 82, 92]]], ["On the other hand, the role of atypical bacteria in hospitalized ARI is poorly understood.", [["ARI", "DISEASE", 65, 68], ["atypical bacteria", "PROBLEM", 31, 48], ["atypical", "OBSERVATION_MODIFIER", 31, 39], ["bacteria", "OBSERVATION", 40, 48]]], ["One assumes that certain bacteria predispose to bacterial super-infections [34] .", [["infections", "DISEASE", 64, 74], ["certain bacteria", "PROBLEM", 17, 33], ["bacterial super-infections", "PROBLEM", 48, 74], ["bacterial", "OBSERVATION_MODIFIER", 48, 57], ["super", "OBSERVATION_MODIFIER", 58, 63], ["infections", "OBSERVATION", 64, 74]]], ["While RV is considered as the common cold virus, the present study showed that this virus accounted for 14% of total SARI cases.", [["SARI", "DISEASE", 117, 121], ["RV", "MULTI-TISSUE_STRUCTURE", 6, 8], ["SARI", "CANCER", 117, 121], ["the common cold virus", "PROBLEM", 26, 47], ["the present study", "TEST", 49, 66], ["this virus", "PROBLEM", 79, 89], ["total SARI cases", "PROBLEM", 111, 127], ["RV", "ANATOMY", 6, 8]]], ["This finding highlights the potential role of RV in public health like other authors already postulated [35] [36] [37] .DiscussionOur study presents some limitations.", [["DiscussionOur study", "TEST", 120, 139], ["RV", "ANATOMY", 46, 48]]], ["Indeed, prevalence of each pathogen may differ for regions having different bioclimatic or demographic patterns, access to healthcare, and connectivity.", [["each pathogen", "PROBLEM", 22, 35]]], ["Since children are more at risk to develop severe infection, our sampling was skewed toward the younger group and likely underestimate the prevalence in adult.", [["infection", "DISEASE", 50, 59], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["severe infection", "PROBLEM", 43, 59], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["infection", "OBSERVATION", 50, 59]]], ["Indeed, few adult cases had been identified at the adult ward mainly because the duration of symptoms prior to admission exceeded the 7 days limit of our SARI case definition.", [["symptoms", "PROBLEM", 93, 101], ["few", "OBSERVATION_MODIFIER", 8, 11]]], ["It was also observed that severe cases were treated on external consultation or admitted at the emergency department for a few hours and then discharged.", [["severe", "OBSERVATION_MODIFIER", 26, 32]]], ["Patients that did not recover, worsened at home, and returned to the hospital were then admitted resulting in prolonged duration of illness (usually more than 7 days) at the time of admission.", [["illness", "DISEASE", 132, 139], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["illness", "PROBLEM", 132, 139], ["worsened", "OBSERVATION_MODIFIER", 31, 39]]], ["Another limitation is to attribute the pathogen(s) that is (are) the main cause that lead to severe illness.", [["illness", "DISEASE", 100, 107], ["severe illness", "PROBLEM", 93, 107], ["pathogen", "OBSERVATION", 39, 47], ["main", "OBSERVATION_MODIFIER", 69, 73], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["illness", "OBSERVATION", 100, 107]]], ["Indeed, we could not exclude that some pathogens may be present due to carriage.ConclusionsTo conclude, the high prevalence of etiology associated to severe infections of relevant pathogens highlights the importance of sustaining national surveillance of SARI to clearly estimate the role of associated pathogens and establish the burden of disease.", [["infections", "DISEASE", 157, 167], ["some pathogens", "PROBLEM", 34, 48], ["carriage", "PROBLEM", 71, 79], ["severe infections of relevant pathogens", "PROBLEM", 150, 189], ["SARI", "PROBLEM", 255, 259], ["associated pathogens", "PROBLEM", 292, 312], ["disease", "PROBLEM", 341, 348], ["could not exclude", "UNCERTAINTY", 11, 28], ["pathogens", "OBSERVATION", 39, 48], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["infections", "OBSERVATION", 157, 167], ["disease", "OBSERVATION", 341, 348]]], ["Further challenges in such program include efforts to implement strategies that capture adult cases as it is relevant to measure the impact of SARI in this population.", [["SARI", "DISEASE", 143, 147], ["SARI", "PROBLEM", 143, 147]]], ["Since vaccines play an important role in preventing SARI, vaccination against important pathogens, including RSV, should be accessible at least for high-risk population in developing countries.", [["RSV", "ORGANISM", 109, 112], ["SARI", "SPECIES", 52, 56], ["RSV", "SPECIES", 109, 112], ["vaccines", "TREATMENT", 6, 14], ["SARI", "PROBLEM", 52, 56], ["vaccination", "TREATMENT", 58, 69], ["important pathogens", "PROBLEM", 78, 97], ["RSV", "TREATMENT", 109, 112]]], ["Indeed, although use of synthetic antibodies against RSV can be provided to certain at-risk infants, this treatment only provides a short-term protection, is not always effective, and is also expensive, putting it beyond the reach of developing countries like Madagascar.ConclusionsSupporting information S1 Table.", [["RSV", "DISEASE", 53, 56], ["RSV", "ORGANISM", 53, 56], ["infants", "ORGANISM", 92, 99], ["synthetic antibodies", "PROTEIN", 24, 44], ["infants", "SPECIES", 92, 99], ["RSV", "SPECIES", 53, 56], ["synthetic antibodies", "TREATMENT", 24, 44], ["RSV", "PROBLEM", 53, 56], ["this treatment", "TREATMENT", 101, 115], ["a short-term protection", "TREATMENT", 130, 153], ["Madagascar", "OBSERVATION", 260, 270]]], ["Clinical diagnosis of patients hospitalized for SARI, Madagascar, November 2010 to July 2013. \ufffd LRTI: Low respiratory tract infection including bronchoalveolitis/exacerbation of chronic obstructive pulmonary disease (COPD), pleuropneumonia, and acute lobar pneumonia; \ufffd\ufffd other: neonatal infection, asthma, laryngitis, influenza-like illness etc. . .", [["respiratory tract", "ANATOMY", 106, 123], ["pulmonary", "ANATOMY", 198, 207], ["lobar", "ANATOMY", 251, 256], ["LRTI", "DISEASE", 96, 100], ["respiratory tract infection", "DISEASE", 106, 133], ["bronchoalveolitis", "DISEASE", 144, 161], ["chronic obstructive pulmonary disease", "DISEASE", 178, 215], ["COPD", "DISEASE", 217, 221], ["pleuropneumonia", "DISEASE", 224, 239], ["pneumonia", "DISEASE", 257, 266], ["neonatal infection", "DISEASE", 278, 296], ["asthma", "DISEASE", 298, 304], ["laryngitis", "DISEASE", 306, 316], ["influenza-like illness", "DISEASE", 318, 340], ["patients", "ORGANISM", 22, 30], ["pulmonary", "ORGAN", 198, 207], ["patients", "SPECIES", 22, 30], ["SARI", "PROBLEM", 48, 52], ["LRTI", "PROBLEM", 96, 100], ["Low respiratory tract infection", "PROBLEM", 102, 133], ["bronchoalveolitis", "PROBLEM", 144, 161], ["exacerbation", "PROBLEM", 162, 174], ["chronic obstructive pulmonary disease", "PROBLEM", 178, 215], ["COPD)", "PROBLEM", 217, 222], ["pleuropneumonia", "PROBLEM", 224, 239], ["acute lobar pneumonia", "PROBLEM", 245, 266], ["neonatal infection", "PROBLEM", 278, 296], ["asthma", "PROBLEM", 298, 304], ["laryngitis", "PROBLEM", 306, 316], ["influenza", "PROBLEM", 318, 327], ["Low", "OBSERVATION_MODIFIER", 102, 105], ["respiratory tract", "ANATOMY", 106, 123], ["infection", "OBSERVATION", 124, 133], ["exacerbation", "OBSERVATION_MODIFIER", 162, 174], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["obstructive", "OBSERVATION_MODIFIER", 186, 197], ["pulmonary", "ANATOMY", 198, 207], ["disease", "OBSERVATION", 208, 215], ["COPD", "OBSERVATION", 217, 221], ["pleuropneumonia", "OBSERVATION", 224, 239], ["acute", "OBSERVATION_MODIFIER", 245, 250], ["lobar", "OBSERVATION_MODIFIER", 251, 256], ["pneumonia", "OBSERVATION", 257, 266], ["neonatal", "OBSERVATION_MODIFIER", 278, 286], ["infection", "OBSERVATION", 287, 296], ["asthma", "OBSERVATION", 298, 304], ["laryngitis", "OBSERVATION", 306, 316], ["influenza", "OBSERVATION", 318, 327]]], ["N = number of included patients. n = number of patients that responded by \"yes\" or \"no\" for a given symptom.", [["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 47, 55], ["symptom", "PROBLEM", 100, 107]]], ["Only bronchiolitis, pneumonia, and bronchopneumonia were statistically analyzed.", [["bronchiolitis", "DISEASE", 5, 18], ["pneumonia", "DISEASE", 20, 29], ["bronchopneumonia", "DISEASE", 35, 51], ["bronchiolitis", "PROBLEM", 5, 18], ["pneumonia", "PROBLEM", 20, 29], ["bronchopneumonia", "PROBLEM", 35, 51], ["bronchiolitis", "OBSERVATION", 5, 18], ["pneumonia", "OBSERVATION", 20, 29], ["bronchopneumonia", "OBSERVATION", 35, 51]]], ["Statistical analyses were performed using Fisher's exact test.", [["Statistical analyses", "TEST", 0, 20], ["Fisher's exact test", "TEST", 42, 61]]], ["Univariate analysis of the distribution of monoinfection and multiple infection detected in SARI adjusted by age groups, November 2010 to July 2013.", [["monoinfection", "DISEASE", 43, 56], ["infection", "DISEASE", 70, 79], ["Univariate analysis", "TEST", 0, 19], ["monoinfection", "PROBLEM", 43, 56], ["multiple infection", "PROBLEM", 61, 79], ["monoinfection", "OBSERVATION", 43, 56], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["infection", "OBSERVATION", 70, 79]]], ["(DOCX) S3", [["(DOCX) S3", "GENE_OR_GENE_PRODUCT", 0, 9], ["S3", "ANATOMY", 7, 9]]]], "1608be64ce4959c3cbf9451b52f16ecefcd2afbc": [["IntroductionSevere acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a novel coronavirus whose first outbreak was reported in December 2019 in Wuhan, China, where a cluster of pneumonia cases was detected, and on 11th March, 2020, WHO declared this outbreak a pandemic [1, 2, 3] .", [["acute respiratory syndrome-coronavirus", "DISEASE", 19, 57], ["coronavirus", "DISEASE", 84, 95], ["pneumonia", "DISEASE", 183, 192], ["IntroductionSevere acute respiratory syndrome-coronavirus-2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["coronavirus", "ORGANISM", 84, 95], ["-coronavirus-2", "SPECIES", 45, 59], ["IntroductionSevere acute respiratory syndrome-coronavirus-2", "SPECIES", 0, 59], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["coronavirus", "PROBLEM", 46, 57], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["a novel coronavirus", "PROBLEM", 76, 95], ["pneumonia cases", "PROBLEM", 183, 198], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["pneumonia", "OBSERVATION", 183, 192]]], ["As of 22nd August 2020, a total of 22.9 million confirmed COVID-19 cases have been reported worldwide with 7,99,350 deaths [4] .", [["deaths", "DISEASE", 116, 122], ["COVID", "TEST", 58, 63]]], ["SARS-CoV-2 belongs to the family Coronaviridae and has 55% 5 nucleotide similarity and 30% protein sequence similarity with SARS-CoV, which caused the previous outbreak of SARS in 2002 [5, 6] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "DISEASE", 124, 132], ["SARS", "DISEASE", 172, 176], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 124, 132], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 124, 132], ["Coronaviridae", "TREATMENT", 33, 46], ["nucleotide similarity", "TEST", 61, 82], ["SARS", "PROBLEM", 124, 128], ["SARS", "PROBLEM", 172, 176]]], ["SASR-CoV2 is a single-stranded RNA virus of positive polarity whose genome is approximately 30 kb in length and encodes for 16 non-structural proteins, four structural and six accessory proteins [7, 8] .", [["SASR-CoV2", "GENE_OR_GENE_PRODUCT", 0, 9], ["SASR", "DNA", 0, 4], ["CoV2", "DNA", 5, 9], ["structural proteins", "PROTEIN", 131, 150], ["accessory proteins", "PROTEIN", 176, 194], ["16 non-structural proteins", "PROBLEM", 124, 150], ["positive polarity", "OBSERVATION_MODIFIER", 44, 61]]], ["The SARS-CoV-2 has a total of six accessory proteins including 3a, 6, 7a, 7b, 8 and 10 [9, 10] .", [["SARS", "DISEASE", 4, 8], ["7a", "GENE_OR_GENE_PRODUCT", 70, 72], ["7b", "GENE_OR_GENE_PRODUCT", 74, 76], ["8", "GENE_OR_GENE_PRODUCT", 78, 79], ["accessory proteins", "PROTEIN", 34, 52], ["3a, 6, 7a, 7b, 8 and 10", "PROTEIN", 63, 86], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8]]], ["Among these accessory proteins, ORF8 is a significantly exclusive protein as it is different from another known SARS-CoV and thus associated with high efficiency 10 in pathogenicity transmission [11, 12] .", [["SARS", "DISEASE", 112, 116], ["ORF8", "GENE_OR_GENE_PRODUCT", 32, 36], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 112, 120], ["accessory proteins", "PROTEIN", 12, 30], ["ORF8", "PROTEIN", 32, 36], ["SARS-CoV", "SPECIES", 112, 120], ["a significantly exclusive protein", "PROBLEM", 40, 73], ["another known SARS-CoV", "PROBLEM", 98, 120], ["high efficiency", "PROBLEM", 146, 161]]], ["The SARS-CoV-2 ORF8 displays arrays of functions; inhibition of interferon 1, promoting viral replication, inducing apoptosis and modulating ER stress [13, 14, 15] .IntroductionThe SARS-CoV-2 ORF8 is a 121 amino acid long protein, which has an N-terminal hydrophobic signal peptide (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) aa) and an ORF8 chain (16-121 aa) [16, 17] .", [["amino acid", "CHEMICAL", 206, 216], ["amino acid", "CHEMICAL", 206, 216], ["N", "CHEMICAL", 244, 245], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 4, 19], ["interferon 1", "GENE_OR_GENE_PRODUCT", 64, 76], ["ER", "GENE_OR_GENE_PRODUCT", 141, 143], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 181, 196], ["SARS-CoV-2 ORF8", "DNA", 4, 19], ["interferon 1", "PROTEIN", 64, 76], ["ER", "PROTEIN", 141, 143], ["SARS-CoV-2 ORF8", "DNA", 181, 196], ["121 amino acid long protein", "PROTEIN", 202, 229], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["interferon", "TREATMENT", 64, 74], ["promoting viral replication", "TREATMENT", 78, 105], ["The SARS", "TEST", 177, 185], ["CoV", "TEST", 186, 189], ["a 121 amino acid long protein", "PROBLEM", 200, 229], ["an N-terminal hydrophobic signal peptide", "TEST", 241, 281], ["an ORF8 chain", "TEST", 356, 369], ["viral replication", "OBSERVATION", 88, 105]]], ["The functional motif (VLVVL) of SARS-CoV-ORF8b, which is responsible for induction of cell stress pathways and activation of macrophages is absent from the SARS-CoV-2 ORF8 protein [18] .", [["cell", "ANATOMY", 86, 90], ["macrophages", "ANATOMY", 125, 136], ["SARS-CoV-ORF8b", "GENE_OR_GENE_PRODUCT", 32, 46], ["cell", "CELL", 86, 90], ["macrophages", "CELL", 125, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 166], ["ORF8b", "DNA", 41, 46], ["macrophages", "CELL_TYPE", 125, 136], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 156, 179], ["SARS", "PROBLEM", 32, 36], ["ORF8b", "PROBLEM", 41, 46], ["cell stress pathways", "PROBLEM", 86, 106], ["activation of macrophages", "PROBLEM", 111, 136], ["the SARS", "TEST", 152, 160], ["CoV", "TEST", 161, 164], ["protein", "TEST", 172, 179]]], ["In 15 the later stages of the SARS-CoV epidemic it was found that a 29 nucleotide deletion in the ORF8 protein caused it to split into ORF8a (39 aa) and ORF8b (84aa) rendering it functionless while the SARS-CoV-2 ORF8 is intact [19] .", [["SARS", "DISEASE", 30, 34], ["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["ORF8", "GENE_OR_GENE_PRODUCT", 98, 102], ["ORF8a", "GENE_OR_GENE_PRODUCT", 135, 140], ["ORF8b", "GENE_OR_GENE_PRODUCT", 153, 158], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 202, 217], ["29 nucleotide deletion", "DNA", 68, 90], ["ORF8 protein", "PROTEIN", 98, 110], ["ORF8a", "DNA", 135, 140], ["SARS-CoV-2 ORF8", "DNA", 202, 217], ["SARS-CoV", "SPECIES", 30, 38], ["the SARS", "PROBLEM", 26, 34], ["a 29 nucleotide deletion", "PROBLEM", 66, 90], ["ORF8b", "TEST", 153, 158], ["the SARS", "TEST", 198, 206], ["CoV", "TEST", 207, 210]]], ["Also, the SARS-CoV ORF8 had a function in interspecies transmission and viral replication efficiency as a reported 382 nucleotide deletion, which included ORF8ab resulted in a reduced ability of viral replication in human cells [20] .", [["cells", "ANATOMY", 222, 227], ["SARS", "DISEASE", 10, 14], ["nucleotide", "CHEMICAL", 119, 129], ["SARS-CoV ORF8", "ORGANISM", 10, 23], ["ORF8ab", "GENE_OR_GENE_PRODUCT", 155, 161], ["human", "ORGANISM", 216, 221], ["cells", "CELL", 222, 227], ["SARS-CoV ORF8", "DNA", 10, 23], ["382 nucleotide deletion", "DNA", 115, 138], ["ORF8ab", "DNA", 155, 161], ["human cells", "CELL_TYPE", 216, 227], ["human", "SPECIES", 216, 221], ["SARS-CoV", "SPECIES", 10, 18], ["human", "SPECIES", 216, 221], ["the SARS", "TEST", 6, 14], ["viral replication efficiency", "PROBLEM", 72, 100], ["nucleotide deletion", "PROBLEM", 119, 138], ["viral replication in human cells", "TREATMENT", 195, 227], ["viral", "OBSERVATION", 72, 77], ["replication efficiency", "OBSERVATION", 78, 100], ["viral replication", "OBSERVATION", 195, 212]]], ["However, the SARS-CoV-2 ORF8 mainly acts as an immune-modulator by down-regulating MHC class I molecules, therefore protecting the 20 infected cells against cytotoxic T cell killing of target cells.", [["cells", "ANATOMY", 143, 148], ["T cell", "ANATOMY", 167, 173], ["cells", "ANATOMY", 192, 197], ["SARS", "DISEASE", 13, 17], ["SARS-CoV-2", "ORGANISM", 13, 23], ["ORF8", "GENE_OR_GENE_PRODUCT", 24, 28], ["cells", "CELL", 143, 148], ["cytotoxic T cell", "CELL", 157, 173], ["cells", "CELL", 192, 197], ["SARS-CoV-2 ORF8", "DNA", 13, 28], ["MHC class I molecules", "PROTEIN", 83, 104], ["target cells", "CELL_TYPE", 185, 197], ["the SARS", "TEST", 9, 17], ["CoV", "TEST", 18, 21], ["the 20 infected cells", "TREATMENT", 127, 148], ["cytotoxic T cell killing of target cells", "PROBLEM", 157, 197], ["cytotoxic T cell killing", "OBSERVATION", 157, 181], ["target cells", "OBSERVATION", 185, 197]]], ["Simultaneously it was proposed forth that it is a potential inhibitor of type 1 interferon signalling pathway which is a key component of antiviral host immune response [21, 22] .IntroductionThe ORF8 also regulates unfolded protein response (UPR) induced due to ER stress by triggering ATF-6 activation, thus promoting infected cell survivability for its own benefit [23] .", [["cell", "ANATOMY", 328, 332], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 73, 90], ["ORF8", "GENE_OR_GENE_PRODUCT", 195, 199], ["unfolded protein response", "GENE_OR_GENE_PRODUCT", 215, 240], ["UPR", "GENE_OR_GENE_PRODUCT", 242, 245], ["ER", "GENE_OR_GENE_PRODUCT", 262, 264], ["ATF-6", "GENE_OR_GENE_PRODUCT", 286, 291], ["cell", "CELL", 328, 332], ["interferon", "PROTEIN", 80, 90], ["ORF8", "PROTEIN", 195, 199], ["UPR", "PROTEIN", 242, 245], ["ER", "PROTEIN", 262, 264], ["ATF-6", "PROTEIN", 286, 291], ["type 1 interferon signalling pathway", "TREATMENT", 73, 109], ["unfolded protein response", "PROBLEM", 215, 240], ["ER stress", "PROBLEM", 262, 271], ["ATF", "TEST", 286, 289], ["infected cell survivability", "TREATMENT", 319, 346], ["infected cell", "OBSERVATION", 319, 332]]], ["Since this protein impacts various host pathogen processes and developed various strategies that allow it to escape through host immune responses, it becomes important to study the 25 mutations in the ORF8 to develop a better understanding of the viral infectivity and for developing efficient therapeutic drugs against it [24] .IntroductionIn this present study, we identified the distinct mutations present across unique variants of the SARS-CoV-2 ORF8 and classified them according to their predicted effect on the host, i.e disease or neutral and the consequences on protein structural stability.", [["SARS", "DISEASE", 439, 443], ["ORF8", "GENE_OR_GENE_PRODUCT", 201, 205], ["SARS-CoV-2", "ORGANISM", 439, 449], ["ORF8", "GENE_OR_GENE_PRODUCT", 450, 454], ["ORF8", "DNA", 201, 205], ["SARS-CoV-2 ORF8", "DNA", 439, 454], ["SARS-CoV", "SPECIES", 439, 447], ["various strategies", "TREATMENT", 73, 91], ["the viral infectivity", "PROBLEM", 243, 264], ["efficient therapeutic drugs", "TREATMENT", 284, 311], ["this present study", "TEST", 344, 362], ["the distinct mutations", "PROBLEM", 378, 400], ["the SARS", "TEST", 435, 443], ["CoV", "TEST", 444, 447], ["disease", "PROBLEM", 528, 535], ["various host", "OBSERVATION_MODIFIER", 27, 39], ["viral infectivity", "OBSERVATION", 247, 264], ["distinct mutations", "OBSERVATION", 382, 400], ["structural stability", "OBSERVATION", 579, 599]]], ["Furthermore, we compared the ORF8 protein of SARS-CoV-2 with that of Bat-RaTG13-CoV and 30 Pangolin-CoV ORF8 and tried to determine the evolutionary relationships with respect to sequence similarity and discussed the rising concern on its originality.", [["ORF8", "GENE_OR_GENE_PRODUCT", 29, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["Bat-RaTG13-CoV", "ORGANISM", 69, 83], ["Pangolin-CoV ORF8", "ORGANISM", 91, 108], ["ORF8 protein", "PROTEIN", 29, 41], ["Bat-RaTG13", "PROTEIN", 69, 79], ["Pangolin", "PROTEIN", 91, 99], ["CoV ORF8", "DNA", 100, 108], ["SARS-CoV", "SPECIES", 45, 53], ["Bat-RaTG13-CoV", "SPECIES", 69, 83], ["Pangolin-CoV", "SPECIES", 91, 103], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["Bat-RaTG13", "TEST", 69, 79], ["CoV", "TEST", 80, 83]]], ["In addition we made a study on polarity and charge of the SARS-CoV-2 ORF8 mutations in two of its distinct domains and explored the possible effect on functionality changes.", [["ORF8", "GENE_OR_GENE_PRODUCT", 69, 73], ["SARS-CoV-2 ORF8 mutations", "DNA", 58, 83], ["a study", "TEST", 20, 27], ["the SARS", "TEST", 54, 62], ["CoV", "TEST", 63, 66], ["2 ORF8 mutations", "TREATMENT", 67, 83]]], ["Following this, we present the possible flow of mutations considering different geographical locations and chronological time scale simultaneously, validating with sequence-based and amino acid conservation-based phylogeny and thereby predicted the possible route 35 taken through the course of assimilation of mutations.Data: ORF8 of SARS-CoV-2As of 14th August, 2020, there were 10,314 complete genomes of SARS-CoV-2 available in the NCBI database and accordingly each genome contains one of the accessory proteins ORF8 and among them only 127 sequences were found to 40 be unique.", [["amino acid", "CHEMICAL", 183, 193], ["SARS", "DISEASE", 335, 339], ["amino acid", "CHEMICAL", 183, 193], ["amino acid", "AMINO_ACID", 183, 193], ["SARS-CoV-2As", "ORGANISM", 335, 347], ["SARS-CoV-2", "ORGANISM", 408, 418], ["ORF8", "GENE_OR_GENE_PRODUCT", 517, 521], ["SARS-CoV-2", "DNA", 408, 418], ["NCBI database", "DNA", 436, 449], ["accessory proteins", "PROTEIN", 498, 516], ["ORF8", "PROTEIN", 517, 521], ["SARS-CoV-2As", "SPECIES", 335, 347], ["SARS-CoV", "SPECIES", 408, 416], ["flow of mutations", "PROBLEM", 40, 57], ["amino acid conservation", "TREATMENT", 183, 206], ["mutations", "PROBLEM", 311, 320], ["SARS", "TEST", 335, 339], ["CoV", "TEST", 340, 343], ["SARS", "TEST", 408, 412], ["CoV", "TEST", 413, 416], ["the NCBI database", "TEST", 432, 449]]], ["The amino acid sequences of the ORF8 were exported in fasta format using file operations through Matlab [25] .", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["ORF8", "GENE_OR_GENE_PRODUCT", 32, 36], ["ORF8", "DNA", 32, 36], ["The amino acid sequences", "TEST", 0, 24]]], ["Among these 127 unique ORF8 protein sequences, only 96 sequences possess various mutations and the remaining sequences do not either possess any mutations or possess ambiguous mutations.", [["ORF8", "GENE_OR_GENE_PRODUCT", 23, 27], ["ORF8 protein sequences", "DNA", 23, 45], ["ORF8 protein sequences", "TEST", 23, 45], ["various mutations", "PROBLEM", 73, 90], ["the remaining sequences", "TEST", 95, 118], ["any mutations", "PROBLEM", 141, 154], ["ambiguous mutations", "PROBLEM", 166, 185]]], ["In this present study, we only concentrate on 96 ORF8 proteins, which are listed in Table 1 .", [["ORF8", "GENE_OR_GENE_PRODUCT", 49, 53], ["ORF8 proteins", "PROTEIN", 49, 62], ["this present study", "TEST", 3, 21]]], ["In order to find mutations, we hereby consider the reference ORF8 protein as the ORF8 sequence (YP 009724396.1) of the SARS-CoV-2 genome (NC 045512) from China: Wuhan [26] .", [["ORF8", "GENE_OR_GENE_PRODUCT", 61, 65], ["ORF8 protein", "PROTEIN", 61, 73], ["ORF8 sequence", "DNA", 81, 94], ["SARS-CoV-2 genome", "DNA", 119, 136], ["SARS-CoV", "SPECIES", 119, 127], ["the ORF8 sequence", "TEST", 77, 94], ["YP", "TEST", 96, 98], ["the SARS", "TEST", 115, 123], ["CoV", "TEST", 124, 127]]], ["45 Only the mutations L3F, T14A, K44R, F104Y and V114I are embedded in the ORF8 proteins of Bat-CoV.55Mutations in proteins are responsible for several genetic orders/disorders.", [["V114I", "GENE_OR_GENE_PRODUCT", 49, 54], ["ORF8", "GENE_OR_GENE_PRODUCT", 75, 79], ["Bat-CoV.55", "GENE_OR_GENE_PRODUCT", 92, 102], ["mutations L3F, T14A, K44R, F104Y and V114I", "DNA", 12, 54], ["ORF8 proteins", "PROTEIN", 75, 88], ["Bat-CoV.55", "PROTEIN", 92, 102], ["Mutations in proteins", "PROBLEM", 102, 123], ["disorders", "PROBLEM", 167, 176]]], ["Identifying these mutations requires novel detection methods, which have been reported in the literature [27] .", [["these mutations", "PROBLEM", 12, 27]]], ["In this study, each unique ORF8 sequence was aligned using NCBI protein p-blast and sometimes using omega blast suites to determine the mismatches and thereby the missense mutations (amino acid changes) are identified [28, 29] .", [["amino acid", "CHEMICAL", 183, 193], ["amino acid", "CHEMICAL", 183, 193], ["ORF8", "GENE_OR_GENE_PRODUCT", 27, 31], ["amino acid", "AMINO_ACID", 183, 193], ["ORF8 sequence", "DNA", 27, 40], ["NCBI protein p-blast", "DNA", 59, 79], ["this study", "TEST", 3, 13], ["omega blast suites", "TREATMENT", 100, 118], ["the mismatches", "PROBLEM", 132, 146], ["the missense mutations (amino acid changes", "PROBLEM", 159, 201]]], ["For the effect of identified mutations, a web-server 'Meta-SNP' was used and also for the structural effects of mutations, another web-server 'I-MUTANT' was used [30, 31] .", [["SNP", "CHEMICAL", 59, 62], ["Meta-SNP'", "DNA", 54, 63], ["identified mutations", "PROBLEM", 18, 38], ["a web-server 'Meta-SNP'", "TREATMENT", 40, 63], ["mutations", "PROBLEM", 112, 121]]], ["The web-server 60 'QUARK' was used for prediction of the secondary structure of ORF8 proteins [32, 33] .Amino Acids Compositions and PhylogenyA protein sequence of ORF8 is composed of twenty different amino acids with various frequencies.", [["Amino Acids", "CHEMICAL", 104, 115], ["amino acids", "CHEMICAL", 201, 212], ["Amino Acids", "CHEMICAL", 104, 115], ["amino acids", "CHEMICAL", 201, 212], ["ORF8", "GENE_OR_GENE_PRODUCT", 80, 84], ["ORF8", "GENE_OR_GENE_PRODUCT", 164, 168], ["amino acids", "AMINO_ACID", 201, 212], ["ORF8 proteins", "PROTEIN", 80, 93], ["ORF8", "PROTEIN", 164, 168], ["ORF8 proteins", "TEST", 80, 93], ["Amino Acids Compositions", "TREATMENT", 104, 128], ["PhylogenyA protein sequence", "TEST", 133, 160], ["twenty different amino acids", "TREATMENT", 184, 212]]], ["Per-residue disorder distribution in sequences of query proteins was evaluated by PONDR-VSL2 [40] , which is one of the more accurate standalone disorder predictors [41, 42, 43] .", [["Per-residue disorder", "DISEASE", 0, 20], ["PONDR", "PROTEIN", 82, 87], ["Per-residue disorder distribution", "PROBLEM", 0, 33], ["query proteins", "TEST", 50, 64]]], ["The per-residue disorder predisposition scores are on a scale from 0 to 1, where values of 0 indicate fully ordered residues, and values of 1 indicate fully disordered residues.", [["per-residue disorder", "DISEASE", 4, 24], ["The per-residue disorder predisposition scores", "PROBLEM", 0, 46], ["a scale", "TEST", 54, 61], ["fully ordered residues", "PROBLEM", 102, 124], ["values", "TEST", 130, 136], ["fully disordered residues", "PROBLEM", 151, 176]]], ["Values above the threshold of 0.5 are considered disordered residues, whereas residues with disorder scores between 0.25 and 0.5 are considered highly flexible, and residues with disorder scores between 0.1 and 0.25 are taken as moderately flexible.ORF8 of SARS-CoV-2The SARS-CoV-2 ORF8 protein (YP 009724396) is a 121 amino acid long protein which has an N-terminal hydrophobic signal peptide (1-15 aa) and an ORF8 chain (16-121 aa).", [["disorder", "DISEASE", 92, 100], ["disorder", "DISEASE", 179, 187], ["SARS", "DISEASE", 257, 261], ["amino acid", "CHEMICAL", 319, 329], ["amino acid", "CHEMICAL", 319, 329], ["N", "CHEMICAL", 356, 357], ["ORF8", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARS-CoV-2", "ORGANISM", 257, 267], ["SARS-CoV-2", "ORGANISM", 271, 281], ["ORF8", "GENE_OR_GENE_PRODUCT", 282, 286], ["ORF8", "PROTEIN", 249, 253], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 271, 294], ["YP 009724396", "PROTEIN", 296, 308], ["121 amino acid long protein", "PROTEIN", 315, 342], ["ORF8 chain", "PROTEIN", 411, 421], ["SARS-CoV", "SPECIES", 257, 265], ["SARS-CoV", "SPECIES", 271, 279], ["Values", "TEST", 0, 6], ["disordered residues", "PROBLEM", 49, 68], ["disorder scores", "TEST", 92, 107], ["disorder scores", "PROBLEM", 179, 194], ["SARS", "PROBLEM", 257, 261], ["CoV", "TEST", 262, 265], ["The SARS", "TEST", 267, 275], ["CoV", "TEST", 276, 279], ["a 121 amino acid long protein", "PROBLEM", 313, 342], ["terminal hydrophobic signal peptide", "PROBLEM", 358, 393], ["an ORF8 chain", "TEST", 408, 421]]], ["A schematic representation of ORF8 (SARS-CoV-2) is presented in Fig.2 .", [["ORF8", "GENE_OR_GENE_PRODUCT", 30, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["ORF8", "DNA", 30, 34], ["Fig.2", "DNA", 64, 69], ["ORF8", "TEST", 30, 34]]], ["It was observed that the total number (63) of hydrophilic residues is more than that (58) of the hydrophobic residues.ORF8 of SARS-CoV-2However, from the predicted secondary structure (Fig.3) , it was found that the highest solubility score is four, indicating that although hydrophilic residues are higher in number, however, they are not highly exposed to the external environment since they are folded inside of the protein therefore this protein is poorly soluble.ORF8 of SARS-CoV-2We further predicted the secondary structure as well as solvent accessibility of ORF8 proteins of SARS-CoV-2, Bat-85RaTG13-CoV and Pangolin-CoV using the ab-initio webserver QUARK (Fig.3 ) and tried to perceive the differences.", [["SARS", "DISEASE", 126, 130], ["ORF8", "GENE_OR_GENE_PRODUCT", 118, 122], ["SARS-CoV", "ORGANISM", 126, 134], ["ORF8", "GENE_OR_GENE_PRODUCT", 468, 472], ["SARS-CoV", "ORGANISM", 476, 484], ["ORF8", "GENE_OR_GENE_PRODUCT", 567, 571], ["SARS-CoV-2", "ORGANISM", 584, 594], ["Bat-85RaTG13-CoV", "ORGANISM", 596, 612], ["Pangolin-CoV", "ORGANISM", 617, 629], ["ORF8", "PROTEIN", 118, 122], ["SARS-CoV-2However", "DNA", 126, 143], ["ORF8", "PROTEIN", 468, 472], ["SARS-CoV-2We", "DNA", 476, 488], ["ORF8 proteins", "PROTEIN", 567, 580], ["Bat-85RaTG13", "PROTEIN", 596, 608], ["CoV", "PROTEIN", 609, 612], ["Pangolin", "PROTEIN", 617, 625], ["CoV", "PROTEIN", 626, 629], ["ab-initio webserver QUARK", "PROTEIN", 640, 665], ["Fig.3", "PROTEIN", 667, 672], ["SARS-CoV-2However", "SPECIES", 126, 143], ["SARS-CoV-2We", "SPECIES", 476, 488], ["SARS-CoV", "SPECIES", 584, 592], ["Bat-85RaTG13-CoV", "SPECIES", 596, 612], ["Pangolin-CoV", "SPECIES", 617, 629], ["hydrophilic residues", "PROBLEM", 46, 66], ["the hydrophobic residues", "PROBLEM", 93, 117], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["the highest solubility score", "TEST", 212, 240], ["hydrophilic residues", "PROBLEM", 275, 295], ["SARS", "PROBLEM", 476, 480], ["CoV", "TEST", 481, 484], ["SARS", "TEST", 584, 588], ["CoV", "TEST", 589, 592], ["Bat-85RaTG13", "TEST", 596, 608], ["CoV", "TEST", 609, 612], ["Pangolin", "TREATMENT", 617, 625], ["the ab-initio webserver QUARK", "TREATMENT", 636, 665], ["hydrophilic residues", "OBSERVATION", 46, 66], ["hydrophobic residues", "OBSERVATION", 97, 117], ["SARS", "OBSERVATION", 126, 130], ["hydrophilic residues", "OBSERVATION", 275, 295], ["higher", "OBSERVATION_MODIFIER", 300, 306], ["secondary structure", "OBSERVATION", 511, 530]]], ["Comparing the ORF8 secondary structures of SARS-CoV-2, Bat-RaTG13-CoV and Pangolin-CoV, the following changes are found at four different locations as presented in Table 2 .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["Bat-RaTG13-CoV", "GENE_OR_GENE_PRODUCT", 55, 69], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 74, 86], ["ORF8", "PROTEIN", 14, 18], ["Bat-RaTG13", "DNA", 55, 65], ["CoV", "DNA", 66, 69], ["Pangolin", "DNA", 74, 82], ["CoV", "DNA", 83, 86], ["SARS-CoV", "SPECIES", 43, 51], ["Bat-RaTG13-CoV", "SPECIES", 55, 69], ["Pangolin-CoV", "SPECIES", 74, 86], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["Bat-RaTG13", "TEST", 55, 65], ["SARS", "OBSERVATION", 43, 47]]], ["Table 2 , it is inferred that the secondary structures of ORF8 (SARS-CoV-2) and that of Bat-RaTG13 are much closer related than the ORF8 of Pangolin-CoV.", [["ORF8", "GENE_OR_GENE_PRODUCT", 58, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["Bat-RaTG13", "GENE_OR_GENE_PRODUCT", 88, 98], ["ORF8", "GENE_OR_GENE_PRODUCT", 132, 136], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 140, 152], ["ORF8", "PROTEIN", 58, 62], ["Bat-RaTG13", "PROTEIN", 88, 98], ["ORF8", "PROTEIN", 132, 136], ["Pangolin", "PROTEIN", 140, 148], ["CoV", "PROTEIN", 149, 152], ["Pangolin-CoV", "SPECIES", 140, 152], ["ORF8", "TEST", 58, 62]]], ["90 It was obtained that the largest conserved region in the ORF8 protein of SARS-CoV-2 is 'PFTINCQE' (in D2), eight amino acids long (Table 3 ) as seen in Fig.4 .", [["SARS", "DISEASE", 76, 80], ["amino acids", "CHEMICAL", 116, 127], ["amino acids", "CHEMICAL", 116, 127], ["ORF8", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 76, 86], ["amino acids", "AMINO_ACID", 116, 127], ["ORF8 protein", "PROTEIN", 60, 72], ["D2", "PROTEIN", 105, 107], ["Fig.4", "PROTEIN", 155, 160], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["eight amino acids", "TREATMENT", 110, 127], ["largest", "OBSERVATION_MODIFIER", 28, 35]]], ["It turned out that the 6.6% region is 100% evolutionary conserved across all 96 distinct variants of the 121 amino acid long ORF8 protein.", [["amino acid", "CHEMICAL", 109, 119], ["amino acid", "CHEMICAL", 109, 119], ["amino acid", "AMINO_ACID", 109, 119], ["ORF8", "GENE_OR_GENE_PRODUCT", 125, 129], ["121 amino acid long ORF8 protein", "PROTEIN", 105, 137], ["amino acid", "TEST", 109, 119]]], ["Most of the conserved regions in SARS-CoV-2 ORF8 (Table 3 and Fig.4 ) lie around helix-coil and strand-coil junctions signifying the functional importance of these regions.", [["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 33, 48], ["Table 3", "GENE_OR_GENE_PRODUCT", 50, 57], ["Fig.4", "GENE_OR_GENE_PRODUCT", 62, 67], ["SARS-CoV-2 ORF8", "DNA", 33, 48], ["Fig.4", "DNA", 62, 67], ["helix-coil", "DNA", 81, 91], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["coil and strand-coil junctions", "TREATMENT", 87, 117], ["SARS", "OBSERVATION", 33, 37]]], ["Helix regions also have conserved amino acids.", [["amino acids", "CHEMICAL", 34, 45], ["amino acids", "CHEMICAL", 34, 45], ["amino acids", "AMINO_ACID", 34, 45], ["amino acids", "TREATMENT", 34, 45], ["amino acids", "OBSERVATION", 34, 45]]], ["Therefore, these regions are conserved in nature.85The ORF8 protein of SARS-CoV-2 has only 55.4% nucleotide similarity and 30% protein identity with that of SARS-CoV as shown in Fig.5 .", [["SARS", "DISEASE", 157, 161], ["nucleotide", "CHEMICAL", 97, 107], ["ORF8", "GENE_OR_GENE_PRODUCT", 55, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 71, 81], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 157, 165], ["ORF8 protein", "PROTEIN", 55, 67], ["Fig.5", "PROTEIN", 178, 183], ["SARS-CoV", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 157, 165], ["The ORF8 protein", "TEST", 51, 67], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["nucleotide similarity", "TEST", 97, 118], ["protein identity", "TEST", 127, 143], ["SARS", "PROBLEM", 157, 161], ["CoV", "PROBLEM", 162, 165]]], ["Although the SARS-CoV-2 ORF8 has differentiating genome characteristics but exhibit high functional similarity with that of SARS-CoV ORF8ab:100\u2022 The SARS-CoV ORF8ab original protein was found to have an N-terminal hydrophobic signal sequence that directs its transport to the endoplasmic reticulum (ER).", [["endoplasmic reticulum", "ANATOMY", 276, 297], ["ER", "ANATOMY", 299, 301], ["SARS", "DISEASE", 124, 128], ["N", "CHEMICAL", 203, 204], ["SARS-CoV-2", "ORGANISM", 13, 23], ["ORF8", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV", "ORGANISM", 124, 132], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 276, 297], ["ER", "GENE_OR_GENE_PRODUCT", 299, 301], ["SARS-CoV-2 ORF8", "DNA", 13, 28], ["SARS-CoV ORF8ab original protein", "PROTEIN", 149, 181], ["N-terminal hydrophobic signal sequence", "PROTEIN", 203, 241], ["ER", "PROTEIN", 299, 301], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 149, 157], ["the SARS", "TEST", 9, 17], ["CoV", "TEST", 18, 21], ["SARS", "TEST", 124, 128], ["The SARS", "TEST", 145, 153], ["CoV ORF8ab original protein", "TEST", 154, 181], ["an N-terminal hydrophobic signal sequence", "PROBLEM", 200, 241], ["endoplasmic reticulum", "ANATOMY", 276, 297]]], ["However, after deletion of 29 nucleotides, which split the ORF8ab protein into ORF8a and ORF8b, it was found that only ORF8a was able to translocate to the ER while ORF8b remained distributed throughout the cell.", [["ER", "ANATOMY", 156, 158], ["cell", "ANATOMY", 207, 211], ["nucleotides", "CHEMICAL", 30, 41], ["ORF8ab", "GENE_OR_GENE_PRODUCT", 59, 65], ["ORF8a", "GENE_OR_GENE_PRODUCT", 79, 84], ["ORF8b", "GENE_OR_GENE_PRODUCT", 89, 94], ["ORF8a", "GENE_OR_GENE_PRODUCT", 119, 124], ["ER", "GENE_OR_GENE_PRODUCT", 156, 158], ["ORF8b", "GENE_OR_GENE_PRODUCT", 165, 170], ["cell", "CELL", 207, 211], ["ORF8ab protein", "PROTEIN", 59, 73], ["ORF8a", "PROTEIN", 79, 84], ["ORF8b", "PROTEIN", 89, 94], ["ORF8a", "PROTEIN", 119, 124], ["ER", "PROTEIN", 156, 158], ["ORF8b", "PROTEIN", 165, 170], ["deletion of 29 nucleotides", "PROBLEM", 15, 41]]], ["Likewise, the SARS-CoV-2 ORF8 protein also contains an N-terminal hydrophobic signal peptide (1-15 aa), which is involved in the same function.105\u2022 The ER has an internal oxidative environment akin to other organelles, which is necessary for protein folding and oxidation processes.", [["organelles", "ANATOMY", 207, 217], ["SARS", "DISEASE", 14, 18], ["N", "CHEMICAL", 55, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["ORF8", "GENE_OR_GENE_PRODUCT", 25, 29], ["ER", "GENE_OR_GENE_PRODUCT", 152, 154], ["organelles", "CELLULAR_COMPONENT", 207, 217], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 14, 37], ["ER", "PROTEIN", 152, 154], ["SARS-CoV", "SPECIES", 14, 22], ["the SARS", "TEST", 10, 18], ["CoV", "TEST", 19, 22], ["ORF8 protein", "TEST", 25, 37], ["an N-terminal hydrophobic signal peptide", "PROBLEM", 52, 92], ["protein folding and oxidation processes", "PROBLEM", 242, 281]]], ["Due to this oxidative environment, formation of intra or inter-molecular cysteine bonds between unpaired cysteine residues takes place as the SARS-CoV ORF8ab protein is an ER resident protein and there are ten cysteine residues present, which exhibit disulphide linkages and form homomultimeric complexes within the ER.105Similarly, the ORF8 of SARS-CoV-2 has also seven cysteines, which may be expected to form these types of disulphide 110 linkages.105\u2022 The SARS-CoV ORF8ab is characterized by the presence of an asparagine residue at position 81 with the Asn-Val-Thr motif responsible for N-linked glycosylation, whereas SARS-CoV-2 ORF8 has an N-linked glycosylation site at Asn (78) and the motif is Asn-Tyr-Thr.105\u2022 The SARS-CoV-2 ORF8 is found to have both protein-protein and protein-DNA interactions while SARS-CoV115ORF8ab shows only protein-protein interactions.115Further, it was found that the ORF8 protein of SARS-CoV-2 is very much similar (95%) to that of Bat-CoV RaTG13 on the basis of sequence similarity as well as on the basis of phylogenetic relationships as shown in Fig.6 .", [["ER", "ANATOMY", 316, 318], ["cysteine", "CHEMICAL", 105, 113], ["SARS", "DISEASE", 345, 349], ["asparagine", "CHEMICAL", 515, 525], ["SARS", "DISEASE", 922, 926], ["cysteine", "CHEMICAL", 73, 81], ["cysteine", "CHEMICAL", 105, 113], ["cysteine", "CHEMICAL", 210, 218], ["disulphide", "CHEMICAL", 251, 261], ["cysteines", "CHEMICAL", 371, 380], ["disulphide", "CHEMICAL", 427, 437], ["asparagine", "CHEMICAL", 515, 525], ["Asn", "CHEMICAL", 558, 561], ["Val", "CHEMICAL", 562, 565], ["Thr", "CHEMICAL", 566, 569], ["N", "CHEMICAL", 592, 593], ["N", "CHEMICAL", 647, 648], ["Asn", "CHEMICAL", 678, 681], ["Thr", "CHEMICAL", 712, 715], ["cysteine", "AMINO_ACID", 73, 81], ["cysteine", "AMINO_ACID", 105, 113], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["ER", "GENE_OR_GENE_PRODUCT", 172, 174], ["ER", "GENE_OR_GENE_PRODUCT", 316, 318], ["SARS-CoV-2", "ORGANISM", 345, 355], ["disulphide 110 linkages", "SIMPLE_CHEMICAL", 427, 450], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 460, 468], ["asparagine", "AMINO_ACID", 515, 525], ["position 81", "AMINO_ACID", 537, 548], ["Thr motif", "AMINO_ACID", 566, 575], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 624, 634], ["ORF8", "GENE_OR_GENE_PRODUCT", 635, 639], ["Asn (78)", "AMINO_ACID", 678, 686], ["Asn-Tyr-Thr", "GENE_OR_GENE_PRODUCT", 704, 715], ["ORF8", "GENE_OR_GENE_PRODUCT", 736, 740], ["DNA", "CELLULAR_COMPONENT", 791, 794], ["SARS-CoV115ORF8ab", "GENE_OR_GENE_PRODUCT", 814, 831], ["ORF8", "GENE_OR_GENE_PRODUCT", 906, 910], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 922, 932], ["Bat-CoV RaTG13", "GENE_OR_GENE_PRODUCT", 971, 985], ["SARS-CoV ORF8ab protein", "PROTEIN", 142, 165], ["ER resident protein", "PROTEIN", 172, 191], ["homomultimeric complexes", "PROTEIN", 280, 304], ["ER", "PROTEIN", 316, 318], ["ORF8", "PROTEIN", 337, 341], ["SARS-CoV ORF8ab", "DNA", 460, 475], ["SARS-CoV-2 ORF8", "PROTEIN", 624, 639], ["N-linked glycosylation site", "PROTEIN", 647, 674], ["Asn-Tyr", "PROTEIN", 704, 711], ["SARS-CoV-2 ORF8", "DNA", 725, 740], ["SARS-CoV115ORF8ab", "PROTEIN", 814, 831], ["ORF8 protein", "PROTEIN", 906, 918], ["Bat-CoV RaTG13", "PROTEIN", 971, 985], ["Fig.6", "PROTEIN", 1088, 1093], ["SARS-CoV", "SPECIES", 142, 150], ["SARS-CoV", "SPECIES", 345, 353], ["SARS-CoV", "SPECIES", 460, 468], ["SARS-CoV", "SPECIES", 725, 733], ["SARS-CoV", "SPECIES", 922, 930], ["Bat-CoV", "SPECIES", 971, 978], ["this oxidative environment", "PROBLEM", 7, 33], ["intra or inter-molecular cysteine bonds", "PROBLEM", 48, 87], ["unpaired cysteine residues", "PROBLEM", 96, 122], ["the SARS", "TEST", 138, 146], ["ten cysteine residues", "PROBLEM", 206, 227], ["disulphide linkages", "PROBLEM", 251, 270], ["SARS", "PROBLEM", 345, 349], ["CoV", "TEST", 350, 353], ["The SARS", "TEST", 456, 464], ["an asparagine residue at position", "PROBLEM", 512, 545], ["the Asn", "TEST", 554, 561], ["N", "PROBLEM", 592, 593], ["linked glycosylation", "PROBLEM", 594, 614], ["SARS", "TEST", 624, 628], ["CoV", "TEST", 629, 632], ["an N-linked glycosylation site", "PROBLEM", 644, 674], ["The SARS", "TEST", 721, 729], ["CoV", "TEST", 730, 733], ["protein", "TEST", 763, 770], ["protein", "TEST", 783, 790], ["SARS-", "TEST", 814, 819], ["CoV115ORF8ab", "TEST", 819, 831], ["protein", "TEST", 843, 850], ["the ORF8 protein", "TEST", 902, 918], ["SARS", "TEST", 922, 926], ["CoV", "TEST", 927, 930], ["Bat-CoV RaTG13", "TEST", 971, 985], ["cysteine residues", "OBSERVATION", 105, 122], ["cysteine residues", "OBSERVATION", 210, 227], ["disulphide linkages", "OBSERVATION", 251, 270], ["seven cysteines", "OBSERVATION", 365, 380], ["asparagine residue", "OBSERVATION", 515, 533]]], ["As we can see from the sequence alignment, there are only six amino acid differences between the SARS-CoV-2 ORF8115and Bat-CoV RaTG13.", [["amino acid", "CHEMICAL", 62, 72], ["amino acid", "CHEMICAL", 62, 72], ["amino acid", "AMINO_ACID", 62, 72], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 119, 126], ["SARS-CoV-2 ORF8115and Bat-CoV RaTG13", "DNA", 97, 133], ["Bat-CoV", "SPECIES", 119, 126], ["the sequence alignment", "TEST", 19, 41], ["six amino acid differences", "PROBLEM", 58, 84], ["the SARS", "TEST", 93, 101], ["CoV", "TEST", 102, 105], ["Bat", "TEST", 119, 122]]], ["All of these mutations in the ORF8 protein with respect to the reference ORF8 sequence of 120 Bat-RaTG13 were found to be neutral type as predicted through webserver Meta-SNP and all of them had a decreasing effect on stability of the protein as determined using the server (I-MUTANT).115We have also aligned the Pangolin-CoV ORF8 sequence with that of SARS-CoV-2 and found that there is a sequence similarity of 88%, as depicted in Fig.7 .", [["SNP", "CHEMICAL", 171, 174], ["ORF8", "GENE_OR_GENE_PRODUCT", 30, 34], ["ORF8", "GENE_OR_GENE_PRODUCT", 73, 77], ["Bat-RaTG13", "GENE_OR_GENE_PRODUCT", 94, 104], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 313, 325], ["SARS-CoV-2", "ORGANISM", 353, 363], ["ORF8 protein", "PROTEIN", 30, 42], ["ORF8 sequence", "DNA", 73, 86], ["120 Bat-RaTG13", "DNA", 90, 104], ["webserver Meta-SNP", "DNA", 156, 174], ["Pangolin-CoV ORF8 sequence", "DNA", 313, 339], ["Fig.7", "PROTEIN", 433, 438], ["Pangolin-CoV", "SPECIES", 313, 325], ["SARS-CoV", "SPECIES", 353, 361], ["these mutations", "PROBLEM", 7, 22], ["SNP", "TREATMENT", 171, 174], ["SARS", "TEST", 353, 357], ["CoV", "TEST", 358, 361], ["a sequence similarity", "TEST", 388, 409], ["mutations", "OBSERVATION", 13, 22], ["decreasing", "OBSERVATION_MODIFIER", 197, 207]]], ["We observed a difference of 15 amino acid residues between the Pangolin-CoV and the SARS-CoV-2 ORF8.", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 63, 75], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 84, 99], ["Pangolin", "PROTEIN", 63, 71], ["CoV", "PROTEIN", 72, 75], ["SARS-CoV-2 ORF8", "PROTEIN", 84, 99], ["Pangolin-CoV", "SPECIES", 63, 75], ["SARS-CoV", "SPECIES", 84, 92], ["15 amino acid residues", "PROBLEM", 28, 50], ["the Pangolin", "TEST", 59, 71], ["the SARS", "TEST", 80, 88], ["CoV", "TEST", 89, 92]]], ["It was 125 analysed that in both the Bat-CoV RaTG13 and the Pangolin-CoV ORF8 protein the mutations L10I, V65A and S84L are occurred.", [["Bat-CoV", "ORGANISM", 37, 44], ["RaTG13", "GENE_OR_GENE_PRODUCT", 45, 51], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 60, 77], ["Bat-CoV RaTG13", "PROTEIN", 37, 51], ["Pangolin-CoV ORF8 protein", "PROTEIN", 60, 85], ["Bat-CoV", "SPECIES", 37, 44], ["Pangolin-CoV", "SPECIES", 60, 72], ["the Bat-CoV RaTG13", "TEST", 33, 51], ["the Pangolin", "TEST", 56, 68]]], ["So, it can be hypothesised that SARS-CoV-2 may have originated from Pangolin-CoV or Bat-CoV RaTG13115ORF8.115Also, the comparison of frequencies of the hydrophobic, hydrophilic and charged amino acids was performed, which are present among the four different ORF8 proteins of SARS-CoV, SARS-CoV-2, Bat RaTG13-CoV and Pangolin-CoV was 130 made.", [["SARS", "DISEASE", 32, 36], ["amino acids", "CHEMICAL", 189, 200], ["SARS", "DISEASE", 276, 280], ["amino acids", "CHEMICAL", 189, 200], ["SARS-CoV-2", "ORGANISM", 32, 42], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 68, 80], ["Bat-CoV RaTG13115ORF8.115", "ORGANISM", 84, 109], ["amino acids", "AMINO_ACID", 189, 200], ["ORF8", "GENE_OR_GENE_PRODUCT", 259, 263], ["SARS-CoV", "ORGANISM", 276, 284], ["SARS-CoV-2", "ORGANISM", 286, 296], ["Bat RaTG13-CoV", "ORGANISM", 298, 312], ["Pangolin-CoV", "ORGANISM", 317, 329], ["ORF8 proteins", "PROTEIN", 259, 272], ["Pangolin-CoV", "SPECIES", 68, 80], ["Bat-CoV", "SPECIES", 84, 91], ["SARS-CoV", "SPECIES", 276, 284], ["SARS-CoV", "SPECIES", 286, 294], ["Bat RaTG13-CoV", "SPECIES", 298, 312], ["Pangolin-CoV", "SPECIES", 317, 329], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["charged amino acids", "TEST", 181, 200], ["SARS", "TEST", 276, 280], ["CoV", "TEST", 281, 284], ["SARS", "TEST", 286, 290], ["CoV", "TEST", 291, 294], ["Bat RaTG13", "TEST", 298, 308], ["CoV", "TEST", 309, 312], ["Pangolin", "TEST", 317, 325], ["CoV", "TEST", 326, 329]]], ["As seen in Table 4 , SARS-CoV-2 ORF8, SARS-CoV ORF8ab, Bat-CoV RaTG13 ORF8 and Pangolin-CoV ORF8, are all similar in terms of hydrophobicity and hydrophilicity and it is known that hydrophobicity and hydrophilicity play an important role in protein folding which determines the tertiary structure of the protein and thereby affect the function.", [["SARS-CoV-2 ORF8", "ORGANISM", 21, 36], ["SARS-CoV ORF8ab", "ORGANISM", 38, 53], ["Bat-CoV", "ORGANISM", 55, 62], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 79, 96], ["SARS-CoV-2 ORF8, SARS-CoV ORF8ab", "DNA", 21, 53], ["Bat-CoV RaTG13 ORF8", "DNA", 55, 74], ["Pangolin", "DNA", 79, 87], ["CoV ORF8", "DNA", 88, 96], ["SARS-CoV", "SPECIES", 38, 46], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["ORF8", "TEST", 32, 36], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["ORF8ab", "TEST", 47, 53], ["Bat-", "TEST", 55, 59], ["CoV", "TEST", 59, 62], ["ORF8", "TEST", 70, 74], ["Pangolin", "TEST", 79, 87], ["hydrophilicity", "PROBLEM", 145, 159], ["hydrophobicity and hydrophilicity", "PROBLEM", 181, 214], ["protein folding", "PROBLEM", 241, 256], ["hydrophobicity", "OBSERVATION", 126, 140], ["hydrophilicity", "OBSERVATION", 145, 159], ["hydrophobicity", "OBSERVATION_MODIFIER", 181, 195], ["hydrophilicity", "OBSERVATION_MODIFIER", 200, 214], ["protein folding", "OBSERVATION", 241, 256]]], ["The ORF8 sequences of SARS-CoV-2, Bat-CoV RaTG13 and Pangolin-CoV have almost the same positive and negative charged amino acids, therefore we can say that probably they have similar kind of electrostatic and hydrophobic interactions, 135 which also contribute to the functionality of the proteins.", [["amino acids", "CHEMICAL", 117, 128], ["amino acids", "CHEMICAL", 117, 128], ["ORF8", "GENE_OR_GENE_PRODUCT", 4, 8], ["SARS-CoV-2", "ORGANISM", 22, 32], ["Bat-CoV RaTG13", "ORGANISM", 34, 48], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 53, 65], ["amino acids", "AMINO_ACID", 117, 128], ["ORF8 sequences", "DNA", 4, 18], ["Pangolin-CoV", "DNA", 53, 65], ["SARS-CoV", "SPECIES", 22, 30], ["Bat-CoV", "SPECIES", 34, 41], ["Pangolin-CoV", "SPECIES", 53, 65], ["The ORF8 sequences", "TEST", 0, 18], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["Bat-CoV RaTG13", "TEST", 34, 48], ["Pangolin", "TEST", 53, 61], ["electrostatic and hydrophobic interactions", "PROBLEM", 191, 233], ["electrostatic", "OBSERVATION", 191, 204], ["hydrophobic interactions", "OBSERVATION", 209, 233]]], ["Again, for the SARS-CoV ORF8ab it was found that the number of positive and negative charged amino acids are closely similar to the SARS-CoV-2 ORF8.", [["SARS", "DISEASE", 15, 19], ["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["SARS-CoV ORF8ab", "GENE_OR_GENE_PRODUCT", 15, 30], ["amino acids", "AMINO_ACID", 93, 104], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 132, 147], ["SARS-CoV ORF8ab", "DNA", 15, 30], ["SARS-CoV-2 ORF8", "DNA", 132, 147], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 132, 140], ["charged amino acids", "TREATMENT", 85, 104], ["the SARS", "TEST", 128, 136], ["CoV", "TEST", 137, 140]]], ["Although, the SARS-CoV sequence bears less similarity with the SARS-CoV-2 but they are probably similar in terms of electrostatic and hydrophobic interactions.115Furthermore, we analysed the three ORF8 sequences and checked for their molecular weight, isoelectric point (PI), 140 hydropathy, net charge and extinction coefficient using a peptide property calculator (https : //pepcalc.com/) and found that all the properties are almost identical, which shows that the ORF8 protein of Bat-CoV RaTG13, Pangolin-CoV and SARS-CoV-2 are very closely related from the chemical aspects of amino acid residues (Fig.8 ). indicating that ORF8 of the Pangolin-CoV is more negatively charged as compared to the SARS-CoV-2 ORF8.", [["SARS", "DISEASE", 14, 18], ["SARS", "DISEASE", 63, 67], ["amino acid", "CHEMICAL", 582, 592], ["amino acid", "CHEMICAL", 582, 592], ["ORF8", "GENE_OR_GENE_PRODUCT", 468, 472], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 484, 491], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 500, 512], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 517, 527], ["amino acid", "AMINO_ACID", 582, 592], ["ORF8", "GENE_OR_GENE_PRODUCT", 628, 632], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 640, 652], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 699, 714], ["SARS-CoV sequence", "DNA", 14, 31], ["ORF8 sequences", "DNA", 197, 211], ["pepcalc.com", "PROTEIN", 377, 388], ["ORF8 protein", "PROTEIN", 468, 480], ["Bat", "PROTEIN", 484, 487], ["CoV RaTG13", "PROTEIN", 488, 498], ["Pangolin", "PROTEIN", 500, 508], ["CoV", "PROTEIN", 509, 512], ["CoV", "PROTEIN", 522, 525], ["ORF8", "PROTEIN", 628, 632], ["Pangolin", "PROTEIN", 640, 648], ["CoV", "PROTEIN", 649, 652], ["SARS-CoV-2 ORF8", "DNA", 699, 714], ["SARS-CoV", "SPECIES", 14, 22], ["Bat-CoV", "SPECIES", 484, 491], ["Pangolin-CoV", "SPECIES", 500, 512], ["SARS-CoV", "SPECIES", 517, 525], ["Pangolin-CoV", "SPECIES", 640, 652], ["SARS-CoV", "SPECIES", 699, 707], ["the SARS-CoV sequence", "TEST", 10, 31], ["the SARS", "TEST", 59, 67], ["the three ORF8 sequences", "TEST", 187, 211], ["their molecular weight", "TEST", 228, 250], ["net charge", "PROBLEM", 292, 302], ["the ORF8 protein", "TEST", 464, 480], ["Bat", "TEST", 484, 487], ["CoV", "TEST", 488, 491], ["RaTG13", "TEST", 492, 498], ["Pangolin", "TEST", 500, 508], ["CoV", "TEST", 509, 512], ["SARS", "TEST", 517, 521], ["CoV", "TEST", 522, 525], ["amino acid residues", "TREATMENT", 582, 601], ["the Pangolin-CoV", "PROBLEM", 636, 652], ["the SARS", "TEST", 695, 703], ["CoV", "TEST", 704, 707], ["probably", "UNCERTAINTY", 87, 95], ["similar", "OBSERVATION_MODIFIER", 96, 103], ["electrostatic", "OBSERVATION", 116, 129], ["hydrophobic interactions", "OBSERVATION", 134, 158], ["amino acid", "OBSERVATION", 582, 592]]], ["Also, since these three proteins have a similar molecular weight, PI, extinction coefficient and nature of hydropathy plot, it would be difficult to differentiate these three proteins by biophysical techniques on the basis of these properties.115The ORF8 of SARS-CoV-2 is significantly different from the ORF8 of Pangolin-CoV and it seems that the ORF8 150 protein (SARS-CoV-2) is imitating the properties as well the structure of ORF8 of Bat RaTG13-CoV as a blueprint.115The differences between the ORF8 of SARS-CoV-2 and Bat-CoV RaTG13 and Pangolin-CoV can be further demonstrated by the analysis of the per-residue intrinsic disorder predispositions of these proteins.", [["SARS", "DISEASE", 258, 262], ["SARS", "DISEASE", 508, 512], ["disorder", "DISEASE", 628, 636], ["PI", "SIMPLE_CHEMICAL", 66, 68], ["ORF8", "GENE_OR_GENE_PRODUCT", 250, 254], ["SARS-CoV-2", "ORGANISM", 258, 268], ["ORF8", "GENE_OR_GENE_PRODUCT", 305, 309], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 313, 325], ["ORF8 150", "GENE_OR_GENE_PRODUCT", 348, 356], ["ORF8", "GENE_OR_GENE_PRODUCT", 431, 435], ["RaTG13-CoV", "GENE_OR_GENE_PRODUCT", 443, 453], ["ORF8", "GENE_OR_GENE_PRODUCT", 500, 504], ["SARS-CoV-2", "ORGANISM", 508, 518], ["Bat-CoV RaTG13", "ORGANISM", 523, 537], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 542, 554], ["ORF8", "PROTEIN", 250, 254], ["ORF8", "DNA", 305, 309], ["ORF8 150 protein", "PROTEIN", 348, 364], ["CoV", "PROTEIN", 371, 374], ["ORF8", "PROTEIN", 431, 435], ["Bat RaTG13", "PROTEIN", 439, 449], ["CoV", "PROTEIN", 450, 453], ["ORF8", "DNA", 500, 504], ["SARS-CoV", "SPECIES", 258, 266], ["Pangolin-CoV", "SPECIES", 313, 325], ["Bat RaTG13-CoV", "SPECIES", 439, 453], ["SARS-CoV", "SPECIES", 508, 516], ["Bat-CoV", "SPECIES", 523, 530], ["Pangolin-CoV", "SPECIES", 542, 554], ["hydropathy plot", "PROBLEM", 107, 122], ["biophysical techniques", "TEST", 187, 209], ["SARS", "TEST", 258, 262], ["CoV", "TEST", 263, 266], ["the ORF8", "TEST", 344, 352], ["protein", "TEST", 357, 364], ["SARS", "TEST", 366, 370], ["CoV", "TEST", 371, 374], ["Bat RaTG13", "TEST", 439, 449], ["SARS", "TEST", 508, 512], ["CoV", "TEST", 513, 516], ["Bat-CoV RaTG13", "TEST", 523, 537], ["the analysis", "TEST", 586, 598], ["the per-residue intrinsic disorder", "PROBLEM", 602, 636], ["these proteins", "PROBLEM", 656, 670], ["hydropathy plot", "OBSERVATION", 107, 122], ["significantly different", "OBSERVATION_MODIFIER", 272, 295]]], ["Results of this analysis are shown in Fig.9A , which illustrates that the intrinsic disorder propensity of the ORF8 from SARS-CoV-2 is closer to that of the ORF8 from Bat-CoV RaTG13 than to the disorder potential of ORF8 from Pangolin-CoV.", [["disorder", "DISEASE", 84, 92], ["SARS", "DISEASE", 121, 125], ["disorder", "DISEASE", 194, 202], ["Fig.9A", "GENE_OR_GENE_PRODUCT", 38, 44], ["ORF8", "GENE_OR_GENE_PRODUCT", 111, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["ORF8", "GENE_OR_GENE_PRODUCT", 157, 161], ["Bat-CoV RaTG13", "GENE_OR_GENE_PRODUCT", 167, 181], ["ORF8", "GENE_OR_GENE_PRODUCT", 216, 220], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 226, 238], ["Fig.9A", "CELL_LINE", 38, 44], ["ORF8", "PROTEIN", 111, 115], ["ORF8", "DNA", 157, 161], ["Bat-CoV RaTG13", "PROTEIN", 167, 181], ["ORF8", "DNA", 216, 220], ["Bat-CoV", "SPECIES", 167, 174], ["Pangolin-CoV", "SPECIES", 226, 238], ["this analysis", "TEST", 11, 24], ["the intrinsic disorder propensity", "PROBLEM", 70, 103], ["SARS", "PROBLEM", 121, 125], ["CoV", "TEST", 126, 129], ["ORF8", "TEST", 216, 220], ["Pangolin", "TEST", 226, 234]]], ["This is in agreement 155 with the results of other analyses conducted in this study.", [["other analyses", "TEST", 45, 59], ["this study", "TEST", 73, 83]]], ["Analysis is conducted using PONDR-VSL2 algorithm [40] , which is one of the more accurate standalone disorder predictors [41, 42, 43] .", [["disorder", "DISEASE", 101, 109], ["Analysis", "TEST", 0, 8]]], ["A disorder threshold is indicated as a thin line (at score = 0.5).", [["A disorder threshold", "PROBLEM", 0, 20], ["a thin line", "TREATMENT", 37, 48], ["disorder", "OBSERVATION", 2, 10]]], ["Residues/regions with the disorder scores > 0.5 are considered as disordered.MutationsEach of the ORF8 amino acid sequences (fasta formatted) are aligned with respect to the ORF8 protein (YP 009724396.1)Mutationsfrom China-Wuhan using multiple sequence alignment tools (NCBI Blastp suite) and found the mutations and their associated positions were detected accordingly [29] .", [["amino acid", "CHEMICAL", 103, 113], ["amino acid", "CHEMICAL", 103, 113], ["ORF8", "GENE_OR_GENE_PRODUCT", 98, 102], ["amino acid", "AMINO_ACID", 103, 113], ["ORF8", "GENE_OR_GENE_PRODUCT", 174, 178], ["ORF8 amino acid sequences", "PROTEIN", 98, 123], ["ORF8 protein", "PROTEIN", 174, 186], ["NCBI Blastp suite", "DNA", 270, 287], ["Residues/regions", "PROBLEM", 0, 16], ["the disorder scores", "PROBLEM", 22, 41], ["the ORF8 amino acid sequences", "TEST", 94, 123], ["multiple sequence alignment tools", "TEST", 235, 268], ["the mutations", "PROBLEM", 299, 312]]], ["It is noted that a mutation from an amino acid A 1 to A 2 at a position p 160 is denoted by Based on observed mutations, it is noticed that amino acids threonine (T) and tryptophan (W) are found to be most vulnerable to mutate to various amino acids.", [["amino acid", "CHEMICAL", 36, 46], ["amino acids", "CHEMICAL", 140, 151], ["threonine", "CHEMICAL", 152, 161], ["tryptophan", "CHEMICAL", 170, 180], ["amino acids", "CHEMICAL", 238, 249], ["amino acid", "CHEMICAL", 36, 46], ["amino acids", "CHEMICAL", 140, 151], ["threonine", "CHEMICAL", 152, 161], ["tryptophan", "CHEMICAL", 170, 180], ["amino acids", "CHEMICAL", 238, 249], ["amino acid A 1", "GENE_OR_GENE_PRODUCT", 36, 50], ["A 2", "GENE_OR_GENE_PRODUCT", 54, 57], ["amino acids", "AMINO_ACID", 140, 151], ["threonine", "AMINO_ACID", 152, 161], ["tryptophan", "AMINO_ACID", 170, 180], ["(W)", "GENE_OR_GENE_PRODUCT", 181, 184], ["amino acids", "AMINO_ACID", 238, 249], ["position p 160", "DNA", 63, 77], ["a mutation", "PROBLEM", 17, 27], ["an amino acid", "TREATMENT", 33, 46], ["amino acids threonine", "TEST", 140, 161], ["tryptophan (W)", "TEST", 170, 184], ["various amino acids", "TEST", 230, 249]]], ["It is noteworthy that the SARS-CoV-2 ORF8 is rapidly undergoing different type of mutations, indicating that it is a highly evolving protein, whereas the Bat-CoV ORF8 is highly conserved (Fig.6) and the Pangolin-CoV ORF8 is 100% conserved (Fig.7) .MutationsA pie chart presenting the frequency distribution of various mutations is shown in Fig.11 .", [["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "ORGANISM", 26, 36], ["ORF8", "GENE_OR_GENE_PRODUCT", 37, 41], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 154, 161], ["ORF8", "GENE_OR_GENE_PRODUCT", 162, 166], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 203, 220], ["SARS-CoV-2 ORF8", "DNA", 26, 41], ["Bat-CoV ORF8", "PROTEIN", 154, 166], ["Fig.6", "DNA", 188, 193], ["Pangolin-CoV ORF8", "DNA", 203, 220], ["SARS-CoV", "SPECIES", 26, 34], ["Bat-CoV", "SPECIES", 154, 161], ["Pangolin-CoV", "SPECIES", 203, 215], ["the SARS", "TEST", 22, 30], ["mutations", "PROBLEM", 82, 91], ["a highly evolving protein", "PROBLEM", 115, 140], ["the Bat", "TEST", 150, 157], ["CoV ORF8", "TEST", 158, 166], ["the Pangolin-CoV ORF8", "TEST", 199, 220], ["various mutations", "PROBLEM", 310, 327]]], ["The N-terminal signal peptide of ORF8 (D1) of SARS-CoV-2 is hydrophobic in nature.", [["SARS", "DISEASE", 46, 50], ["ORF8", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["ORF8", "PROTEIN", 33, 37], ["D1", "PROTEIN", 39, 41], ["The N-terminal signal peptide", "TEST", 0, 29], ["SARS", "PROBLEM", 46, 50], ["hydrophobic", "OBSERVATION_MODIFIER", 60, 71]]], ["We further analysed (Table 5) the mutations and observed that hydrophobic to hydrophobic mutations are dominating, indicating that hydrophobicity of the domain is maintained and thus we can postulate that there is probably no functional change in the hydrophobic N-terminal signal peptide.", [["N", "CHEMICAL", 263, 264], ["the mutations", "PROBLEM", 30, 43], ["hydrophobic to hydrophobic mutations", "PROBLEM", 62, 98], ["hydrophobicity of the domain", "PROBLEM", 131, 159], ["functional change", "PROBLEM", 226, 243], ["probably no", "UNCERTAINTY", 214, 225], ["functional change", "OBSERVATION", 226, 243]]], ["Further, it was found that there was a change from hydrophilicity to hydrophobicity in two positions, thus enhancing Distinct non-synonymous mutations and the associated frequency of mutations, predicted effect (using Meta-SNP) as well as the predicted change of structural stability (using I-MUTANT) due to mutation(s) are presented in Table 6 .", [["I-MUTANT", "GENE_OR_GENE_PRODUCT", 291, 299], ["I", "PROTEIN", 291, 292], ["MUTANT", "PROTEIN", 293, 299], ["a change from hydrophilicity to hydrophobicity", "PROBLEM", 37, 83], ["enhancing Distinct non-synonymous mutations", "PROBLEM", 107, 150], ["mutations", "PROBLEM", 183, 192], ["Meta-SNP)", "TREATMENT", 218, 227], ["mutation", "PROBLEM", 308, 316], ["hydrophobicity", "OBSERVATION_MODIFIER", 69, 83], ["enhancing", "OBSERVATION_MODIFIER", 107, 116], ["Distinct", "OBSERVATION_MODIFIER", 117, 125], ["non-synonymous mutations", "OBSERVATION", 126, 150], ["structural stability", "OBSERVATION", 263, 283]]], ["The most frequent mutation in the ORF8 proteins turned out to be L84S (hydrophobic (L) to non-charged hydrophilic (S)) which is a clade (S) determining mutation with frequency 23 [44] .", [["ORF8", "GENE_OR_GENE_PRODUCT", 34, 38], ["ORF8 proteins", "PROTEIN", 34, 47], ["L84S", "PROTEIN", 65, 69], ["hydrophobic (L)", "PROTEIN", 71, 86], ["The most frequent mutation", "PROBLEM", 0, 26], ["the ORF8 proteins", "TEST", 30, 47]]], ["It is observed from Based on predicted effects and change of structural stability, mutations are grouped into four classes as shown in Table 190 7.", [["mutations", "PROBLEM", 83, 92], ["structural stability", "OBSERVATION", 61, 81]]], ["In Table 8 , the list of unique ORF8 protein IDs and their associated mutations with domain(s) and the predicted effects and changes of structural stability are presented.", [["ORF8", "GENE_OR_GENE_PRODUCT", 32, 36], ["ORF8 protein IDs", "PROTEIN", 32, 48], ["their associated mutations", "PROBLEM", 53, 79], ["structural stability", "OBSERVATION", 136, 156]]], ["Further, based on the three different types of mutations viz. neutral, disease and mix of neutral & disease, all the ORF8 proteins are classified into three groups which are adumbrated in Table 9 .", [["ORF8", "GENE_OR_GENE_PRODUCT", 117, 121], ["ORF8 proteins", "PROTEIN", 117, 130], ["mutations viz", "PROBLEM", 47, 60], ["neutral, disease", "PROBLEM", 62, 78], ["neutral & disease", "PROBLEM", 90, 107], ["disease", "OBSERVATION", 71, 78], ["disease", "OBSERVATION", 100, 107]]], ["Note that, other than these two strains, there are other sixty-four other ORF8 sequences, which do not possess any of these two strain-determining mutations.", [["ORF8", "GENE_OR_GENE_PRODUCT", 74, 78], ["ORF8 sequences", "DNA", 74, 88], ["four other ORF8 sequences", "TEST", 63, 88]]], ["This clarifies that the ORF8 protein is certainly one of the fundamental proteins which directs the pathogenicity of a variety of strains of SARS-CoV-2.Remarks Based on Mutations over ORF8 Proteins of SARS-CoV-2, Bat-CoV and Pangolin-CoVTo study the evolution of mutations and to observe the relationships among three ORF8 proteins, we compared SARS-215CoV-2 ORF8 with that of Bat-CoV RaTG13 and Pangolin-CoV ORF8.", [["SARS", "DISEASE", 141, 145], ["ORF8", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV-2", "ORGANISM", 141, 151], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 211], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 213, 220], ["Pangolin-CoVTo", "GENE_OR_GENE_PRODUCT", 225, 239], ["ORF8", "GENE_OR_GENE_PRODUCT", 318, 322], ["ORF8", "GENE_OR_GENE_PRODUCT", 359, 363], ["Bat-CoV RaTG13", "GENE_OR_GENE_PRODUCT", 377, 391], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 396, 413], ["ORF8 protein", "PROTEIN", 24, 36], ["SARS-CoV-2, Bat-CoV and Pangolin-CoVTo", "DNA", 201, 239], ["ORF8 proteins", "PROTEIN", 318, 331], ["SARS-215CoV-2 ORF8", "DNA", 345, 363], ["Bat-CoV RaTG13", "PROTEIN", 377, 391], ["Pangolin-CoV ORF8", "DNA", 396, 413], ["SARS-CoV", "SPECIES", 141, 149], ["Bat-CoV", "SPECIES", 377, 384], ["Pangolin-CoV", "SPECIES", 396, 408], ["the ORF8 protein", "TEST", 20, 36], ["SARS", "PROBLEM", 141, 145], ["CoV", "TEST", 146, 149], ["SARS", "TEST", 201, 205], ["CoV", "TEST", 206, 209], ["Bat-CoV", "TEST", 213, 220], ["Pangolin", "TREATMENT", 225, 233], ["CoVTo study", "TEST", 234, 245], ["mutations", "PROBLEM", 263, 272], ["SARS", "TEST", 345, 349], ["Bat", "TEST", 377, 380], ["CoV RaTG13", "TEST", 381, 391], ["Pangolin", "TEST", 396, 404]]], ["The detailed analysis of all mutations is presented in Table 12 .215Based on Table 12 , it can be suggested that reverse mutations will lead to the same sequence for the SARS-CoV-2 ORF8 protein will have the same sequence as that of Bat-CoV RaTG13 and Pangolin-CoV ORF8 proteins in the near future.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 170, 180], ["ORF8", "GENE_OR_GENE_PRODUCT", 181, 185], ["Bat-CoV RaTG13", "GENE_OR_GENE_PRODUCT", 233, 247], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 252, 269], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 170, 193], ["Bat-CoV RaTG13 and Pangolin-CoV ORF8 proteins", "PROTEIN", 233, 278], ["SARS-CoV", "SPECIES", 170, 178], ["Bat-CoV", "SPECIES", 233, 240], ["Pangolin-CoV", "SPECIES", 252, 264], ["The detailed analysis", "TEST", 0, 21], ["all mutations", "TEST", 25, 38], ["reverse mutations", "PROBLEM", 113, 130], ["the SARS", "TEST", 166, 174], ["CoV", "TEST", 175, 178], ["Bat-CoV RaTG13", "TEST", 233, 247], ["Pangolin", "TEST", 252, 260]]], ["We can also conclude that SARS-CoV-2 is showing genetically reverse engineering when compared with Bat-CoV 220 RaTG13 and Pangolin-CoV ORF8.L84SThe reversal of mutation also happened here and it was found that the frequency of Leucine to Serine mutation at 84th position is quite high. predisposition in the vicinity of residue 50, whereas the lowest disorder propensity in the vicinity of residue 70 is found in variants QKV06506.1 and QKQ29929.1.", [["SARS", "DISEASE", 26, 30], ["Leucine", "CHEMICAL", 227, 234], ["disorder", "DISEASE", 351, 359], ["Leucine", "CHEMICAL", 227, 234], ["Serine", "CHEMICAL", 238, 244], ["Bat-CoV 220 RaTG13", "ORGANISM", 99, 117], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 122, 134], ["Leucine", "AMINO_ACID", 227, 234], ["Serine", "AMINO_ACID", 238, 244], ["Pangolin-CoV ORF8.L84", "DNA", 122, 143], ["Bat-CoV", "SPECIES", 99, 106], ["Pangolin-CoV", "SPECIES", 122, 134], ["SARS-CoV", "TEST", 26, 34], ["CoV", "TEST", 103, 106], ["RaTG13", "TEST", 111, 117], ["Pangolin", "TEST", 122, 130], ["mutation", "PROBLEM", 160, 168], ["Serine mutation", "TEST", 238, 253], ["the lowest disorder propensity", "PROBLEM", 340, 370], ["mutation", "OBSERVATION", 160, 168], ["high", "OBSERVATION_MODIFIER", 280, 284]]], ["Finally, although variant QMU91370.1 is almost indistinguishable from variant QJS56890.1 within the first 40 residues, its intrinsic disorder predisposition in the vicinity of residue 70 is one of the lowest among all the proteins analysed in this study.", [["disorder", "DISEASE", 133, 141], ["QMU91370.1", "GENE_OR_GENE_PRODUCT", 26, 36], ["its intrinsic disorder predisposition", "PROBLEM", 119, 156], ["this study", "TEST", 243, 253], ["intrinsic disorder", "OBSERVATION", 123, 141]]], ["Interestingly, comparison of the Fig.9 (A) and Fig.9 (B) show that the variability in the disorder predisposition between many variants of the protein ORF8 from SARS-CoV-2 isolates is 235 noticeably greater than that between the reference ORF8 from SARS-CoV-2 and ORF8 proteins from Bat-CoV RaTG13Sl No Mutation in ORF8 (SARS-CoVand Pangolin-CoV.Possible Flow of Mutations over ORF8Here we present five different possible mutation flows according to the date of collection of the virus sample from patients [45] .", [["disorder", "DISEASE", 90, 98], ["SARS", "DISEASE", 161, 165], ["Fig.9 (A)", "GENE_OR_GENE_PRODUCT", 33, 42], ["Fig.9 (B)", "GENE_OR_GENE_PRODUCT", 47, 56], ["ORF8", "GENE_OR_GENE_PRODUCT", 151, 155], ["SARS-CoV-2", "ORGANISM", 161, 171], ["ORF8", "GENE_OR_GENE_PRODUCT", 239, 243], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 249, 259], ["ORF8", "GENE_OR_GENE_PRODUCT", 264, 268], ["Bat-CoV", "ORGANISM", 283, 290], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 333, 345], ["patients", "ORGANISM", 498, 506], ["protein ORF8", "PROTEIN", 143, 155], ["ORF8", "PROTEIN", 239, 243], ["SARS-CoV-2 and ORF8 proteins", "PROTEIN", 249, 277], ["ORF8", "DNA", 315, 319], ["ORF8Here", "DNA", 378, 386], ["patients", "SPECIES", 498, 506], ["SARS-CoV", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 249, 257], ["Bat-CoV", "SPECIES", 283, 290], ["SARS-CoVand Pangolin-CoV", "SPECIES", 321, 345], ["the disorder predisposition", "PROBLEM", 86, 113], ["the protein ORF8", "TEST", 139, 155], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["SARS", "TEST", 249, 253], ["CoV", "TEST", 254, 257], ["ORF8 proteins", "TEST", 264, 277], ["Bat", "TEST", 283, 286], ["CoV RaTG13Sl", "TEST", 287, 299], ["Mutation", "PROBLEM", 303, 311], ["ORF8", "TEST", 315, 319], ["SARS", "TEST", 321, 325], ["Pangolin", "TEST", 333, 341], ["Flow of Mutations", "PROBLEM", 355, 372], ["mutation flows", "PROBLEM", 422, 436], ["the virus sample", "TEST", 476, 492], ["Flow", "OBSERVATION", 355, 359]]], ["Sequence homology-and amino acid compositions-based phylogenies have been drawn for the ORF8 proteins 240 associated in each flow.Flow-IIn this flow of mutations (Fig.13 In order to support these mutation flows, we analysed the protein sequence similarity based on phylogeny and amino acid 255 composition.", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 279, 289], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 279, 289], ["amino acid", "AMINO_ACID", 22, 32], ["ORF8", "GENE_OR_GENE_PRODUCT", 88, 92], ["amino acid 255", "AMINO_ACID", 279, 293], ["ORF8 proteins 240", "PROTEIN", 88, 105], ["Sequence homology", "TEST", 0, 17], ["amino acid compositions", "TEST", 22, 45], ["the ORF8 proteins", "TEST", 84, 101], ["Flow", "TEST", 130, 134], ["mutations (Fig", "TREATMENT", 152, 166], ["these mutation flows", "TEST", 190, 210], ["the protein sequence similarity", "TEST", 224, 255], ["amino acid", "TEST", 279, 289]]], ["The reference ORF8 sequence YP 009724396 is found to be much more similar to the variants QMT48896.1 and QMI92505.1, which are more similar to each other as depicted in the sequence based phylogeny (Fig.14 (left) ).", [["ORF8 sequence", "DNA", 14, 27], ["The reference ORF8 sequence YP", "TEST", 0, 30], ["more similar", "OBSERVATION_MODIFIER", 127, 139], ["left", "ANATOMY_MODIFIER", 207, 211]]], ["This sequence based similarity of the ORF8 proteins QMT48896.1 and QMI92505.1 is illustrated in the chronology of mutations as shown in Fig.13 .", [["ORF8", "GENE_OR_GENE_PRODUCT", 38, 42], ["ORF8 proteins", "PROTEIN", 38, 51], ["QMT48896.1", "PROTEIN", 52, 62], ["QMI92505.1", "PROTEIN", 67, 77], ["the ORF8 proteins", "TEST", 34, 51]]], ["Similarly, the mutation flow of the sequences QMT96239.1 and QMU92030.1 is supported by the respective sequence-based similarity.", [["QMT96239.1", "DNA", 46, 56], ["QMU92030.1", "DNA", 61, 71], ["the sequences", "TEST", 32, 45]]], ["The network of five ORF8 protein variants from the US is justified based on similar amino acid compositions/conservations across the five sequences as shown in Fig.14 (right) .Flow-IIIn this flow of mutations (Fig.15 ), we observed one sequence with first-order mutations, i.e where only one mutation accumulated in the sequence.", [["amino acid", "CHEMICAL", 84, 94], ["amino acid", "CHEMICAL", 84, 94], ["ORF8", "GENE_OR_GENE_PRODUCT", 20, 24], ["amino acid", "AMINO_ACID", 84, 94], ["Fig.14", "GENE_OR_GENE_PRODUCT", 160, 166], ["ORF8 protein variants", "PROTEIN", 20, 41], ["Fig.14", "PROTEIN", 160, 166], ["five ORF8 protein variants", "TEST", 15, 41], ["the US", "TEST", 47, 53], ["similar amino acid compositions", "TREATMENT", 76, 107], ["the five sequences", "TEST", 129, 147], ["Flow", "TEST", 176, 180], ["one mutation", "PROBLEM", 288, 300], ["right", "ANATOMY_MODIFIER", 168, 173]]], ["Additionally, four sequences (all are from the US) were identified with second order mutations 265 stating that four sequences were found to have two mutations. to the hydrophobic phenylalanine (F), so it may account for disrupting the ionic interactions.", [["phenylalanine", "CHEMICAL", 180, 193], ["phenylalanine", "CHEMICAL", 180, 193], ["phenylalanine", "AMINO_ACID", 180, 193], ["four sequences", "TEST", 14, 28], ["the US", "TEST", 43, 49], ["four sequences", "TEST", 112, 126], ["may account for", "UNCERTAINTY", 205, 220]]], ["As it is a neutral mutation, the sequence accumulated two neutral mutations.", [["a neutral mutation", "PROBLEM", 9, 27], ["neutral mutations", "OBSERVATION", 58, 75]]], ["The protein sequence QLH58953.1 acquired a second mutation, P38S, which was found to be of disease-increasing type and the polarity also changed from hydrophobic to hydrophilic, thus 270 indicating these mutations may have some significant importance.", [["The protein sequence", "TEST", 0, 20], ["a second mutation", "TEST", 41, 58], ["P38S", "TEST", 60, 64], ["disease", "PROBLEM", 91, 98], ["increasing type", "PROBLEM", 99, 114], ["these mutations", "PROBLEM", 198, 213], ["disease", "OBSERVATION", 91, 98], ["increasing", "OBSERVATION_MODIFIER", 99, 109], ["type", "OBSERVATION_MODIFIER", 110, 114]]], ["The protein sequence QLH58821.1 possesses a second mutation, V62L, which was found to be of neutral type with no change in polarity.", [["QLH58821.1", "DNA", 21, 31], ["The protein sequence", "TEST", 0, 20], ["a second mutation", "TEST", 42, 59], ["change in polarity", "PROBLEM", 113, 131]]], ["Here, this sequence accumulated two neutral mutations, which may account for some functional changes.Flow-IIBy comparing both the sequence-based phylogeny ( Fig.16 (left) ) and amino acid conservation-based phylogeny (Fig.16 (right)), we found that according to sequence-based phylogeny the Australian sequence is closely related to the ORF8 275 Wuhan sequence.", [["amino acid", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 177, 187], ["amino acid", "AMINO_ACID", 177, 187], ["ORF8 275 Wuhan sequence", "DNA", 337, 360], ["this sequence", "TEST", 6, 19], ["two neutral mutations", "PROBLEM", 32, 53], ["some functional changes", "PROBLEM", 77, 100], ["Flow", "TEST", 101, 105], ["the sequence", "TEST", 126, 138], ["amino acid conservation", "TEST", 177, 200], ["neutral mutations", "OBSERVATION", 36, 53], ["may account for", "UNCERTAINTY", 61, 76], ["left", "ANATOMY_MODIFIER", 165, 169]]], ["However, according to the pathway, it should be closely related to both the Wuhan sequence and the sequences having second order mutation.", [["Wuhan sequence", "DNA", 76, 90]]], ["This can be attributed to the presence of 119 amino acid residues instead of 121 aa residues.", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["119 amino acid residues", "TREATMENT", 42, 65]]], ["In this case, the sequence has a two amino acid deletion, therefore, it is present at first node.280Here we analysed the US sequences considering the Wuhan sequence (YP 009724396.1) as the reference and found one sequence, QKC05159.1, with a single mutation and seven sequences with two mutations each (Fig.17 ).", [["node", "ANATOMY", 92, 96], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "AMINO_ACID", 37, 47], ["US sequences", "DNA", 121, 133], ["Wuhan sequence", "DNA", 150, 164], ["a two amino acid deletion", "PROBLEM", 31, 56], ["the US sequences", "TEST", 117, 133], ["a single mutation", "TEST", 240, 257], ["acid deletion", "OBSERVATION", 43, 56], ["node", "OBSERVATION", 92, 96]]], ["The first sequence, QKC05159.1, contained the L84S mutation (strain determining mutation), which was of neutral type.", [["L84S", "GENE_OR_GENE_PRODUCT", 46, 50], ["QKC05159.1", "DNA", 20, 30], ["The first sequence", "TEST", 0, 18], ["the L84S mutation", "PROBLEM", 42, 59], ["neutral type", "OBSERVATION", 104, 116]]], ["However, the polarity changed from hydrophobic to hydrophilic, which may account for some significant change of function.", [["some significant change of function", "PROBLEM", 85, 120], ["polarity", "OBSERVATION_MODIFIER", 13, 21], ["hydrophobic", "OBSERVATION_MODIFIER", 35, 46], ["hydrophilic", "OBSERVATION_MODIFIER", 50, 61], ["may account for", "UNCERTAINTY", 69, 84], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["change", "OBSERVATION", 102, 108]]], ["The sequences that accumulated 2nd mutation along with L84S are as follows: \u2022 QMS53022.1: This protein sequence acquired a second mutation at position 11, which changed the hydrophilic amino acid threonine (T) to hydrophobic amino acid isoleucine (I) therefore affecting the ionic interactions.", [["amino acid", "CHEMICAL", 185, 195], ["threonine", "CHEMICAL", 196, 205], ["amino acid isoleucine", "CHEMICAL", 225, 246], ["amino acid", "CHEMICAL", 185, 195], ["threonine", "CHEMICAL", 196, 205], ["amino acid", "CHEMICAL", 225, 235], ["isoleucine", "CHEMICAL", 236, 246], ["amino acid", "AMINO_ACID", 185, 195], ["threonine", "AMINO_ACID", 196, 205], ["amino acid", "AMINO_ACID", 225, 235], ["isoleucine", "AMINO_ACID", 236, 246], ["L84S", "DNA", 55, 59], ["position 11", "PROTEIN", 142, 153], ["The sequences", "TEST", 0, 13], ["2nd mutation", "PROBLEM", 31, 43], ["This protein sequence", "TEST", 90, 111], ["the hydrophilic amino acid threonine", "TREATMENT", 169, 205], ["hydrophobic amino acid isoleucine", "TREATMENT", 213, 246], ["ionic interactions", "OBSERVATION", 275, 293]]], ["This 290 mutation was found to be a diseased-increasing type, so it may affect the structure of the protein.280\u2022 QMT50804.1: This sequence gained a second mutation, E19D, which was predicted to be of disease-increasing type with no change in polarity.", [["a diseased-increasing type", "PROBLEM", 34, 60], ["a second mutation", "PROBLEM", 146, 163], ["disease", "PROBLEM", 200, 207], ["change in polarity", "PROBLEM", 232, 250], ["diseased", "OBSERVATION", 36, 44], ["increasing", "OBSERVATION_MODIFIER", 45, 55], ["disease", "OBSERVATION", 200, 207]]], ["The sequence first accumulated a neutral mutation then a disease-increasing mutation, signifying that these mutations may have some functional importance.280\u2022 QJD48694.1: H112Q occurred as second mutation in this sequence, which was found to be of disease-increasing 295 type with no change in polarity.", [["a neutral mutation", "PROBLEM", 31, 49], ["a disease", "PROBLEM", 55, 64], ["increasing mutation", "PROBLEM", 65, 84], ["these mutations", "PROBLEM", 102, 117], ["second mutation", "PROBLEM", 189, 204], ["this sequence", "TEST", 208, 221], ["disease", "PROBLEM", 248, 255], ["change in polarity", "PROBLEM", 284, 302], ["neutral mutation", "OBSERVATION", 33, 49], ["disease", "OBSERVATION", 248, 255]]], ["Consequently, these mutations may contribute to immune evasion property of the virus.280\u2022 QKV06506.1: This sequence possesses the S67F mutation, which was predicted to be of neutral type, which changed the hydrophilic serine (S) to the hydrophobic phenylalanine (F), thus interfering with the ionic interactions that may increase or decrease the affinity of the viral protein for a particular host cell protein.300\u2022 QKV40062.1: This sequence acquired a second mutation at Q72H, which was found to be a neutral mutation and no change in polarity was observed.", [["cell", "ANATOMY", 398, 402], ["phenylalanine", "CHEMICAL", 248, 261], ["serine", "CHEMICAL", 218, 224], ["phenylalanine", "CHEMICAL", 248, 261], ["S67F", "GENE_OR_GENE_PRODUCT", 130, 134], ["serine", "AMINO_ACID", 218, 224], ["phenylalanine", "AMINO_ACID", 248, 261], ["host cell", "CELL", 393, 402], ["viral protein", "PROTEIN", 362, 375], ["host cell protein", "PROTEIN", 393, 410], ["these mutations", "PROBLEM", 14, 29], ["immune evasion", "PROBLEM", 48, 62], ["the virus", "PROBLEM", 75, 84], ["This sequence", "TEST", 102, 115], ["the S67F mutation", "PROBLEM", 126, 143], ["neutral type", "PROBLEM", 174, 186], ["the ionic interactions", "TREATMENT", 289, 311], ["the viral protein", "TREATMENT", 358, 375], ["a neutral mutation", "PROBLEM", 500, 518], ["change in polarity", "PROBLEM", 526, 544], ["neutral mutation", "OBSERVATION", 502, 518], ["no", "UNCERTAINTY", 523, 525], ["change", "OBSERVATION_MODIFIER", 526, 532]]], ["As this sequence accumulated two neutral mutations, it can be assumed that neutral mutations also have a significant importance.300\u2022 QKV07730.1: The T11A mutation occurred as the second mutation in this sequence, which was predicted to be of disease-increasing type and the polarity was changed from hydrophilic to hydrophobic, hence the structure and 305 function of the protein are expected to differ.300From the sequence based phylogeny (Fig.18 (left) ) it was observed that the Wuhan sequence was the first to originate.300Although, QKC05159.1 is the first sequence in our flow considering the time, it was found that in the phylogenetic tree it is present at fourth node instead of second node, which is probably due to the presence of ambiguous mutations in this sequence.", [["fourth node", "ANATOMY", 664, 675], ["node", "ANATOMY", 694, 698], ["T11A", "GENE_OR_GENE_PRODUCT", 149, 153], ["fourth node", "MULTI-TISSUE_STRUCTURE", 664, 675], ["node", "MULTI-TISSUE_STRUCTURE", 694, 698], ["Wuhan sequence", "DNA", 482, 496], ["QKC05159.1", "DNA", 537, 547], ["two neutral mutations", "PROBLEM", 29, 50], ["neutral mutations", "PROBLEM", 75, 92], ["The T11A mutation", "PROBLEM", 145, 162], ["the second mutation", "PROBLEM", 175, 194], ["disease", "PROBLEM", 242, 249], ["increasing type and the polarity", "PROBLEM", 250, 282], ["hydrophilic to hydrophobic", "PROBLEM", 300, 326], ["the sequence based phylogeny", "TEST", 411, 439], ["the Wuhan sequence", "TEST", 478, 496], ["ambiguous mutations in this sequence", "PROBLEM", 741, 777], ["neutral mutations", "OBSERVATION", 33, 50], ["disease", "OBSERVATION", 242, 249], ["increasing", "OBSERVATION_MODIFIER", 250, 260], ["type", "OBSERVATION_MODIFIER", 261, 265], ["phylogenetic tree", "OBSERVATION", 629, 646], ["fourth", "OBSERVATION_MODIFIER", 664, 670], ["node", "OBSERVATION", 671, 675], ["second", "OBSERVATION_MODIFIER", 687, 693], ["node", "OBSERVATION", 694, 698], ["probably due to", "UNCERTAINTY", 709, 724], ["ambiguous mutations", "OBSERVATION", 741, 760]]], ["It was also determined that QKV07730.1 is very similar to QMT50804.1 and again QMT28672.1 is more similar 310 to both of them.", [["QKV07730.1", "SIMPLE_CHEMICAL", 28, 38]]], ["From the amino acid based analysis (Fig.18(right) ) it was found that the Wuhan sequence has a high conservation similarity with that of QKV06506.1, thus proving that this sequence was identified chronologically after the Wuhan sequence followed by QKC05159.1 and QMT28672.1, which again are very similar to each other.Flow IVIn the possible flow of mutations (Fig.19) , we have found one sequence with a single mutation, six sequences with two mutations, and another two sequences with three mutations.", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "AMINO_ACID", 9, 19], ["Wuhan sequence", "DNA", 74, 88], ["the amino acid based analysis", "TEST", 5, 34], ["the Wuhan sequence", "TEST", 218, 236], ["Flow", "TEST", 319, 323], ["mutations", "PROBLEM", 350, 359], ["a single mutation", "TEST", 403, 420], ["two mutations", "TEST", 441, 454], ["another two sequences", "TEST", 460, 481], ["possible", "UNCERTAINTY", 333, 341], ["flow", "OBSERVATION_MODIFIER", 342, 346]]], ["The US sequence QKC05159.1 was identified to have the L84S mutation, which is a strain determining mutation and was predicted to be a neutral mutation where polarity was changed from hydrophobic to hydrophilic.", [["L84S", "GENE_OR_GENE_PRODUCT", 54, 58], ["US sequence QKC05159.1", "DNA", 4, 26], ["L84S", "DNA", 54, 58], ["The US sequence", "TEST", 0, 15], ["the L84S mutation", "PROBLEM", 50, 67], ["a strain determining mutation", "PROBLEM", 78, 107], ["a neutral mutation", "PROBLEM", 132, 150]]], ["The sequences that accumulated second mutations along with L84S are as following and 320 it should be noted that the mutational accumulation occurred in a single strain: \u2022 QLH01196.1: The A65S mutation occurred as a second mutation in this US sequence, which was found to be 325 of neutral type.", [["A65S", "GENE_OR_GENE_PRODUCT", 188, 192], ["L84S", "DNA", 59, 63], ["US sequence", "DNA", 240, 251], ["second mutations", "PROBLEM", 31, 47], ["the mutational accumulation", "PROBLEM", 113, 140], ["The A65S mutation", "PROBLEM", 184, 201], ["a second mutation", "PROBLEM", 214, 231], ["this US sequence", "TEST", 235, 251]]], ["However, the polarity changed from hydrophobic to hydrophilic, thus potentially influencing the function of the protein.Flow IV\u2022 QMU91334.1: This US sequence possesses the D63G mutation, which was predicted to be of neutral type.", [["D63G", "GENE_OR_GENE_PRODUCT", 172, 176], ["US sequence", "DNA", 146, 157], ["hydrophobic to hydrophilic", "PROBLEM", 35, 61], ["This US sequence", "TEST", 141, 157], ["the D63G mutation", "PROBLEM", 168, 185], ["polarity", "OBSERVATION_MODIFIER", 13, 21], ["hydrophobic", "OBSERVATION_MODIFIER", 35, 46], ["neutral type", "OBSERVATION", 216, 228]]], ["However, the polarity changed from hydrophilic to hydrophobic so, this sequence accumulated two neutral mutations, which may allow the virus to evolve in terms of virulence. serine (S).", [["serine", "CHEMICAL", 174, 180], ["serine", "AMINO_ACID", 174, 180], ["this sequence", "TEST", 66, 79], ["two neutral mutations", "PROBLEM", 92, 113], ["the virus", "PROBLEM", 131, 140], ["virulence", "PROBLEM", 163, 172], ["polarity", "OBSERVATION_MODIFIER", 13, 21], ["hydrophilic", "OBSERVATION_MODIFIER", 35, 46], ["neutral mutations", "OBSERVATION", 96, 113], ["virulence", "OBSERVATION", 163, 172]]], ["The mutation was neutral, thus accumulating two neutral and one disease-increasing mutations, being of 335 significant importance for the evolution of the virus.", [["two neutral and one disease", "PROBLEM", 44, 71], ["increasing mutations", "PROBLEM", 72, 92], ["the virus", "PROBLEM", 151, 160], ["neutral", "OBSERVATION_MODIFIER", 48, 55], ["disease", "OBSERVATION", 64, 71], ["virus", "OBSERVATION", 155, 160]]], ["We identified one more sequence QLH57924.1, which possesses another third mutation, F16L, which was predicted to be a neutral mutation and no polarity change was observed.Flow IVThis sequence acquired three neutral mutations that may promote virus survival.Flow IV\u2022 QKU37052.1: This sequence with the W45L mutation was reported in Saudi Arabia, which was found to be of disease-increasing type with no polarity change.", [["QKU37052.", "CHEMICAL", 266, 275], ["QLH57924.1", "GENE_OR_GENE_PRODUCT", 32, 42], ["W45L", "GENE_OR_GENE_PRODUCT", 301, 305], ["QLH57924.1", "DNA", 32, 42], ["W45L", "DNA", 301, 305], ["a neutral mutation", "PROBLEM", 116, 134], ["polarity change", "PROBLEM", 142, 157], ["Flow IVThis sequence", "TEST", 171, 191], ["three neutral mutations", "PROBLEM", 201, 224], ["virus survival", "TREATMENT", 242, 256], ["Flow IV", "TREATMENT", 257, 264], ["disease", "PROBLEM", 370, 377], ["polarity change", "PROBLEM", 402, 417], ["no", "UNCERTAINTY", 139, 141], ["polarity change", "OBSERVATION", 142, 157], ["disease", "OBSERVATION", 370, 377], ["increasing", "OBSERVATION_MODIFIER", 378, 388], ["no", "UNCERTAINTY", 399, 401], ["polarity change", "OBSERVATION", 402, 417]]], ["Therefore, this sequence also accumulated one neutral and one 340 disease-increasing mutation, which may affect both the structure and function of the protein.Flow IV\u2022 QMT96539.1: The F104S mutation was reported in the US sequence, which was found to be of disease-increasing type and the polarity changed from hydrophobic to hydrophilic.", [["US sequence", "DNA", 219, 230], ["this sequence", "TEST", 11, 24], ["increasing mutation", "PROBLEM", 74, 93], ["Flow IV", "TEST", 159, 166], ["The F104S mutation", "TEST", 180, 198], ["the US sequence", "TEST", 215, 230], ["disease", "PROBLEM", 257, 264], ["increasing type", "PROBLEM", 265, 280], ["hydrophobic to hydrophilic", "PROBLEM", 311, 337], ["increasing", "OBSERVATION_MODIFIER", 74, 84], ["mutation", "OBSERVATION", 85, 93], ["disease", "OBSERVATION", 257, 264], ["increasing", "OBSERVATION_MODIFIER", 265, 275], ["type", "OBSERVATION_MODIFIER", 276, 280], ["polarity", "OBSERVATION_MODIFIER", 289, 297]]], ["Altogether, the sequence possesses one neutral and one disease-increasing mutation that may allow the virus to acquire new properties for better survival strategies.Flow IVSequence-based phylogeny (Fig.20 (left) ) suggested that the Wuhan sequence originated first.", [["Wuhan sequence", "DNA", 233, 247], ["one disease", "PROBLEM", 51, 62], ["increasing mutation", "PROBLEM", 63, 82], ["the virus", "PROBLEM", 98, 107], ["better survival strategies", "TREATMENT", 138, 164], ["Flow IVSequence", "TEST", 165, 180], ["the Wuhan sequence", "TEST", 229, 247]]], ["Due to the presence 345 of an ambiguous amino acid sequence, QKC05159.1 did not show close similarity to the Wuhan sequence.Flow IVBased on sequence based phylogeny (Fig.20 (left) ) it was observed that Wuhan sequence originated first.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "AMINO_ACID", 40, 50], ["Wuhan sequence", "DNA", 109, 123], ["Wuhan sequence", "DNA", 203, 217], ["an ambiguous amino acid sequence", "TEST", 27, 59], ["sequence based phylogeny", "TEST", 140, 164]]], ["Due to presence of ambiguous amino acids sequence QKC05159.1 was not observed in close proximity to Wuhan sequence.", [["amino acids", "CHEMICAL", 29, 40], ["amino acids", "CHEMICAL", 29, 40], ["amino acids", "AMINO_ACID", 29, 40], ["Wuhan sequence", "DNA", 100, 114], ["ambiguous amino acids sequence", "TEST", 19, 49]]], ["QKG86865.1 and QLH57924.1 were found to have third order mutations and they are assumed to be closely related by the flow and the same has been supported by amino acid conservation-based phylogeny (Fig.20 (right) ).350Flow-V QJR88780.1 (Australia) possesses the mutation L84S with reference to the Wuhan ORF8 sequence YP 009724396.1 (Fig.21) .", [["QKG86865.1", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "AMINO_ACID", 157, 167], ["Wuhan ORF8 sequence", "DNA", 298, 317], ["amino acid conservation", "TREATMENT", 157, 180]]], ["Another sequence QJR88936.1 was reported, which possesses a second mutation, V62L.", [["QJR88936.1", "DNA", 17, 27], ["V62L", "DNA", 77, 81], ["Another sequence", "TEST", 0, 16]]], ["This mutation was predicted to be neutral with no change in polarity.", [["This mutation", "PROBLEM", 0, 13], ["change in polarity", "PROBLEM", 50, 68]]], ["However, the hydrophobicity increased.", [["the hydrophobicity", "PROBLEM", 9, 27], ["hydrophobicity", "OBSERVATION_MODIFIER", 13, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["This sequence belongs to a particular strain and acquired two neutral mutations, indicating that these mutations may play some important role in the function of ORF8a.", [["ORF8a", "GENE_OR_GENE_PRODUCT", 161, 166], ["ORF8a", "PROTEIN", 161, 166], ["a particular strain", "PROBLEM", 25, 44], ["acquired two neutral mutations", "PROBLEM", 49, 79], ["these mutations", "PROBLEM", 97, 112]]], ["As can be seen from both the sequence-based phylogeny and amino acid conservation-based phylogeny (Fig.22) , the Wuhan sequence has originated earlier and the sequences QJR88780.1 and QJR88936.1 are more closely related to each other than to the Wuhan sequence as both sequences have one common mutation not present in the Wuhan sequence.360Among SARS-CoV-2 proteins, the ORF8 accessory protein is crucial because it plays a vital role in bypassing the host immune surveillance mechanism.", [["amino acid", "CHEMICAL", 58, 68], ["SARS", "DISEASE", 347, 351], ["amino acid", "CHEMICAL", 58, 68], ["amino acid", "AMINO_ACID", 58, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 347, 357], ["ORF8", "GENE_OR_GENE_PRODUCT", 372, 376], ["Fig.22", "DNA", 99, 105], ["Wuhan sequence", "DNA", 113, 127], ["Wuhan sequence", "DNA", 246, 260], ["Wuhan sequence", "DNA", 323, 337], ["SARS-CoV-2 proteins", "PROTEIN", 347, 366], ["ORF8 accessory protein", "PROTEIN", 372, 394], ["SARS-CoV", "SPECIES", 347, 355], ["amino acid conservation", "TEST", 58, 81], ["the Wuhan sequence", "TEST", 109, 127], ["the sequences", "TEST", 155, 168], ["one common mutation", "PROBLEM", 284, 303], ["Among SARS", "TEST", 341, 351], ["CoV", "TEST", 352, 355]]], ["This protein is found to have a wide variety of mutations and among them L84S (23) and S24L (7) have highest frequency of occurrence, which bears distinct functional significance as well.", [["L84S (23)", "GENE_OR_GENE_PRODUCT", 73, 82], ["This protein", "TEST", 0, 12], ["a wide variety of mutations", "PROBLEM", 30, 57], ["wide", "OBSERVATION_MODIFIER", 32, 36]]], ["It has been reported that L84S and S24L show antagonistic effects on the protein folding stability of SARS-CoV-2 [44].", [["L84S", "GENE_OR_GENE_PRODUCT", 26, 30], ["S24L", "GENE_OR_GENE_PRODUCT", 35, 39], ["S24L", "PROTEIN", 35, 39], ["SARS-CoV", "SPECIES", 102, 110], ["antagonistic effects", "PROBLEM", 45, 65], ["SARS", "TEST", 102, 106], ["CoV", "TEST", 107, 110]]], ["L84S destabilizes protein folding, therefore up-regulating the host-immune activity and S24L favours folding stability positively, thus enhancing the 365 functionality of ORF8 protein.", [["L84S", "SIMPLE_CHEMICAL", 0, 4], ["S24L", "GENE_OR_GENE_PRODUCT", 88, 92], ["ORF8", "GENE_OR_GENE_PRODUCT", 171, 175], ["L84S", "PROTEIN", 0, 4], ["S24L", "PROTEIN", 88, 92], ["ORF8 protein", "PROTEIN", 171, 183], ["protein folding", "PROBLEM", 18, 33], ["ORF8 protein", "TEST", 171, 183], ["protein folding", "OBSERVATION", 18, 33]]], ["L84S is already established as a strain determining mutation and since according to our studies both L84S and S24L do not occur together in a single sequence of SARS-CoV-2 ORF8 protein, it is proposed that virus with the S24L mutation is a new strain altogether.", [["L84S", "GENE_OR_GENE_PRODUCT", 0, 4], ["L84S", "GENE_OR_GENE_PRODUCT", 101, 105], ["S24L", "GENE_OR_GENE_PRODUCT", 110, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["ORF8", "GENE_OR_GENE_PRODUCT", 172, 176], ["S24L", "GENE_OR_GENE_PRODUCT", 221, 225], ["L84S", "DNA", 0, 4], ["L84S", "DNA", 101, 105], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 161, 184], ["a strain determining mutation", "PROBLEM", 31, 60], ["our studies", "TEST", 84, 95], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["the S24L mutation", "PROBLEM", 217, 234], ["new", "OBSERVATION_MODIFIER", 240, 243]]], ["We also observed that hydrophobic to hydrophobic mutations are dominant in the D1 domain.", [["D1 domain", "PROTEIN", 79, 88], ["hydrophobic to hydrophobic mutations", "PROBLEM", 22, 58], ["hydrophobic mutations", "OBSERVATION", 37, 58], ["dominant", "OBSERVATION_MODIFIER", 63, 71]]], ["Therefore, hydrophobicity is an important property for the N-terminal signal peptide.360However, in the D2 domain, hydrophobic to hydrophilic mutations are observed more frequently, consequently making the 370 ionic interactions more favourable and allowing the protein to evolve in terms of better efficacy in pathogenicity.360The ORF8 sequence of SARS-CoV-2 shows 93% similarity with the Bat-CoV RaTG13 and 88% similarity with that of the Pangolin-CoV ORF8.", [["N", "CHEMICAL", 59, 60], ["ORF8", "GENE_OR_GENE_PRODUCT", 332, 336], ["SARS-CoV-2", "ORGANISM", 349, 359], ["Bat-CoV RaTG13", "ORGANISM", 390, 404], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 441, 458], ["D2 domain", "PROTEIN", 104, 113], ["ORF8 sequence", "DNA", 332, 345], ["Bat-CoV RaTG13", "DNA", 390, 404], ["Pangolin-CoV ORF8", "DNA", 441, 458], ["SARS-CoV", "SPECIES", 349, 357], ["Bat-CoV", "SPECIES", 390, 397], ["Pangolin-CoV", "SPECIES", 441, 453], ["hydrophobic to hydrophilic mutations", "PROBLEM", 115, 151], ["The ORF8 sequence", "TEST", 328, 345], ["SARS", "TEST", 349, 353], ["CoV", "TEST", 354, 357], ["the Bat", "TEST", 386, 393], ["CoV RaTG13", "TEST", 394, 404], ["hydrophilic mutations", "OBSERVATION", 130, 151], ["pathogenicity", "OBSERVATION", 311, 324]]], ["Thus, the ORF8 protein of SARS-CoV-2 can be considered as a valuable candidate for evolutionary deterministic studies and for the identification of the origin of SARS-CoV-2 as a whole.", [["SARS", "DISEASE", 162, 166], ["ORF8", "GENE_OR_GENE_PRODUCT", 10, 14], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV-2", "ORGANISM", 162, 172], ["ORF8 protein", "PROTEIN", 10, 22], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 162, 170], ["the ORF8 protein", "TEST", 6, 22], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["evolutionary deterministic studies", "TEST", 83, 117]]], ["We also analysed a wide variety of mutations in the SARS-CoV-2 ORF8, where we compared it with the ORF8 of Bat-CoV RaTG13 and 375 Pangolin-CoV in relation to charge and hydrophobicity perspectives and we found that the Bat-CoV RaTG13 ORF8 protein exhibits exactly the same properties as that of the SARS-CoV-2 ORF8 protein, whereas the properties of the Pangolin-CoV ORF8 are relatively less similar to the SARS-CoV-2 ORF8.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["ORF8", "GENE_OR_GENE_PRODUCT", 63, 67], ["ORF8", "GENE_OR_GENE_PRODUCT", 99, 103], ["Bat-CoV RaTG13", "ORGANISM", 107, 121], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 130, 142], ["Bat-CoV", "GENE_OR_GENE_PRODUCT", 219, 226], ["ORF8", "GENE_OR_GENE_PRODUCT", 234, 238], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 299, 309], ["ORF8", "GENE_OR_GENE_PRODUCT", 310, 314], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 354, 371], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 407, 422], ["SARS-CoV-2 ORF8", "DNA", 52, 67], ["ORF8", "DNA", 99, 103], ["Bat-CoV RaTG13 ORF8 protein", "PROTEIN", 219, 246], ["SARS-CoV-2 ORF8 protein", "PROTEIN", 299, 322], ["Pangolin", "PROTEIN", 354, 362], ["CoV ORF8", "PROTEIN", 363, 371], ["SARS-CoV-2 ORF8", "DNA", 407, 422], ["Bat-CoV", "SPECIES", 107, 114], ["Pangolin-CoV", "SPECIES", 130, 142], ["Pangolin-CoV", "SPECIES", 354, 366], ["SARS-CoV", "SPECIES", 407, 415], ["the Bat-CoV RaTG13 ORF8 protein", "TEST", 215, 246], ["the SARS", "TEST", 295, 303], ["CoV", "TEST", 304, 307], ["ORF8 protein", "TEST", 310, 322], ["the Pangolin", "TEST", 350, 362], ["the SARS", "TEST", 403, 411], ["CoV", "TEST", 412, 415]]], ["Furthermore, to study the evolutionary nature of mutations in the ORF8, we aligned three bat sequences and found that two of them were exactly the same and there were only six amino acid differences in the third with respect to the other two sequences.", [["amino acid", "CHEMICAL", 176, 186], ["amino acid", "CHEMICAL", 176, 186], ["ORF8", "GENE_OR_GENE_PRODUCT", 66, 70], ["amino acid", "AMINO_ACID", 176, 186], ["ORF8", "DNA", 66, 70], ["mutations", "PROBLEM", 49, 58], ["three bat sequences", "TEST", 83, 102], ["six amino acid differences", "PROBLEM", 172, 198], ["amino acid", "OBSERVATION", 176, 186]]], ["So, only two variants were identified for Bat-CoV.380Therefore, it shows that the rate of occurrence of mutations is slow in the Bat-CoV RaTG13 ORF8.", [["Bat-CoV RaTG13 ORF8", "GENE_OR_GENE_PRODUCT", 129, 148], ["Bat-CoV RaTG13 ORF8", "PROTEIN", 129, 148], ["Bat-CoV", "SPECIES", 129, 136], ["mutations", "PROBLEM", 104, 113]]], ["However, for pangolins no differences were observed among four Pangolin-CoV ORF8 sequences and therefore only a single variant of ORF8 is present.", [["pangolins", "CHEMICAL", 13, 22], ["pangolins", "GENE_OR_GENE_PRODUCT", 13, 22], ["Pangolin-CoV ORF8", "GENE_OR_GENE_PRODUCT", 63, 80], ["ORF8", "GENE_OR_GENE_PRODUCT", 130, 134], ["Pangolin-CoV ORF8 sequences", "DNA", 63, 90], ["ORF8", "DNA", 130, 134], ["Pangolin-CoV", "SPECIES", 63, 75], ["pangolins", "PROBLEM", 13, 22], ["four Pangolin-CoV ORF8 sequences", "TEST", 58, 90]]], ["Based on sequence alignment, biochemical characteristics and secondary structural analysis, the Bat-CoV, the Pangolin-CoV and the SARS-CoV-2 ORF8 displayed a high similarity index.", [["Bat-CoV", "ORGANISM", 96, 103], ["Pangolin-CoV", "GENE_OR_GENE_PRODUCT", 109, 121], ["SARS-CoV-2", "ORGANISM", 130, 140], ["ORF8", "GENE_OR_GENE_PRODUCT", 141, 145], ["Pangolin-CoV and the SARS-CoV-2 ORF8", "DNA", 109, 145], ["Pangolin-CoV", "SPECIES", 109, 121], ["SARS-CoV", "SPECIES", 130, 138], ["sequence alignment", "TEST", 9, 27], ["biochemical characteristics", "TEST", 29, 56], ["secondary structural analysis", "TEST", 61, 90], ["the Bat-CoV", "TEST", 92, 103], ["the Pangolin", "TEST", 105, 117], ["the SARS", "TEST", 126, 134], ["CoV", "TEST", 135, 138], ["a high similarity index", "PROBLEM", 156, 179]]], ["Additionally, in the ORF8 of SARS-CoV-2, certain mutations were found to exhibit exact reversal with respect to bats and pangolins and therefore pointing towards the genomic origin of SARS-CoV-2.380However, unlike Bat-CoV and Pangolin-CoV, the mutational distribution of the ORF8 (SARS-CoV-2) is widespread ranging from the position 3 to 121, having no defined conserved region.", [["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 184, 188], ["ORF8", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV-2", "ORGANISM", 29, 39], ["pangolins", "GENE_OR_GENE_PRODUCT", 121, 130], ["SARS-CoV", "ORGANISM", 184, 192], ["Bat-CoV", "ORGANISM", 214, 221], ["Pangolin-CoV", "ORGANISM", 226, 238], ["ORF8", "GENE_OR_GENE_PRODUCT", 275, 279], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["ORF8", "DNA", 21, 25], ["ORF8", "DNA", 275, 279], ["position 3 to 121", "DNA", 324, 341], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 184, 192], ["Bat-CoV", "SPECIES", 214, 221], ["Pangolin-CoV", "SPECIES", 226, 238], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["certain mutations", "PROBLEM", 41, 58], ["pangolins", "TREATMENT", 121, 130], ["CoV", "TEST", 189, 192], ["Bat-CoV", "TEST", 214, 221], ["Pangolin", "TEST", 226, 234], ["SARS", "TEST", 281, 285], ["CoV", "TEST", 286, 289], ["widespread", "OBSERVATION_MODIFIER", 296, 306], ["ranging", "OBSERVATION_MODIFIER", 307, 314]]], ["This surprises the scientific community enormously.380Further this property differentiates the SARS-CoV-2 ORF8 from that of Bat-CoV and Pangolin-CoV, thus raising the question over the natural trail of evolution of mutations in SARS-CoV-2.390We further predicted the types and effects of mutations of 95 sequences and grouped them into four domains and found that diseased type mutations with decreasing effect on stability are more prominent.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV-2.390", "CHEMICAL", 228, 242], ["SARS-CoV-2 ORF8", "ORGANISM", 95, 110], ["Bat-CoV", "ORGANISM", 124, 131], ["Pangolin-CoV", "ORGANISM", 136, 148], ["SARS-CoV", "ORGANISM", 228, 236], ["SARS-CoV-2 ORF8", "DNA", 95, 110], ["95 sequences", "DNA", 301, 313], ["SARS-CoV", "SPECIES", 95, 103], ["Bat-CoV", "SPECIES", 124, 131], ["Pangolin-CoV", "SPECIES", 136, 148], ["SARS-CoV-2.390", "SPECIES", 228, 242], ["the SARS", "PROBLEM", 91, 99], ["CoV", "TEST", 100, 103], ["Pangolin", "TREATMENT", 136, 144], ["mutations in SARS", "PROBLEM", 215, 232], ["CoV", "TEST", 233, 236], ["mutations of 95 sequences", "PROBLEM", 288, 313], ["diseased type mutations", "PROBLEM", 364, 387], ["diseased", "OBSERVATION", 364, 372], ["type mutations", "OBSERVATION", 373, 387], ["decreasing", "OBSERVATION_MODIFIER", 393, 403], ["effect", "OBSERVATION_MODIFIER", 404, 410], ["stability", "OBSERVATION_MODIFIER", 414, 423], ["more prominent", "OBSERVATION_MODIFIER", 428, 442]]], ["Consequently, it is hypothesized that these mutations are promoting the viral survival rate.", [["these mutations", "PROBLEM", 38, 53], ["viral survival", "OBSERVATION", 72, 86]]], ["Furthermore, we tracked the possible flow of mutations in accordance to time and geographic locations and validated our proposal with respect to sequence-based and amino acid conservation-based phylogeny and therefore putting forward the order of accumulation of mutations.Conflict of InterestsThe authors do not have any conflicts of interest to declare.", [["amino acid", "CHEMICAL", 164, 174], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "AMINO_ACID", 164, 174], ["mutations", "PROBLEM", 45, 54], ["amino acid conservation", "TREATMENT", 164, 187], ["mutations", "PROBLEM", 263, 272]]]], "PMC7477604": [["IntroductionThe coronavirus disease-2019 (COVID-19) pandemic has caused untold suffering among all aspects of human lives.", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["coronavirus disease-2019 (COVID-19", "SPECIES", 16, 50], ["human", "SPECIES", 110, 115], ["The coronavirus disease", "PROBLEM", 12, 35], ["pandemic", "PROBLEM", 52, 60], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["Without any specific treatment or a vaccine in sight, and the sheer magnitude of cases, worldwide healthcare systems have been hugely impacted (Mamun & Griffiths, 2020a).", [["a vaccine", "TREATMENT", 34, 43]]], ["The restricted social interaction brought about by the protracted lockdowns can have a negative impact both emotionally and psychologically (Dsouza et al., 2020).", [["restricted", "OBSERVATION_MODIFIER", 4, 14], ["social interaction", "OBSERVATION", 15, 33]]], ["Financial recession, economic fallout, joblessness, and closure of businesses are all associated with protracted lockdowns, and have the potential to cause mental instability.", [["joblessness", "DISEASE", 39, 50], ["Financial recession", "PROBLEM", 0, 19], ["economic fallout", "PROBLEM", 21, 37], ["joblessness", "PROBLEM", 39, 50], ["closure of businesses", "TREATMENT", 56, 77], ["mental instability", "PROBLEM", 156, 174], ["recession", "OBSERVATION", 10, 19], ["economic", "OBSERVATION_MODIFIER", 21, 29], ["fallout", "OBSERVATION", 30, 37], ["businesses", "OBSERVATION", 67, 77], ["instability", "OBSERVATION", 163, 174]]], ["A recent study conducted in Bangladesh amongst unemployed individuals observed higher than normal prevalence rates of depression (82%), anxiety (61.5%) and stress (64.8%), such high prevalence rates have not been reported elsewhere in other cohorts (Mamun et al., 2020a).", [["depression", "DISEASE", 118, 128], ["anxiety", "DISEASE", 136, 143], ["individuals", "ORGANISM", 58, 69], ["A recent study", "TEST", 0, 14], ["depression", "PROBLEM", 118, 128], ["anxiety", "PROBLEM", 136, 143], ["stress", "TEST", 156, 162], ["such high prevalence rates", "PROBLEM", 172, 198]]], ["Therefore, it is clearly evident that the financial crisis associated with the COVID-19-related lockdowns can negatively impact the mental health of the masses (Oyesanya et al., 2015;Rafi et al., 2020) and in some extreme cases have the potential to even push the vulnerable population towards suicide (Bhuiyan et al., 2020; Dsouza et al., 2020;Mamun & Ullah, 2020).IntroductionDuring the COVID-19 lockdown, India appears to have had a sudden surge in the reported cases of suicides.", [["COVID-19", "DNA", 79, 87], ["the financial crisis", "PROBLEM", 38, 58], ["the COVID", "TEST", 75, 84], ["the masses", "PROBLEM", 149, 159], ["masses", "OBSERVATION", 153, 159]]], ["The first reported case of suicide related to COVID-19 was in India wherein the victim committed suicide because of the fear of contracting the infection (Goyal et al., 2020).", [["COVID-19", "CHEMICAL", 46, 54], ["infection", "DISEASE", 144, 153], ["the infection", "PROBLEM", 140, 153], ["infection", "OBSERVATION", 144, 153]]], ["The study reported the most common suicide causalities to be (i) fear of infection (n=21) (ii) financial crisis (n=15), (iii) testing positive for COVID-19 (n=7), while the causes for the remaining 26 cases included (iv) being lonely due to home quarantine, (v) being socially boycotted and pressure to be quarantined because others thought the person had COVID-19 (vi) experiencing COVID-19 work-related stress, (vii) being unable to return home after lockdown was imposed, and (viii) being unable to buy alcohol (among those with alcohol use disorder) (Dsouza et al., 2020).IntroductionOne of the possible limitations of this study was its inability to report the professions of the individuals committing suicide, which might also have had a potential impact on the study\u2019s findings.", [["infection", "DISEASE", 73, 82], ["alcohol", "CHEMICAL", 506, 513], ["alcohol use disorder", "DISEASE", 532, 552], ["alcohol", "CHEMICAL", 506, 513], ["alcohol", "CHEMICAL", 532, 539], ["alcohol", "SIMPLE_CHEMICAL", 506, 513], ["person", "SPECIES", 345, 351], ["The study", "TEST", 0, 9], ["infection (n=21) (ii) financial crisis", "PROBLEM", 73, 111], ["COVID", "TEST", 147, 152], ["pressure", "TREATMENT", 291, 299], ["COVID", "TEST", 356, 361], ["COVID", "TEST", 383, 388], ["this study", "TEST", 623, 633], ["the study", "TEST", 765, 774], ["infection", "OBSERVATION", 73, 82]]], ["For instance, individuals with lower income are at a greater risk of suicide, owing to the lockdown associated financial distress as compared to those who are financially stable and have higher incomes (Oyesanya et al., 2015;Mamun & Ullah, 2020).", [["financial distress", "PROBLEM", 111, 129]]], ["Therefore, the present study assessed suicide victims based on a specific high-profile occupation (celebrities working in the entertainment industry).", [["the present study", "TEST", 11, 28]]], ["The present study also examined the probable causality of suicides both before and during the COVID-19 pandemic period.MethodsIn the absence of any updated and functional suicide surveillance system, this study collated relevant information from press reports.", [["The present study", "TEST", 0, 17], ["this study", "TEST", 200, 210]]], ["In context of COVID-19-related suicides, this method has become widely used (e.g., Bhuiyan et al., 2020; Dsouza et al., 2020; Griffiths & Mamun, 2020;Mamun et al., 2020b;2020c).", [["COVID", "TEST", 14, 19]]], ["The search terms included, \u2018Indian cinema celebrities\u2019, \u2018celebrity suicides\u2019, \u2018COVID-19 pandemic\u2019, \u2018depression\u2019, \u2018financial strife\u2019, and \u2018lockdown related restriction\u2019.ResultsOver the past 17 years, several celebrities of Indian cinema have committed suicide.", [["pandemic\u2019", "DISEASE", 88, 97], ["depression", "DISEASE", 100, 110], ["strife\u2019", "DISEASE", 124, 131], ["depression", "PROBLEM", 100, 110]]], ["Between 2002and 2019, 16 such cases of celebrity suicide have been reported in the media (ten males and six females) details of which are presented in the Table 1.", [["celebrity suicide", "DISEASE", 39, 56]]], ["Furthermore, the most common cause of reported suicide during the different time periods was depression (n=17) although, family problems (n=3), bipolar disorder (n=1), and personal reasons (n=1) along with one case wherein the cause of suicide was unreported.", [["depression", "DISEASE", 93, 103], ["bipolar disorder", "DISEASE", 144, 160], ["depression", "PROBLEM", 93, 103], ["bipolar disorder", "PROBLEM", 144, 160], ["most common", "OBSERVATION_MODIFIER", 17, 28]]], ["Mumbai was the city with the highest number of alleged suicides (n=10), followed by Chennai (n=4), Hyderabad (n=3), New Delhi (n=2), Kerala (n=2), Indore (n=1) and the village of Mandhya in Karanataka (n=1).DiscussionTo the best of the authors\u2019 knowledge, the present study is the first to assess the nature of suicide and its associated causality among Indian celebrities.", [["New Delhi (n=2)", "PROBLEM", 116, 131], ["Kerala (n", "TREATMENT", 133, 142], ["the present study", "TEST", 256, 273], ["suicide", "PROBLEM", 311, 318]]], ["The incidence of reported suicides appeared to increase during the COVID-19 pandemic.", [["the COVID", "TEST", 63, 72], ["pandemic", "PROBLEM", 76, 84], ["suicides", "OBSERVATION", 26, 34], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["There have been many published reports discussing suicidality during the ongoing COVID-19 pandemic (e.g., Bhuiyan et al., 2020; Dsouza et al., 2020; Goyal et al., 2020; Griffiths & Mamun, 2020; Mamun & Griffiths, 2020a; Mamun & Ullah, 2020; Mamun et al., 2020b; 2020c).", [["suicidality", "DISEASE", 50, 61], ["suicidality", "PROBLEM", 50, 61]]], ["A key difference between the Indian celebrity suicides during the ongoing COVID-19 pandemic and the non-COVID-19 pandemic-related suicides is the time period over which they occurred.", [["pandemic", "DISEASE", 113, 121], ["the ongoing COVID", "TEST", 62, 79], ["pandemic", "PROBLEM", 83, 91], ["difference", "OBSERVATION_MODIFIER", 6, 16]]], ["More specifically, while the 16 celebrity suicides prior to the COVID-19 pandemic were spread over 17 years (2002-2019), the seven celebrity suicides during the COVID-19 pandemic occurred within a three-month period.", [["the COVID", "TEST", 60, 69], ["the COVID", "TEST", 157, 166]]], ["Depression was reported to be the most common cause of celebrity suicides both before and during the COVID-19 pandemic, but the increased incidence of celebrity suicides during the ongoing pandemic suggests a possible association between COVID-19-related restrictions and the exacerbation of preexisting mental health conditions such as depression that increases the risk of suicidality among Indian celebrities.", [["Depression", "DISEASE", 0, 10], ["depression", "DISEASE", 337, 347], ["suicidality", "DISEASE", 375, 386], ["Depression", "PROBLEM", 0, 10], ["the COVID", "TEST", 97, 106], ["COVID", "TEST", 238, 243], ["preexisting mental health conditions", "PROBLEM", 292, 328], ["depression", "PROBLEM", 337, 347], ["suicidality", "PROBLEM", 375, 386], ["increased", "OBSERVATION_MODIFIER", 128, 137]]], ["Strict spatial distancing measures along with social isolation tend to increase anxiety, which can have far-reaching consequences amongst the vulnerable (e.g., elderly, those with preexisting medical conditions such as respiratory problems) and those with preexisting mental conditions (e.g., depression, anxiety, etc.).", [["respiratory", "ANATOMY", 219, 230], ["anxiety", "DISEASE", 80, 87], ["respiratory problems", "DISEASE", 219, 239], ["depression", "DISEASE", 293, 303], ["anxiety", "DISEASE", 305, 312], ["Strict spatial distancing measures", "TREATMENT", 0, 34], ["social isolation", "TREATMENT", 46, 62], ["anxiety", "PROBLEM", 80, 87], ["preexisting medical conditions", "PROBLEM", 180, 210], ["respiratory problems", "PROBLEM", 219, 239], ["preexisting mental conditions", "PROBLEM", 256, 285], ["depression", "PROBLEM", 293, 303], ["anxiety", "PROBLEM", 305, 312], ["spatial", "OBSERVATION_MODIFIER", 7, 14], ["distancing", "OBSERVATION", 15, 25]]], ["These factors have the potential to increase the risk of suicidality (Mamun & Griffiths, 2020b; 2020c).", [["suicidality", "DISEASE", 57, 68], ["suicidality", "PROBLEM", 57, 68]]], ["Lockdown-associated loneliness has the capacity to cause depression, which if left untreated, can lead the sufferer towards suicidality, amongst the celebrities as well as non-celebrities.DiscussionMoreover, celebrity suicide risk factors during the COVID-19 pandemic (e.g., depression) appear to be more restricted than those reported for the Indian general population (Dsouza et al., 2020).", [["loneliness", "DISEASE", 20, 30], ["depression", "DISEASE", 57, 67], ["suicidality", "DISEASE", 124, 135], ["depression", "DISEASE", 275, 285], ["the capacity", "PROBLEM", 35, 47], ["depression", "PROBLEM", 57, 67], ["suicidality", "PROBLEM", 124, 135], ["the COVID", "TEST", 246, 255], ["pandemic", "PROBLEM", 259, 267], ["depression", "PROBLEM", 275, 285]]], ["The presence of depression as a probable cause of suicide is fairly different from the suicide causality reported from other south Asian countries.", [["depression", "DISEASE", 16, 26], ["depression", "PROBLEM", 16, 26], ["suicide", "PROBLEM", 50, 57], ["the suicide causality", "PROBLEM", 83, 104], ["depression", "OBSERVATION", 16, 26], ["probable cause", "UNCERTAINTY", 32, 46]]], ["For instance, Mamun and Ullah (2020) reported Pakistani COVID-19 suicidality cases wherein the economic recession was the cause of 12 of the reported 16 cases, while the probable cause of suicide in the remaining four cases was fear of COVID-19 infection.", [["suicidality", "DISEASE", 65, 76], ["COVID-19", "CHEMICAL", 236, 244], ["infection", "DISEASE", 245, 254], ["Pakistani COVID", "TREATMENT", 46, 61], ["the economic recession", "PROBLEM", 91, 113], ["suicide", "PROBLEM", 188, 195], ["COVID-19 infection", "PROBLEM", 236, 254], ["probable cause", "UNCERTAINTY", 170, 184], ["infection", "OBSERVATION", 245, 254]]], ["One potential limitation of this Pakistani study is that it only included the general population not the celebrities.", [["this Pakistani study", "TEST", 28, 48], ["limitation", "OBSERVATION_MODIFIER", 14, 24]]], ["Even though lockdown-associated economic recession might have the potential to cause depression which can further lead to suicide, depression as the suicide causality was not mentioned in any of the 16 cases discussed by Mamun and Ullah (2020).", [["depression", "DISEASE", 85, 95], ["depression", "DISEASE", 131, 141], ["lockdown", "PROBLEM", 12, 20], ["economic recession", "PROBLEM", 32, 50], ["depression", "PROBLEM", 85, 95], ["depression", "PROBLEM", 131, 141], ["the suicide causality", "PROBLEM", 145, 166], ["economic", "OBSERVATION_MODIFIER", 32, 40], ["recession", "OBSERVATION", 41, 50]]], ["While, depression is usually seen as a distal cause, economic recession tends to be a proximal cause (Mamun & Griffiths, 2020d).DiscussionSimilar findings have also been observed in studies conducted across Bangladesh, where financial distress was reported as being the most common suicide causality (Bhuiyan et al., 2020), although some studies have reported other causes of suicide including fear of COVID-19 infection (Mamun & Griffiths, 2020a).", [["depression", "DISEASE", 7, 17], ["infection", "DISEASE", 411, 420], ["depression", "PROBLEM", 7, 17], ["economic recession", "PROBLEM", 53, 71], ["financial distress", "PROBLEM", 225, 243], ["COVID-19 infection", "PROBLEM", 402, 420], ["depression", "OBSERVATION", 7, 17], ["distal", "OBSERVATION_MODIFIER", 39, 45], ["economic recession", "OBSERVATION", 53, 71]]], ["The economic crisis as a result of COVID-19 lockdown has also been reported in suicidal pacts among a mother and son in Bangladesh as well as a couple in India.", [["COVID-19 lockdown", "CHEMICAL", 35, 52], ["COVID-19 lockdown", "DNA", 35, 52], ["The economic crisis", "PROBLEM", 0, 19], ["economic crisis", "OBSERVATION", 4, 19]]], ["Similarly, the fear of COVID-19 infection was also reported as the cause of suicidal pact amongst a newlywed couple in India (Griffiths & Mamun, 2020).DiscussionCelebrity suicides in some instances have pushed their diehard fans and the vulnerable towards suicidality, in what is referred to as copycat suicides (Jeong et al., 2012).", [["COVID-19", "CHEMICAL", 23, 31], ["infection", "DISEASE", 32, 41], ["suicidal pact", "DISEASE", 76, 89], ["suicidality", "DISEASE", 256, 267], ["COVID-19", "ORGANISM", 23, 31], ["COVID-19", "SPECIES", 23, 31], ["COVID-19 infection", "PROBLEM", 23, 41], ["infection", "OBSERVATION", 32, 41]]], ["Therefore, it is imperative for the press media to take it as a moral responsibility not to sensationalize the celebrity suicide cases and be extremely cautious and responsible while reporting celebrity suicides (Mamun & Griffiths, 2020d).", [["the press media", "TREATMENT", 32, 47]]], ["The criteria relevant to the reporting of the celebrity suicide cases advise the journalists to be cautious in reporting without sensationalizing the suicide (World Health Organization, 2017).ConclusionEven though there have been a number of high-profile instances of Indian celebrity suicides over the past two decades owing mostly to depression, the apparent increase in incidence of celebrity suicides during the ongoing pandemic suggests a possible association between COVID-19-related restrictions and the exacerbation of preexisting mental health conditions such as depression that may increase the risk of suicidality among Indian celebrities.", [["depression", "DISEASE", 336, 346], ["depression", "DISEASE", 572, 582], ["suicidality", "DISEASE", 613, 624], ["depression", "PROBLEM", 336, 346], ["COVID", "TEST", 473, 478], ["preexisting mental health conditions", "PROBLEM", 527, 563], ["depression", "PROBLEM", 572, 582], ["suicidality", "PROBLEM", 613, 624], ["high", "OBSERVATION_MODIFIER", 242, 246], ["-profile", "OBSERVATION_MODIFIER", 246, 254], ["increase", "OBSERVATION_MODIFIER", 361, 369]]], ["Counseling should be provided to those who have a history of mental health illness.", [["mental health illness", "PROBLEM", 61, 82]]]]}